<SEC-DOCUMENT>0001628280-21-009912.txt : 20210512
<SEC-HEADER>0001628280-21-009912.hdr.sgml : 20210512
<ACCEPTANCE-DATETIME>20210512080700
ACCESSION NUMBER:		0001628280-21-009912
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		43
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210512
DATE AS OF CHANGE:		20210512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neoleukin Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001404644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36327
		FILM NUMBER:		21913533

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 360 - 1616 EASTLAKE AVE EAST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
		BUSINESS PHONE:		206-732-2133

	MAIL ADDRESS:	
		STREET 1:		SUITE 360 - 1616 EASTLAKE AVE EAST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AQUINOX PHARMACEUTICALS, INC
		DATE OF NAME CHANGE:	20140128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AQUINOX PHARMACEUTICALS (USA) INC
		DATE OF NAME CHANGE:	20070626
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nltx-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:31968e29-d77b-4652-a911-b8dbe2ac7135,g:21241be8-d08e-4bb7-a15e-85390d577d03,d:ce342ca3b91243dbba4e0415051faf5e--><html xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:nltx="http://www.aqxpharma.com/20210331" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nltx-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80L2ZyYWc6MDBmODJjZDg0YjM3NDQwZjlkMzM4OGZjZjgzMDFhOGMvdGFibGU6MmY3ZTM2YmQ4NzJlNGJlODgxZmQ3ZWIzMDcxOTQ5OGMvdGFibGVyYW5nZToyZjdlMzZiZDg3MmU0YmU4ODFmZDdlYjMwNzE5NDk4Y180LTEtMS0xLTA_2d5e8387-a5f2-44b4-87c2-d8e052a0f798">false</ix:nonNumeric><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80L2ZyYWc6MDBmODJjZDg0YjM3NDQwZjlkMzM4OGZjZjgzMDFhOGMvdGFibGU6MmY3ZTM2YmQ4NzJlNGJlODgxZmQ3ZWIzMDcxOTQ5OGMvdGFibGVyYW5nZToyZjdlMzZiZDg3MmU0YmU4ODFmZDdlYjMwNzE5NDk4Y182LTEtMS0xLTA_9e4ff311-4231-4851-90d9-cb4879ba2048">2021</ix:nonNumeric><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80L2ZyYWc6MDBmODJjZDg0YjM3NDQwZjlkMzM4OGZjZjgzMDFhOGMvdGFibGU6MmY3ZTM2YmQ4NzJlNGJlODgxZmQ3ZWIzMDcxOTQ5OGMvdGFibGVyYW5nZToyZjdlMzZiZDg3MmU0YmU4ODFmZDdlYjMwNzE5NDk4Y183LTEtMS0xLTA_d10f45d7-5c46-4afc-8ca7-1642e91b1ca8">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80L2ZyYWc6MDBmODJjZDg0YjM3NDQwZjlkMzM4OGZjZjgzMDFhOGMvdGFibGU6MmY3ZTM2YmQ4NzJlNGJlODgxZmQ3ZWIzMDcxOTQ5OGMvdGFibGVyYW5nZToyZjdlMzZiZDg3MmU0YmU4ODFmZDdlYjMwNzE5NDk4Y18xMC0xLTEtMS0w_76b2c1b3-556c-4291-92bf-9a17e157e5b8">0001404644</ix:nonNumeric><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80L2ZyYWc6MDBmODJjZDg0YjM3NDQwZjlkMzM4OGZjZjgzMDFhOGMvdGFibGU6MmY3ZTM2YmQ4NzJlNGJlODgxZmQ3ZWIzMDcxOTQ5OGMvdGFibGVyYW5nZToyZjdlMzZiZDg3MmU0YmU4ODFmZDdlYjMwNzE5NDk4Y18xMS0xLTEtMS0w_47852c28-eabc-44ad-b48b-a29e9f5e43a7">12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nltx-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i797ac540a3b740b69e583df082006363_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="icc523caa747b4d5eb5d5ca5694c0c619_I20210510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i72e0b8f57ad04762bb88e13980f63afe_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i119066f786864fd79f80c0f67e219cee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i721ff67bd330469e98cd841901180f38_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef7407a22bd487e896bbba912705914_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i266aceeba1c54778bbfe3444ba803e5b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a3c3ccbbb4b4a8a9dea4828d5509b0f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida9e53c7555c4440b86abfb9775901e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1041684bd2f5499d8dd06947bdad86bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied83e64ea1b341e98a9122c058ff0cab_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45378b9878734ebc86bd47e3bef959f0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2670e284ec83470abde183cca23912e2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21996bf832504aa398e0b3fbeb65538e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0750d237a2a948d79ac2746dea7b630e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib50df656baa2413f963433dc3384d0a1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4c61b32dc0641ba9b2270ba1aeb5cdf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ad21f0531d446c49ab28a1a53a165c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02841c927886459ea84b517e8630c500_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief2d01c144814d3782789c4d46b928c0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8415c2681fa4e7d8847b9a1e693685a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ab1dbbff5ce4c3e9ead9a82f62dedef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b5f0e7d56e3478eab62216caa641a6b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24b77291445c421fa209b58e0176120b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idba78dc2d87a4ad5ab6727062f43f0f9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60f915889b8c437cb2397db911f55730_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c27f1e7af754f9fb0d20083db327bd7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e27bb42a4374782b35ac38cec07ae0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24f310adc03d4c76a4887bd28c38a5d6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i1325199026084dc49257e149e0b3a800_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>nltx:option</xbrli:measure></xbrli:unit><xbrli:context id="ie7cd5ec78bdb4b6ead8826027dfad8c0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i186a9002297b4b929c09d8989bae5a4c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpaceAdditionalOfficesAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1820fca965074a6f98dbdf687a1aa94b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpaceAdditionalOfficesAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic81ac6cce2184282919e6dd0d38cfbd0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic47a8fba428642d0b3fb3e9e489dc7e3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c816066ede34186900132e7d337049c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c754f9fd824cb2941da29469f252a2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i178f16263cfa423ea5c90d8ffe50b7f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e04e99cd904341a315c6717663230d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7b28ced8c3b4718806223d24c59e395_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa60425c3f5c4d85b3d489026b24a8a3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fa730f0e05d4b36bba4fddc150cf94d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5d5cc27aae8459ea2268fcc0dd30291_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="offering"><xbrli:measure>nltx:offering</xbrli:measure></xbrli:unit><xbrli:context id="iabf13b01541848a4a4d24235b9abaf91_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i113d3b53a82f4678a7755be62a27ead5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59886d9904cc4c3ab0992b2f6912e53b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id43f9e75cf9e406b9efb82314fd3ead5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fbcd4fa4d7841719a7590a1e6e12f2f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8565cb16e67b45f5a5e7d8807f927fe7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ice342ca3b91243dbba4e0415051faf5e_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">__________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDAx_d76713c4-4db5-4da9-a963-25d6cc434a9d">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.612%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6NGRlYzBmY2E3ODU2NDg2YzkwZDk2Yjk5MDQ4NTBmMWYvdGFibGVyYW5nZTo0ZGVjMGZjYTc4NTY0ODZjOTBkOTZiOTkwNDg1MGYxZl8wLTAtMS0xLTE1MjM_89f84970-8226-46cf-99b3-2bbe83d50729">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT&#160;OF&#160;1934</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8zMjk4NTM0ODg2NzMy_8181a407-2311-4888-a89b-a0f5d4614ba5">March&#160;31, 2021</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6NmE3MjgxYzcwMzdhNGU3Mzk5ZDYxODk4OGEzMmY0NjAvdGFibGVyYW5nZTo2YTcyODFjNzAzN2E0ZTczOTlkNjE4OTg4YTMyZjQ2MF8wLTAtMS0xLTE1MjU_ffc79b5d-5cff-4d0b-bbb6-499e1a56053d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT&#160;OF&#160;1934</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDAz_460dd580-ab4a-4e98-92cc-ec5371982dca">001-36327</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">__________________________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDAy_bf9b4cca-ae72-44c4-afa9-34a8be269c9d">Neoleukin Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">__________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6YjAwZmQ5MGI0Y2IzNGI5OGEyNGYwMjczNmU0MDZmYTMvdGFibGVyYW5nZTpiMDBmZDkwYjRjYjM0Yjk4YTI0ZjAyNzM2ZTQwNmZhM18wLTAtMS0xLTE1Mzc_e60ad720-59c3-4ca5-be58-17513b90512d">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6YjAwZmQ5MGI0Y2IzNGI5OGEyNGYwMjczNmU0MDZmYTMvdGFibGVyYW5nZTpiMDBmZDkwYjRjYjM0Yjk4YTI0ZjAyNzM2ZTQwNmZhM18wLTItMS0xLTE1Mzk_6e752e84-32fe-4e3c-82b3-8433c26e825d">98-0542593</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDA0_7be60768-08e2-41a8-8742-c72c25702a54">188 East Blaine Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDA1_31113d1f-3e0c-40e7-8943-a62e00462e9c">Suite 450</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDA2_b0850576-1d76-45e7-9a79-27ba38adf235">Seattle</ix:nonNumeric>, <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDA3_51bbf4db-8a69-4860-9103-fcf523cc3eef">Washington</ix:nonNumeric> <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDA5_8dd01e5f-9fb9-4e88-8955-6845948dfef0">98102</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code): (<ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDIw_5f53f69b-c014-4951-bacd-64e94ab0f15a">866</ix:nonNumeric>) <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDI0_46f84c3f-5d13-485e-8b9e-914e6f1ee34b">245-0312</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">__________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6NmU2ZjEyZThjNGI0NDUyZGE4N2UzYjVhMTIxY2M4NmYvdGFibGVyYW5nZTo2ZTZmMTJlOGM0YjQ0NTJkYTg3ZTNiNWExMjFjYzg2Zl8xLTAtMS0xLTE1NDE_83965bc9-e72e-4a76-be15-65cc3f93c063">Common Stock, par value $0.000001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6NmU2ZjEyZThjNGI0NDUyZGE4N2UzYjVhMTIxY2M4NmYvdGFibGVyYW5nZTo2ZTZmMTJlOGM0YjQ0NTJkYTg3ZTNiNWExMjFjYzg2Zl8xLTEtMS0xLTE1NDM_ee24215f-ca8c-43dc-aeb7-b2b1aa60248c">NLTX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6NmU2ZjEyZThjNGI0NDUyZGE4N2UzYjVhMTIxY2M4NmYvdGFibGVyYW5nZTo2ZTZmMTJlOGM0YjQ0NTJkYTg3ZTNiNWExMjFjYzg2Zl8xLTItMS0xLTE1NDU_529bfa66-da9c-4d1c-a85b-2876b60d1f44">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDE1_79ad0e71-b1b8-478c-ba31-bfd2e32b8e23">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDE2_39a893be-d406-479a-828a-dbd5c00c6fea">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.273%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6MzQ2MTIyNTAxZmJkNGI3OWI2MDQ0Y2FkYjUzM2JkMDgvdGFibGVyYW5nZTozNDYxMjI1MDFmYmQ0Yjc5YjYwNDRjYWRiNTMzYmQwOF8yLTAtMS0xLTE1ODI_22e50935-d394-4d5c-88d7-2a35a7974762">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6MzQ2MTIyNTAxZmJkNGI3OWI2MDQ0Y2FkYjUzM2JkMDgvdGFibGVyYW5nZTozNDYxMjI1MDFmYmQ0Yjc5YjYwNDRjYWRiNTMzYmQwOF8yLTMtMS0xLTE1ODQ_bd4c3b52-2b0e-4a3c-9275-e94232ed0b31">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6MzQ2MTIyNTAxZmJkNGI3OWI2MDQ0Y2FkYjUzM2JkMDgvdGFibGVyYW5nZTozNDYxMjI1MDFmYmQ0Yjc5YjYwNDRjYWRiNTMzYmQwOF80LTMtMS0xLTE1ODY_ea445021-d758-4a87-a710-da279067d62c">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDQz_c9de3b7b-4da2-4ae7-84fc-cc48d0020764">&#9746;</ix:nonNumeric></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;10, 2021, there were <ix:nonFraction unitRef="shares" contextRef="icc523caa747b4d5eb5d5ca5694c0c619_I20210510" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8zMjk4NTM0ODg1NjUz_5217f85b-ed56-4c63-9f6a-e5bfd3d5f526">42,345,720</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ice342ca3b91243dbba4e0415051faf5e_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neoleukin Therapeutics, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quarterly Report on Form 10-Q</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarter Ended March&#160;31, 2021</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.860%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_10">PART&#160;I. FINANCIAL INFORMATION (Unaudited)</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_13">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_13">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_13">2</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_22">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_22">3</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_25">4</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_31">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_31">5</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_34">6</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_85">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_85">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_85">11</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_115">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_115">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_115">16</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_118">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_118">17</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_121">PART&#160;II.&#160;OTHER&#160;INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_124">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_124">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_124">18</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_127">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_127">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_127">18</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_130">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_130">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_130">59</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_133">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_133">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_133">59</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_136">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_136">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_136">59</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_139">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_139">59</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_142">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_142">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_142">60</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_145">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_145">60</a></span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated herein or as the context otherwise requires, references in this report to, &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Neoleukin Therapeutics, Inc. (formerly Aquinox Pharmaceuticals, Inc.), a Delaware corporation. The name &#8220;Neoleukin&#8221; is a registered trademark of the Company in the United States.&#160;&#160;This report also contains references to registered marks, trademarks and trade names of other companies that are property of their respective holders.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ice342ca3b91243dbba4e0415051faf5e_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I.&#160;FINANCIAL INFORMATION</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_13"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Financial Statements</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">alance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands of U.S. dollars, except per share and share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:68.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMy0xLTEtMS0w_6eca62de-f384-4b50-a169-2f61c61aa97e">178,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMy0zLTEtMS0w_1680fabc-b825-44e3-8ec4-7d57b740edbc">192,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfNC0xLTEtMS0w_d937d6c6-ff2d-4e2f-863c-02d481a509cf">2,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfNC0zLTEtMS0w_74b09617-f811-44dc-b204-22dfa49ab6fd">1,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfNS0xLTEtMS0w_d6e255e0-1797-4faa-8691-8beef6cadc10">181,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfNS0zLTEtMS0w_9f7aadf9-b18f-41f1-9fcd-d1e4d9c68003">194,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfNy0xLTEtMS0w_9c08c7e8-bd03-47f1-a1d8-cb6f9d608559">5,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfNy0zLTEtMS0w_e130b09d-8b46-4ec1-ab38-a9990ec60cdf">3,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfOC0xLTEtMS0w_a2a959a6-2361-4e45-a8c3-10c63ce5247e">11,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfOC0zLTEtMS0w_102d2cf3-e219-452a-a60c-72f7adfb69cf">10,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfOS0xLTEtMS0w_c6a74332-ab7d-498d-bddb-8063dfc4b423">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfOS0zLTEtMS0w_a9237de4-0254-4367-9a71-482a8202af02">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTAtMS0xLTEtMA_2156e46c-cd92-43e2-975f-b22b4569a2d9">1,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTAtMy0xLTEtMA_f3173a81-8040-46ca-a5e4-8e46c474c574">1,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTEtMS0xLTEtMA_9981a96f-43b0-45f2-b45d-75e52a3b810c">200,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTEtMy0xLTEtMA_41f52134-33d1-4904-bc3e-64ee660c5bb7">210,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTUtMS0xLTEtMA_82d1a181-c33c-4351-8f34-7635305590ee">7,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTUtMy0xLTEtMA_6b4ad554-3475-4cc3-aa44-ab6d9b2bf446">7,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTYtMS0xLTEtMA_65b10a39-8b42-4865-bfba-bf27e809fc18">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTYtMy0xLTEtMA_7a99a45b-18c4-4c57-954e-9b8b255d8fe2">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTctMS0xLTEtMA_92de2549-8e3b-48cd-b850-09f241dbf26a">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTctMy0xLTEtMA_f190cd5e-c0cb-4401-ad81-7720a312139f">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTgtMS0xLTEtMA_58fed7f0-7ed2-4a8c-9b72-971e5aef41cb">8,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTgtMy0xLTEtMA_6b0845aa-2573-46b1-bf93-0822534e2caa">7,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTktMS0xLTEtMA_93c45be6-30e8-4dab-b61e-c153be7bc874">12,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTktMy0xLTEtMA_fb0bda72-fa11-4bc4-8d8c-71394131da24">11,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjAtMS0xLTEtMA_0d60c502-a9f0-48d7-8ea2-3403de9c806f">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjAtMy0xLTEtMA_06fc9d6c-6a61-432b-95d0-1d9e064ba2e9">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjEtMS0xLTEtMA_7cfc1a8b-837d-4572-a13e-ac1a307369ef">21,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjEtMy0xLTEtMA_10ef7548-3df4-43d9-9b4a-08757000a4ae">19,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzUyOA_2dfcb8d6-7052-4ccb-a4c7-16ed746cc598"><ix:nonFraction unitRef="usdPerShare" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzUyOA_ca6ae320-111c-438d-a9a6-cfb4d4c150d4">0.000001</ix:nonFraction></ix:nonFraction> par value - authorized, <ix:nonFraction unitRef="shares" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzU0Mw_553c9764-406f-4fbd-958b-a6a8e86e58cd"><ix:nonFraction unitRef="shares" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzU0Mw_7ebe67b0-20dc-48a4-9337-fffe1ddd5114">100,000,000</ix:nonFraction></ix:nonFraction> as of March 31, 2021 and December 31, 2020; issued and outstanding, <ix:nonFraction unitRef="shares" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzU1Ng_5a0f628e-b572-46c6-8499-ebb97fd1a6e6"><ix:nonFraction unitRef="shares" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzU1Ng_ed61630b-d644-442b-a6b0-86bafe59b786">42,326,033</ix:nonFraction></ix:nonFraction> as of March 31, 2021 and <ix:nonFraction unitRef="shares" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzU2OQ_17efd600-5549-4cc0-92b4-4074e34c1e7e"><ix:nonFraction unitRef="shares" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzU2OQ_3b7e3ad2-6022-409e-afb6-58a613a6bba5">42,196,296</ix:nonFraction></ix:nonFraction> as of December 31, 2020.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMS0xLTEtMA_be575588-a0df-4023-842a-3d187ae48deb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMy0xLTEtMA_8aded4a4-ed8b-4647-8686-70d2e4e024fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzUyNg_183089ea-e2d3-4bad-b382-f717aae15f46"><ix:nonFraction unitRef="usdPerShare" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzUyNg_8ec7343d-6d54-48b4-a8af-71c05c3e5e00">0.000001</ix:nonFraction></ix:nonFraction> par value - authorized, <ix:nonFraction unitRef="shares" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzUzOQ_0493a311-d913-47b3-8f6a-6e03843ecd7f"><ix:nonFraction unitRef="shares" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzUzOQ_7353904d-26b9-43f9-ab90-e76000c7bd56">5,000,000</ix:nonFraction></ix:nonFraction> as of March 31, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzYwNw_8ac291ef-4c83-4fe9-98d4-f06e624288a5"><ix:nonFraction unitRef="shares" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzYwNw_b457ae89-df21-400e-a4a1-5f33d47140a1"><ix:nonFraction unitRef="shares" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzYwNw_c84adfe8-b920-425d-aad5-d8997c37b71e"><ix:nonFraction unitRef="shares" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzYwNw_cd726b63-5e88-4c3e-b85a-be8646b12847">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding as of March 31, 2021 and December 31, 2020.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjYtMS0xLTEtMA_db200e1d-de43-4f59-a914-3101f11b4779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjYtMy0xLTEtMA_39adcb93-40f8-48d4-8947-4068ef01e687">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjctMS0xLTEtMA_6e7d340c-3fe7-40db-8177-73bc8818a82c">526,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjctMy0xLTEtMA_2ee01d08-51b5-4945-9b28-e34cff1265ff">524,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjgtMS0xLTEtMA_0fd30f02-33d4-4e42-acc1-fded504df46b">347,756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjgtMy0xLTEtMA_6cd095bf-ea3c-4b88-bef7-2d6af3851b01">332,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjktMS0xLTEtMA_ca93b3aa-6794-43c6-9506-698fe5d7699e">178,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjktMy0xLTEtMA_4064e8ec-a709-4468-a40a-da56f775762f">191,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMzAtMS0xLTEtMA_39273899-cc7b-4770-a1e1-ccd957f969f6">200,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMzAtMy0xLTEtMA_1f8e3590-4637-4210-af52-6901812eed5d">210,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these condensed consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ice342ca3b91243dbba4e0415051faf5e_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands of U.S. dollars, except per share and share amounts)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMy0xLTEtMS0w_b2eb9414-6c70-43cf-b878-088001de4660">9,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMy0zLTEtMS0w_8de2fd80-3133-4f88-8826-eee9b4361943">5,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfNS0xLTEtMS0w_880a598b-20fc-471e-8c3c-7c713e95da59">5,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfNS0zLTEtMS0w_7cb96bd5-5c1c-41f0-899f-a1892eff27ad">3,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfNy0xLTEtMS0w_87a5d99b-9209-47ff-b0c8-31130127e8cb">14,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfNy0zLTEtMS0w_f9c9805c-4cb2-46db-918e-188aee992d3a">9,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (loss), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfOC0xLTEtMS0w_8dad52e8-fd17-472b-aa3f-0f2fb4576073">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfOC0zLTEtMS0w_d9334f0d-dd1f-404a-83dc-ee75378de281">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfOS0xLTEtMS0w_413e2158-2431-4129-b701-5e834f22a514">14,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfOS0zLTEtMS0w_a4682a72-adb2-455f-b6fc-c0141317048f">8,642</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common stock &#8211; basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTAtMS0xLTEtMA_d6f40278-2b07-4bb7-b668-a84f0904c5f5"><ix:nonFraction unitRef="usdPerShare" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTAtMS0xLTEtMA_ebd3ba38-459d-4769-b109-4aad6f3fa13f">0.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTAtMy0xLTEtMA_1a7b0390-ef14-4d16-8686-b80db9b19def"><ix:nonFraction unitRef="usdPerShare" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTAtMy0xLTEtMA_42fc5b1e-fc50-4282-a439-2bec62bb5c04">0.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTEtMS0xLTEtMA_d1515bd7-2590-441f-831a-8d502c1a414f"><ix:nonFraction unitRef="shares" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTEtMS0xLTEtMA_dadb8e3e-517a-44c4-97b6-953606d9ff21">54,944,421</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTEtMy0xLTEtMA_9da7aeea-40ca-45f2-a550-f39f91747a08"><ix:nonFraction unitRef="shares" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTEtMy0xLTEtMA_f0a965b3-ce3f-437b-b3e0-4b78539e2d4b">49,168,451</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ice342ca3b91243dbba4e0415051faf5e_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands of U.S. dollars)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMy0xLTEtMS0w_a935c853-fe69-4c6e-97d8-9e5277f55c83">14,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMy0zLTEtMS0w_afbd6e99-c515-4f39-9205-032d318eba11">8,642</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfNS0xLTEtMS0w_f70a2c3d-bb0a-4d30-b262-91d14a45fde4">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfNS0zLTEtMS0w_08ecd9c3-5da6-42bb-b84c-0b8f95b4ff22">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfNy0xLTEtMS0w_207ed9b7-a1c8-40f4-90d5-225ab01dbd30">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfNy0zLTEtMS0w_8c6d3dd4-e7a4-417a-b7e1-c618cddd77c9">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfOS0xLTEtMS0w_0a80aec5-c47c-433b-9124-5510b4089691">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfOS0zLTEtMS0w_7963bc35-05fe-443d-9d53-3773fe66c2c5">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange (gain)/loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTEtMS0xLTEtMA_a2ff24a0-bfa4-4f97-be45-d8324532b59e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTEtMy0xLTEtMA_996001b6-aa8c-4fd8-a7af-8577f769d2e5">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTMtMS0xLTEtMA_da4c03e5-8f95-4d9f-b98f-0cb895182494">813</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTMtMy0xLTEtMA_350d8f5d-06b7-42a8-b629-e8687b7f02bc">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTQtMS0xLTEtMA_4d140df7-886c-4274-ba82-3e29524c4eb5">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTQtMy0xLTEtMA_769b0e5f-0077-4c3b-89e8-499989f75359">878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTItMS0xLTEtMTI2MA_9faf77a4-ce43-4b69-9ed6-6194cafecb95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" name="nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTItMy0xLTEtMTI2MA_291b31e7-3261-4a6f-b5e9-233f9d93c758">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" name="nltx:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTYtMS0xLTEtMA_34c7b900-5e72-433c-85b2-76c1ab79edc9">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" sign="-" name="nltx:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTYtMy0xLTEtMA_0627c4b4-77e6-46ad-a9c4-7952ae4fcf8b">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTctMS0xLTEtMA_c533b9bb-eeac-4c41-8e3e-d8ef065744ec">13,358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTctMy0xLTEtMA_4fb6ef5f-750e-4114-be92-fbbe2a3c5f3a">6,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjEtMS0xLTEtMA_d07e2f02-6076-437b-a7cc-368a09dd0357">1,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjEtMy0xLTEtMA_6a4a22c1-cfd9-4bad-9c1d-17bd109fea40">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjItMS0xLTEtMA_63149497-141d-40b1-bc9a-503d3f65d276">1,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjItMy0xLTEtMA_b4c8d401-8f20-4fab-b057-a5025595dddf">107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjctMS0xLTEtMA_8a9a6b68-43d8-4bb2-8b43-dbafebc5f8cc">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjctMy0xLTEtMA_ff31b1bc-6d72-49d5-87df-41bcd463825c">3,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment on finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjgtMS0xLTEtMA_01d8dab8-ae83-4a6d-aa40-163df23e27aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjgtMy0xLTEtMA_946b29a9-5686-4fe8-b1b9-1b1196517dfb">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjktMS0xLTEtMA_547f8927-504d-4202-8cb7-2c285aa10ac4">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjktMy0xLTEtMA_57a12d47-10be-478b-b7c5-e7b3d157b1b2">3,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzEtMS0xLTEtMA_00c0810d-3e81-448f-8744-b3c2e978029d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzEtMy0xLTEtMA_57487ad1-2a46-4906-ad5a-cea7af5d6ed3">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash during the period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzItMS0xLTEtMA_9983bb33-dad5-4728-a967-71221c4f0bbd">14,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzItMy0xLTEtMA_7863909f-c7a8-4d62-843f-dbd5ab00e7c9">3,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzMtMS0xLTEtMA_0a538a13-a4c8-41e5-b15c-0c43b3eda9ed">193,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef7407a22bd487e896bbba912705914_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzMtMy0xLTEtMA_9ef81a7a-a16f-48ab-a20a-7a4d90a6a220">143,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzUtMS0xLTEtMA_af10c7cb-a3d0-4ccf-ba26-07466d6216f1">179,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i266aceeba1c54778bbfe3444ba803e5b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzUtMy0xLTEtMA_631d204a-e41b-465e-bd64-a3d7ce6ee2f1">139,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment unpaid at period-end</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzgtMS0xLTEtMA_2e5175df-5905-4b70-ad0c-4f98b8ad224d">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzgtMy0xLTEtMA_25299278-6929-4dc0-9473-09bf71b734dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities arising from obtaining ROU asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzktMS0xLTEtMA_6ebbe4b4-0eaf-4989-9dc6-1d145a7f0efa">1,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzktMy0xLTEtMA_809e1c96-23c7-4c84-95b3-5b0cc9315e11">9,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ice342ca3b91243dbba4e0415051faf5e_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands of U.S. dollars, except share amounts)</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.975%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-In</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Stockholders'</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a3c3ccbbb4b4a8a9dea4828d5509b0f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMi0xLTEtMS0w_3ced02a9-3d1a-4bd3-8cb6-fb645acb4238">37,996,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida9e53c7555c4440b86abfb9775901e1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMi05LTEtMS0w_9e658468-018d-4e53-8d3b-9a874927dc9e">441,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1041684bd2f5499d8dd06947bdad86bf_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMi0xMS0xLTEtMA_86c2b7e8-2201-453d-b323-535a42d8c69d">299,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef7407a22bd487e896bbba912705914_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMi0xMy0xLTEtMA_1e1c05c9-c3a1-4273-90bb-b13b4360358c">141,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued upon exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied83e64ea1b341e98a9122c058ff0cab_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMy0xLTEtMS0w_3ebf0fea-195a-48df-9ed9-10dec6f79a0b">376,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45378b9878734ebc86bd47e3bef959f0_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMy05LTEtMS0w_9077fd7d-e143-4f75-82ea-d4e6c2f9936d">3,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMy0xMy0xLTEtMA_4e2b21fd-7f51-4174-bde1-8fb3ed3cc926">3,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied83e64ea1b341e98a9122c058ff0cab_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNC0xLTEtMS0w_729c266e-f030-49ed-a90c-d3a0e98f1a6a">13,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45378b9878734ebc86bd47e3bef959f0_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNS05LTEtMS0w_9001be4b-3a80-498b-a399-0689dee0a118">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNS0xMy0xLTEtMA_ff4550a7-3d03-4e24-b286-5efd17f0100f">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2670e284ec83470abde183cca23912e2_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNi0xMS0xLTEtMA_389db3ee-0c93-499d-95af-a5df508955f1">8,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNi0xMy0xLTEtMA_231d8d44-6df3-498e-bc7b-8bbe2265b2ab">8,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21996bf832504aa398e0b3fbeb65538e_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNy0xLTEtMS0w_77e4412b-e010-4205-a6a2-140f2ec7c49c">38,386,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0750d237a2a948d79ac2746dea7b630e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNy05LTEtMS0w_f34f5db3-1054-4466-8851-9ccfc140d372">445,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib50df656baa2413f963433dc3384d0a1_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNy0xMS0xLTEtMA_f26f9153-4edf-457b-86c5-f1541070fe24">308,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i266aceeba1c54778bbfe3444ba803e5b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNy0xMy0xLTEtMA_48fee9c8-c13a-47fd-8435-58fefcb531a3">137,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4c61b32dc0641ba9b2270ba1aeb5cdf_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfOS0xLTEtMS04MDI_43c57925-69f4-44d5-aa13-9e597ca7b212">42,196,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad21f0531d446c49ab28a1a53a165c3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfOS01LTEtMS04MTE_679f139d-8102-4a21-b46d-4297d108ee77">524,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02841c927886459ea84b517e8630c500_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfOS03LTEtMS04MTY_c637d7ec-3b8a-43a8-851c-b7558e03f1e5">332,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfOS05LTEtMS04MjA_68789182-0bed-4737-9557-868bfa0afda6">191,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued upon exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief2d01c144814d3782789c4d46b928c0_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTAtMS0xLTEtODAy_92b15079-4062-460a-b436-77e44c8288d8">91,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8415c2681fa4e7d8847b9a1e693685a_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTAtNS0xLTEtODEx_c792d1a0-faec-41af-87f6-08988507930a">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTAtOS0xLTEtODIw_3e8b8392-196b-493d-a616-cc663751a914">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief2d01c144814d3782789c4d46b928c0_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTEtMS0xLTEtODAy_f8789208-2dc5-42aa-a012-8a58b7d0128b">38,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8415c2681fa4e7d8847b9a1e693685a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTItNS0xLTEtODEx_c85e4fbe-c548-4b7d-83a8-b74e512fd64f">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTItOS0xLTEtODIw_215c2142-88fa-42e6-b05e-d94a0a6d5f68">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ab1dbbff5ce4c3e9ead9a82f62dedef_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTMtNy0xLTEtODE2_842ced1f-fd93-49cd-929a-8c62d787d7fd">14,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTMtOS0xLTEtODIw_c1d3afe0-9676-4936-98bc-994471f5b61c">14,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b5f0e7d56e3478eab62216caa641a6b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTQtMS0xLTEtMTgzMQ_300292f9-b97f-44ed-bbfd-98996538a334">42,326,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b77291445c421fa209b58e0176120b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTQtNS0xLTEtMTgzMQ_1fe1820a-6e23-46b4-8531-5dc0fce61ce5">526,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idba78dc2d87a4ad5ab6727062f43f0f9_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTQtNy0xLTEtMTgzMQ_b2e21fe0-216f-42c1-a9f8-ac7f921fda6c">347,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTQtOS0xLTEtMTgzMQ_629bd104-664e-48b8-aa5d-9e537cbbff9c">178,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ice342ca3b91243dbba4e0415051faf5e_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="ice342ca3b91243dbba4e0415051faf5e_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zNy9mcmFnOjBjNDJiNzJjYmU4ZjRkMzY4MjJhZjhjYWYxN2FmYjY4L3RleHRyZWdpb246MGM0MmI3MmNiZThmNGQzNjgyMmFmOGNhZjE3YWZiNjhfNDQx_0985142e-ceec-4e1b-8d12-69a54af141a7" continuedAt="ife64868af5364fbc95028e3cc5f9da87" escape="true">Nature of operations</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ife64868af5364fbc95028e3cc5f9da87">Neoleukin Therapeutics, Inc. (&#8220;Neoleukin&#8221; or &#8220;the Company&#8221;) is&#160;a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using&#160;de novo&#160;protein design technology. Neoleukin uses sophisticated computational methods to design&#160;proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.</ix:continuation>&#160;</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2NA_a86039c9-d31a-4911-a00a-f3708754c588" continuedAt="ic1283188db5645cf82caa1919777392e" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="ic1283188db5645cf82caa1919777392e" continuedAt="i2b91155f5513400988c094141efdf991"><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY1OQ_42ee2120-f168-48d4-977d-7956a8716f2e" continuedAt="i71e78fe54af44bf78d0624b2ce9bfe4e" escape="true">Basis of presentation</ix:nonNumeric></span></div><ix:continuation id="i71e78fe54af44bf78d0624b2ce9bfe4e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are presented in United States (&#8220;U.S.&#8221;) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information.&#160;&#160;Accordingly, these consolidated financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the Securities and Exchange Commission on March 25, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company sold all of the issued and outstanding capital stock of Aquinox Pharmaceuticals, Inc. (Canada) (&#8220;Aquinox Canada&#8221;) to an unrelated third party. On December 31, 2020, Neoleukin Corporation, the Company's wholly owned subsidiary, was merged into the Company. As a result, the Company has consisted of a single operating company since December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position of the Company as of March&#160;31, 2021, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year.</span></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2NQ_aefff34c-0e04-4a64-9c4d-9790719df072" continuedAt="i6beead22499f4b8cac3f9f1d037551ef" escape="true">Use of estimates and assumptions</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6beead22499f4b8cac3f9f1d037551ef">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, the incremental borrowing rate utilized in the measurement of operating and finance lease liabilities, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical, clinical, and other accruals. Actual results could differ from those estimates.</ix:continuation></span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2MA_29d967d5-b47e-44b4-84d7-04f5a7790948" continuedAt="i59b5da6f56be4b74b4816e4e3ab27d28" escape="true">Reclassification</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i59b5da6f56be4b74b4816e4e3ab27d28">The Company reclassified prior year changes in operating lease right-of-use assets and operating lease liabilities in the condensed consolidated statements of cash flows to conform to current year presentation. This reclassification had no effect on net cash used in operating activities.</ix:continuation></span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2MQ_f1d802d3-c023-44f9-81e4-c35c00dc1f50" continuedAt="iaafe2be274a24976816202545e76de71" escape="true">Leases</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaafe2be274a24976816202545e76de71" continuedAt="ie20ea3cd26194a14819c4bba8180c0e3">At contract inception, the Company determines if the contract is or contains a lease. Lease liabilities are recognized on the lease commencement date based on the estimated present value of lease payments over the lease term. To determine the present value of the lease payments, the Company utilizes its estimated incremental borrowing rate based on information available at the lease commencement date as the interest rate implicit in the lease is typically not readily determinable. The related right-of-use assets are recorded net of any lease incentives received. Variable lease cost primarily includes building operating expenses as charged to the Company by its landlords and payments for lessor-owned assets that are not covered by a tenant improvement allowance.</ix:continuation></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><ix:continuation id="i2b91155f5513400988c094141efdf991"><ix:continuation id="ie20ea3cd26194a14819c4bba8180c0e3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes options to extend the lease in its lease liability and right-of-use asset when it is reasonably certain that it will exercise that option. None of the Company's options to extend the rental term of any of its existing leases were considered reasonably certain as of March&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases of office space and equipment, the Company has elected to not separate the lease components from the non-lease components.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases of office space with a lease term of <ix:nonNumeric contextRef="i60f915889b8c437cb2397db911f55730_I20210331" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfMzI5ODUzNDg5NTcxMQ_969d1cf0-8091-4d12-b469-9ad85efc040b">12</ix:nonNumeric> months or less and which do not include an option to purchase the underlying asset, the Company has elected to recognize the lease payments in the statement of operations on a straight-line basis over the lease term.</span></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2Ng_8a5fbe6f-9889-4c10-9e12-49278606422d" continuedAt="ia32d727a458d4f9e9a3e4f1f48e75ca1" escape="true">Fair value of financial instruments</ix:nonNumeric></span></div><ix:continuation id="ia32d727a458d4f9e9a3e4f1f48e75ca1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, restricted cash, receivables, accounts payable and other liabilities, approximate their fair values because of their nature and/or short maturities.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, and December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i3c27f1e7af754f9fb0d20083db327bd7_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfMzI5ODUzNDg5NTc1Ng_12a614b8-e9c1-438e-bf49-d86394836d01">156.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1e27bb42a4374782b35ac38cec07ae0b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfMzI5ODUzNDg5NTc3NQ_08e5ec65-2289-4884-92ce-98c833439e57">108.3</ix:nonFraction> million in money market funds, respectively. Money market funds are level one financial instruments as they are valued at fair value, which is the closing price reported by the fund sponsor from an actively traded exchange.</span></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:8.01pt"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2Mg_785d90fa-5953-48f7-a15d-d94170d58a4a" continuedAt="i23b1282e474642f699a015aa61490980" escape="true">Earnings (loss) per share</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i23b1282e474642f699a015aa61490980">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Common stock equivalents such as outstanding stock options and unvested restricted stock units are included in the calculation of diluted earnings per share only in periods of net income. Such common stock equivalents are excluded in the calculation of diluted net loss per share in periods of net loss as inclusion of such amounts would be anti-dilutive. Outstanding pre-funded warrants as of March 31, 2021 of <ix:nonFraction unitRef="shares" contextRef="i24f310adc03d4c76a4887bd28c38a5d6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNDg4MQ_79c096ec-22e7-465c-a913-636a35e1f146">12,663,010</ix:nonFraction> are considered outstanding as of their issuance date and are included in the basic and diluted net loss per share calculation because they are fully vested and exercisable at any time after <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:durday" name="nltx:ClassOfWarrantOrRightNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfMTY0OTI2NzQ2MDI4NQ_7b0e53bb-4366-41e8-b188-45116c011080">61</ix:nonNumeric> days' notice for a nominal cash consideration.</ix:continuation></span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2Nw_7704dfee-12e2-4d0a-8a9b-3ae708a16c97" continuedAt="i4ff416925a724aff8a83757cd793823e" escape="true">Recently issued and recently adopted accounting standards</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4ff416925a724aff8a83757cd793823e">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2019-12 &#8220;Simplifying the Accounting for Income Taxes.&#8221; The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by Accounting Standards Codification (&#8220;ASC&#8221;) Topic 740 - Income Taxes and clarifying existing guidance to facilitate consistent application. ASU 2019-12 became effective for fiscal years and interim periods beginning after December 15, 2020. The Company adopted this standard on January 1, 2021 on a prospective basis. The adoption of this ASU did not have a material impact on the Company's financial condition, results of operations, cash flows, and financial statement disclosures.</ix:continuation></span></div></ix:continuation><div id="ice342ca3b91243dbba4e0415051faf5e_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="nltx:CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RleHRyZWdpb246YWU4ZWFjYzAzZWM5NDcxNzkyNWVkYTRjY2I2YjgzMWVfNTUz_1a74ccfa-3353-4fb6-afef-7031ca663d73" continuedAt="i58eb2f60e19c4705947751dc2c3b7656" escape="true">Cash, cash equivalents and restricted cash</ix:nonNumeric></span></div><ix:continuation id="i58eb2f60e19c4705947751dc2c3b7656"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash, included in other non-current assets in the condensed consolidated balance sheets, includes $<ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RleHRyZWdpb246YWU4ZWFjYzAzZWM5NDcxNzkyNWVkYTRjY2I2YjgzMWVfMTQ4_e0343f5a-7684-4707-a588-08dbb0477bf7">0.9</ix:nonFraction> million in cash deposits the Company maintains with its bank as collateral for the irrevocable letters of credit related to its lease obligations.</span></div><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RleHRyZWdpb246YWU4ZWFjYzAzZWM5NDcxNzkyNWVkYTRjY2I2YjgzMWVfNTU0_13de5cfe-63da-4aa5-8846-0545b09ad9b5" escape="true"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RleHRyZWdpb246YWU4ZWFjYzAzZWM5NDcxNzkyNWVkYTRjY2I2YjgzMWVfNTU0_4a5c8147-a3fd-4d66-8e25-10d94bd45efb" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hat sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:68.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RhYmxlOmE2ZDQwYzJiN2E0NjRmMmY4NDlmZTMzMzk5Mzc4Mzc3L3RhYmxlcmFuZ2U6YTZkNDBjMmI3YTQ2NGYyZjg0OWZlMzMzOTkzNzgzNzdfMS0xLTEtMS0w_4ab1b2a6-26c5-42fa-a24e-84baa944f8de">178,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RhYmxlOmE2ZDQwYzJiN2E0NjRmMmY4NDlmZTMzMzk5Mzc4Mzc3L3RhYmxlcmFuZ2U6YTZkNDBjMmI3YTQ2NGYyZjg0OWZlMzMzOTkzNzgzNzdfMS0zLTEtMS0w_b0d6ec06-1c5b-46a2-924f-46aa49ba1c26">192,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RhYmxlOmE2ZDQwYzJiN2E0NjRmMmY4NDlmZTMzMzk5Mzc4Mzc3L3RhYmxlcmFuZ2U6YTZkNDBjMmI3YTQ2NGYyZjg0OWZlMzMzOTkzNzgzNzdfMi0xLTEtMS0w_13f42e25-5919-4914-b3b8-210e43a0a22f">878</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RhYmxlOmE2ZDQwYzJiN2E0NjRmMmY4NDlmZTMzMzk5Mzc4Mzc3L3RhYmxlcmFuZ2U6YTZkNDBjMmI3YTQ2NGYyZjg0OWZlMzMzOTkzNzgzNzdfMi0zLTEtMS0w_1b43425b-c077-4f67-ba3c-47c16f2781b3">878</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RhYmxlOmE2ZDQwYzJiN2E0NjRmMmY4NDlmZTMzMzk5Mzc4Mzc3L3RhYmxlcmFuZ2U6YTZkNDBjMmI3YTQ2NGYyZjg0OWZlMzMzOTkzNzgzNzdfMy0xLTEtMS0w_54531493-a6a1-4ef2-96d8-d5448c626b7f">179,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RhYmxlOmE2ZDQwYzJiN2E0NjRmMmY4NDlmZTMzMzk5Mzc4Mzc3L3RhYmxlcmFuZ2U6YTZkNDBjMmI3YTQ2NGYyZjg0OWZlMzMzOTkzNzgzNzdfMy0zLTEtMS0w_7861861e-69f4-45d8-8cd1-e8adf1594455">193,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="ice342ca3b91243dbba4e0415051faf5e_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMTY0OTI2NzQ0OTU0Nw_1315ee9b-5ea9-42e6-99e2-1a8f6d66359b" continuedAt="i60111acfabea414dbad2573eb258af37" escape="true"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzY2MA_dc33993c-9040-4f45-b42a-a416437a472c" continuedAt="i8739cbc458954402a4da3a9534c70e83" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i60111acfabea414dbad2573eb258af37"><ix:continuation id="i8739cbc458954402a4da3a9534c70e83"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into lease arrangements for its facilities as well as certain equipment, classified either as operating or finance leases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease agreement, as amended by the execution of two subsequent amendments,&#160;for approximately <ix:nonFraction unitRef="sqft" contextRef="i1325199026084dc49257e149e0b3a800_I20210331" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMjA5_13c5c2b7-3088-4c5a-a415-e68aa1a56ff4">33,300</ix:nonFraction> square feet of office space in Seattle, Washington for the Company&#8217;s principal executive offices, a laboratory for research and development, and related uses. The lease commenced on January 15, 2020 and expires on February 1, 2029, with the option to extend the lease for <ix:nonFraction unitRef="option" contextRef="ie7cd5ec78bdb4b6ead8826027dfad8c0_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="nltx:NumberOfOptionToExtendLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfOTAx_d1a91fbf-e71e-415c-81fc-75d2514455fa">two</ix:nonFraction> <ix:nonNumeric contextRef="i1325199026084dc49257e149e0b3a800_I20210331" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMTY0OTI2NzQ0OTU1OQ_c42f7789-f252-490e-a6ea-6fc7367ffa83">five-year</ix:nonNumeric> terms.&#160;&#160;The lease provides for a tenant improvement allowance of up to $<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="nltx:TenantImprovementAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfOTc5_a20c9101-c9a0-4f94-988d-02a056bba244">9.5</ix:nonFraction> million. As of March&#160;31, 2021, there was a tenant improvement allowance receivable of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="nltx:TenantImprovementAllowanceReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMTU3Nw_74c7a09b-fa8e-4880-8ace-48238fa019f7">1.3</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded in other current assets related to reimbursable build-out costs incurred by the Company. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease agreement&#160;for approximately <ix:nonFraction unitRef="sqft" contextRef="i186a9002297b4b929c09d8989bae5a4c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMjMwNg_ded3e68f-4c7a-4b4e-b0d0-62b723d3221c">6,272</ix:nonFraction> square feet of office space in Seattle, Washington, for additional office and laboratory space for research and development and related uses. In March 2021, the Company executed an amendment to this lease pursuant to which the contractual lease term was extended through September 30, 2026, unless terminated earlier, with the option to extend the lease for an additional <ix:nonNumeric contextRef="i186a9002297b4b929c09d8989bae5a4c_I20210331" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMTY0OTI2NzQ0OTU3MA_2a033f74-9103-4305-8cc8-9de396724311">28-month</ix:nonNumeric> term. The execution of this amendment was accounted for as a modification to the lease due to the extension of the lease term and an increase in lease payments, and the Company recorded an increase in the lease liability and related right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="i1820fca965074a6f98dbdf687a1aa94b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="nltx:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzI5ODUzNDg4OTM2MQ_a26b0b91-a832-491e-b8ab-bb8e0c7aa84a"><ix:nonFraction unitRef="usd" contextRef="i1820fca965074a6f98dbdf687a1aa94b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzI5ODUzNDg4OTM2MQ_bdd1566c-5598-47c4-b744-66ccb286c1dd">1.6</ix:nonFraction></ix:nonFraction> million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, and December 31, 2020, the Company&#8217;s operating lease right-of-use assets were $<ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzU0MA_012f05c8-1db2-418e-a920-56c6d24e3cc9">11.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzU0Nw_6345d9dd-d3f0-44e1-969e-470e6684b84c">10.2</ix:nonFraction> million, respectively.&#160;&#160;As of March&#160;31, 2021, and December&#160;31, 2020, the Company&#8217;s finance lease right-of-use assets were $<ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzYzNw_b8d57cb4-c083-48b0-a667-85e54ea86ca3">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzY0NA_97a3fc06-2121-4345-9cf2-dbf591e384ed">0.3</ix:nonFraction> million, respectively.</span></div></ix:continuation></ix:continuation><div id="ice342ca3b91243dbba4e0415051faf5e_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMjU4MQ_cfec714f-bf81-4110-ba3b-378449d7e894" continuedAt="ieaea8af7769a450489d31171b29c7a56" escape="true">Equity</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:continuation id="ieaea8af7769a450489d31171b29c7a56" continuedAt="i8f0898d9cb6040feb3d29b0fa2e9d448">&#160;</ix:continuation></span></div><ix:continuation id="i8f0898d9cb6040feb3d29b0fa2e9d448" continuedAt="i981fca18fc494532ad08c419318cacb4"><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt">Common stock and pre-funded warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue  <ix:nonFraction unitRef="shares" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkwNQ_79d27548-a898-4e5b-84d2-9cd881b9cfbd">100,000,000</ix:nonFraction> shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkxMQ_3b9015c2-a6f9-48a6-bb62-fd60099a7695">0.000001</ix:nonFraction> as of March 31, 2021.  As of March&#160;31, 2021 and December&#160;31, 2020 the total number of shares of common stock issued and outstanding was <ix:nonFraction unitRef="shares" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkxOA_08c852b2-14e1-4c2d-beb8-69e6bb176c71"><ix:nonFraction unitRef="shares" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkxOA_6802d460-30fa-4b94-b816-d5d7e734a389">42,326,033</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkyNA_a10b0cfa-c272-46fa-ab7b-2c6dc652a644"><ix:nonFraction unitRef="shares" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkyNA_e8d2f445-9b50-4275-a318-a5dddde08dbe">42,196,296</ix:nonFraction></ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the Company also has pre-funded warrants outstanding to purchase an aggregate of  <ix:nonFraction unitRef="shares" contextRef="i24f310adc03d4c76a4887bd28c38a5d6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkzMA_3ab6c1c0-c2da-4725-bc65-9bbf30bda21a">12,663,010</ix:nonFraction> shares of common stock. The pre-funded warrants are exercisable at any time, with <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:durday" name="nltx:ClassOfWarrantOrRightNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTg5NQ_7b0e53bb-4366-41e8-b188-45116c011080">61</ix:nonNumeric> days' notice, for an exercise price of <ix:nonFraction unitRef="usdPerShare" contextRef="i24f310adc03d4c76a4887bd28c38a5d6_I20210331" decimals="6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkzNg_8da9cbd2-284e-4098-91eb-ba8528aee0c1">0.000001</ix:nonFraction>, except that the pre-funded warrants cannot be exercised by the stockholders if, after giving effect thereto, the stockholders would beneficially own more than <ix:nonFraction unitRef="number" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="INF" name="nltx:PercentageOfOutstandingStockPerStockholderMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTk0NA_a99ec7f2-c40b-4f47-9636-3196de9fe1a9">9.99</ix:nonFraction>% of the outstanding common stock, subject to certain exceptions. The holders of the pre-funded warrants will not have the right to vote on any matter except to the extent required by Delaware law.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt">Stock-based compensation expense</span></div><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMjU4Mg_2e7c46eb-9e40-42c7-9be6-272de685a024" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is classified in the condensed consolidated statement of operations as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81ac6cce2184282919e6dd0d38cfbd0_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQ2ZTQ3NTFlODRiYzQ3YzM5MTA4NGNmMDA5MGQxY2NiL3RhYmxlcmFuZ2U6NDZlNDc1MWU4NGJjNDdjMzkxMDg0Y2YwMDkwZDFjY2JfMi0xLTEtMS0w_946bc114-0f7e-469d-80e0-5c65dc201ff2">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic47a8fba428642d0b3fb3e9e489dc7e3_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQ2ZTQ3NTFlODRiYzQ3YzM5MTA4NGNmMDA5MGQxY2NiL3RhYmxlcmFuZ2U6NDZlNDc1MWU4NGJjNDdjMzkxMDg0Y2YwMDkwZDFjY2JfMi0zLTEtMS0w_2a0aba38-18b3-45c2-9c89-4f280e6bdebb">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c816066ede34186900132e7d337049c_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQ2ZTQ3NTFlODRiYzQ3YzM5MTA4NGNmMDA5MGQxY2NiL3RhYmxlcmFuZ2U6NDZlNDc1MWU4NGJjNDdjMzkxMDg0Y2YwMDkwZDFjY2JfMy0xLTEtMS0w_145cda5f-f479-4aa6-9021-a81d7c0b4a42">1,402</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c754f9fd824cb2941da29469f252a2_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQ2ZTQ3NTFlODRiYzQ3YzM5MTA4NGNmMDA5MGQxY2NiL3RhYmxlcmFuZ2U6NDZlNDc1MWU4NGJjNDdjMzkxMDg0Y2YwMDkwZDFjY2JfMy0zLTEtMS0w_d1e5ecd7-9e55-4263-90dc-d5d059eb7f81">401</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQ2ZTQ3NTFlODRiYzQ3YzM5MTA4NGNmMDA5MGQxY2NiL3RhYmxlcmFuZ2U6NDZlNDc1MWU4NGJjNDdjMzkxMDg0Y2YwMDkwZDFjY2JfNC0xLTEtMS0w_42a6dac9-5e94-471a-94bb-18e5c6930b0c">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQ2ZTQ3NTFlODRiYzQ3YzM5MTA4NGNmMDA5MGQxY2NiL3RhYmxlcmFuZ2U6NDZlNDc1MWU4NGJjNDdjMzkxMDg0Y2YwMDkwZDFjY2JfNC0zLTEtMS0w_ca591192-762f-473d-a380-f1542c7ea417">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation cost for all stock-based compensation plans was $<ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfODA2_a490fa3c-9b84-477f-820d-a119a44eef81">23.8</ix:nonFraction> million as of March&#160;31, 2021. This cost is expected to be recognized over a weighted average remaining vesting period of <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfOTEw_dd9a9671-cf40-4f29-8ff6-0a6b97002799">3.00</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><ix:continuation id="i981fca18fc494532ad08c419318cacb4" continuedAt="ia9b74e310acf494fa6a1cf3029cfb7f3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMjU3OA_fb781708-528b-4872-9343-4768a57b045e" continuedAt="i0b62a7793a6c49b1b53751ca25717fc3" escape="true">The fair values of stock options granted are estimated using the Black-Scholes option pricing model with the following weighted average assumptions:</ix:nonNumeric></span></div><div><ix:continuation id="i0b62a7793a6c49b1b53751ca25717fc3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfMi0xLTEtMS0w_fb2b45fe-2ae3-43b1-8256-b1c709d363fd">89.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfMi0zLTEtMS0w_e1f33154-e713-45fb-b48a-ec10ff00fc51">90.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfMy0xLTEtMS0w_46bc34b8-7e64-43a1-8951-e48add53a17a">0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfMy0zLTEtMS0w_39e24204-49e3-4b75-a9c4-d9934109bbb9">0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected terms (years)</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfNC0xLTEtMS0w_1e20de3c-0775-4172-8e5e-5dee8be41716">6.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfNC0zLTEtMS0w_e3904d87-df12-4afe-b598-f4c5a937d6bb">6.05</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfNS0xLTEtMS0w_21f3c167-874c-4f3b-a121-9fb8bb68e854">0.61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfNS0zLTEtMS0w_89aef8b0-35a7-43bc-a3cc-493346626883">0.78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt">Stock options</span></div><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMjU3OQ_fca4a007-0a30-418c-9e8b-955c5018e636" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity and related information for the three months ended March 31, 2021 is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life<br/>&#160;(in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value <br/>(in Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMS0xLTEtMS0w_1b07595f-b18c-4f42-ad69-3804e2300876">6,846,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMS0zLTEtMS0w_dea0e78a-3998-4538-9132-092fea08aeb0">6.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i178f16263cfa423ea5c90d8ffe50b7f9_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMS01LTEtMS0w_22bc58fe-1973-4c5e-9d20-522ad284dab7">8.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119066f786864fd79f80c0f67e219cee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMS03LTEtMS0w_43429dbf-3772-48a9-856e-da184fd6d945">53,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMi0xLTEtMS0w_bf4635a1-1f4e-4de7-8f5a-9fbc6220b6dc">140,800</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMi0zLTEtMS0w_d56b650b-a372-4d4d-aee5-6ab8fbb1776c">12.83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMy0xLTEtMS0w_fa0e5f60-de4b-429f-bbe4-c3a5d7d67a46">91,737</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMy0zLTEtMS0w_ffcf4edc-61a7-4a6f-9d12-a039c6d16916">3.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled/forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNC0xLTEtMS0w_7e447441-78b7-4e07-b7a4-74b89fbefea3">3,774</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNC0zLTEtMS0w_c9aae6f1-370d-4f2e-a710-4755dc758cd8">16.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNS0xLTEtMS0w_a2a32b46-8140-422c-b473-57ac9437b69f">6,891,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNS0zLTEtMS0w_035c5a21-4900-441d-8fa2-7d2bdedb91cd">6.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNS01LTEtMS0w_b822ae79-1b1d-4b95-8857-f3e95a3d890d">8.51</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNS03LTEtMS0w_8911f23f-d550-4648-b214-5e6b43d94f8b">40,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2021</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNi0xLTEtMS0w_60ccd56e-6291-4e0e-9986-41957c0506da">2,205,214</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNi0zLTEtMS0w_b8fd9b0d-4fc1-4abf-8f00-0c567c2ce63b">5.04</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNi01LTEtMS0w_77a4e97f-5df5-4866-9010-54d4f9898b1f">7.68</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNi03LTEtMS0w_82f6ec4e-9a9b-4712-a05c-1fb403bb53d4">16,908</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4ODY0NQ_fa0e5f60-de4b-429f-bbe4-c3a5d7d67a46">91,737</ix:nonFraction> shares of common stock were issued upon exercise of options with an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4ODU1NQ_698c281e-6c5d-4b85-bce3-9ea383f423d8">1.0</ix:nonFraction> million. During the three months ended March&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4ODY1NQ_a070ff5c-74f0-43a3-8d41-fd2dd2085ea7">376,311</ix:nonFraction> shares of common stock were issued upon exercise of options with an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4ODYzOQ_c17c2654-87b5-4570-9124-df8f829bf6d1">1.3</ix:nonFraction> million. The weighted-average grant date fair value of options granted during the three months ended March&#160;31, 2021 and March&#160;31, 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4ODcyMA_d98b4108-9d75-485d-a7cd-1aa6a6286846">9.43</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4ODcyOA_28d3612a-a0c1-4005-9371-483c70d7eb3c">5.62</ix:nonFraction> per share, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt">Restricted stock units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMjU4MA_39e683d6-ca59-4d2a-9173-d3dbab906ce0" continuedAt="i4f26f4c1534845eb897826274770067a" escape="true">A summary of the Company&#8217;s restricted stock unit activity and related information for the three months ended March 31, 2021 is as follows:</ix:nonNumeric></span></div><div><ix:continuation id="i4f26f4c1534845eb897826274770067a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69e04e99cd904341a315c6717663230d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfMS0xLTEtMS0w_11cec3cc-9fda-4b53-99c0-2ff67d1a2fab">186,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i69e04e99cd904341a315c6717663230d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfMS0zLTEtMS0w_e7235523-160e-4efb-9844-d9dda0d0a3f5">8.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfMi0xLTEtMS0w_46d19543-1455-4546-86ed-04dae4c9ee00">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfMi0zLTEtMS0w_9ef5f863-a963-4b01-807d-de62ff47e085">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfMy0xLTEtMS0w_e743326b-76b3-44d5-a89f-4aa8b5fa1bf6">38,000</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfMy0zLTEtMS0w_b0205a34-8449-4343-b938-992c2f8d37a1">5.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfNC0xLTEtMS0w_326952b0-4978-4500-b1d2-19688f76f1eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfNC0zLTEtMS0w_7e1354a6-9ffc-45da-b501-fd0fb6bb6d36">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at March 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7b28ced8c3b4718806223d24c59e395_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfNS0xLTEtMS0w_ac5a57ba-7c16-46d5-b3df-b05e37377b89">148,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7b28ced8c3b4718806223d24c59e395_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfNS0zLTEtMS0w_9dba81d6-8d0a-47de-9ea7-94be31584fa7">8.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><ix:continuation id="ia9b74e310acf494fa6a1cf3029cfb7f3" continuedAt="i5b17237918914dfb8b3d73b58528797f"><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt">Employee stock purchase plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;) was adopted by the Company&#8217;s Board of Directors in March 2020 and approved by the Company&#8217;s stockholders in May 2020. A total of <ix:nonFraction unitRef="shares" contextRef="ifa60425c3f5c4d85b3d489026b24a8a3_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMTg5NA_0201d7df-3f0a-4942-96a0-eec00e7b9f59">759,936</ix:nonFraction> shares of common stock have been reserved for issuance under the 2020 ESPP.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5b17237918914dfb8b3d73b58528797f">Subject to share and dollar limits as described in the plan, the 2020 ESPP allows eligible employees to contribute, through payroll deductions, up to <ix:nonFraction unitRef="number" contextRef="i6fa730f0e05d4b36bba4fddc150cf94d_I20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMTY0OTI2NzQ0NzE4Mg_c94772f9-4597-4980-806c-91095e1528f6">15</ix:nonFraction>% of their earnings for the purchase of shares of the Company&#8217;s common stock at the lower of <ix:nonFraction unitRef="number" contextRef="ia5d5cc27aae8459ea2268fcc0dd30291_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMTY0OTI2NzQ0NzE4Nw_cacab82e-3dad-45e4-a8c8-18f7253bbca7">85</ix:nonFraction>% of the closing price of the Company&#8217;s common stock on the first trading day of the offering period or <ix:nonFraction unitRef="number" contextRef="ia5d5cc27aae8459ea2268fcc0dd30291_D20210101-20210331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMTY0OTI2NzQ0NzE5Mg_c5419a23-9e33-4b81-baf3-96fd9493a27e">85</ix:nonFraction>% of the closing price of the Company&#8217;s common stock on the last trading day of the offering period. There are <ix:nonFraction unitRef="offering" contextRef="ia5d5cc27aae8459ea2268fcc0dd30291_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="nltx:EmployeeStockPurchasePlanNumberOfOfferingPerYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMjQzNw_6edcecca-1cb3-48be-b0dd-30b572532afd">two</ix:nonFraction> <ix:nonNumeric contextRef="ia5d5cc27aae8459ea2268fcc0dd30291_D20210101-20210331" format="ixt-sec:durwordsen" name="nltx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMTY0OTI2NzQ0NzE4MA_f927265d-dd36-40cd-86dd-68bcf74d6d44">six-month</ix:nonNumeric> offering periods during each fiscal year, ending on May 15 and November 15.</ix:continuation>&#160;&#160;</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RleHRyZWdpb246NTIwMGRiNzQ2ZmJkNGQxZDkwZDAwOTY4NDQ2MTNiN2RfMjAy_4145f1ef-5a75-4251-a7c1-61438b9ee839" continuedAt="i28bb6dcff4064afbbc05047d595753a5" escape="true">Earnings (loss) per share</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i28bb6dcff4064afbbc05047d595753a5" continuedAt="ibfde171eecb14dfdb6deefcb533817c2"><ix:nonNumeric contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RleHRyZWdpb246NTIwMGRiNzQ2ZmJkNGQxZDkwZDAwOTY4NDQ2MTNiN2RfMjAx_719f941f-84e6-4c57-a717-8e12242a3b5f" continuedAt="id1bdb96ad45e4a7296a7a491989e2ec6" escape="true">The Company excluded the following potentially dilutive shares from diluted net loss per share as the effect would have been anti-dilutive for all periods presented:</ix:nonNumeric></ix:continuation></span></div><div style="margin-top:6pt"><ix:continuation id="ibfde171eecb14dfdb6deefcb533817c2"><ix:continuation id="id1bdb96ad45e4a7296a7a491989e2ec6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabf13b01541848a4a4d24235b9abaf91_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfMi0xLTEtMS0w_168bdb5e-de31-4325-ba1e-4687ad6ba193">6,891,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i113d3b53a82f4678a7755be62a27ead5_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfMi0zLTEtMS0w_3666a20e-a6e3-4cb3-8905-bedb3afcf2d2">5,344,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59886d9904cc4c3ab0992b2f6912e53b_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfMy0xLTEtMS0w_30d52489-ef19-44e6-8731-efe82d4633c6">148,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id43f9e75cf9e406b9efb82314fd3ead5_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfMy0zLTEtMS0w_739597f4-9bbf-4fe9-83c1-eb8ff277093f">134,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable under 2020 ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5fbcd4fa4d7841719a7590a1e6e12f2f_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfNS0xLTEtMS0w_282518ab-e507-4f49-a232-ad2962f8d693">22,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8565cb16e67b45f5a5e7d8807f927fe7_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfNS0zLTEtMS0w_39df8943-ba40-40c3-a52e-a7919487e6e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfNi0xLTEtMS0w_af5d3b25-bdde-42c9-9cfc-90aca3666884">7,062,599</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfNi0zLTEtMS0w_60dd108c-505a-4fe0-a333-f573f84105e9">5,478,927</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_76"></div><div style="margin-top:9pt"><span><br/></span></div><div id="ice342ca3b91243dbba4e0415051faf5e_79"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div id="ice342ca3b91243dbba4e0415051faf5e_46"></div><div style="margin-top:6pt"><span><br/></span></div><div id="ice342ca3b91243dbba4e0415051faf5e_67"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of&#160;Financial Condition and Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with the unaudited interim condensed consolidated financial statements and notes thereto included elsewhere in this report and our audited consolidated financial statements and notes included as part of our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical facts are &#8220;forward-looking statements&#8221; for purposes of these provisions, including those relating to future events or our future financial performance and financial guidance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;intend&#8221; or &#8220;continue,&#8221; the negative of terms like these or other comparable terminology, and other words or terms of similar meaning in connection with any discussion of future operating or financial performance. These statements are only predictions. All forward-looking statements included in this document are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Any or all of our forward-looking statements in this document may turn out to be wrong. Actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors, including, among other things, impacts on our business due to health pandemics or other contagious outbreaks, such as the current COVID-19 pandemic. In evaluating these statements, you should specifically consider various factors, including the risks outlined under the caption &#8220;Risk Factors&#8221; set forth in Item 1A of Part II of this quarterly report on Form 10-Q, as well as those contained from time to time in our other filings with the SEC. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation, and autoimmunity using </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein design technology. We use sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Existing protein engineering treatments generally involve the modification of native proteins. With our proprietary platform we design completely new protein structures from the ground up, capable of demonstrating specific biological properties. Through this method we are able to produce proteins that, while resembling native proteins, may have novel molecular interfaces, differential activation of specific cell types, increased stability, or improved biodistribution compared to native proteins in order to deliver greater therapeutic benefit. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins have the capacity to be cytokine receptor agonists, antagonists, or result in conditional activation of specific cytokine receptors such that they may regulate inflammation or the immune response to cancer. We are initially focused on key cytokine mimetics, which we refer to as Neoleukin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cytokine mimetics. Neoleukin d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e novo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cytokine mimetics can be modified to adjust affinity, thermodynamic stability, resistance to biochemical modification, pharmacokinetic characteristics, and targeting to tumor or inflamed tissues.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, Neoleukin Therapeutics, Inc. ("Former Neoleukin"), completed its merger with Aquinox, in accordance with the terms of the Agreement and Plan of Merger dated August 5, 2019  ("Merger Agreement"), by and among Aquinox, Former Neoleukin and Apollo Sub, Inc., a wholly-owned subsidiary of Aquinox. Pursuant to the Merger Agreement, Apollo Sub, Inc. merged with and into Former Neoleukin, with Former Neoleukin surviving the merger as a wholly-owned subsidiary of Aquinox (the "Merger"). Upon completion of the Merger, Aquinox was renamed Neoleukin Therapeutics, Inc. and Former Neoleukin was renamed Neoleukin Corporation. On July 31, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, we sold all issued and outstanding capital stock of our Canadian subsidiary, Aquinox Pharmaceuticals (Canada) Inc. to an unrelated third party. On December 31, 2020, Neoleukin Corporation was merged into Neoleukin Therapeutics, Inc.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NL-201</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, NL-201, is an IL-2/IL-15 immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while maintaining high-affinity binding to the beta and gamma subunits. In multiple preclinical animal models, a precursor to NL-201 demonstrated substantial anti-tumor activity without detectable binding to CD25, as compared to native IL-2. Following these preclinical studies, we further refined our precursor to extend its half-life, resulting in our NL-201 product candidate. We have since completed multi-dose, non-GLP and GLP toxicology studies of NL-201 in rats and non-human primates. This included completion of GLP in-life dosing with no unexpected toxicities observed. NL-201 is intended to be used as either a single-agent or in combination with complementary therapeutic modalities, including checkpoint inhibitors. In addition, we believe NL-201 holds promise in combination with allogenic cell therapy to expand and maintain populations of transplanted CAR-T and natural killer ("NK") cells.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IL-2 is one of the few immuno-oncology drugs proven to work as a single agent. IL-2 has a demonstrated mechanism of action for treating tumors; however, it has encountered issues as a therapeutic due to the biased activation of cells that contain CD25. CD25 induces conformational changes in IL-2 that enable high-affinity binding to the beta and gamma subunits of the IL-2 receptor. Preferential binding to endothelial cells expressing CD25 is believed to exacerbate vascular leak syndrome, while preferential activation of CD25-expressing regulatory T cells can inhibit anti-cancer immune responses. Due to IL-2&#8217;s potential for high toxicity, with vascular leak syndrome and cytokine storm being frequent side effects, and reduced efficacy over time, its use as a therapeutic has been limited. Further, low-dose treatments have generally been insufficient to demonstrate activity.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the problem posed by IL-2 is well understood, it has been difficult to modify native IL-2 to retain potent activation of IL-2 receptor signaling while eliminating binding to CD25. Instead of modifying native IL-2, computational methods were used to design a new sequence with the proper intermolecular interactions to efficiently bind the beta and gamma subunits while eliminating CD25 binding. As opposed to traditional recombinant human, or humanized, protein therapeutics, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proteins are entirely novel sequences with limited homology to native proteins. While there is a potential that patients may mount an anti-drug immune response against NL-201, we believe that this risk may be mitigated by several factors, including the stability of the protein and its resistance to proteolytic degradation.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submitted our Investigational New Drug Application ("IND") to begin a Phase 1 clinical trial for NL-201 in December 2020. On January 7, 2021, we received a clinical hold letter from the U.S. Food and Drug Administration ("FDA") related to the IND in which the FDA informed us that we needed to develop a new assay that more precisely measures the amount of protein being administered and demonstrate with this assay that dose and administration procedures will accurately deliver the intended dose of NL-201. The FDA also had additional requests not related to the clinical hold to be addressed by amendment of the IND. On April 23, 2021, the FDA removed the clinical hold.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021 we announced dosing the first patient in a Phase 1 clinical trial of NL-201 for advanced solid tumors. The Phase 1 study is planned to enroll up to 120 patients with advanced, relapsed, or refractory solid tumors. Patients will receive monotherapy, intravenous NL-201 and may continue treatment until disease progression. The trial will assess safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. When the recommended dose and schedule are determined, we expect to enroll indication-specific expansion cohorts of patients with renal cell carcinoma and melanoma.  The trial will be conducted at multiple sites in North America and Australia. The first patient was dosed in Australia. </span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research Programs</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond our initial focus on NL-201, our research team is working on further applying </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protein design principles to develop therapeutics to address significant unmet medical needs in other areas, including immuno-oncology, inflammation, and autoimmunity. Our research is powered by the Neoleukin platform, our computational </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">framework for developing highly selective, hyper-stable</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins. Beyond NL-201, we are developing targeted and conditionally active IL-2/IL-15 mimetics, as well as cytokine mimetic programs for other oncology targets. Our research team is also actively applying the Neoleukin platform to generate </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> receptor agonist and antagonist candidates against multiple targets of interest for inflammatory and autoimmune indications. As we validate additional candidates, they will enter our preclinical pipeline.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the COVID-19 public health emergency, we have been investigating the application of our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein technology to prevent or treat SARS-CoV-2 infection. In November 2020, we announced the publication of our scientific work in the journal Science detailing the creation of CTC-445.2d, ("NL-CVX1"), a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein decoy that is specifically designed to block infection of SARS-CoV-2, the virus causing the ongoing COVID-19 pandemic. Our findings demonstrated that NL-CVX1 blocks infection of human cells in vitro, even when a high viral burden is used. Furthermore, intranasal administration of NL-CVX1 protected Syrian hamsters from a lethal dose of SARS-CoV-2. We are evaluating a potential first-in-human trial of NL-CVX1, and will continue to assess the program as the SARS-CoV-2 landscape evolves.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finances</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to secure adequate additional funding, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in&#8209;licenses or acquisitions.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon our current operating plan, we believe our cash-on-hand will be sufficient to fund operations into 2023.</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_94"></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has spread across the globe and continues to impact worldwide economic activity. During this unprecedented time, protecting the health and well-being of our employees and community is a top priority. In addition, we are focused on maintaining continuity of our research, development and business activities while balancing potential impacts from the COVID-19 pandemic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we transitioned to a work from home policy for our employees and discontinued all work-related travel. In the first quarter of 2021, some employees returned to working in person at Neoleukin facilities in accordance with guidance from Washington State and the U.S. Centers for Disease Control and Prevention ("CDC").  Business-critical research and&#160;development work has continued throughout the pandemic, adhering to employee safety guidelines. We continually assess our work policies and monitor guidance from the state and the CDC in order to determine any changes to current work practices.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ice342ca3b91243dbba4e0415051faf5e_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating loss for the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,707&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,498&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,209&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,948&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,071&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred under arrangements with third parties, such as contract research organizations ("CROs"), manufacturing organizations, and consultants, personnel related costs (including stock-based compensation and travel expenses), facility-related costs, and lab supplies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months March&#160;31, 2021, research and development expenses were $9.7 million, compared to $5.5 million for the three months ended March&#160;31, 2020. The increase in research and development expenses during the three months ended March&#160;31, 2021 was primarily due to increased expenses incurred from IND-enabling and clinical trial startup activities related to our lead product candidate, NL-201, and in connection with the advancement of other Neoleukin technologies. The increase is also due to facility-related costs associated with the build-out of our new headquarters and laboratory in Seattle, Washington. </span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel related costs (stock-based compensation and travel expenses), facility-related costs, insurance, and professional fees for consulting, legal and accounting services.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021, general and administrative expenses were $5.2 million, compared to $3.6 million for the three months ended March&#160;31, 2020.&#160;&#160;The increase in general and administrative expenses during the three months ended March&#160;31, 2021 was primarily due to increases in personnel-related costs and professional service fees as we continue to grow our operations, along with facility related costs associated with the build-out of our new headquarters in Seattle, Washington. </span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (loss), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (loss), net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest income during the three months ended March&#160;31, 2021 as compared to the three months ended March&#160;31, 2020 of $0.4 million is due primarily to a decrease in interest rates. </span></div><div id="ice342ca3b91243dbba4e0415051faf5e_100"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred net losses and negative cash flows from our operations. Our operating activities used $13.4 million and $6.4 million of cash flows during the three months ended March&#160;31, 2021 and 2020, respectively. As of March&#160;31, 2021, we had an accumulated deficit of $347.8 million, working capital of $172.9 million, and cash and cash equivalents of $178.4 million. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the three months ended March&#160;31, 2021 and 2020:&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,358)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,440)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,390&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,165)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,168)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in operating activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March 31, 2021 increased compared to the three months ended March 31, 2020 due to an increase in operating expenses resulting primarily from expenses incurred in developing our lead product candidate, NL-201, and in connection with the advancement of other Neoleukin technologies. The increase is also due to facility related costs associated with the build-out of our new headquarters in Seattle, Washington.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, cash used in investing activities consisted primarily of acquiring laboratory equipment and office furnishings. </span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by financing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, net cash provided by financing activities was primarily the result of proceeds from stock option exercises.</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_103"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating and Capital Expenditure Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated product revenue or achieved profitability since our inception and we expect to continue to incur net losses for the foreseeable future.&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$178.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Based on our current business plans, we believe that our existing cash and cash equivalents will be sufficient to fund our planned operations into 2023.&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, our future capital requirements and the period for which we expect our existing resources to support our operations, fund expansion, develop new or enhanced products, or otherwise respond to competitive pressures, may vary significantly from our expectation and we may need to seek additional funds sooner than planned.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless and until we generate sufficient revenue to be profitable, we will seek to fund our operations through public or private equity or debt financings or other sources. If we raise additional funds through the issuance of convertible debt securities, these securities could have rights senior to those of our common stock and could contain covenants that restrict our operations. There can be no assurance that we will be able to obtain additional equity or debt financing on terms acceptable to us, if at all. Our failure to obtain sufficient funds on acceptable terms when needed could have a negative impact on our business, results of operations, financial condition, cash flows and future prospects. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and characteristics of any future product candidates we develop or may acquire;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope, progress, results and costs of researching and developing our product candidates or any future product candidates, and conducting preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of, and the costs involved in, obtaining regulatory approvals for any future product candidates;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of manufacturing our future product candidates and any products that may achieve regulatory approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of commercialization activities if any future product candidates are approved for sale, including marketing, sales and distribution costs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing, receipt and amount of sales of, or royalties on, future approved products, if any;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any product liability or other lawsuits related to our products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential delays in our preclinical studies, our development programs and our planned clinical trials due to the effects of the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the expenses needed to attract and retain skilled personnel; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation.      </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Item 1A of Part II of this Quarterly Report titled &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements.</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_106"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future minimum contractual commitments were reported in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC. As a result of the lease amendment executed in March 2021, as discussed in Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Notes to the Condensed Consolidated Financial Statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q, future operating lease payments through 2026 have increased by $1.9 million. </span></div><div id="ice342ca3b91243dbba4e0415051faf5e_109"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. A summary of our significant accounting policies is presented in Part II, Item 8 of our Annual Report on Form 10-K for the year ended December&#160;31, 2020. There have been no material changes to our significant accounting policies during the three months ended March&#160;31, 2021.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2(g),&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently issued and recently adopted accounting standards</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form&#160;10-Q.</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_112"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements.</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_115"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a &#8220;smaller reporting company,&#8221; as defined by Rule 12b-2 of the Exchange Act, and pursuant to Item 305 of Regulation S-K, we are not required to provide quantitative and qualitative disclosures about market risk.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ice342ca3b91243dbba4e0415051faf5e_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of disclosure controls and procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;Under the supervision and with the participation of our principal executive officer and principal financial officer, our management conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on management&#8217;s evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are designed to, and are effective to, provide assurance at a reasonable level that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in internal control over financial reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;Our management, including our Chief Executive Officer and Chief Financial Officer, evaluated any changes in our internal control over financial reporting during the period ended March 31, 2021, and has concluded that there were no changes that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ice342ca3b91243dbba4e0415051faf5e_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other&#160;Information</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_124"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time be named as a party to legal claims, actions and complaints, including matters involving employment, intellectual property or others. We are not presently a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div style="margin-top:9pt"><span><br/></span></div><div><span><br/></span></div><div id="ice342ca3b91243dbba4e0415051faf5e_127"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in our common stock involves various risks, and prospective investors are urged to carefully consider the matters discussed in the section titled &#8220;Risk Factors&#8221; prior to making an investment in our common stock. These risks include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We will require substantial additional capital to finance our operations which may not be available to us on acceptable terms, or at all. If we fail to obtain necessary financing, we may be unable to complete the development and potential commercialization of our product candidates.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We have incurred significant losses in every quarter since our inception and anticipate that we will continue to incur significant losses in the future.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We have a limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We currently have no source of product revenue and may never become profitable.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our product candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we are unable to complete development of, or commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our business is heavily dependent on the success of our Neoleukin platform and of our most advanced product candidate, NL-201. Existing and future preclinical studies and clinical trials of our product candidates may not be successful, and if we are unable to commercialize these product candidates or experience significant delays in doing so, our business will be materially harmed.  </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our clinical trials or those of any future collaborators may reveal significant adverse events not seen in our preclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our approach to the discovery and development of our therapeutic treatments is based on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protein design technology which is unproven and may not result in marketable products.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We rely on and expect to continue to rely on third parties to conduct certain of our preclinical studies and clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines or terminate the relationship, our development program could be delayed with potentially material and adverse effects on our business, financial condition, results of operations, and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We rely on and expect to continue to rely on third-party manufacturers and suppliers to supply components of our product candidates. The loss of our third-party manufacturers or suppliers, or our or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The outbreak of the novel strain of coronavirus, SARS-CoV-2, which causes COVID-19, could adversely impact our business, including our preclinical development activities and clinical trial activities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If we are not able to obtain, maintain, and enforce patent protection for our product candidates, our Neoleukin platform technology, or other proprietary technologies we may develop, development and commercialization of our product candidates may be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the following risk factors, in addition to the other information contained in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and related notes. If any of the events described in the following risk factors occurs, our business, operating results and financial condition could be adversely affected. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Capital Needs</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional capital to finance our operations which may not be available to us on acceptable terms, or at all. If we fail to obtain necessary financing, we may be unable to complete the development and potential commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of biopharmaceutical product candidates is capital-intensive. If our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand or create our development, regulatory, manufacturing, marketing, and sales capabilities. We have used substantial funds to develop our technology and product candidates and will require significant funds to conduct further research and development and preclinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates and to manufacture and market products, if any, which are approved for commercial sale. In addition, we expect to continue incurring costs associated with operating as a public company.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies and clinical trials for our product candidates will require substantial funds to complete. As of March&#160;31, 2021, we had approximately $178.4 million in cash and cash equivalents. We expect to incur substantial expenditures in the foreseeable future as we seek to advance&#160;NL-201&#160;and any future product candidates through preclinical and clinical development, the regulatory approval process and, if approved, commercial launch activities. Based on our current operating plan, we believe that our available cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into 2023. However, our future capital requirements and the period for which we expect our existing resources to support our operations, fund expansion, develop new or enhanced products, or otherwise respond to competitive pressures, may vary significantly from what we expect and we may need to seek additional funds sooner than planned. Our monthly spending levels vary based on new and ongoing research and development and other corporate activities. Because the length of time and activities associated with successful research and development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any marketing and commercialization activities for approved products. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing, cost and progress of preclinical and clinical development activities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and scope of preclinical and clinical programs we decide to pursue;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress of the development efforts of parties with whom we have entered or may in the future enter into collaborations and/or research and development agreements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and amount of milestone and other payments we may receive or make under our collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain our current licenses and to establish new collaboration arrangements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs involved in prosecuting and enforcing patent and other intellectual property claims;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of manufacturing our product candidates by third parties;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of regulatory submissions and timing of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential delays in our preclinical studies, our development programs and our clinical trial activities due to the effects of the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of commercialization activities if our product candidates or any future product candidates are approved for sale, including marketing, sales and distribution costs; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We do not expect to realize revenue from sales of commercial products or royalties from licensed products in the foreseeable future, if at all, and, in no event, before our product candidates are clinically tested, approved for commercialization and successfully marketed.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to seek additional funding in the future and currently intend to do so through additional collaborations and/or licensing agreements, public or private equity offerings or debt financings, credit or loan facilities, or a combination of one or more of these funding sources. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Our future debt financings, if available, are likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets. If we raise additional funds through licensing or collaboration arrangements with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. We also could be required to seek collaborators for product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. Failure to obtain capital when needed on acceptable terms may force us to delay, limit or terminate our product development and commercialization of our current or future product candidates, which could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses in every quarter since our inception and anticipate that we will continue to incur significant losses in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company with a limited operating history. Investment in biotechnology is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval or become commercially viable. We do not have any products approved by regulatory authorities for marketing or commercial sale, we have not generated any revenue from product sales to date, and all of our product candidates are in early clinical or preclinical development. We continue to incur significant expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses in every reporting period since our inception in 2003. For the three-months ended March&#160;31, 2021 and March&#160;31, 2020, we reported net losses of $14.9 million and $8.6 million, respectively.&#160;For the years ended December 31, 2020 and 2019, we reported net losses of $33.3 million and $69.4 million, respectively. As of March&#160;31, 2021, we had an accumulated deficit since inception of $347.8 million.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and operating losses for the foreseeable future as we seek to identify, acquire and conduct research and development of future product candidates, and potentially begin to commercialize any future products that may achieve regulatory approval. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our financial condition. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. Our prior losses and expected future losses have had, and will continue to have, an adverse effect on our financial condition. If any of our future product candidates fail in clinical trials or do not gain regulatory approval, or if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations to date have been primarily limited to organizing and staffing our company, acquiring product and technology rights, discovering and developing novel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> de novo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proteins, undertaking preclinical studies and early clinical development activities, and, prior to the merger, developing small molecule drug candidates and conducting clinical trials of rosiptor. We have not yet obtained regulatory approval for any product candidate. Consequently, evaluating our performance, viability or possibility of future success will be more difficult than if we had a longer operating history or approved products on the market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no source of product revenue and may never become profitable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenues from commercial product sales, or otherwise. Our ability to generate revenue from product sales and achieve profitability will depend upon our ability, alone or with any future collaborators, to successfully commercialize any products that we may develop, in-license, or acquire in the future. Even if we can successfully achieve regulatory approval for any future product candidates, we do not know when any of these products will generate revenue from product sales for us, if at all. Our ability to generate revenue from any of our future product candidates also depends on several additional factors, including our or any future collaborators&#8217; ability to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">complete development activities, including the necessary clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">complete and submit Biologics License Applications, or BLAs, to the U.S. Food and Drug Administration, or FDA, and obtain regulatory approval for indications for which there is a commercial market;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">set a commercially viable price for our products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of bulk drug substances and drug products to maintain that supply;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">develop a commercial organization capable of sales, marketing and distribution for any products for which we obtain marketing approval and intend to sell ourselves in the markets in which we choose to commercialize on our own;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">find suitable distribution partners to help us market, sell, and distribute our approved products in other markets;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain coverage and adequate reimbursement from third-party payors, including government and private payors;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">achieve market acceptance for our products, if any;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish, maintain and protect our intellectual property rights; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">attract, hire, and retain qualified personnel.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because of the numerous risks and uncertainties associated with biological product development, any future product candidates may not advance through development or achieve the endpoints of applicable clinical trials. Therefore, we are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability. In addition, our expenses could increase beyond expectations if we decide, or are required by the FDA or foreign regulatory authorities, to perform studies or trials in addition to those that we currently anticipate. Even if we can complete the development and regulatory process for any future product candidates, we anticipate incurring significant costs associated with commercializing these products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we can generate revenues from the sale of any future product candidates that may be approved, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require additional capital to finance our operations which may not be available to us on acceptable terms, or at all. If we fail to obtain necessary financing, we may be unable to complete the development and potential commercialization of future product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. Our operations have consumed substantial amounts of cash since inception. If we identify and advance any current or future product candidates into clinical trials and launch and commercialize any product candidates for which we receive regulatory approval, we expect research and clinical development expenses, and our selling, general and administrative expenses to increase substantially. In connection with our ongoing activities, we believe that our existing cash and cash equivalents will be sufficient to fund our operating requirements for at least the next 12&#160;months. However, circumstances may cause us to consume capital more rapidly than we anticipate. We will likely require additional capital for the further development and potential commercialization of future product candidates and may also need to raise additional funds sooner to pursue a more accelerated development of future product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to secure additional financing, fundraising efforts may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize future product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we do not raise additional capital when required or on acceptable terms, we may need to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significantly delay, scale back or discontinue clinical trials related to the development or commercialization of any of our future product candidates or cease operations altogether;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek strategic alliances for research and development programs at an earlier stage than we would otherwise desire or on terms less favorable than might otherwise be available; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">relinquish, or license on unfavorable terms, our rights to any future product candidates that we otherwise would seek to develop or commercialize ourselves.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to conduct additional fundraising activities and we do not raise additional capital in sufficient amounts or on terms acceptable to us, we may be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#8220;Risk Factors&#8221; section. We have based this estimate on assumptions that may prove to be wrong, and we could spend our available capital resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to identify additional product candidates for development;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if we in-license or acquire product candidates from third parties, the cost of in-licensing or acquisition;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the initiation, progress, timing, costs and results of clinical trials for any future product candidates;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical development plans we establish for any future product candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the achievement of milestones and our obligation to make milestone payments under our present or any future in-licensing agreements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and characteristics of product candidates that we discover, or in-license and develop;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the outcome, timing and cost of regulatory review by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"> the cost to establish, maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending, and enforcing any patent claims and maintaining and enforcing other intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"> the effects of the COVID-19 pandemic on our business and financial results;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"> the effect of competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"> the costs and timing of the implementation of commercial-scale outsourced manufacturing activities; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"> the costs and timing of establishing sales, marketing, distribution, and pharmacovigilance capabilities for any product candidates for which we may receive regulatory approval in territories where we choose to commercialize products on our own.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our business, results of operations, financial condition and cash flows, and future prospects could be materially adversely affected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Discovery, Development and Commercialization</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we are unable to complete development of, or commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are in the early stages of our development efforts. We have no products on the market and all of our product candidates, including&#160;NL-201,&#160;are still in early clinical, preclinical or drug discovery stages, and we may not ever obtain regulatory approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates.  Additionally, we have a portfolio of targets and programs that are in earlier stages of discovery and preclinical development and may never advance to clinical-stage development. If we do not receive regulatory approvals for clinical testing and commercialization of our product candidates, we may not be able to continue our operations.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have the financial resources to continue development of, or to enter into collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">preclinical study results may show the product candidate to be less effective than desired or to have harmful or problematic side effects, which could cause us to delay or even abandon clinical testing;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product-related side effects experienced by patients in our clinical trials or by individuals using drugs or therapeutic biologics similar to our product candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our third-party manufacturers&#8217; inability to successfully manufacture our products or to meet regulatory specifications;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability of any third-party contract manufacturer to scale up manufacturing of our product candidates and those of our collaborators to supply the needs of clinical trials or commercial sales;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in submitting INDs or comparable foreign applications or delays or failures in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">conditions imposed by the FDA, the European Medicines Agency, or EMA, or other applicable regulatory authorities regarding the scope or design of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in enrolling patients in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">high drop-out rates of our clinical trial patients;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to obtain alternative sources of supply for which we have a single source for product candidate components or materials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">greater than anticipated costs of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manufacturing costs, formulation issues, pricing or reimbursement issues or other factors that no longer make a product candidate economically feasible;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">harmful side effects or inability of our product candidates to meet efficacy endpoints during clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure to demonstrate a benefit-risk profile acceptable to the FDA, EMA or other applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unfavorable inspection and review by the FDA, EMA or other applicable regulatory authorities of one or more clinical trial sites or manufacturing facilities used in the testing and manufacture of any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays and changes in regulatory requirements, policy, and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">varying interpretations of our data by the FDA, EMA or other applicable regulatory authorities.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our future partners&#8217; inability to complete development of, or commercialize our product candidates, or significant delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, cancer therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for advanced cancers, i.e. third-line or beyond. When cancer is detected early enough, first-line therapy, usually chemotherapy, surgery, radiation therapy, immunotherapy, hormone therapy, or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. We expect our clinical trials for&#160;NL-201&#160;will be with patients who have received one or more prior treatments. Subsequently, for those of our products that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of therapy. Any product candidates we develop, even if approved, may not be successfully approved for earlier lines of therapy, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, prior to any such approvals, we will likely have to conduct additional clinical trials, which are often very lengthy, expensive, and have a significant risk of failure.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is heavily dependent on the success of our Neoleukin platform and of our most advanced product candidate,&#160;NL-201.&#160;Existing and future preclinical studies and clinical trials of our product candidates may not be successful, and if we are unable to commercialize these product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is heavily dependent on our ability to obtain regulatory approval of and then successfully launch and commercialize our product candidates. We have invested a significant portion of our efforts and financial resources in the development of our proprietary system of advanced computational algorithms and methods for the design of functional&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;proteins, which we refer to as our Neoleukin platform, with an initial focus on key cytokine mimetics, which we refer to as Neoleukin&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;cytokine mimetics. Our lead product candidate,&#160;NL-201,&#160;is a Neoleukin&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;protein derived from our Neoleukin platform. However,&#160;NL-201&#160;and our other product candidates are still in early stages of development. Our ability to generate commercial product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our lead product candidates. Our product candidates may not be successful in clinical trials or receive regulatory approval. Even if they are successful in clinical trials, regulatory authorities may not complete their review in a timely manner, or additional delays may result if an FDA Advisory Committee or other regulatory authority recommends&#160;non-approval&#160;or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials, and the review process. Regulatory authorities may approve a product candidate for targets, disease indications or patient populations that are not as broad as we intended or desired, approve more limited indications than requested, or require distribution restrictions or strong safety language, such as contraindications or boxed warnings. Regulatory authorities may also require Risk Evaluation and Mitigation Strategies, or REMS, or the performance of costly post-marketing clinical trials. Even if we successfully obtain regulatory approvals to market our product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries. In order to market and sell our product candidates in the European Union and many other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. The approval procedure varies among countries and can involve additional testing. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may be required to expend significant resources to obtain regulatory approval, which may not be on a timely basis or successful at all, and to comply with ongoing regulations in these jurisdictions.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our Neoleukin platform,&#160;NL-201,&#160;and our other product candidates will depend on many factors, including the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successful completion of necessary preclinical studies to enable the initiation of clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successful enrollment of patients in, and the completion of, our clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining adequate financing to perform the expensive clinical development programs anticipated for approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">receiving required regulatory authorizations for the development and approvals for the commercialization of our product candidates;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establishing and maintaining arrangements with third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and their components;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">enforcing and defending our intellectual property rights and claims;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">achieving desirable therapeutic properties for our product candidates&#8217; intended indications;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with third parties;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">effectively competing with other therapies, including those that are currently in development; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining an acceptable safety profile of our product candidates through clinical trials and following regulatory approval.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve any one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current or future clinical trials or those of any future collaborators may reveal significant adverse events not seen in our preclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If significant adverse events or other side effects are observed in any of our clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, we may be required to pause, delay, or abandon the trials or our development efforts of one or more product candidates altogether, we may be required to have more restrictive labeling, or we may experience the delay or denial of regulatory approval by the FDA, EMA or other applicable regulatory authorities. We, the FDA, EMA or other applicable regulatory authorities, or an Institutional Review Board, or IRB, may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. We designed NL-201 to mimic the therapeutic activity of the cytokine interleukin-2, or IL-2, and interleukin-15, or IL-15, while limiting the toxicity cause by the preferential binding of native IL-2 and native IL-15 to cells that co-express the alpha subunit known as CD25. However, it is possible NL-201 will demonstrate significant adverse events similar to, or in addition to, those associated with IL-2 and IL-15, such as vascular leak syndrome, hypotension, impaired kidney and liver function, and mental status changes. Therapies involving cytokines have been known to cause side effects such as neurotoxicity and cytokine release syndrome.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins are a new class of therapeutics that have not been previously tested in humans. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins can be substantially different from all known proteins and as a result, it is unknown to what extent, if any, these</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins will produce immunologic reactions in patients. Immunologic reactions could substantially limit the effectiveness of the treatment, the duration of treatment, or represent safety risks.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if any of our product candidates receives marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits of the product outweigh its risks, which may include, among other things, a Medication Guide outlining the risks of the product for distribution to patients and a communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by any of our products, several potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may suspend or withdraw approvals of such product;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may require additional warnings on the label of such product;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to change the way such a product is administered or conduct additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reputation may suffer.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our products may be&#160;delayed and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the commercialization of our products may be delayed or never achieved and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of our therapeutic treatments is based on novel de novo protein design technology that are unproven and may not result in marketable products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends primarily upon our ability to discover, develop, and commercialize a pipeline of product candidates using our Neoleukin platform. Unlike traditional protein-based therapeutics that modify native proteins, our Neoleukin platform designs new proteins from the ground up. Our platform uses advanced computational algorithms and methods to design functional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins that are hyper-stable, modifiable, and are designed to optimize desired intermolecular interactions and eliminate undesirable interactions. While we believe this approach will enable us to develop product candidates that may offer unique therapeutic benefits, the scientific basis of our efforts to develop product candidates using our Neoleukin platform is ongoing and may not result in viable product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have had favorable preclinical study results related to NL-201,&#160;we are still in the early stages of product development of NL-201. Our approach may be unsuccessful in moving&#160;NL-201&#160;through clinical development, discovering additional product candidates, and NL-201 or any product candidates that we are currently developing may be shown to have harmful side effects or may have other characteristics that may necessitate additional clinical testing or make the product candidates unmarketable or unlikely to receive marketing approval. If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, NL-201 is our only product candidate currently being tested in a clinical trial, and testing is in the early stages. We have not tested any of our other product candidates&#160;in any clinical trials.  We may ultimately discover that our Neoleukin platform and any product candidates resulting therefrom do not possess certain properties required for therapeutic effectiveness. Our product candidates may also be unable to remain stable in the human body for the period of time required for the drug to reach the target tissue, or they may trigger immune responses that inhibit the activity of the product candidate or that cause adverse side effects in humans. We may spend substantial funds attempting to mitigate these properties and may never succeed in doing so. In addition, product candidates based on our Neoleukin platform may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies.&#160;Our Neoleukin platform and any product candidates resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective, or harmful ways.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied product candidates. Because the FDA has no prior experience with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins as therapeutics, we anticipate that this may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates. We or any future partners may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintain regulatory approval. If the products resulting from our Neoleukin platform and research programs prove to be ineffective, unsafe, or commercially unviable, our Neoleukin Platform and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical development involve a lengthy and expensive process, with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in early clinical, preclinical or earlier development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will receive regulatory approval. To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies and lengthy, complex, and expensive clinical trials that our product candidates are safe and effective in humans. Clinical testing can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the success of later-stage clinical trials. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing, and we have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or to unfavorable safety profiles, notwithstanding promising results in earlier trials, and we could face similar setbacks. There is typically a high rate of failure of product candidates proceeding through clinical trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support clinical development of our current or any of our future product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencement of our future clinical trials is subject to finalizing the trial design and receiving approval from the FDA to proceed with clinical testing or similar approval from the EMA or other comparable foreign regulatory authorities. Even after we submit our IND or comparable submissions in other jurisdictions, the FDA, EMA, or comparable foreign regulatory authorities could disagree that we have satisfied their requirements to commence our clinical trials or disagree with our study design, which may require us to complete additional preclinical studies or amend our protocols or impose stricter conditions on the commencement of clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter substantial delays in the commencement or completion, or termination or suspension, of our clinical trials, which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or any collaborators may experience delays in initiating or completing clinical trials or may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize&#160;NL-201&#160;or any future product candidates, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be unable to generate sufficient preclinical, toxicology, or other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> data to obtain regulatory authorizations to commence a clinical trial;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may experience issues in reaching a consensus with regulatory authorities on trial design;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulators or institutional review boards, ethics committees, FDA, EMA or other applicable regulatory authorities, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical trial sites may deviate from trial protocol or drop out of a trial;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may elect to, or regulators, IRBs, or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of clinical trials of any of our product candidates may be greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate to initiate or complete a given clinical trial;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be unable to obtain or manufacture sufficient quantities of our product candidates for use in clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reports from clinical testing of other therapies may raise safety or efficacy concerns about our product candidates; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may fail to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidate as well as data emerging from other molecules in the same class as our product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA, EMA or other regulatory authorities, or&#160;if a clinical trial is recommended for suspension or termination by the Data Safety Monitoring Board, or the DSMB, for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse&#160;side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Clinical studies may also be delayed or terminated as a result of ambiguous or negative interim results. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to&#160;the denial of regulatory approval of our product candidates. Further, the FDA, EMA, or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in clinical testing or obtaining marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition, and results of operations significantly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the number and location of clinical sites we enroll, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the inability to obtain and maintain patient consents, the risk that enrolled participants will drop out before completion, competing clinical trials, and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or therapeutic biologics that may be approved for the indications being investigated by us. Furthermore, we expect to rely on our collaborators, CROs, and clinical trial sites to ensure the proper and timely conduct of our future clinical trials, including the patient enrollment process, and we have limited influence over their performance. Additionally, we could encounter delays if treating physicians encounter unresolved ethical issues associated with enrolling patients in future clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, slow down or halt our product candidate development and approval process and jeopardize our ability to seek and obtain the marketing approval required to commence product sales and generate revenue, which would cause the value of our company to decline and limit our ability to obtain additional financing if needed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, preliminary, and topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish preliminary or topline data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the more complete data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies or clinical trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or topline data we previously published. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available.  As a result, interim, preliminary, and topline data should be viewed with caution until the final data are available. Adverse differences between interim, preliminary or topline data and final data could significantly harm our reputation and business prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain regulatory approval in international jurisdictions would prevent any future product candidates from being marketed outside the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our products in the European Union and other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products in certain countries. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. A failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of any of our future product candidates by regulatory authorities in the European Union or another jurisdiction, the commercial prospects of that product candidate may be significantly diminished and our business prospects could decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of, and commercialization of, our future product candidates and affect the prices we may obtain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern, among other things, marketing approvals, coverage, pricing and reimbursement for new drug products vary from country to country. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our future product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States in recent years, Congress has considered reductions in Medicare reimbursement for drugs administered by physicians. The Centers for Medicare and Medicaid Services, or CMS, the agency that administers the Medicare program, also has the authority to revise reimbursement rates and to implement coverage restrictions for drugs. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of, and reimbursement for, any approved products, which in turn could affect the price we can receive for those products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in establishing their own coverage polices and reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, President Obama signed into law the Affordable Care Act in an effort to, among other things, broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers and impose additional health policy reforms. The Affordable Care Act, among other things, also expanded manufacturers&#8217; rebate liability to include covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations, increased the minimum rebate due for innovator drugs from 15.1% of average manufacturer price, or AMP, to 23.1% of AMP and capped the total rebate amount for innovator drugs at 100% of AMP. The Affordable Care Act and subsequent legislation and regulation also revised the definition of AMP for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices. Furthermore, the Affordable Care Act imposes a significant annual, nondeductible fee on companies that manufacture or import certain branded prescription drug products. Substantial provisions affecting compliance were enacted, which may affect our business practices with healthcare practitioners, and a significant number of provisions are not yet, or have only recently become, effective. Certain provisions of the Affordable Care Act have been subject to judicial and Congressional challenges to repeal or replace certain aspects of the Affordable Care Act. Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act repealed, effective January&#160;1, 2019, the&#160;tax-based&#160;shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. The Affordable Care Act has also been subject to judicial challenge.&#160;In December 2018, a federal district court judge, in a challenge brought by a number of state attorneys general, found the Affordable Care Act unconstitutional in its entirety. Pending appeals, which could take some time, the Affordable Care Act is still operational in all respects.&#160;Congress may consider other legislation to repeal or replace elements of the Affordable Care Act. Because of the continued uncertainty about the implementation of Affordable Care Act, including the potential for&#160;further legal challenges or repeal of Affordable Care Act, we cannot quantify or predict with any </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certainty the likely impact of the Affordable Care Act or its repeal on our business, prospects, financial condition or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August&#160;2, 2011, the President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year that went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2029 unless additional Congressional action is taken. On January&#160;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. Furthermore, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products. For example, there have been several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer&#8217;s patient programs, and reform government program reimbursement methodologies for drug products. We cannot be sure whether additional legislative changes will be enacted, or whether existing regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our future product candidates, if any, may be.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the European Union and other potentially significant markets for our future product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. Furthermore, the increased emphasis on managed healthcare in the United States and on country and regional coverage, pricing and reimbursement controls in the European Union will put additional pressure on product coverage, pricing, reimbursement and utilization, which may adversely affect our business, results of operations, financial condition and cash flows and future prospects. These pressures can arise from various sources, including but not limited to, rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates even if our product candidates obtain marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand our operations outside of the United States, we must comply with numerous laws and regulations in each jurisdiction in which we plan to operate. We must also comply with U.S. laws applicable to the foreign operations of U.S. businesses and individuals, such as the Foreign Corrupt Practices Act, or FCPA. The creation and implementation of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCPA prohibits any U.S. individual or business from paying,&#160;offering, authorizing payment or offering anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the U.S. Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside the United States, or the sharing with certain&#160;non-U.S.&#160;nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expanding presence outside the United States will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize our future product candidates, the products may not receive coverage and adequate reimbursement from third-party payors, which could harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any products successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government authorities, private health insurers, health maintenance organizations and third-party payors. Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from government healthcare programs, such as Medicare and Medicaid, and private health insurers are critical to new product acceptance. Patients are unlikely to use our future product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. As a result, government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors may also seek additional clinical evidence, beyond the data required to obtain marketing approval, demonstrating clinical benefits and value in specific patient populations before covering our products for those patients. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, what that level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign&#160;regulatory </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities. Moreover, obtaining coverage does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sales and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used. Reimbursement rates may also be based in part on existing reimbursement amounts for lower cost drugs or may be bundled into the payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage and reimbursement determination process is often a time-consuming and costly process with no assurance that coverage and adequate reimbursement will be obtained or applied consistently. Third-party payors often rely upon Medicare coverage policy and payment&#160;limitations in setting their own coverage and reimbursement policies. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never marketed a drug before. If we are able to identify and develop or acquire a product candidate that is ultimately approved for sale but are unable to establish an effective sales force and marketing infrastructure or enter into acceptable third-party sales and marketing or licensing arrangements, we may be unable to generate any revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have an infrastructure for the sales, marketing and distribution of pharmaceutical drug products and the cost of establishing and maintaining such an infrastructure may exceed the cost-effectiveness of doing so. In addition,  NL-201 is our only product candidate in clinical development, and such clinical development is in the early stages. If we are able to successfully advance NL-201 through clinical development or to identify and establish other product candidates and advance them through clinical development, in order to market any products that may ultimately be approved by the FDA and comparable foreign regulatory authorities, we must build our sales, marketing, managerial and other&#160;non-technical&#160;capabilities or make arrangements with third parties to perform these services. If we are unable to establish adequate sales, marketing, and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may not become profitable. We will be competing with many companies that have extensive and well-funded sales and marketing operations. Without an internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to use our Neoleukin platform to expand our pipeline of product candidates and develop marketable products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends in part upon our ability to discover, develop, and commercialize products based on our Neoleukin platform, which may fail to identify other potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. If any of these events occur, we may be forced to abandon our development efforts for a program or for multiple programs, which would materially harm our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial, and human resources.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus our research and development efforts on our lead product candidate,&#160;NL-201,&#160;with initial indications including renal cell carcinoma and melanoma. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential. Due to the ongoing COVID-19 public health emergency, we are also utilizing a portion of our research and computational bandwidth to investigate the potential application of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protein technology toward COVID-19. Our resource allocation decisions may cause us to fail to capitalize on viable commercial </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, including companies developing novel treatments and technology platforms in oncology. If these companies develop technologies or&#160;product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of drugs is highly competitive. Our product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do and we may not be able to successfully compete. We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies, and emerging biotechnology companies, as well as with technologies and product candidates being developed at academic institutions, governmental agencies, and other public and private research institutions. Our competitors have developed, are developing, or will develop product candidates and processes competitive with our product candidates and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments, including those based on novel technology platforms that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are trying, or may try, to develop product candidates. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical, and interleukin and immunoregulatory therapeutics fields. Competition from many sources exists or may arise in the future. Our competitors include larger and better funded biopharmaceutical, biotechnological, and therapeutics companies, including companies focused on oncology therapeutics, as well as numerous small companies. Moreover, we also compete with current and future therapeutics developed at universities and other research institutions. Some of these companies are well-capitalized and, in contrast to us, have significant clinical experience, and may include our future partners. In addition, these companies compete with us in recruiting scientific and managerial talent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend partially on our ability to develop and commercialize therapeutics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, or less expensive than the therapeutics we develop.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate,&#160;NL-201,&#160;is under development for the treatment of advanced solid tumors, including melanoma and renal cell carcinoma. If&#160;approved, it would face competition from approved advanced melanoma and renal cell carcinoma treatments, including multiple checkpoint inhibitors, tyrosine kinase inhibitors, VEGF inhibitors, recombinant human&#160;IL-2,&#160;and several chemotherapy drugs or combinations. Further, we are aware of several&#160;IL-2&#160;or&#160;IL-15&#160;agonists in various stages of clinical and preclinical development.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales, and supply resources or experience than we have. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage, and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive, or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect the product candidates we develop will be regulated as biological&#160;products, or biologics, and therefore&#160;they may be subject to competition sooner than anticipated.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009, or the BPCIA, was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar biological products (both highly similar and interchangeable biosimilar biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the first licensure date of the reference product licensed under a BLA. The law is complex and some provisions are still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biological product submitted for licensure under a BLA is eligible for a period of exclusivity that commences on the date of its licensure, unless its date of licensure is not considered a date of first licensure because it falls within an exclusion under the PBCIA. There is a risk that this exclusivity could be shortened due to congressional action or otherwise, potentially creating the opportunity for generic competition sooner than anticipated. Most states have enacted substitution laws that permit substitution of only interchangeable biosimilars.&#160;&#160;The extent to which a highly similar biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for&#160;non-biological&#160;products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on and expect to continue to  rely on third parties to conduct certain of our preclinical studies and  clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines or terminate the relationship, our development program could be delayed with potentially material and adverse effects on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely and intend to continue to rely in the future on third-party clinical investigators, CROs, clinical data management organizations, and consultants to assist or provide the design, conduct, supervision, and monitoring of preclinical studies and clinical trials of our product candidates. Because we rely on and intend to continue to rely on these third parties and will not have the ability to conduct all preclinical studies or clinical trials independently, we will have less control over the timing, quality, and other aspects of preclinical studies and clinical trials than we would have had we conducted them on our own. These investigators, CROs, and consultants will not be our employees, and we will have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful, or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial as well as applicable legal and regulatory requirements. The FDA generally requires preclinical studies to be conducted in accordance with Good Laboratory Practices, or GLPs, and clinical trials to be conducted in accordance with Good Clinical Practices, or GCPs, including for designing, conducting, recording, and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials as a result of our reliance on third parties could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on and expect to continue to rely on third-party manufacturers and suppliers to supply components of our product candidates. The loss of our third-party manufacturers or suppliers, or our or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate facilities for drug manufacturing, storage, distribution, or quality testing. We currently rely, and expect to continue to rely, on third-party contract manufacturers to manufacture bulk drug substances, drug products, raw materials, samples, components, or other materials and reports, and conduct fill-finish services. Reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves. Our third-party manufacturers may prioritize another customer&#8217;s needs in front of ours, especially in the event of a global pandemic. Additionally, raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects, may be in short supply, and may significantly increase in price. There can be no assurance that our preclinical and clinical development product supplies will not be limited, available at acceptable prices. In particular, any replacement of our manufacturer could require significant effort and expertise because there may be a limited number of qualified replacements.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for a product candidate is subject to review by the FDA, EMA, or other applicable regulatory authorities. We, and our suppliers and manufacturers, must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as current Good Manufacturing Practices, or cGMPs. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the FDA and foreign regulatory authorities. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or other applicable regulatory authorities, we may not be able to rely on their manufacturing facilities for the manufacture of elements of our product candidates and approval may be delayed. Moreover, although we do not control the manufacturing process at our contract manufacturers and are completely dependent on them for compliance with current regulatory requirements, we are responsible for ensuring that our products comply with regulatory requirements. If any of our manufacturers fails to comply with such requirements or to perform its obligations in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such to another third party. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to enable us, or to have another third party, manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines; and we may be required to repeat some of the development program. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. Any manufacturing facilities used to produce our products will be subject to periodic review and inspection by the FDA, EMA, or other applicable regulatory authorities, including for continued compliance with cGMP requirements, quality control, quality assurance, and corresponding maintenance of records and documents. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements, comply with cGMPs, or maintain a compliance status acceptable to the FDA, EMA, or other applicable regulatory authorities could adversely affect our business in a number of ways, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an inability to initiate or continue clinical trials of product candidates under development;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">loss of the cooperation of future collaborators;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">requirements to cease distribution or to recall batches of our product candidates; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our contract manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. For example, the outbreak of COVID-19 has spread across the globe and has resulted in extended shutdowns of businesses in the United States, Canada and many other countries and has had ripple effects to businesses around the world. Global health concerns, such as COVID-19, could also result in adverse effects to our manufacturing operations. If our contract manufacturers were to encounter any of these difficulties, our ability to provide our product candidates to patients in preclinical and clinical trials, or to provide product for treatment of patients once approved, would be jeopardized.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our third-party manufacturers may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our products for patients, if approved, could be delayed or stopped.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are biopharmaceuticals, and the process of manufacturing biopharmaceuticals is complex, time-consuming, highly regulated, and subject to multiple risks. Our contract manufacturers must comply with legal requirements, cGMPs, and guidelines for the bulk manufacturing, fill-finish services, packaging, and storage of biopharmaceuticals used in clinical trials and, if approved, marketed products. Our contract manufacturers may have limited experience in the manufacturing of cGMP batches.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing biopharmaceuticals is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered at our third-party manufacturers&#8217; facilities, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Moreover, if the FDA determines that our third-party manufacturers&#8217; facilities are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny approval of our application until the deficiencies are corrected or we replace the manufacturer in our application with a manufacturer that is in compliance.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process&#160;scale-up,&#160;process reproducibility, stability issues, compliance with cGMPs, lot consistency and timely availability of raw materials. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product, or provide fill-finish services, to specifications acceptable to the FDA, EMA, or other applicable regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scaling up a biopharmaceutical manufacturing process is a difficult and uncertain task, and our third-party manufacturers may not have the necessary capabilities to complete the implementation, manufacturing, and development process. If we are unable to adequately validate or&#160;scale-up&#160;the manufacturing process at our current manufacturers&#8217; facilities, we will need to transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If we are able to adequately validate and&#160;scale-up&#160;the manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates or products will not occur in the future. Our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein product candidates may not demonstrate sufficient long-term stability to support a BLA filing or obtain approval, or the product shelf life may be limited by stability results. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. If our third-party manufacturers were to encounter any of these difficulties, our ability to provide any product candidates to patients in planned clinical trials and products to patients, once approved, would be jeopardized. Any delay, interruption or other issues that arise in the manufacture, fill- finish, packaging, or storage of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse development affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of any of our product candidates or products, if approved, and could have an adverse effect on our business, prospects, financial condition, and results of operations.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our process development efforts, we also may make changes to the manufacturing processes at various points during development, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing clinical trials or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may, in the future, seek to enter into collaborations with other third parties for the discovery, development and commercialization of our product candidates. If our collaborators cease development efforts under our collaboration agreements, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products, and we may never receive milestone payments or future royalties under these agreements.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect a significant portion of our future revenue and cash resources to be derived from collaboration agreements or other similar agreements into which we may enter in the future for research, development, and commercialization of other therapeutic technologies or product candidates. Biopharmaceutical companies are our likely future collaborators for any marketing, distribution, development, licensing, or broader collaboration arrangements. If we fail to enter into future collaborations on commercially reasonable terms, or at all, or such collaborations are not successful, we may not be able to execute our strategy to develop certain targets, product candidates, or disease areas that we believe could benefit from the resources of either larger biopharmaceutical companies or those specialized in a particular area of relevance.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from research and development collaborations depends upon continuation of the collaborations, payments for research and development services, and resulting options to acquire any licenses of successful product candidates, and the achievement of milestones, contingent payments, and royalties, if any, derived from future </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products developed from our research. If we are unable to successfully advance the development of our product candidates or achieve milestones, revenue and cash resources from milestone payments under our collaboration agreements will be substantially less than expected.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to future collaboration agreements, we expect to have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Moreover, our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our product candidates may pose the following risks to us:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the foregoing, our current and any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. Any failure to successfully develop or commercialize our product candidates pursuant to our current or any future collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, to the extent that any of our future collaborators were to terminate a collaboration agreement, we may be forced to independently develop these product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have conflicts with our collaborators that could delay or prevent the development or commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have conflicts with our collaborators, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during our collaboration. If any conflicts arise with any of our collaborators, such collaborator may act in a manner that is adverse to our best interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a collaborator to pay us milestone payments or royalties we believe are due to us under a collaboration, which could require us to raise additional capital; uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness by the collaborator to cooperate in the development or manufacture of the product, including providing us with product data or materials; unwillingness on the part of a collaborator to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating of litigation or alternative dispute resolution options by either party to resolve the dispute; or&#160;attempts by either party to terminate the agreement.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expenses, and present significant distractions to our management.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may consider strategic transactions, such as additional collaborations, acquisitions of companies, asset purchases, and&#160;out-&#160;or&#160;in-licensing&#160;of product candidates or technologies that we believe will complement or augment our existing business. In particular, we will evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or biopharmaceutical companies. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the collaborator terminates the collaboration. In addition, a significant number of recent business combinations among large pharmaceutical companies has resulted in a reduced number of potential future strategic partners. Our collaborators may consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our&#160;assessment of the strategic partner&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed strategic partner&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA, or other applicable regulatory authorities, the potential market for the subject product candidate, the&#160;costs and complexities of manufacturing and delivering such product candidate to patients, the potential&#160;of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. Moreover, if we acquire assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such assets if we are not able to successfully integrate them with our existing technologies. We may encounter numerous difficulties in developing, testing, manufacturing, and marketing any new products resulting from a strategic acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that following any such collaboration, or other strategic transaction, we will achieve the expected synergies to justify the transaction. For example, such transactions may require us to incur&#160;non-recurring&#160;or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty, and cost in facilitating the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership, and the inability to retain key employees of any acquired business.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and would have a material and adverse effect on our business, financial condition, results of operations, and prospects. Conversely, any failure to enter any additional collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outbreak of the novel strain of coronavirus, SARS-CoV-2, which causes COVID-19,&#160;could adversely impact our business, including our preclinical and clinical development activities.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks could adversely impact our business. The outbreak of a novel strain of coronavirus, which causes the disease called COVID-19,&#160;has evolved into a global pandemic. As a result of the&#160;COVID-19&#160;pandemic, or similar pandemics, we may experience disruptions that could severely impact our business, manufacturing, preclinical development activities, preclinical studies and clinical trial activities, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays or disruptions in preclinical development activities, including non-clinical experiments and investigational new drug application-enabling good laboratory practice standard toxicology studies due to unforeseen circumstances in supply chain;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies, which may impact timelines for regulatory submission, trial initiation, and regulatory approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption or delays in our CROs and collaborators meeting expected deadlines or complying with regulatory requirements related to preclinical development activities, preclinical studies, and clinical trial activities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruptions of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, productions slowdowns, limited availability of raw materials, or stoppages and disruptions in delivery systems;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays or difficulties in any planned clinical site initiation, including difficulties in obtaining IRB approvals, recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays or difficulties in enrolling patients in clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increased rates of patients withdrawing from any planned clinical trials following enrollment as a result of contracting COVID-19 or being forced to quarantine;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">diversion of healthcare resources away from the conduct of our preclinical development activities, preclinical studies and clinical trials, including the diversion of hospitals serving as clinical trial sites and potential clinical trial sites, and hospital staff supporting the conduct of clinical trial activities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed non-essential), which may impact the integrity of subject data and planned clinical study endpoints;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limitations on employee or collaborator resources that would otherwise be focused on the conduct of our preclinical development activities, preclinical studies and clinical trial activities, including because of sickness of employees or their families, the desire of employees to avoid contact with </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">large groups of people, an increased reliance on working from home or mass transit disruptions; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced ability to engage with the medical and investor communities due to the cancellation of conferences scheduled throughout the year.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors arising from the&#160;COVID-19&#160;pandemic&#160;could worsen in countries afflicted with&#160;COVID-19, or could return to countries where the pandemic has been partially contained, each of which could further adversely impact our ability to conduct preclinical development activities, preclinical studies and clinical trial activities and our business generally, and could have a material adverse impact on our operations and financial condition and results.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the trading prices for our common stock and other biopharmaceutical companies, as well as the broader equity and debt markets, have been highly volatile as a result of the&#160;COVID-19&#160;pandemic and the resulting impact on economic activity. As a result, we may face difficulties raising capital when needed, and any such sales may be on unfavorable terms to us. Further, to the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of existing stockholders will be diluted.&#160;</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may impact our business, manufacturing, preclinical development activities, preclinical studies and clinical trial activities and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of COVID-19, the duration of the pandemic, the potential for a second pandemic after it is contained, travel restrictions and actions to address the pandemic or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow our organization, and we may experience difficulties in managing our growth and expanding our operations, which could adversely affect our business.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had approximatel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y 78 full-time employees. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial and other resources. In addition, we have limited experience in product development. As our product candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development and regulatory capabilities and contract with other organizations to provide manufacturing and other capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers, and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial, and management controls, reporting systems, and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. Our inability to successfully manage our growth and expand our operations could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued service of key management, advisors and other specialized personnel. We currently do not maintain key person insurance on any of these individuals. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations, and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our product candidates and technologies related to our Neoleukin Platform, and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time&#160;without penalty.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We also face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation, and commercialization. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates will be limited which could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors are and will be subject, directly and indirectly, to applicable anti-kickback, fraud and abuse, privacy, transparency and other healthcare laws and regulations, which could expose us to penalties, including without limitation, civil, criminal and administrative sanctions, civil penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, integrity obligations, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings and the curtailment or restructuring of our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biopharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our future arrangements with third-party payors and customers who are in a position to purchase, recommend and/or prescribe our product candidates for which we obtain marketing approval. These broadly applicable fraud and abuse and other healthcare laws and regulations may constrain our future business or financial arrangements and relationships with healthcare professionals, principal investigators, consultants, customers, and third-party payors and other entities, including our marketing practices, educational programs and pricing policies. Restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Anti-Kickback Statute, which, among other things, prohibits persons from knowingly and willfully soliciting, offering, receiving or providing paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal civil and criminal false claims laws, including the federal civil False Claims Act, and civil monetary penalty laws impose criminal and civil penalties, including through civil whistleblower or qui tam actions, among other things, prohibits individuals or entities from knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or from knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA, which, among other things, imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g. public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA, as amended by HITECH, and its implementing regulations, which also imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without the appropriate authorization by entities subject to the law, such as health plans, healthcare clearinghouses and healthcare providers;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS, information related to &#8220;payments or other transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians (as defined above) and their immediate family members and payments or other &#8220;transfers of value&#8221; to such physician owners and their immediate family members; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">analogous local, state and foreign laws and regulations, including: state anti-kickback and false claims laws which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by state governmental and non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government; local, state and foreign laws that require drug manufacturers to track gifts and other remuneration and items of value provided to healthcare professionals and entities and file reports relating to pricing and marketing information and/or register their pharmaceutical sales representatives; and local, state and foreign laws that govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our internal operations and any business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Recent healthcare reform legislation has also strengthened these laws. For example, the Affordable Care Act, among other things, amends the intent requirement of the federal Anti-Kickback Statute, such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act codified case law that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to penalties, including without limitation, significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, integrity obligations, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Moreover, we expect there will continue to be federal, state, local and foreign laws and regulations, proposed and implemented, that could impact our operations and business. The extent to which future legislation or regulations, if any, relating to healthcare fraud abuse laws or enforcement, may be enacted or what effect such legislation or regulation would have on our business remains uncertain.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form strategic alliances in the future, and we may not realize the benefits of such alliances.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form strategic alliances, create joint ventures or collaborations or enter into licensing arrangements with third parties that we believe will complement or augment our existing business. These relationships or those like them may require us to incur&#160;non-recurring&#160;and other charges, increase our near- and long-term expenditures, issue securities that dilute our stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for any future drug candidates and programs because our research and development pipeline may be insufficient, our drug candidates and programs may be deemed to be at too early a stage of development for </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborative effort and third parties may not view our drug candidates and programs as having the requisite potential to demonstrate safety and efficacy. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction. Any delays in entering into new strategic partnership agreements related to our drug candidates could also delay the development and commercialization of our drug candidates and reduce their competitiveness even if they reach the market.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state data privacy and security, fraud and abuse and other healthcare laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our&#160;pre-clinical&#160;studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct for our directors, officers and employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, results of operations, financial condition and cash flows from future prospects, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and will face an even greater risk if we commercialize any of our product candidates. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">decreased demand for any product candidates that we may develop;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injury to our reputation and significant negative media attention; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant time and costs to defend the related litigation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">loss of revenue; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inability to commercialize any product candidates that we may develop. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently maintain product liability insurance coverage for our clinical trials, but the amount may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coverage for each new clinical trial we begin and if we successfully commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in future acquisitions that could disrupt our business, cause dilution to our stockholders and harm our business, results of operations, financial condition and cash flows and future prospects.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, in the future, make acquisitions of, or investments in, companies that we believe have products or capabilities that are a strategic or commercial fit with our future product candidates and business or otherwise offer opportunities for our company. In connection with these acquisitions or investments, we may:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issue stock that would dilute our stockholders&#8217; percentage of ownership;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">incur debt and assume liabilities; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">incur amortization expenses related to intangible assets or incur large and immediate write-offs.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to complete acquisitions on favorable terms, if at all. If we do complete an acquisition, we cannot assure you that it will ultimately strengthen our competitive position or that it will be viewed positively by customers, financial markets or investors. Furthermore, future acquisitions could pose numerous additional risks to our operations, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">problems integrating the purchased business, products or technologies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increases to our expenses;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the failure to discover undisclosed liabilities of the acquired asset or company;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">diversion of management&#8217;s attention from their day-to-day responsibilities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">harm to our operating results or financial condition;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">entrance into markets in which we have limited or no prior experience; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential loss of key employees, particularly those of the acquired entity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to complete any acquisitions or effectively integrate the operations, products or personnel gained through any such acquisition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our U.S. net operating losses to offset future taxable income will be subject to Section 382 limitations and may be limited by other factors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had U.S. net operating losses, or NOLs, of $58.1 million, for federal tax purposes, for which we have recorded a full valuation allowance, and R&amp;D credit carryovers of $1.0 million, which may be offset by future taxable income. These NOLs and tax credit carryforwards will expire in various years beginning in 2028, if not utilized. Unused losses incurred in taxable years beginning on or prior to December 31, 2017 will carry forward to offset future taxable income, if any, until such unused losses expire. Under the Tax Cuts and Jobs Act, as modified by the CARES Act, unused U.S. federal NOLs generated in tax years beginning after December 31, 2017, will not expire and may be carried forward indefinitely but the deductibility of such federal NOLs (particularly those generated in taxable years beginning after December 31, 2020) in taxable years beginning after December 31, 2020, is limited to 80% of current year taxable income. It is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act or the CARES Act. Utilization of the NOLs will be subject to an annual limitation due to historical or future ownership changes rules pursuant to Sections 382 and 383 of the Internal Revenue Code, or the Code.  In addition, if we have experienced an ownership change in the past or will experience an ownership change as a result of future changes in our stock ownership, some of which changes are outside of our control, the tax benefits related to the NOLs may be limited or lost. Any such disallowances may result in greater tax liabilities than we would incur in the absence of such a limitation and any increased liabilities could adversely affect our business, results of operations, financial condition, cash flow and future prospects. As a result, even if we attain profitability, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain, maintain, and enforce patent protection for our product candidates, our Neoleukin platform technology, or other proprietary technologies we may develop, development and commercialization of our product candidates may be adversely affected.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including&#160;in-licenses&#160;of intellectual property rights of others, for our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. Under our License Agreement with the University of Washington, dated July&#160;8, 2019, as amended on October 29, 2020, effective July 24, 2020, we have an exclusive license to develop and commercialize products covered by patent applications with claims covering the composition of matter of key molecule families as well as methods of using the computational algorithms that form the basis of the Neoleukin platform. However, we may not be able to apply for patents on certain aspects of our product candidates in a timely fashion or at all. Further, we may not be able to prosecute all necessary or desirable patent applications, or maintain, enforce, and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing, and prosecution of all patent applications that we license from third parties, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our future issued or granted patents will not later be found to be invalid or unenforceable or that any future issued or granted patents will include claims that are sufficiently broad to cover our product candidates or to provide meaningful protection from our competitors. Moreover, the patent position of biotechnology and biopharmaceutical companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and product candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely affect our position in the market.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the&#160;other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March&#160;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot&#160;be certain that we were the first to make the inventions claimed in our pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a large number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and biopharmaceutical patents. As such, we do not know the degree of future protection that we will have on our proprietary products and technology. The process of obtaining patents is time consuming, expensive and sometimes unpredictable.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once granted, for a given period after allowance or grant patents may remain open to opposition, interference,&#160;re-examination,&#160;post-grant review,&#160;inter partes&#160;review, nullification, or derivation action in court or before patent offices or similar proceedings, during which time third parties can raise objections against such initial grant. Such proceedings may continue for a protracted period of time and an adverse determination in any such proceedings </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could reduce the scope of the allowed or granted claims thus attacked, or could result in our patents being invalidated in whole or in part, or&#160;being held unenforceable, which could allow third parties to commercialize our product candidates and compete directly with us without payment to us. In addition, there can be no assurance that:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others will not or may not be able to make, use or sell compounds that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or license;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our licensors, or our future collaborators are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our licensors, or our future collaborators are the first to file patent applications covering certain aspects of our inventions;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a third party may not challenge our patents and, if challenged, a court would hold that our patents are valid, enforceable and infringed;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any issued patents that we own or have licensed or that we may license in the future will provide us with any competitive advantages, or will not be challenged by third parties;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the patents of others will not have a material or adverse effect on our business, financial condition, results of operations, and prospects; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors or collaborators fail to maintain patent applications and later-issued patents covering our product candidates, our competitors might be able to enter the market, which could have a material and adverse effect on our business, financial condition, results of operations, and prospects. In addition, if the breadth or strength of protection provided by our patent applications and later-issued patents is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be required to incur significant expenses to strengthen our intellectual property rights, and our intellectual property rights may be inadequate to protect our competitive position.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive and time-consuming, and we or our future potential licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our future potential licensors will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them. Further, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the expiration of the patent. However, the applicable authorities, including the FDA in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and these </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreign laws may also be subject to change. For example, methods of treatment and manufacturing processes may not be patentable in certain jurisdictions. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our patent applications and the enforcement or defense of our issued patents may be impacted by the application of or changes in U.S. and foreign standards.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standards that the USPTO and foreign patent offices use to grant patents are not always applied predictably or uniformly and can change. Consequently, our pending patent applications may not be allowed and, if allowed, may not contain the type and extent of patent claims that will be adequate to conduct our business as planned. Additionally, any issued patents we currently own or obtain in the future may have a shorter patent term than expected or may not contain claims that will permit us to stop competitors from using our technology or similar technology or from copying our product candidates. Similarly, the standards that courts use to interpret patents are not always applied predictably or uniformly and may evolve, particularly as new technologies develop. In addition, changes to patent laws in the United States or other countries may be applied retroactively to affect the validation enforceability, or term of our patent. For example, the U.S. Supreme Court has recently modified some legal standards applied by the USPTO in examination of U.S. patent applications, which may decrease the likelihood that we will be able to obtain patents and may increase the likelihood of challenges to patents we obtain or license. In addition, changes to the U.S. patent system have come into force under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, which was signed into law in September 2011. The Leahy-Smith Act included a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first to file&#8221; system in which the first inventor to file&#160;a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in opposition, derivation, reexamination, inter-partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, which could adversely affect our competitive position.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we cannot predict with certainty the impact the Leahy-Smith Act or any potential future changes to the U.S. or foreign patent systems will have on the operation of our business, the Leahy-Smith Act and such future changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, results of operations, financial condition and cash flows and future prospects.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining any patent protection we may receive will depend on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these requirements.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.&#160;Non-compliance&#160;events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits,&#160;non-payment&#160;of fees and failure to properly legalize and submit formal documents. If we or our future potential licensors fail to maintain the patents and patent applications covering our future product candidates, our competitive position would be adversely affected.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, including our senior management, were previously employed at universities or at other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Some of these employees, including members of our senior management, executed proprietary rights,&#160;non-disclosure&#160;and&#160;non-competition&#160;agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or&#160;know-how&#160;of others in their work for us, we may be subject to claims that we, or these employees, have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. We are not aware of any threatened or pending claims related to these matters or concerning the agreements with our senior management, but in the future litigation may be necessary to defend against such claims. In addition, third parties may from time to time make claims over what we regard as our intellectual property, or we may get into disputes with licensors or licensees of our intellectual property rights over the interpretation of the license terms. Our licensors may have the right to terminate their license agreements with us or pursue damages or other legal remedies. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented&#160;know-how,&#160;technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into&#160;non-disclosure&#160;and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturing organizations, consultants, advisors and other third parties. We also generally enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the United States may be less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect all of our employees to assign&#160;their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary&#160;know-how,&#160;information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not currently clear how the FDA&#8217;s disclosure policies may change in the future, if at all.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on our product candidates throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we and our licensors or future collaborators may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements for patentability may differ in certain countries, particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. In India, unlike the United States, there is no link between regulatory approval of a drug and its patent status. Furthermore, generic or biosimilar drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; or collaborators&#8217; patents, requiring us or our licensors or collaborators to engage in complex, lengthy and costly litigation or other proceedings. Generic or biosimilar drug manufacturers may develop, seek approval for, and launch biosimilar versions of our products. In addition to India, certain countries in Europe and developing countries, including China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors or collaborators may have limited remedies if patents are infringed or if we or our licensors or collaborators are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our and our licensors&#8217; or collaborators&#8217; efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to any competitive advantage we may have.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Others may be able to make compounds that are the same as or similar to our future product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We or any of our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We or any of our licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">It is possible that our pending patent applications will not lead to issued patents.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We may not develop additional proprietary technologies that are patentable.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The patents of others may have an adverse effect on our business.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance, resulting in substantial losses for investors.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been, and is likely to continue to be, volatile for the foreseeable future. The trading price of our common stock could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this report, these factors include:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of competitive products or technologies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory actions with respect to our products or our competitors&#8217; products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">results of clinical trials, including both safety and efficacy, of any of our future product candidates or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of expenses related to any of our future product candidates or clinical development programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the results of our efforts to in-license or acquire additional product candidates or products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sales of our common stock by us, our insiders or our other stockholders;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">market conditions in the pharmaceutical and biotechnology sectors; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general economic, industry and market conditions, including market volatility and economic uncertainty related to the COVID-19 pandemic.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of these risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section and elsewhere in this report, could have a dramatic and material adverse impact on the market price of our common stock.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation, or certificate of incorporation, and amended and restated bylaws, or bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, or remove our current management. These include provisions that:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit our board of directors to issue up to 5,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that all vacancies on our board of directors, including as a result of newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not provide for cumulative voting rights, thereby allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that special meetings of our stockholders may be called only by the board of directors or by such person or persons requested by a majority of the board of directors to call such meetings.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management. Because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under Delaware law, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Any provision of our certificate of incorporation or bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The exclusive forum provisions in our certificate of incorporation and bylaws may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware will be the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, or the DGCL, our certificate of incorporation, or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act of 1933, as amended, or the Securities Act, inasmuch as Section 22 of the Securities Act, creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rule and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we amended and restated our bylaws to provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a Federal Forum Provision. Our decision to adopt a&#160;Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act&#160;must be brought in federal court and cannot be brought in state court.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These choice of forum provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are no longer an&#160;&#8220;emerging growth company,&#8221; however, we are still a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we ceased to be an&#160;&#8220;emerging growth company,&#8221; as defined in the&#160;Jumpstart Our Business Startups Act of 2012, or JOBS Act, on December 31, 2019, we are a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. As a smaller reporting company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become a "large accelerated filer" and have to comply with more rigorous disclosure and reporting requirements and regulations.</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cease to be a &#8220;smaller reporting company&#8221; or a &#8220;non-accelerated filer&#8221; in the future, we may be subject to certain disclosure requirements that are applicable to other public companies that had not been applicable to us previously. These requirements include:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"> compliance with the auditor attestation requirements in the assessment of our internal control over financial reporting once we are an accelerated filer or large accelerated filer;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"> compliance with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"> full disclosure and analysis obligations regarding executive compensation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to comply with the applicable regulations in a timely manner, if at all. Inability to comply with these regulations could impact our ability to raise additional capital.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been and will continue to be volatile. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders, directors and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates together beneficially own a majority of our outstanding voting stock. These stockholders are able to determine the outcome of all matters requiring stockholder approval. For example, these stockholders are able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately report our business, results of operations, financial condition and cash flows and future prospects, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures and that we furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting that results in more than a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. Section&#160;404 of the Sarbanes-Oxley Act also generally requires an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. However, for as long as we are not an accelerated filer or large accelerated filer, we intend to take advantage of the exemption permitting us not to comply with the independent registered public accounting firm attestation requirement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compliance with Section&#160;404 will require that we incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section&#160;404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we fail to identify and to remediate any significant deficiencies or material weaknesses that may be identified, or encounter problems or delays in the implementation of internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq Stock Market, or NASDAQ, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of computer system failures or security breaches.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect, store and transmit confidential information, including intellectual property, proprietary business information and personal information. Despite the implementation of security measures, our internal computer systems, and those of our CROs and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyberattacks, natural disasters, fire, terrorism, war and telecommunication and electrical failures. Cyberattacks are increasing in their frequency, sophistication and intensity. Cyberattacks could include the deployment of harmful malware,&#160;denial-of-service&#160;attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Significant disruptions of our information technology systems or security breaches could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), and could result in financial, legal, business and reputational harm to us.&#160;If such disruptions were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our future product candidates could be delayed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics such as the COVID-19 pandemic and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We do not carry insurance for all categories of risk that our business may encounter. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of product candidates could be disrupted, if the operations of these suppliers are affected by a&#160;man-made&#160;or natural disaster or other business interruption. The ultimate impact on us, our significant suppliers and our general infrastructure of being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster. Further, any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, results of operations, financial condition and cash flows from future prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and will incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we have incurred and will incur significant legal, accounting and other expenses that we did not incur as a private company, and these expenses will likely increase even more given we are no longer an &#8220;emerging growth company.&#8221; We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and NASDAQ. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have substantially increased our legal and financial compliance costs and made some activities more time-consuming and costly. The increased costs will increase our consolidated net loss. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past and may in the future grant rights to some of our stockholders that require us to register the resale of our common stock or other securities on behalf of these stockholders and/or facilitate public offerings of our securities held by these stockholders, including in connection with potential future acquisition or capital-raising transactions. For example, in connection with our public offering of common stock on September&#160;19, 2016, we entered into a registration rights agreement with the Baker Entities that together, based on information available to us, collectively beneficially owned approximately 45.1% of our common stock as of September&#160;19, 2016. Under the registration rights agreement, we agree that, if at any time and from time to time after December&#160;19, 2016, the Baker Entities demand that we register their shares of our common stock for resale under the Securities Act, we would be obligated to effect such registration. On January&#160;6, 2017, pursuant to the registration rights agreement, we registered for resale, from time to time, up to 10,536,092 shares of our common stock held by the Baker Entities. Our registration obligations under this registration rights agreement cover all shares now held or hereafter acquired by the Baker Entities, would be in effect for up to ten years, and would include our obligation to facilitate certain underwritten public offerings of our common stock by the Baker Entities in the future. If the Baker Entities or any other holders of registration rights with respect to our common stock, by exercising their registration and/or underwriting rights or otherwise, sell a large number of our shares, or the market perceives that the Baker Entities or such holders intend to sell a large number of our shares, this could adversely affect the market price of our common stock. We have registered all currently reserved shares of common stock that we may issue under our equity compensation plans and intend to register in the future any additional reserved or issued shares of common stock. These registered shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. We have also filed registration statements covering the sale of up to $400.0&#160;million of any combination of our common stock, preferred stock, debt securities or warrants and may conduct one or more sales of securities pursuant to such registration statement, from time to time.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#ice342ca3b91243dbba4e0415051faf5e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell substantial amounts of common stock or securities convertible into or exchangeable for common stock. These future issuances of common stock or common stock-related securities, including the exercise of outstanding options and any additional shares issued in connection with acquisitions, if any, may result in material dilution to our stockholders. New investors could also gain rights, preferences and privileges senior to those of holders of our common stock.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our 2014 Equity Incentive Plan, our compensation committee is authorized to grant equity-based incentive awards to our directors, executive officers and other employees and service providers, including officers, employees and service providers of our subsidiaries and affiliates. Future option grants and issuances of common stock under our 2014 Equity Incentive Plan may have an adverse effect on the market price of our common stock.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us, or our business. If one or more of the securities or industry analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_130"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_133"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_136"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ice342ca3b91243dbba4e0415051faf5e_139"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ice342ca3b91243dbba4e0415051faf5e_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.872%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101.htm">Second Amendment to Lease, dated March 24, 2021, by and between Neoleukin Therapeutics, Inc. and ARE-Seattle No. 28, LLC</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div id="ice342ca3b91243dbba4e0415051faf5e_145"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neoleukin Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 12, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jonathan G. Drachman</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jonathan G. Drachman<br/>President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 12, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert Ho</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert Ho<br/>Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i683a18b1520644fda5a37e5f803243e8_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECOND AMENDMENT TO LEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS SECOND AMENDMENT TO LEASE (this &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is made as of March __, 2021, by and between </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARE-EASTLAKE AVENUE NO. 3, LLC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Landlord and Tenant are parties to that certain Lease Agreement dated as of September&#160;23, 2019, as amended by that certain First Amendment to Lease dated as of June 18, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (as amended, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Pursuant to the Lease, Tenant leases certain premises known as Suite 360 containing approximately 6,272 rentable square feet (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in that certain building located at 1616 Eastlake Avenue East, Seattle, Washington.  The Premises are more particularly described in the Lease.  Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to the terms set forth in the First Amendment, the Base Term of the Lease is scheduled to expire on September 30, 2021.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Landlord and Tenant desire, subject to the terms and conditions set forth below, to amend the Lease to extend the Term of the Lease through September 30, 2026 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Amendment Expiration Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Term of the Lease is hereby extended through the Second Amendment Expiration Date.  Tenant has accepted and occupies the Premises and Tenant&#8217;s continued occupancy of the Premises during the period commencing October 1, 2021 through the Second Amendment Expiration Date shall be on an &#8220;as-is&#8221; basis and, except as expressly provided in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below, Landlord shall have no obligation to provide any tenant improvement allowance or make any improvements or alterations to the Premises.  For the avoidance of doubt, Tenant no longer has the right to terminate the Lease early pursuant to the terms of the First Amendment, and the First Amendment is hereby null and void and of no further force or effect as of the date of this Second Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Base Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Tenant shall continue to pay Base Rent as provided under the Lease through September 30, 2021.  Commencing on October 1, 2021, Tenant shall pay Base Rent in the amount of $59.00 per rentable square foot of the Premises per year.  Commencing on October 1, 2022, and on each subsequent October 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through the Second Amendment Expiration Date (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Amendment Adjustment Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Base Rent shall be increased by multiplying the Base Rent payable immediately before such Second Amendment Adjustment Date by 2.5% and adding the resulting amount to the Base Rent payable immediately before such Second Amendment Adjustment Date. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Premises Improvements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Landlord shall make available to Tenant a tenant improvement allowance in the amount of $5.00 per rentable square foot of the Premises, or $31,360.00 in the aggregate (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Improvement Allowance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), for the design and construction of fixed and permanent improvements desired by and performed by Tenant and reasonably acceptable to Landlord in the Premises (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Premises Improvements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which Premises Improvements shall be constructed pursuant to a scope of work reasonably acceptable to Landlord and Tenant.  The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Improvement Allowance shall be available only for the design and construction of the Premises Improvements.  Tenant acknowledges that upon the expiration of the Term of the Lease, the Premises Improvements shall become the property of Landlord and may not be removed by Tenant.  Except for the Improvement Allowance, Tenant shall be solely responsible for all of the costs of the Premises Improvements.  The Premises Improvements shall be treated as Alterations and shall be undertaken pursuant to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Lease.  The contractor for the Premises Improvements shall be selected by Tenant, subject to Landlord&#8217;s approval, which approval shall not be unreasonably withheld, conditioned or delayed.  Prior to the commencement of the Premises Improvements, Tenant shall deliver to Landlord a copy of any contract with Tenant&#8217;s contractors, and certificates of insurance from any contractor performing any part of the Premises Improvements evidencing industry standard commercial general liability, automotive liability, &#8220;builder&#8217;s risk&#8221;, and workers&#8217; compensation insurance.  Tenant shall cause the general contractor to provide a certificate of insurance naming Landlord, Alexandria Real Estate Equities, Inc., and Landlord&#8217;s lender (if any) as additional insureds for the general contractor&#8217;s liability coverages required above.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Premises Improvements (and prior to any final disbursement of the Improvement Allowance) Tenant shall deliver to Landlord the following items&#58; (i)&#160;sworn statements setting forth the names of all contractors and subcontractors who did work on the Premises Improvements and final lien waivers from all such contractors and subcontractors&#59; and (ii) &#8220;as built&#8221; plans for the Premises Improvements.  Notwithstanding the foregoing, if the cost of the Premises Improvements exceeds the Improvement Allowance, Tenant shall be required to pay such excess in full prior to Landlord having any obligation to fund any remaining portion of the Improvement Allowance.  The Improvement Allowance shall only be available for use by Tenant for the construction of the Premises Improvements commencing on the date of this Second Amendment through the date that is 18 months after the date of this Second Amendment (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outside Improvement Allowance Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Any portion of the Improvement Allowance which has not been properly requested by Tenant from Landlord on or before the Outside Improvement Allowance Date shall be forfeited and shall not be available for use by Tenant. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Right to Extend Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Tenant shall have the right to extend the Term of the Lease upon the following terms and conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">Extension Right</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Tenant shall have 1 right (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Extension Right</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to extend the term of this Lease for a period of 28 months (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Extension Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on the same terms and conditions as the Lease (other than with respect to Base Rent and the Improvement Allowance) by giving Landlord written notice of its election to exercise each Extension Right at least 9 months prior, and no earlier than 12 months prior, to the Second Amendment Expiration Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Upon the commencement of any Extension Term, Base Rent shall be payable at the Market Rate (as defined below).  Base Rent shall thereafter be adjusted on each annual anniversary of the commencement of such Extension Term by a percentage as determined by Landlord and agreed to by Tenant at the time the Market Rate is determined.  As used herein, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Rate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the rate that comparable landlords of comparable buildings have accepted in current transactions from non-equity (i.e., not being offered equity in the buildings) and nonaffiliated tenants of similar financial strength for space of comparable size, quality (including all Tenant Improvements, Alterations and other improvements) and floor height in Class A laboratory&#47;office buildings in the South Lake Union area of Seattle for a comparable term, with the determination of the Market Rate to take into account all relevant factors, including tenant inducements, views, parking costs, leasing commissions, allowances or concessions, if any.  Notwithstanding the foregoing, the Market Rate shall in no event be less than the Base Rent payable as of the date immediately preceding the commencement of such Extension Term. In addition, Landlord may impose a market rent for the parking rights provided hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, on or before the date which is 210 days prior to the expiration of the Base Term of this Lease, Tenant has not agreed with Landlord&#8217;s determination of the Market Rate and the rent escalations during the Extension Term after negotiating in good faith, Tenant shall be deemed to have elected arbitration as described in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Tenant acknowledges and agrees that, if Tenant has elected to exercise the Extension Right by delivering notice to Landlord as required in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tenant shall have no right thereafter to rescind or elect not to extend the term of this Lease for the Extension Term.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.13pt">Arbitration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:26.24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 10 days of Tenant&#8217;s notice to Landlord of its election (or deemed election) to arbitrate Market Rate and escalations, each party shall deliver to the other a proposal containing the Market Rate and escalations that the submitting party believes to be correct (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Extension Proposal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  If either party fails to timely submit an Extension Proposal, the other party&#8217;s submitted proposal shall determine the Base Rent and escalations for the Extension Term.  If both parties submit Extension Proposals, then Landlord and Tenant shall meet within 7 days after delivery of the last Extension Proposal and make a good faith attempt to mutually appoint a single Arbitrator (and defined below) to determine the Market Rate and escalations.  If Landlord and Tenant are unable to agree upon a single Arbitrator, then each shall, by written notice delivered to the other within 10 days after the meeting, select an Arbitrator.  If either party fails to timely give notice of its selection for an Arbitrator, the other party&#8217;s submitted proposal shall determine the Base Rent for the Extension Term.  The 2 Arbitrators so appointed shall, within 5 business days after their appointment, appoint a third Arbitrator.  If the 2 Arbitrators so selected cannot agree on the selection of the third Arbitrator within the time above specified, then either party, on behalf of both parties, may request such appointment of such third Arbitrator by application to any state court of general jurisdiction in the jurisdiction in which the Premises are located, upon 10 days prior written notice to the other party of such intent.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:23.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decision of the Arbitrator(s) shall be made within 30 days after the appointment of a single Arbitrator or the third Arbitrator, as applicable.  The decision of the single Arbitrator shall be final and binding upon the parties.  The average of the two closest Arbitrators in a three Arbitrator panel shall be final and binding upon the parties.  Each party shall pay the fees and expenses of the Arbitrator appointed by or on behalf of such party and the fees and expenses of the third Arbitrator shall be borne equally by both parties.  If the Market Rate and escalations are not determined by the first day of the Extension Term, then Tenant shall pay Landlord Base Rent in an amount equal to the Base Rent in effect immediately prior to the Extension Term and increased by the Rent Adjustment Percentage until such determination is made.  After the determination of the Market Rate and escalations, the parties shall make any necessary adjustments to such payments made by Tenant.  Landlord and Tenant shall then execute an amendment recognizing the Market Rate and escalations for the Extension Term.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:21.36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arbitrator</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall be any person appointed by or on behalf of either party or appointed pursuant to the provisions hereof and&#58;  (i) shall be (A) a member of the American Institute of Real Estate Appraisers with not less than 10 years of experience in the appraisal of improved office and high tech industrial real estate in the greater Seattle metropolitan area, or (B) a licensed commercial real estate broker with not less than 15 years&#8217; experience representing landlords and&#47;or tenants in the leasing of high tech or life sciences space in the greater Seattle metropolitan area, (ii) devoting substantially all of their time to professional appraisal or brokerage work, as applicable, at the time of appointment and (iii) be in all respects impartial and disinterested.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">Rights Personal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Extension Right is personal to Tenant and is not assignable without Landlord&#8217;s consent, which may be granted or withheld in Landlord&#8217;s sole discretion separate and apart from any consent by Landlord to an assignment of Tenant&#8217;s interest in the Lease, except that they may be assigned in connection with any Permitted Assignment of the Lease.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.13pt">Exceptions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Notwithstanding anything set forth above to the contrary, the Extension Right shall, at Landlord&#8217;s option, not be in effect and Tenant may not exercise the Extension Right&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:26.24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during any period of time that Tenant is in default under any provision of the Lease (beyond any applicable notice and cure periods)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:23.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if Tenant has been in Default under any provision of the Lease 3 or more times, whether or not the Defaults are cured, during the 12 month period immediately prior to the date that Tenant intends to exercise the Extension Right, whether or not the Defaults are cured.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">No Extensions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The period of time within which the Extension Right may be exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise the Extension Right.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.9pt">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Extension Right shall, at Landlord&#8217;s option, terminate and be of no further force or effect even after Tenant&#8217;s due and timely exercise of the Extension Right, if, after such exercise, but prior to the commencement date of the Extension Term, (i) Tenant fails to timely cure any default by Tenant under this Lease&#59; or (ii) Tenant has Defaulted 3 or more times during the period from the date of the exercise of the Extension Right to the date of the commencement of the Extension Term, whether or not such Defaults are cured.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Early Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Subject to the provisions of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tenant shall have the one-time right after the mutual execution and delivery of this Second Amendment by delivery of written notice to Landlord no later than the date that is concurrent with Tenant&#8217;s delivery of a New Lease to Landlord (or Landlord&#8217;s Affiliate), to terminate this Lease, without payment of a termination fee, if, prior to the Second Amendment Expiration Date, Tenant has entered into a new lease (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Lease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) with Landlord or an Affiliate (as defined below) pursuant to which Tenant shall lease space (not including that certain space currently leased by Tenant at 188 E. Blaine Street) in the Seattle area larger than the then-current size of the Premises (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), for a term acceptable to Landlord and&#47;or Affiliate for such New Premises and, otherwise, upon terms and conditions acceptable to Landlord or Affiliate and Tenant in their respective sole discretion.  If Tenant and Landlord (or Affiliate) enter into a New Lease and Tenant timely delivers written notice as provided above to Landlord, then this Lease shall terminate upon the date that Tenant commences paying base rent under the New Lease for the New Premises.  Tenant acknowledges that nothing contained herein shall obligate Landlord or Affiliate in any way to enter into a New Lease nor shall anything contained herein be construed to grant to Tenant any option or right to lease any space at another property owned by Landlord or Affiliate.  As used herein, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean an entity controlled by, under common control with, or controlling Landlord including, without limitation, any of the constituent members of Landlord or Alexandria Real Estate Equities, Inc.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the avoidance of doubt, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 39</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the original Lease is hereby deleted and is null and void and of no further force or effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFAC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the U.S. Department of Treasury and any statute, executive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">order, or regulation relating thereto (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFAC Rules</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), (b) not listed on, and shall not during the Term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List maintained by OFAC and&#47;or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in connection with the transaction reflected in this Second Amendment and that no Broker brought about this Second Amendment, other than Kidder Mathews.  Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than Kidder Mathews, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Second Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Tenant Notice Address</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  From and after the date of this Second Amendment, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant&#8217;s Notice Address</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; on page 1 of the Lease is hereby deleted and replaced with the following&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Tenant Notice Address&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With a Copy to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neoleukin Therapeutics&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neoleukin Therapeutics<br>188 E. Blaine Street, Suite 450&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;188 E. Blaine Street, Suite 450<br>Seattle, WA 98102&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seattle, WA 98102<br>Attn&#58; General Counsel&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attn&#58; Director of Real Estate &#38; Facilities</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">This Second Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions.  This Second Amendment may be amended only by an agreement in writing, signed by the parties hereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.13pt">This Second Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, representatives, officers, directors, divisions, subsidiaries, affiliates, assigns, heirs, successors in interest and shareholders.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">This Second Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  Electronic signatures shall be deemed original signatures for purposes of this Second Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.13pt">Except as amended and&#47;or modified by this Second Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Second Amendment.  In the event of any conflict between the provisions of this Second Amendment and the provisions of the Lease, the provisions of this Second Amendment shall prevail.  Whether or not specifically amended by this Second Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Second Amendment.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Signatures are on the next page&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Landlord and Tenant have executed this Second Amendment as of the day and year first above written.</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TENANT&#58;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Delaware corporation</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Its&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LANDLORD&#58;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARE-EASTLAKE AVENUE NO. 3, LLC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,<br>a Delaware limited liability company </font></div><div style="padding-left:216pt;text-indent:-216pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:252pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;ALEXANDRIA REAL ESTATE EQUITIES, L.P.,<br>a Delaware limited partnership,<br>managing member</font></div><div style="margin-bottom:24pt;padding-left:288pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;ARE-QRS CORP.,<br>a Maryland corporation,<br>general partner</font></div><div style="padding-left:288pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;________________________</font></div><div style="padding-left:288pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Its&#58;________________________</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i204f21b822f441759b89cdab4557f5b1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jonathan G. Drachman, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of Neoleukin Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent function)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;12, 2021 </font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.947%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jonathan G. Drachman</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan G. Drachman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i87effb5e1f8c4eb4b580d3e73e41787b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert Ho, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of Neoleukin Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent function)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;12, 2021 </font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.947%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert Ho </font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Ho </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic3c29fcbebe14cf69b6e409aaa3f33f3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Neoleukin Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Jonathan G. Drachman, President and Chief Executive Officer of the Company, and Robert Ho, Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the undersigned have set their hands hereto as of the 12th day of May 2021. </font></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.222%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jonathan G. Drachman</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert Ho</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan G. Drachman</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Ho</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Neoleukin Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>nltx-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:31968e29-d77b-4652-a911-b8dbe2ac7135,g:21241be8-d08e-4bb7-a15e-85390d577d03-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nltx="http://www.aqxpharma.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.aqxpharma.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nltx-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nltx-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nltx-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nltx-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.aqxpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated&#160;Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated&#160;Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Natureofoperations" roleURI="http://www.aqxpharma.com/role/Natureofoperations">
        <link:definition>2101101 - Disclosure - Nature of operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://www.aqxpharma.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>2102102 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails">
        <link:definition>2404401 - Disclosure - Summary of significant accounting policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cashcashequivalentsandrestrictedcash" roleURI="http://www.aqxpharma.com/role/Cashcashequivalentsandrestrictedcash">
        <link:definition>2105103 - Disclosure - Cash, cash equivalents and restricted cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsandrestrictedcashTables" roleURI="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashTables">
        <link:definition>2306301 - Disclosure - Cash, cash equivalents and restricted cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsandrestrictedcashAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashAdditionalInformationDetails">
        <link:definition>2407402 - Disclosure - Cash, cash equivalents and restricted cash - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2408403 - Disclosure - Cash, cash equivalents and restricted cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.aqxpharma.com/role/Leases">
        <link:definition>2109104 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails">
        <link:definition>2410404 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.aqxpharma.com/role/Equity">
        <link:definition>2111105 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.aqxpharma.com/role/EquityTables">
        <link:definition>2312302 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/EquityAdditionalInformationDetails">
        <link:definition>2413405 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofStockbasedCompensationExpenseDetails" roleURI="http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails">
        <link:definition>2414406 - Disclosure - Equity - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofWeightedAverageAssumptionsDetails" roleURI="http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails">
        <link:definition>2415407 - Disclosure - Equity - Schedule of Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofStockOptionsActivityDetails" roleURI="http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails">
        <link:definition>2416408 - Disclosure - Equity - Schedule of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofNonvestedRestrictedStockUnitActivityDetails" roleURI="http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails">
        <link:definition>2417409 - Disclosure - Equity - Summary of Nonvested Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Earningslosspershare" roleURI="http://www.aqxpharma.com/role/Earningslosspershare">
        <link:definition>2118106 - Disclosure - Earnings (loss) per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningslosspershareTables" roleURI="http://www.aqxpharma.com/role/EarningslosspershareTables">
        <link:definition>2319303 - Disclosure - Earnings (loss) per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails" roleURI="http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails">
        <link:definition>2420410 - Disclosure - Earnings (loss) per share - Schedule of basic and diluted net loss per common stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember" abstract="true" name="OfficeSpaceAdditionalOfficesAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_PercentageOfOutstandingStockPerStockholderMaximum" abstract="false" name="PercentageOfOutstandingStockPerStockholderMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nltx_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_TenantImprovementAllowanceReceivable" abstract="false" name="TenantImprovementAllowanceReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock" abstract="false" name="CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nltx_ClassOfWarrantOrRightNoticePeriod" abstract="false" name="ClassOfWarrantOrRightNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nltx_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" abstract="false" name="EmployeeStockPurchasePlanNumberOfOfferingPerYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nltx_A2020EmployeeStockPurchasePlanMember" abstract="true" name="A2020EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" abstract="true" name="OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_NumberOfOptionToExtendLease" abstract="false" name="NumberOfOptionToExtendLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nltx_TenantImprovementAllowance" abstract="false" name="TenantImprovementAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>nltx-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:31968e29-d77b-4652-a911-b8dbe2ac7135,g:21241be8-d08e-4bb7-a15e-85390d577d03-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CoverPage" xlink:type="simple" xlink:href="nltx-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f6fbd9ae-f072-483c-adeb-556dc69dd1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4588dde2-4133-480e-babb-454f63c37779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f6fbd9ae-f072-483c-adeb-556dc69dd1e6" xlink:to="loc_us-gaap_LiabilitiesCurrent_4588dde2-4133-480e-babb-454f63c37779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3aa7697b-4776-46c7-b206-fad1bab41c50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f6fbd9ae-f072-483c-adeb-556dc69dd1e6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3aa7697b-4776-46c7-b206-fad1bab41c50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_439485a7-f79b-496e-82ef-03b0666bdfcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f6fbd9ae-f072-483c-adeb-556dc69dd1e6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_439485a7-f79b-496e-82ef-03b0666bdfcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1a641c28-37c1-4f0f-8d70-152e8ee450bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c73dc7b9-62a9-40dc-ae7e-96748bc954e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1a641c28-37c1-4f0f-8d70-152e8ee450bf" xlink:to="loc_us-gaap_AssetsCurrent_c73dc7b9-62a9-40dc-ae7e-96748bc954e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bc43de6e-cdf5-4fb8-beae-c02ba43c9cca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1a641c28-37c1-4f0f-8d70-152e8ee450bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bc43de6e-cdf5-4fb8-beae-c02ba43c9cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_39b036ab-352f-4605-b969-acee742ed026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1a641c28-37c1-4f0f-8d70-152e8ee450bf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_39b036ab-352f-4605-b969-acee742ed026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_058dd3e1-d6e4-4a68-ae82-f4e19a06da74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1a641c28-37c1-4f0f-8d70-152e8ee450bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_058dd3e1-d6e4-4a68-ae82-f4e19a06da74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9c4ce89e-3b8a-417f-bd35-da06d9aa1ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1a641c28-37c1-4f0f-8d70-152e8ee450bf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9c4ce89e-3b8a-417f-bd35-da06d9aa1ee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2cf4563e-ae28-4bf4-abe9-f1382cfe55b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6159926a-d617-4a6d-960a-288a2feb4bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2cf4563e-ae28-4bf4-abe9-f1382cfe55b0" xlink:to="loc_us-gaap_CommonStockValue_6159926a-d617-4a6d-960a-288a2feb4bc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2e58f20d-68b9-4e9b-8092-d564a345f3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2cf4563e-ae28-4bf4-abe9-f1382cfe55b0" xlink:to="loc_us-gaap_PreferredStockValue_2e58f20d-68b9-4e9b-8092-d564a345f3e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1b60482d-7a65-4adb-b874-32b1cc2f1bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2cf4563e-ae28-4bf4-abe9-f1382cfe55b0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1b60482d-7a65-4adb-b874-32b1cc2f1bfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c974990e-f6f7-4018-9558-c6dbf10cc70e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2cf4563e-ae28-4bf4-abe9-f1382cfe55b0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c974990e-f6f7-4018-9558-c6dbf10cc70e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7b6bcb87-3bfa-477e-ab23-207e46a965a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b4add9bb-a944-48d1-91e8-ddec80b066eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7b6bcb87-3bfa-477e-ab23-207e46a965a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b4add9bb-a944-48d1-91e8-ddec80b066eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0dac7388-93dc-4810-b9d8-1c5a2a84e5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7b6bcb87-3bfa-477e-ab23-207e46a965a9" xlink:to="loc_us-gaap_OtherAssetsCurrent_0dac7388-93dc-4810-b9d8-1c5a2a84e5b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_21562175-7760-44a0-871b-3c400340a323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_fe8cba67-b6bf-4bdf-8297-315f6c31f8b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21562175-7760-44a0-871b-3c400340a323" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_fe8cba67-b6bf-4bdf-8297-315f6c31f8b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b854850-a750-4c24-916a-841b3cd1094d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21562175-7760-44a0-871b-3c400340a323" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b854850-a750-4c24-916a-841b3cd1094d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_131cbb7c-f5a3-4b88-8a37-69569db4dfe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21562175-7760-44a0-871b-3c400340a323" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_131cbb7c-f5a3-4b88-8a37-69569db4dfe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cc9f5e00-9419-448b-b67b-0ae31e4d5b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f31aff3c-5868-4c38-b1ae-50774cd9afaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cc9f5e00-9419-448b-b67b-0ae31e4d5b50" xlink:to="loc_us-gaap_Liabilities_f31aff3c-5868-4c38-b1ae-50774cd9afaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_055d70fa-8778-4845-83c3-eda6f134a621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cc9f5e00-9419-448b-b67b-0ae31e4d5b50" xlink:to="loc_us-gaap_StockholdersEquity_055d70fa-8778-4845-83c3-eda6f134a621" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_05d44f0a-80ac-4b81-b9d3-72de0a230194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b02855a5-83f6-412d-a3c0-8c19fc84cddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_05d44f0a-80ac-4b81-b9d3-72de0a230194" xlink:to="loc_us-gaap_OperatingIncomeLoss_b02855a5-83f6-412d-a3c0-8c19fc84cddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7d6cf277-6289-4c89-8466-ca328f1584f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_05d44f0a-80ac-4b81-b9d3-72de0a230194" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7d6cf277-6289-4c89-8466-ca328f1584f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_34d8ec9d-3463-4685-b17f-a2b006abc998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_da74e981-cfa7-4360-a693-a416520c9057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_34d8ec9d-3463-4685-b17f-a2b006abc998" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_da74e981-cfa7-4360-a693-a416520c9057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_db043195-9e11-4a10-afe1-c701a6f80017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_34d8ec9d-3463-4685-b17f-a2b006abc998" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_db043195-9e11-4a10-afe1-c701a6f80017" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5e6454cf-2fb0-409a-8914-0eeeb6823991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cb2d6bf-3463-48be-aa6e-7912c2b2f2e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5e6454cf-2fb0-409a-8914-0eeeb6823991" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cb2d6bf-3463-48be-aa6e-7912c2b2f2e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_88307560-8662-4322-97af-693413492a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5e6454cf-2fb0-409a-8914-0eeeb6823991" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_88307560-8662-4322-97af-693413492a08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a138d503-5251-4d90-9b6b-2089d9847ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5e6454cf-2fb0-409a-8914-0eeeb6823991" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a138d503-5251-4d90-9b6b-2089d9847ca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5d3bd4e-b038-41f4-ab5d-3d5a60f6cedf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5e6454cf-2fb0-409a-8914-0eeeb6823991" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5d3bd4e-b038-41f4-ab5d-3d5a60f6cedf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eea06020-681f-418c-88e5-c4aeed841933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_82d41c59-348c-40c6-a33c-dc5cbccf0351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eea06020-681f-418c-88e5-c4aeed841933" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_82d41c59-348c-40c6-a33c-dc5cbccf0351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f13337dc-b9dd-4676-9649-1b95753bee3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eea06020-681f-418c-88e5-c4aeed841933" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f13337dc-b9dd-4676-9649-1b95753bee3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3219667f-2bcb-41a0-aff7-3eb51fb1a8d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_acf6d266-59fb-4d90-9c80-0ba4dba7cd84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3219667f-2bcb-41a0-aff7-3eb51fb1a8d7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_acf6d266-59fb-4d90-9c80-0ba4dba7cd84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67aa024e-3215-478f-a829-d7bc2c19e0a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ca38aa65-01fd-41d3-8660-eef64a8d02c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67aa024e-3215-478f-a829-d7bc2c19e0a9" xlink:to="loc_us-gaap_NetIncomeLoss_ca38aa65-01fd-41d3-8660-eef64a8d02c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d806c3d2-3657-413d-b090-d90dfdc99bba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67aa024e-3215-478f-a829-d7bc2c19e0a9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d806c3d2-3657-413d-b090-d90dfdc99bba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_70e0892f-3728-492e-aee1-fc527696b7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67aa024e-3215-478f-a829-d7bc2c19e0a9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_70e0892f-3728-492e-aee1-fc527696b7b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_736c19b0-d212-4c8d-b6e1-c4557b1dfc56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67aa024e-3215-478f-a829-d7bc2c19e0a9" xlink:to="loc_us-gaap_ShareBasedCompensation_736c19b0-d212-4c8d-b6e1-c4557b1dfc56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_c8e3bc77-19e4-4074-8cfe-1b11ddebf2c7" xlink:href="nltx-20210331.xsd#nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67aa024e-3215-478f-a829-d7bc2c19e0a9" xlink:to="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_c8e3bc77-19e4-4074-8cfe-1b11ddebf2c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseLiability_acb32fa0-c18d-4798-a9e9-8c98cfca2273" xlink:href="nltx-20210331.xsd#nltx_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67aa024e-3215-478f-a829-d7bc2c19e0a9" xlink:to="loc_nltx_IncreaseDecreaseInOperatingLeaseLiability_acb32fa0-c18d-4798-a9e9-8c98cfca2273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ff4e75e1-1874-42f0-bd31-2b488bcbe48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67aa024e-3215-478f-a829-d7bc2c19e0a9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ff4e75e1-1874-42f0-bd31-2b488bcbe48e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_dd788c8b-857d-4b47-897b-f62ffa28908e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67aa024e-3215-478f-a829-d7bc2c19e0a9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_dd788c8b-857d-4b47-897b-f62ffa28908e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_aff63d35-61cd-4145-9fd4-4079748ac5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67aa024e-3215-478f-a829-d7bc2c19e0a9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_aff63d35-61cd-4145-9fd4-4079748ac5c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Natureofoperations" xlink:type="simple" xlink:href="nltx-20210331.xsd#Natureofoperations"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Natureofoperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="nltx-20210331.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="nltx-20210331.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Cashcashequivalentsandrestrictedcash" xlink:type="simple" xlink:href="nltx-20210331.xsd#Cashcashequivalentsandrestrictedcash"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Cashcashequivalentsandrestrictedcash" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashTables" xlink:type="simple" xlink:href="nltx-20210331.xsd#CashcashequivalentsandrestrictedcashTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#CashcashequivalentsandrestrictedcashAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc348637-ca5c-48d9-88be-91c619aa3b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1ea01282-a7da-4025-8aa8-f7706e49b95e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc348637-ca5c-48d9-88be-91c619aa3b80" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1ea01282-a7da-4025-8aa8-f7706e49b95e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_9fc19e03-0c69-4914-ab8a-7ec8b814e1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc348637-ca5c-48d9-88be-91c619aa3b80" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_9fc19e03-0c69-4914-ab8a-7ec8b814e1f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Leases" xlink:type="simple" xlink:href="nltx-20210331.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#LeasesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Equity" xlink:type="simple" xlink:href="nltx-20210331.xsd#Equity"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Equity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquityTables" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquityTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/EquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquityAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/EquityAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquitySummaryofStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquityScheduleofWeightedAverageAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquityScheduleofStockOptionsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Earningslosspershare" xlink:type="simple" xlink:href="nltx-20210331.xsd#Earningslosspershare"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Earningslosspershare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EarningslosspershareTables" xlink:type="simple" xlink:href="nltx-20210331.xsd#EarningslosspershareTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/EarningslosspershareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>nltx-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:31968e29-d77b-4652-a911-b8dbe2ac7135,g:21241be8-d08e-4bb7-a15e-85390d577d03-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CoverPage" xlink:type="simple" xlink:href="nltx-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/CoverPage" xlink:type="extended" id="i68017ce692c645b4aacbe170339b48c1_CoverPage"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i0970d001f05a4747865fd0e73f2f7a88_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ie56219918ae14fbaa12518a777cd96b1_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i3251452470a3472baad3caf093c2c8c6_CondensedConsolidatedStatementsofOperations"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="idaef82626156433bb6742e100405ca52_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i36e85b9e0a324de4aaca1c0fc86da91a_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_816af07a-3202-4716-ad44-8966f475240b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_816af07a-3202-4716-ad44-8966f475240b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7b5b12a0-a469-4f69-80d6-0a549ae9cb11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_SharesOutstanding_7b5b12a0-a469-4f69-80d6-0a549ae9cb11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aca46251-5cb3-4f40-b483-de78297f304d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_StockholdersEquity_aca46251-5cb3-4f40-b483-de78297f304d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e063acd6-426f-4497-8fab-cba8461a99c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e063acd6-426f-4497-8fab-cba8461a99c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d161b8a7-705e-43a0-9f8e-1eaf138df1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d161b8a7-705e-43a0-9f8e-1eaf138df1cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ebde4e82-5f54-4168-8a9b-c8ddc1adf93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ebde4e82-5f54-4168-8a9b-c8ddc1adf93f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d8a636c4-4078-4c19-839b-3cd40c146d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d8a636c4-4078-4c19-839b-3cd40c146d3f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6d9c62d0-bef4-4073-84ff-5afb4068b7e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_NetIncomeLoss_6d9c62d0-bef4-4073-84ff-5afb4068b7e7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_96b6f751-3a90-40ca-b2af-d78f2bcc8ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dfff5bed-bc32-44a7-b283-0bee9b62ec22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3ce87c70-8f96-4bad-a12b-32122832acc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_816af07a-3202-4716-ad44-8966f475240b" xlink:to="loc_us-gaap_StatementTable_3ce87c70-8f96-4bad-a12b-32122832acc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9244a2c2-dd2b-47d0-88dc-759753744ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3ce87c70-8f96-4bad-a12b-32122832acc2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9244a2c2-dd2b-47d0-88dc-759753744ae3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9244a2c2-dd2b-47d0-88dc-759753744ae3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9244a2c2-dd2b-47d0-88dc-759753744ae3" xlink:to="loc_us-gaap_EquityComponentDomain_9244a2c2-dd2b-47d0-88dc-759753744ae3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb7a1ed5-772e-4878-9321-91557c786372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9244a2c2-dd2b-47d0-88dc-759753744ae3" xlink:to="loc_us-gaap_EquityComponentDomain_cb7a1ed5-772e-4878-9321-91557c786372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7d58861f-d30f-4445-b0f3-3bf4139b34ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb7a1ed5-772e-4878-9321-91557c786372" xlink:to="loc_us-gaap_CommonStockMember_7d58861f-d30f-4445-b0f3-3bf4139b34ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_546490a8-2302-4a24-b06b-257c4d48957e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb7a1ed5-772e-4878-9321-91557c786372" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_546490a8-2302-4a24-b06b-257c4d48957e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4c31d0c1-9ac2-4365-b337-f45af6795be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb7a1ed5-772e-4878-9321-91557c786372" xlink:to="loc_us-gaap_RetainedEarningsMember_4c31d0c1-9ac2-4365-b337-f45af6795be5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Natureofoperations" xlink:type="simple" xlink:href="nltx-20210331.xsd#Natureofoperations"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Natureofoperations" xlink:type="extended" id="ifa0b3d70bfa24600834cf33566b6a66e_Natureofoperations"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="nltx-20210331.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended" id="id42f52e59ba84df0ae3b54af15a76947_Summaryofsignificantaccountingpolicies"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="nltx-20210331.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended" id="i79b76dc117fb49eab29c1ebaad84048d_SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" xlink:type="extended" id="iedd429e1ef8a418daa557d629a251380_SummaryofsignificantaccountingpoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c2bbd2fd-bd1b-4968-afda-0954166dbacc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c75fb017-507a-40ff-8240-c9e14dfe9608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c2bbd2fd-bd1b-4968-afda-0954166dbacc" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c75fb017-507a-40ff-8240-c9e14dfe9608" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0656b923-7851-452e-8c55-3ce1c0faa615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c2bbd2fd-bd1b-4968-afda-0954166dbacc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0656b923-7851-452e-8c55-3ce1c0faa615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9e0e3971-77fb-47e7-9fa5-3b95abbec122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c2bbd2fd-bd1b-4968-afda-0954166dbacc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9e0e3971-77fb-47e7-9fa5-3b95abbec122" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ClassOfWarrantOrRightNoticePeriod_b81e045d-8397-4ae4-b00a-55f6d6e9d930" xlink:href="nltx-20210331.xsd#nltx_ClassOfWarrantOrRightNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c2bbd2fd-bd1b-4968-afda-0954166dbacc" xlink:to="loc_nltx_ClassOfWarrantOrRightNoticePeriod_b81e045d-8397-4ae4-b00a-55f6d6e9d930" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:href="nltx-20210331.xsd#nltx_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c2bbd2fd-bd1b-4968-afda-0954166dbacc" xlink:to="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0728784-3d5e-44c9-8e4e-5a18726ba470" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:to="loc_srt_RangeAxis_c0728784-3d5e-44c9-8e4e-5a18726ba470" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0728784-3d5e-44c9-8e4e-5a18726ba470_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c0728784-3d5e-44c9-8e4e-5a18726ba470" xlink:to="loc_srt_RangeMember_c0728784-3d5e-44c9-8e4e-5a18726ba470_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_daebfcef-985a-439a-93af-eff4bd128d45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c0728784-3d5e-44c9-8e4e-5a18726ba470" xlink:to="loc_srt_RangeMember_daebfcef-985a-439a-93af-eff4bd128d45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ffbea4cf-7471-4e6a-9cd5-c96566b2a35c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_daebfcef-985a-439a-93af-eff4bd128d45" xlink:to="loc_srt_MaximumMember_ffbea4cf-7471-4e6a-9cd5-c96566b2a35c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ad782ae2-615f-49fb-8b2c-2e1276fe53ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ad782ae2-615f-49fb-8b2c-2e1276fe53ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ad782ae2-615f-49fb-8b2c-2e1276fe53ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ad782ae2-615f-49fb-8b2c-2e1276fe53ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ad782ae2-615f-49fb-8b2c-2e1276fe53ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f78e8d0-f272-4131-a733-96d2d527e25b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ad782ae2-615f-49fb-8b2c-2e1276fe53ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f78e8d0-f272-4131-a733-96d2d527e25b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_5813d74d-bf1c-47ef-9c5f-2a1e867d6339" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f78e8d0-f272-4131-a733-96d2d527e25b" xlink:to="loc_srt_OfficeBuildingMember_5813d74d-bf1c-47ef-9c5f-2a1e867d6339" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_821c6f5a-0b79-46f8-b8ad-3b4ca99ce0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_821c6f5a-0b79-46f8-b8ad-3b4ca99ce0e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_821c6f5a-0b79-46f8-b8ad-3b4ca99ce0e0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_821c6f5a-0b79-46f8-b8ad-3b4ca99ce0e0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_821c6f5a-0b79-46f8-b8ad-3b4ca99ce0e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_02b02923-b272-4484-a595-9ca78bf3fe38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_821c6f5a-0b79-46f8-b8ad-3b4ca99ce0e0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_02b02923-b272-4484-a595-9ca78bf3fe38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0cdd2d45-2406-4416-831c-1dad5d80d688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_02b02923-b272-4484-a595-9ca78bf3fe38" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0cdd2d45-2406-4416-831c-1dad5d80d688" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d3eaa46e-dea1-4841-a6c2-c919d908ba37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d3eaa46e-dea1-4841-a6c2-c919d908ba37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d3eaa46e-dea1-4841-a6c2-c919d908ba37_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d3eaa46e-dea1-4841-a6c2-c919d908ba37" xlink:to="loc_us-gaap_ClassOfStockDomain_d3eaa46e-dea1-4841-a6c2-c919d908ba37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9a68114d-02e1-4d70-b8d5-823edb714c62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d3eaa46e-dea1-4841-a6c2-c919d908ba37" xlink:to="loc_us-gaap_ClassOfStockDomain_9a68114d-02e1-4d70-b8d5-823edb714c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedWarrantsMember_4c1ac131-a531-4745-adf6-8ea297d0eb15" xlink:href="nltx-20210331.xsd#nltx_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9a68114d-02e1-4d70-b8d5-823edb714c62" xlink:to="loc_nltx_PreFundedWarrantsMember_4c1ac131-a531-4745-adf6-8ea297d0eb15" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Cashcashequivalentsandrestrictedcash" xlink:type="simple" xlink:href="nltx-20210331.xsd#Cashcashequivalentsandrestrictedcash"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Cashcashequivalentsandrestrictedcash" xlink:type="extended" id="i686dd3c4538b438c98931f371742ec86_Cashcashequivalentsandrestrictedcash"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashTables" xlink:type="simple" xlink:href="nltx-20210331.xsd#CashcashequivalentsandrestrictedcashTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashTables" xlink:type="extended" id="ieac35f7f0f88496a865df1724cabf572_CashcashequivalentsandrestrictedcashTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#CashcashequivalentsandrestrictedcashAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashAdditionalInformationDetails" xlink:type="extended" id="ia387e366c75d40608750a906b4bdb26a_CashcashequivalentsandrestrictedcashAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="ia51e7a1341714bc9ba486024fcce2a66_CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Leases" xlink:type="simple" xlink:href="nltx-20210331.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Leases" xlink:type="extended" id="idd80bd58f5ae4df8bf7c577a6c2ae9bc_Leases"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" id="i0b7858c963764e48835e6dca2c2ff38e_LeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_97ee1a0e-b771-4a72-aaf8-775bf9c15663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_97ee1a0e-b771-4a72-aaf8-775bf9c15663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NumberOfOptionToExtendLease_b2bcac1e-dfa9-46cb-b134-0aac5ac79d4b" xlink:href="nltx-20210331.xsd#nltx_NumberOfOptionToExtendLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_nltx_NumberOfOptionToExtendLease_b2bcac1e-dfa9-46cb-b134-0aac5ac79d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3e948d5b-076a-4053-aa54-5036856f4636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3e948d5b-076a-4053-aa54-5036856f4636" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TenantImprovementAllowance_5a4e6bb6-0326-4575-a33b-0c30d91fe9af" xlink:href="nltx-20210331.xsd#nltx_TenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_nltx_TenantImprovementAllowance_5a4e6bb6-0326-4575-a33b-0c30d91fe9af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TenantImprovementAllowanceReceivable_c9785339-672d-44c4-84d9-3379a21c728e" xlink:href="nltx-20210331.xsd#nltx_TenantImprovementAllowanceReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_nltx_TenantImprovementAllowanceReceivable_c9785339-672d-44c4-84d9-3379a21c728e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_7faf4663-a519-421f-9cb7-296fc4d6796e" xlink:href="nltx-20210331.xsd#nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_7faf4663-a519-421f-9cb7-296fc4d6796e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseLiability_7ff17bec-2d29-4d7e-a97c-b179f9e33144" xlink:href="nltx-20210331.xsd#nltx_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_nltx_IncreaseDecreaseInOperatingLeaseLiability_7ff17bec-2d29-4d7e-a97c-b179f9e33144" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_42aceb63-8d94-4329-b36f-7ef6ca859740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_42aceb63-8d94-4329-b36f-7ef6ca859740" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_c65f25cf-eb4e-41da-bf66-4a2fd5c4ec45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_c65f25cf-eb4e-41da-bf66-4a2fd5c4ec45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1272edfb-ef07-4571-a008-034fbbf94401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1272edfb-ef07-4571-a008-034fbbf94401" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ba4920f0-d9c7-4beb-8280-9db4a70426f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1272edfb-ef07-4571-a008-034fbbf94401" xlink:to="loc_srt_StatementGeographicalAxis_ba4920f0-d9c7-4beb-8280-9db4a70426f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ba4920f0-d9c7-4beb-8280-9db4a70426f4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ba4920f0-d9c7-4beb-8280-9db4a70426f4" xlink:to="loc_srt_SegmentGeographicalDomain_ba4920f0-d9c7-4beb-8280-9db4a70426f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dee6ae4f-0b36-46f9-8987-376907e9e066" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ba4920f0-d9c7-4beb-8280-9db4a70426f4" xlink:to="loc_srt_SegmentGeographicalDomain_dee6ae4f-0b36-46f9-8987-376907e9e066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_d9641d50-d9df-426c-81cf-1280f1259615" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_dee6ae4f-0b36-46f9-8987-376907e9e066" xlink:to="loc_stpr_WA_d9641d50-d9df-426c-81cf-1280f1259615" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_125559cf-1d90-4dd9-a1da-381656fc5f22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1272edfb-ef07-4571-a008-034fbbf94401" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_125559cf-1d90-4dd9-a1da-381656fc5f22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_125559cf-1d90-4dd9-a1da-381656fc5f22_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_125559cf-1d90-4dd9-a1da-381656fc5f22" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_125559cf-1d90-4dd9-a1da-381656fc5f22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f94bb0b2-dcc8-4208-89aa-3f2c1d2a7205" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_125559cf-1d90-4dd9-a1da-381656fc5f22" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f94bb0b2-dcc8-4208-89aa-3f2c1d2a7205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_dfb0e912-830e-42ee-9e9a-6499b4f4c398" xlink:href="nltx-20210331.xsd#nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f94bb0b2-dcc8-4208-89aa-3f2c1d2a7205" xlink:to="loc_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_dfb0e912-830e-42ee-9e9a-6499b4f4c398" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember_026693db-98c1-46b4-9cd3-ad3f2387e03f" xlink:href="nltx-20210331.xsd#nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f94bb0b2-dcc8-4208-89aa-3f2c1d2a7205" xlink:to="loc_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember_026693db-98c1-46b4-9cd3-ad3f2387e03f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Equity" xlink:type="simple" xlink:href="nltx-20210331.xsd#Equity"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Equity" xlink:type="extended" id="i14ec68a2936a474688181dd4df294530_Equity"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquityTables" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquityTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/EquityTables" xlink:type="extended" id="ic8cb6135c91c4b95b2c3d15fe9d31798_EquityTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/EquityAdditionalInformationDetails" xlink:type="extended" id="i1a9f686cba3441458059a7e48c312d99_EquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_88b804ec-d02d-4797-8e66-ecb849f4093a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_88b804ec-d02d-4797-8e66-ecb849f4093a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a0d2b7d5-1833-4105-ab2d-433ec2fb3414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a0d2b7d5-1833-4105-ab2d-433ec2fb3414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_73095508-cd69-4ca5-81f9-4694f1dda48f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_CommonStockSharesIssued_73095508-cd69-4ca5-81f9-4694f1dda48f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f14dd4ea-89bc-401d-ad00-3355402e23fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f14dd4ea-89bc-401d-ad00-3355402e23fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8696dc0e-86e2-4126-9e40-6998252bbc57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8696dc0e-86e2-4126-9e40-6998252bbc57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ClassOfWarrantOrRightNoticePeriod_00db6302-d2da-450b-9219-0db4c0e9256a" xlink:href="nltx-20210331.xsd#nltx_ClassOfWarrantOrRightNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_nltx_ClassOfWarrantOrRightNoticePeriod_00db6302-d2da-450b-9219-0db4c0e9256a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2b498ae7-60c1-45dd-b97d-05167c7a680b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2b498ae7-60c1-45dd-b97d-05167c7a680b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PercentageOfOutstandingStockPerStockholderMaximum_35c998b5-cd2a-4672-bf9b-179413a9458e" xlink:href="nltx-20210331.xsd#nltx_PercentageOfOutstandingStockPerStockholderMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_nltx_PercentageOfOutstandingStockPerStockholderMaximum_35c998b5-cd2a-4672-bf9b-179413a9458e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_54a6c4e9-282a-4743-95f3-32062aefed75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_54a6c4e9-282a-4743-95f3-32062aefed75" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7211dbd4-7094-4888-be33-1518683bc1a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7211dbd4-7094-4888-be33-1518683bc1a7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_192389df-6289-439e-82da-c0a6fa168d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_192389df-6289-439e-82da-c0a6fa168d4e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5bff1ef9-11d7-42bc-a6db-42f487681dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5bff1ef9-11d7-42bc-a6db-42f487681dd6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9a00bb0-48a1-475d-8ba0-43a3257ee4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9a00bb0-48a1-475d-8ba0-43a3257ee4d9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f7cb2410-7474-45de-9d02-bd3329cdd1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f7cb2410-7474-45de-9d02-bd3329cdd1c1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ac1019e4-5e49-41ea-bcbd-18469bc9cb77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ac1019e4-5e49-41ea-bcbd-18469bc9cb77" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_80c54359-ab25-4d80-87d0-1eca817cf9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_80c54359-ab25-4d80-87d0-1eca817cf9fe" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_f80836c5-44bb-4d15-8512-4f2bb5b7b945" xlink:href="nltx-20210331.xsd#nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_f80836c5-44bb-4d15-8512-4f2bb5b7b945" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_4524a2e6-9994-4e6f-bfd0-e207f8932c95" xlink:href="nltx-20210331.xsd#nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_4524a2e6-9994-4e6f-bfd0-e207f8932c95" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a630ef7-2347-46a4-94d9-698a3686a6af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a630ef7-2347-46a4-94d9-698a3686a6af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_48ad2977-1f12-4178-9fe3-facffc39e580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a630ef7-2347-46a4-94d9-698a3686a6af" xlink:to="loc_us-gaap_AwardTypeAxis_48ad2977-1f12-4178-9fe3-facffc39e580" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ad2977-1f12-4178-9fe3-facffc39e580_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_48ad2977-1f12-4178-9fe3-facffc39e580" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ad2977-1f12-4178-9fe3-facffc39e580_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_667d58f9-5aa9-43ce-929d-5cb55ccfee82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_48ad2977-1f12-4178-9fe3-facffc39e580" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_667d58f9-5aa9-43ce-929d-5cb55ccfee82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b2611f09-e104-4d4c-a3e7-457c2e217c20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_667d58f9-5aa9-43ce-929d-5cb55ccfee82" xlink:to="loc_us-gaap_EmployeeStockMember_b2611f09-e104-4d4c-a3e7-457c2e217c20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_aaa52237-be79-4f4b-bf88-f04e003ec6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a630ef7-2347-46a4-94d9-698a3686a6af" xlink:to="loc_us-gaap_PlanNameAxis_aaa52237-be79-4f4b-bf88-f04e003ec6d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aaa52237-be79-4f4b-bf88-f04e003ec6d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_aaa52237-be79-4f4b-bf88-f04e003ec6d6" xlink:to="loc_us-gaap_PlanNameDomain_aaa52237-be79-4f4b-bf88-f04e003ec6d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ace25562-1f20-4fb3-b053-80139079b3ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_aaa52237-be79-4f4b-bf88-f04e003ec6d6" xlink:to="loc_us-gaap_PlanNameDomain_ace25562-1f20-4fb3-b053-80139079b3ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_A2020EmployeeStockPurchasePlanMember_8e581b40-16a3-4845-a6d2-1de3cbb66516" xlink:href="nltx-20210331.xsd#nltx_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ace25562-1f20-4fb3-b053-80139079b3ff" xlink:to="loc_nltx_A2020EmployeeStockPurchasePlanMember_8e581b40-16a3-4845-a6d2-1de3cbb66516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_77e4aea8-30a1-4375-b8a1-df942b227d61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a630ef7-2347-46a4-94d9-698a3686a6af" xlink:to="loc_us-gaap_StatementClassOfStockAxis_77e4aea8-30a1-4375-b8a1-df942b227d61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_77e4aea8-30a1-4375-b8a1-df942b227d61_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_77e4aea8-30a1-4375-b8a1-df942b227d61" xlink:to="loc_us-gaap_ClassOfStockDomain_77e4aea8-30a1-4375-b8a1-df942b227d61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ec78729e-b3c0-4a1c-b2a5-5a6a79fb459c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_77e4aea8-30a1-4375-b8a1-df942b227d61" xlink:to="loc_us-gaap_ClassOfStockDomain_ec78729e-b3c0-4a1c-b2a5-5a6a79fb459c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedWarrantsMember_56445eeb-e547-4d93-a1f8-858f3ec6ea98" xlink:href="nltx-20210331.xsd#nltx_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ec78729e-b3c0-4a1c-b2a5-5a6a79fb459c" xlink:to="loc_nltx_PreFundedWarrantsMember_56445eeb-e547-4d93-a1f8-858f3ec6ea98" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquitySummaryofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i67745da877d54d57b29861e45203c12c_EquitySummaryofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e47c2e-9c32-4809-a79f-b0a6092e92c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7efbcb87-f274-4e3d-8181-78f065352812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e47c2e-9c32-4809-a79f-b0a6092e92c3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7efbcb87-f274-4e3d-8181-78f065352812" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_409594aa-d0d4-4c76-b3b8-b8f64a75c1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e47c2e-9c32-4809-a79f-b0a6092e92c3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_409594aa-d0d4-4c76-b3b8-b8f64a75c1a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_60489a3b-0e44-4982-b49b-85eca42f022e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_409594aa-d0d4-4c76-b3b8-b8f64a75c1a3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_60489a3b-0e44-4982-b49b-85eca42f022e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_60489a3b-0e44-4982-b49b-85eca42f022e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_60489a3b-0e44-4982-b49b-85eca42f022e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_60489a3b-0e44-4982-b49b-85eca42f022e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d544b344-1989-4b9c-9cec-8d4465d6a750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_60489a3b-0e44-4982-b49b-85eca42f022e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d544b344-1989-4b9c-9cec-8d4465d6a750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8fde495f-9707-4d5e-ab8f-77380bcf6572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d544b344-1989-4b9c-9cec-8d4465d6a750" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8fde495f-9707-4d5e-ab8f-77380bcf6572" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e88e5ec6-8687-4329-a05b-6d6f27e79b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d544b344-1989-4b9c-9cec-8d4465d6a750" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e88e5ec6-8687-4329-a05b-6d6f27e79b89" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquityScheduleofWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended" id="i34c49a256c9c4bbca7ba596cb2d4ff07_EquityScheduleofWeightedAverageAssumptionsDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquityScheduleofStockOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails" xlink:type="extended" id="ic7004c2de7c14fa69a78b529cf82bb41_EquityScheduleofStockOptionsActivityDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails" xlink:type="extended" id="i700a5c1291d1497a871a115a7ba4c13d_EquitySummaryofNonvestedRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5054da3c-e53b-44f1-b087-80dbcc7441ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5054da3c-e53b-44f1-b087-80dbcc7441ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6ff9d83-c633-48d1-89e7-f2014e1664dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6ff9d83-c633-48d1-89e7-f2014e1664dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4f818dc4-a7f5-440a-83e0-d03101f0c7c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4f818dc4-a7f5-440a-83e0-d03101f0c7c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c3fa0ae7-1889-4f4d-b43a-0cbbd57f7537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c3fa0ae7-1889-4f4d-b43a-0cbbd57f7537" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4a74d925-496d-4846-b17e-c3b40580e78f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4a74d925-496d-4846-b17e-c3b40580e78f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af1a820c-302e-4a32-9257-085bac6ffd06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5054da3c-e53b-44f1-b087-80dbcc7441ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3664d162-53da-4119-9d59-732ce2315de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3664d162-53da-4119-9d59-732ce2315de5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a81b1c74-88fa-447c-b33a-b41c71efe389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a81b1c74-88fa-447c-b33a-b41c71efe389" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3e00d271-f211-4d86-b1c4-1327267fbf1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3e00d271-f211-4d86-b1c4-1327267fbf1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9c4aa22f-a4a7-4059-877a-8611eb432abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9c4aa22f-a4a7-4059-877a-8611eb432abe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cd211f53-effc-4dc1-b280-af5cad2d84ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_250f7721-5952-4746-9283-3b9d09640912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5054da3c-e53b-44f1-b087-80dbcc7441ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_250f7721-5952-4746-9283-3b9d09640912" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c29a6a6-7cc9-41bc-b011-20308d30b27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_250f7721-5952-4746-9283-3b9d09640912" xlink:to="loc_us-gaap_AwardTypeAxis_7c29a6a6-7cc9-41bc-b011-20308d30b27b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c29a6a6-7cc9-41bc-b011-20308d30b27b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7c29a6a6-7cc9-41bc-b011-20308d30b27b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c29a6a6-7cc9-41bc-b011-20308d30b27b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe9fb30b-1195-4b29-aac5-3c1e53d54b63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7c29a6a6-7cc9-41bc-b011-20308d30b27b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe9fb30b-1195-4b29-aac5-3c1e53d54b63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5033c0b7-7c50-4576-8a59-8fe8dd300f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe9fb30b-1195-4b29-aac5-3c1e53d54b63" xlink:to="loc_us-gaap_RestrictedStockMember_5033c0b7-7c50-4576-8a59-8fe8dd300f85" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Earningslosspershare" xlink:type="simple" xlink:href="nltx-20210331.xsd#Earningslosspershare"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Earningslosspershare" xlink:type="extended" id="i9ca5a2f27d024709be2ba53c1547160a_Earningslosspershare"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EarningslosspershareTables" xlink:type="simple" xlink:href="nltx-20210331.xsd#EarningslosspershareTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/EarningslosspershareTables" xlink:type="extended" id="i083854acc4404a268e88cb29e4a29901_EarningslosspershareTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails" xlink:type="extended" id="i809a7e1a1cce455abf0a3d1afd48b193_EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2f1a2e3f-d89e-417a-b7b6-ab40a9b965b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_df16dfbb-356c-4970-9290-41241d5295bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2f1a2e3f-d89e-417a-b7b6-ab40a9b965b0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_df16dfbb-356c-4970-9290-41241d5295bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a945b086-9678-4335-b2de-42060e0fba62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2f1a2e3f-d89e-417a-b7b6-ab40a9b965b0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a945b086-9678-4335-b2de-42060e0fba62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_061b7cd9-d357-4ae5-b26e-ecfb4ac3608f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a945b086-9678-4335-b2de-42060e0fba62" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_061b7cd9-d357-4ae5-b26e-ecfb4ac3608f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_061b7cd9-d357-4ae5-b26e-ecfb4ac3608f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_061b7cd9-d357-4ae5-b26e-ecfb4ac3608f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_061b7cd9-d357-4ae5-b26e-ecfb4ac3608f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_237acb8d-70b5-4ecc-992b-7c7a3db7f48c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_061b7cd9-d357-4ae5-b26e-ecfb4ac3608f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_237acb8d-70b5-4ecc-992b-7c7a3db7f48c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2de0fd1b-d483-4b02-8a34-4f4e570693fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_237acb8d-70b5-4ecc-992b-7c7a3db7f48c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2de0fd1b-d483-4b02-8a34-4f4e570693fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_35629ae8-8adf-4786-82d2-025c9206e25d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_237acb8d-70b5-4ecc-992b-7c7a3db7f48c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_35629ae8-8adf-4786-82d2-025c9206e25d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5fd91150-8a9e-426e-9b7d-b8272f6c592e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_237acb8d-70b5-4ecc-992b-7c7a3db7f48c" xlink:to="loc_us-gaap_EmployeeStockMember_5fd91150-8a9e-426e-9b7d-b8272f6c592e" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>nltx-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:31968e29-d77b-4652-a911-b8dbe2ac7135,g:21241be8-d08e-4bb7-a15e-85390d577d03-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_04aa803b-2e1f-4d0d-841f-e5fe0458c9f4_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square feet of office space leased</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_245bdedd-79e1-4dde-865d-36a0668c87f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_3585841b-ee86-4e34-8278-0890987b0dd7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6d7d1495-e947-47f9-9cfa-94c90cad7221_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_265a801e-6e05-4d9b-b670-abc226002257_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_05e57d47-8311-4cb5-ba3d-4e2deeb0541d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2d16972b-989b-4eb9-b16d-05191e5d6975_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_97a386f0-2bfa-4c31-b755-00edd535dc22_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f940ecfc-5574-4418-9c81-927663bbe752_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_12568726-7263-43af-b925-f2bb537393cc_negatedLabel_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_8a09da44-5a74-4bde-baf4-1903aa2f96e2_terseLabel_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in right-of-use asset</link:label>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Right of Use Assets</link:label>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Right of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:href="nltx-20210331.xsd#nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a565472c-7864-4340-b5bf-7e5b1ba02248_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_445b2c38-9315-45de-8fa4-5b95fb2acbe0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_6342a886-2386-4fe2-834f-c5ec93b79c17_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_76a1b70d-31a1-4152-857a-e6696d268ea1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5eb32692-eddc-4a62-9d09-b96b7e6f1747_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e2dc8e2b-fc7e-4d16-85cc-fd561c2e8f23_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember_43f13140-f5db-4a6d-835e-eef25651a9a3_terseLabel_en-US" xlink:label="lab_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space, additional offices and laboratory</link:label>
    <link:label id="lab_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember_label_en-US" xlink:label="lab_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space, Additional Offices and Laboratory [Member]</link:label>
    <link:label id="lab_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember_documentation_en-US" xlink:label="lab_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space, Additional Offices and Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember" xlink:href="nltx-20210331.xsd#nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember" xlink:to="lab_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_7fab9f22-a889-4043-961a-f7d1708112a0_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b83127ab-79b9-4e76-9d74-8c9fe73777b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4d486e02-f090-428f-ba15-2a210496606a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_aa0aeaad-ab55-44d9-9d7b-ee1695b2f05e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_0c706c5b-339b-4eb5-abaa-583b6be92b37_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5a7a639e-3145-4e35-ae49-1bde9fa64479_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_e1c9b945-6ff2-46b9-912b-1e182e3dc0c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cba34aae-a37a-4b8d-b22e-8cf77bdaaeb5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7064dc29-001d-4cc4-a765-ba51fc6857c3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a2210b34-0fcb-4c70-aa5b-52a09fb64941_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_33fe23f5-012c-41bf-8b31-b26255e01f1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_28902c78-453d-4438-b2d8-1b8d6ac4b2e2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b58ee621-8139-4c0a-9452-6470addc70c3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ea18fa41-d55b-4b24-87e9-4115adcdfd59_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_58edf4ac-6fdd-4dec-8f2d-421976d9c436_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_84b43848-cbaa-4011-a0a7-2400f624dca4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fec87f54-b556-4b68-8225-f4c2155fc83d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_64e06dfe-b923-4925-a7bf-fe9c662b14e9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33336b55-76cf-451e-b420-fc7714628bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_3dc74191-5cd0-45df-ba9a-48b94a661540_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b3bea057-ff56-4868-9bb6-e12dae643076_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8e609868-8476-4d9a-affe-9e4187087cb4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_98adba62-64d5-4289-8b3b-6c33bd357f9d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_fe410ead-6da5-4a7c-8fd3-55f747d7cad0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b81f4a72-ef2b-4a42-81ea-793f81f17723_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_842f4a07-430b-4b73-a03b-c25ad9692613_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_059e3771-dbcd-48ed-bc36-65e640e48c06_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9be624ea-3702-4371-9149-034bc51dfdae_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_948d5bfa-eaf0-492c-9539-db14bb0ea7f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5dccd23-3b57-4635-8566-344222696686_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_362077ff-7f15-4972-bb23-e74173a306b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e523624f-0df3-4ae1-9186-56ce06f183ff_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_857b2e5a-d961-4a17-8a20-bc4cc8d7b9c8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficeBuildingMember_0cdf1187-cd50-4599-8748-3067f99d9291_terseLabel_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space</link:label>
    <link:label id="lab_srt_OfficeBuildingMember_label_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficeBuildingMember" xlink:to="lab_srt_OfficeBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_b79939e3-3f5a-4744-8b33-4d18b1636222_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP, purchase price of common stock, percent of market price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_51c57406-0f39-4dea-950e-64bebb94750f_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_ffcf10c0-0348-45be-98cd-de7ce491a69d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_74b436da-5739-4a31-9c5e-ec3700733858_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock - $0.000001 par value - authorized, 5,000,000 as of March 31, 2021 and December 31, 2020; 0 issued and outstanding as of March 31, 2021 and December 31, 2020.</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b919dc91-9f1a-475e-a1a6-84e4d1def0b7_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7004a69d-86fe-41db-b18c-cd3312739226_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Number of Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5b5ebafc-3707-4563-904f-440df8cdd194_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_A2020EmployeeStockPurchasePlanMember_f2601d34-a470-4fda-ac2c-402013166206_terseLabel_en-US" xlink:label="lab_nltx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_nltx_A2020EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_nltx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_nltx_A2020EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_nltx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_A2020EmployeeStockPurchasePlanMember" xlink:href="nltx-20210331.xsd#nltx_A2020EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_A2020EmployeeStockPurchasePlanMember" xlink:to="lab_nltx_A2020EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f4e7cfa2-b373-4e04-9c2b-dda78f660e14_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_16a8fb82-e4f7-4a49-855a-0255d7a5f5af_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding pre-funded warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_3ccfeaa4-3c2e-4710-998c-b72b64d6bce1_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment on finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_TenantImprovementAllowanceReceivable_d427b17e-2a92-49cf-b6dc-b16e295ffa2c_terseLabel_en-US" xlink:label="lab_nltx_TenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance receivable reimbursable by the landlord</link:label>
    <link:label id="lab_nltx_TenantImprovementAllowanceReceivable_label_en-US" xlink:label="lab_nltx_TenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance Receivable</link:label>
    <link:label id="lab_nltx_TenantImprovementAllowanceReceivable_documentation_en-US" xlink:label="lab_nltx_TenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Element represents the carrying amount as of balance sheet date of amounts receivable related to tenant improvement allowance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TenantImprovementAllowanceReceivable" xlink:href="nltx-20210331.xsd#nltx_TenantImprovementAllowanceReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_TenantImprovementAllowanceReceivable" xlink:to="lab_nltx_TenantImprovementAllowanceReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_16efeddd-57ea-4bc1-afee-e91cd9389aa4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0423ad89-7766-4428-b645-2f6b91d4f44e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_46412d52-6875-4cee-9b59-61ccb115597c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_390666e8-350c-4186-949d-d6386363abe0_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_73f1fd24-b077-4397-810e-8c7b66f95f08_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled/ forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3d3d869a-0390-4077-b7c5-f5b081979990_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_52c54321-7231-4879-a3ff-93182f8e6427_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f21fab47-93b5-409e-8584-021cc6f30142_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ae8c1c3e-2520-4a3f-9f3e-25e826db8bd8_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c293982b-a5ab-4d5b-9137-516d5efcff29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ffe79b06-6503-4abe-a841-3dd3f72fc618_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_957dfe61-a55d-476c-9742-0c29b0675593_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8099dd65-8023-42cc-97c5-5281ebfceceb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of potentially dilutive shares from diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_1a6e2365-b416-46ab-ae37-4ecd59acab41_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ea10ee56-3697-47d2-a14b-7487fecb1294_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common stock &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_f12ab8aa-fc48-4c3b-b38c-ed95b23b9430_terseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Washington</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_96200e93-adcd-4d6c-b482-01078d1ac7b8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected terms (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_NumberOfOptionToExtendLease_880d2335-4194-4973-9c6c-91594a61437e_terseLabel_en-US" xlink:label="lab_nltx_NumberOfOptionToExtendLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of option to extend leases</link:label>
    <link:label id="lab_nltx_NumberOfOptionToExtendLease_label_en-US" xlink:label="lab_nltx_NumberOfOptionToExtendLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Option To Extend Lease</link:label>
    <link:label id="lab_nltx_NumberOfOptionToExtendLease_documentation_en-US" xlink:label="lab_nltx_NumberOfOptionToExtendLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of option to extend lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NumberOfOptionToExtendLease" xlink:href="nltx-20210331.xsd#nltx_NumberOfOptionToExtendLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_NumberOfOptionToExtendLease" xlink:to="lab_nltx_NumberOfOptionToExtendLease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b7ac2ab9-ed9e-4d48-88d0-c60673aa9f12_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0e2e8d47-1650-456c-b214-74b588a4c8ef_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8ba92652-797e-4de3-ad68-551663524055_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c2f2aa68-510d-4ea9-a667-5f20334e6023_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_609b919c-4e96-46f4-85d9-01a3c73daddc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b96c63d1-5430-4bb0-9aa7-2b936e07f8ca_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_88163b86-57b3-49ac-af86-c85dd7e2e991_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_df821fac-a4e0-403d-8b8c-f3d6455212c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d10051ac-f7d4-4fab-b6ed-fefaf70281d8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1d615659-bf23-4230-9acb-643b3fb0a1b8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of pre-funded warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2300ffcd-4a63-4413-ba04-bd58c361f618_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - $0.000001 par value - authorized, 100,000,000 as of March 31, 2021 and December 31, 2020; issued and outstanding, 42,326,033 as of March 31, 2021 and 42,196,296 as of December 31, 2020.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_635f0417-17c3-4ae9-a32f-ba5c35adc26c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f09e91e6-6430-4159-81f5-9cb3b228f8be_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5d35ee9e-549e-4b51-8da2-e0cd66bd8391_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_00d69a8e-37a9-4b84-b8ab-06fb4d4915f3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_247c56ba-2580-47f9-96fd-343d7e4878bf_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_32482619-57c3-4808-8539-b15881d88aa5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Weighted Average Remaining Contractual Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_60981027-7827-4e68-9d4d-944e49d1a6ef_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_641933ce-3b45-49fb-9114-8dbb98f5907c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_72daed86-eb46-476f-82bd-1ea825cf55ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_b6f38b3b-121b-47b5-b451-2bdca153e4b6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_26980384-74c7-4496-8fbe-7ebdfac13d19_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b8df4684-51d5-4c4c-9519-edb690f74f15_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_99893050-3e94-402c-af35-4babe1bb61d4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5692c77-4f46-4988-a677-948df1b3c431_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f4f22e08-3312-4467-a0bb-7a6daf8efed9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2e66ce40-0086-4430-9524-f3323c2d2376_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c2adec69-2062-406a-8a0e-3de3b6433eba_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_07e3ff18-db39-4fd7-bf9f-4e4a3e09949b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_36a0d1f1-c163-4c3e-97ba-16afb009e5d3_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_6f39b2ce-bf15-4fb7-a018-8731c17efc96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2c4bae33-c6c2-4f4d-be2f-2eab087de3ae_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock_96850384-39b8-4b0a-8488-5016913b06fd_terseLabel_en-US" xlink:label="lab_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock_label_en-US" xlink:label="lab_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Restricted Cash1 Disclosure [Text Block]</link:label>
    <link:label id="lab_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock_documentation_en-US" xlink:label="lab_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Restricted Cash Disclosure Text Block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock" xlink:href="nltx-20210331.xsd#nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock" xlink:to="lab_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_058f6c30-8afb-4e83-8c98-0658cca05879_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment unpaid at period-end</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ebb40a58-c517-4b90-be1f-43037a98b153_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a056b4bc-2f52-4767-8a7e-b632ae1abd6f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_9fa712c3-677b-4182-8b4d-c9c5d5a3b86d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f063d5ad-1631-44aa-a3f0-2caa1dd21d1e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e93f3eeb-1c37-4361-a937-591a7994a5eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP max contribution rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ab4ebd05-4442-4414-845f-11ec7f31b66f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1cac6fbf-4c9e-4132-bc38-1addd1521b9e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_e1c84d78-7eb0-4dda-aef1-0c7960e18fa8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement extended period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_dbe07894-bfe5-4d8d-bc36-7e60f67f5a25_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58d0634e-fd52-4536-88b4-34d33b873dc6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_7a11a607-6f8f-4b48-be1e-18e8d1a99449_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable under 2020 ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6a497584-a8a2-4ea5-94bc-d9e8b72b26a4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_73aec897-0b63-4c1d-a2d4-d70d4fb870d7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4ba03c1b-45c1-4d8b-8fff-2ec55ba530c0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5fe2654b-0436-401c-95ea-c67634c46701_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_897ea6b8-3c52-4321-9ad6-b535d8c14d2c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53e46c74-4de9-47f8-b8ec-afc69119a38c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c1b23941-bd47-47ec-aec1-c786e39e26fd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5efbc752-70c0-4ac7-b27d-132cd5bfece0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_43c517f6-cb6b-47fd-a467-1ad3207a6f05_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e396f85f-c74e-4746-abf4-5a53f14de9b0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1c8de3d9-a4a1-4bad-8ee1-193e0769b381_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_ce1fb367-2b5e-4762-9186-2bdb53f3a319_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_906630bf-7dd4-48fb-a65b-7fef828e630c_terseLabel_en-US" xlink:label="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP number of offerings per year</link:label>
    <link:label id="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_label_en-US" xlink:label="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Number Of Offering Per Year</link:label>
    <link:label id="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_documentation_en-US" xlink:label="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">employee stock purchase plan number of offering per year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" xlink:href="nltx-20210331.xsd#nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" xlink:to="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_804322c1-c3e0-43d2-bdaf-e37f2d29a610_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_TenantImprovementAllowance_63813ea0-f3f2-4795-bb39-4144be1ec110_terseLabel_en-US" xlink:label="lab_nltx_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements (up to)</link:label>
    <link:label id="lab_nltx_TenantImprovementAllowance_label_en-US" xlink:label="lab_nltx_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance</link:label>
    <link:label id="lab_nltx_TenantImprovementAllowance_documentation_en-US" xlink:label="lab_nltx_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of tenant improvement allowance pursuant to lease arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TenantImprovementAllowance" xlink:href="nltx-20210331.xsd#nltx_TenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_TenantImprovementAllowance" xlink:to="lab_nltx_TenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_374732d4-cc88-4664-8eec-82b2624532af_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_6cabe5a4-a111-43c6-9b7d-4e8fdb8191cb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_151679a7-9989-4041-952b-85c31c380de3_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_086aa7f0-0881-481e-bed8-5d0a70dcb3a9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_11e3f540-c6b0-490e-b2ba-096143b38867_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseLiability_8269ebc5-5fb2-4aae-914a-aeacfbc0e876_terseLabel_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseLiability_64e1f89b-c430-44a9-b151-5588cc324c64_verboseLabel_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in lease liability</link:label>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="nltx-20210331.xsd#nltx_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_nltx_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f7446d99-197e-4ef5-b641-0ff3605924ae_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_67d39feb-5c1d-48e1-8b0e-0565089abfc0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b489e48e-7067-4aeb-8e71-e07e9247e444_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5b876616-af74-4615-9e56-259fc428c22b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3992767f-981a-4afc-82aa-3d21116e85a5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7dee1eba-4ebf-4c81-8fa9-bc4836b91fa7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_121094f4-ed56-417f-8a38-1c09b04bf094_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f02c430e-1c5d-4fcd-8dd8-39af43e8b5e6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d944230e-e033-43e3-8f43-f07254a5a0d9_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign exchange (gain)/loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2dc8263a-042b-47df-ad0b-21b3a79a578e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1c08e861-16ad-4103-867f-c11ac2f0182f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value for options granted in period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f12932f3-800d-4ef7-8056-db2451f4b5cb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_057ef672-6cea-4114-bf1d-23983d7080ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2ed178a8-0e57-426c-9f47-18af061090f9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_053d6440-3c58-4f9d-a78c-716bc0bd1690_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_63c40ea5-f89c-4249-8334-d38713489942_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract" xlink:to="lab_us-gaap_LesseeDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_136ce545-9cdf-4e06-b557-11975c40383c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d4f03ca1-cca8-4d00-b8cd-00fbd17ec816_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_71b319b0-68ed-4a38-969f-403054c83afa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost, weighted-average period recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_SignificantAccountingPoliciesTable_22e8cc61-5fbf-459e-91b4-677225444205_terseLabel_en-US" xlink:label="lab_nltx_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nltx_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nltx_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nltx_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nltx_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SignificantAccountingPoliciesTable" xlink:href="nltx-20210331.xsd#nltx_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_SignificantAccountingPoliciesTable" xlink:to="lab_nltx_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ca75563b-4040-4b6c-9f2a-c7a3ff31746e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c4596b4a-676e-45c1-b6f0-46f1c0bad98f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_367cfb54-0bcc-4d27-9718-1b369d1f15da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4179c1c3-76c5-4dbd-a6dc-d70925fea9d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e72d895-82ea-49de-a3d7-3b15182a5c31_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7394ce6c-85e7-419c-9e78-a594b86f3663_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_84a5bb75-2162-4d75-aa40-6c5397418abe_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_060f7d95-62b5-4098-b205-4ab82ff00316_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5646b6d8-7d36-412a-8a36-1cc055dbb1a9_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ff204893-2f17-4ca6-a59a-eadaa8084951_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77f7d4f9-11ac-4f3a-a45d-1323d67339a5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eec28a3d-1686-45a4-ba12-3d6d09902fed_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon exercises of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a0b22e1c-da98-45f7-80b6-3143b6c0c2c8_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_PreFundedWarrantsMember_38592321-206d-4894-8be2-a38fec7e4c14_terseLabel_en-US" xlink:label="lab_nltx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants</link:label>
    <link:label id="lab_nltx_PreFundedWarrantsMember_label_en-US" xlink:label="lab_nltx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
    <link:label id="lab_nltx_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_nltx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre funded warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedWarrantsMember" xlink:href="nltx-20210331.xsd#nltx_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_PreFundedWarrantsMember" xlink:to="lab_nltx_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0bb95e39-1a35-44f5-bf7b-93582464d7a4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash during the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_b360f64c-be43-47bc-9a10-4083be3288cd_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (loss), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_9bb71f84-2ba1-428f-a998-0bc50f55a035_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_ebd79ab6-dc9c-4eed-bd17-36f1638b142e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c639d0d5-7247-4283-bd16-9f1952f8d5fc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c957d6fd-fb7f-44b8-9744-6bba00e33209_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_16c066af-75a4-446e-828d-94c6ed9c1929_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ec6ff619-ab4f-4aa7-afcb-45bd79006acb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_056f469a-ca24-4c5f-9214-14336847c7e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d1c5d24c-8a00-4813-8942-87cbfb6bdeef_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e8456fed-8cb5-4956-8b10-9c5e058846b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled/forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1578fdac-b8a8-4026-99c2-22352458e64c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_933283cc-f3ee-4146-bb90-3024b285c4cb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_33bfb425-a73b-4117-9961-0127cdbb1e46_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_cb70cc54-35cc-4b60-a4b3-e992fbfbf517_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_683fd2b8-b2b8-4cb1-9f5f-b898b598e0d0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_1ac49ccd-db1a-4d95-9923-adb9bc1997e9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_04538e72-b75d-4578-bafc-69046dceabc8_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities arising from obtaining ROU asset</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_545963bd-79ce-479e-8b20-a3e5539e890a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e636ba8b-885e-435d-82c7-8c021e68a22c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b12361d7-0720-450f-b76e-f36a8f19cb5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79fac168-9e20-4755-b22c-eeed4bb40d39_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34ecca07-1bcb-4caf-ad4f-25a635fd0081_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5272bf26-78cf-4c05-9007-c3f3853ac809_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_f0b1e4f2-2792-48fd-9413-84251262c727_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_dfe3778e-3fc2-442c-8376-82f2b2ac1e85_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common stock &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_887b9dc7-a73f-412c-9416-a58d2b05da71_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_383eceb5-6eb1-4117-9c15-2136389371bb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_034e80ac-2e3f-4f20-9ec8-2ed7cdc2a1e1_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_45107bd5-fbbf-462c-997d-6c46353486e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_059bc9df-0768-47a3-8461-4c140caeab7c_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates and assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_323fd586-2eae-4d9f-a41f-1811759680c7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fb448ffc-6362-4c84-8420-9e38dde63921_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_bdd1e466-f432-4604-98c8-851e73a3b45a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_71363083-9eaf-49f2-a669-c3ed7486e145_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6f32ef61-0f2b-4dda-b483-6d5ca7701b32_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_077bc7cf-9440-4a38-89cf-7b0347b9bf86_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon exercises of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_728ad49e-100a-43ab-8cd6-f85f556cb616_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_eba1dfdb-0acd-43ca-8d24-2e0b0777e60c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum_34fad5e1-0583-47fa-b12e-7db4af2c9521_terseLabel_en-US" xlink:label="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding stock per stockholder, maximum</link:label>
    <link:label id="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum_label_en-US" xlink:label="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Outstanding Stock Per Stockholder, Maximum</link:label>
    <link:label id="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum_documentation_en-US" xlink:label="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Outstanding Stock Per Stockholder, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PercentageOfOutstandingStockPerStockholderMaximum" xlink:href="nltx-20210331.xsd#nltx_PercentageOfOutstandingStockPerStockholderMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_PercentageOfOutstandingStockPerStockholderMaximum" xlink:to="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f57712be-483a-4487-b454-5e1360aa4f07_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_503a3739-b8b9-4bdb-93db-23b7394f9d87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_467ada5c-25ff-42d9-8367-0f3d9b1f33f5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3037c4cd-f437-46a4-aabd-e8ebf0c5de1d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a8c44afe-3851-4b51-ba33-70d28ab253b2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2b71b265-1111-4296-bab2-6cc8ede3eecb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c6350a68-6995-4cbe-80d7-782808e56c61_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_849d9c4b-3892-445d-8d91-bdb8cd7b42df_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c1e91000-0049-44aa-9f95-f38228323735_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ec045fe6-c210-4166-8cdd-36e55be8b7de_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares reserved for issuance under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_01120888-3568-4ed9-b962-28e7fed0f4b8_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8b5c8194-5bbe-4ec5-b079-9838c13c4760_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9a3f2a2e-4c18-446a-8e13-9f4980bbddfe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ede09c35-684d-4956-8768-bb0e6527e90d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f872860d-9aec-4b3e-9b7f-ca6cc89f9862_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_fa5c8f0b-0456-4798-868f-484bce791352_terseLabel_en-US" xlink:label="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space, principal executive offices and laboratory</link:label>
    <link:label id="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_label_en-US" xlink:label="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space, Principal Executive Offices and Laboratory [Member]</link:label>
    <link:label id="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_documentation_en-US" xlink:label="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space, Principal Executive Offices and Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" xlink:href="nltx-20210331.xsd#nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" xlink:to="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41004644-f88d-40aa-a04b-35cca9ecf530_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_01457438-cf9a-4b19-9169-9af51d478258_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_ClassOfWarrantOrRightNoticePeriod_06b132b0-6839-4b09-b811-ae8570f18528_terseLabel_en-US" xlink:label="lab_nltx_ClassOfWarrantOrRightNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, notice period for nominal cash consideration</link:label>
    <link:label id="lab_nltx_ClassOfWarrantOrRightNoticePeriod_label_en-US" xlink:label="lab_nltx_ClassOfWarrantOrRightNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Notice Period</link:label>
    <link:label id="lab_nltx_ClassOfWarrantOrRightNoticePeriod_documentation_en-US" xlink:label="lab_nltx_ClassOfWarrantOrRightNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ClassOfWarrantOrRightNoticePeriod" xlink:href="nltx-20210331.xsd#nltx_ClassOfWarrantOrRightNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_ClassOfWarrantOrRightNoticePeriod" xlink:to="lab_nltx_ClassOfWarrantOrRightNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_d73fb490-3d5b-4368-8b16-8c9d58fc5cb2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ad35cc0e-d5a5-43bd-ae38-ca243d585eab_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLossAbstract_a029efd4-d28d-44cf-8bbd-2cdce5c18e51_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract" xlink:to="lab_us-gaap_OperatingIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d89f2855-2e78-43fd-853e-a81d7a0d22e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_63daf64a-ba90-434c-ba1d-4b72049cf757_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9c260c10-daa7-4d22-a845-26cce47aa99a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_c3af3da6-3b99-4b31-bdc4-5dcf19b38a2e_terseLabel_en-US" xlink:label="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP offering period</link:label>
    <link:label id="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="nltx-20210331.xsd#nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_14c92d28-d342-4840-a3d1-9ff417a079a4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ba670c1-8575-4423-bfc6-27c0467ba39f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ead180d8-c0a8-46ab-84fa-bb8fce8d6bfd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fd2db103-a494-4d62-8bfd-e9f885c4d520_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_46ae0bb1-ac94-43dc-b7c8-6ee632c4f3fb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently issued and recently adopted accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_498cbbf5-fd64-4c84-b9aa-13f2e7f85d74_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_06c2d2c8-5bf0-4683-9eae-9a1f9f19fce9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>nltx-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:31968e29-d77b-4652-a911-b8dbe2ac7135,g:21241be8-d08e-4bb7-a15e-85390d577d03-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CoverPage" xlink:type="simple" xlink:href="nltx-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f2a6dbb3-c3b0-475b-a6fa-dce46a15148b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_DocumentType_f2a6dbb3-c3b0-475b-a6fa-dce46a15148b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_be456624-e5d7-4e8e-bd02-71a9e91f90cf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_DocumentQuarterlyReport_be456624-e5d7-4e8e-bd02-71a9e91f90cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9dd1ac53-449f-40c6-8664-db2da8fdef3f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_DocumentPeriodEndDate_9dd1ac53-449f-40c6-8664-db2da8fdef3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_22a3e079-7c45-4c68-95c5-68704828ebdc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_DocumentTransitionReport_22a3e079-7c45-4c68-95c5-68704828ebdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_822e8447-8e0b-49b3-a276-a1396d1c7869" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityFileNumber_822e8447-8e0b-49b3-a276-a1396d1c7869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1ab9a2a4-22b2-4f56-be43-fae47e439a21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityRegistrantName_1ab9a2a4-22b2-4f56-be43-fae47e439a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_da72059e-fb95-49b7-8f96-a4bbe1cfbf80" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_da72059e-fb95-49b7-8f96-a4bbe1cfbf80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1939a27a-321a-477e-88c4-020f0fde8387" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityTaxIdentificationNumber_1939a27a-321a-477e-88c4-020f0fde8387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c80141b0-87f4-48c7-95d9-d328971d172a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityAddressAddressLine1_c80141b0-87f4-48c7-95d9-d328971d172a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_eabd5e11-61dc-40de-94c0-b3a7d779072d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityAddressAddressLine2_eabd5e11-61dc-40de-94c0-b3a7d779072d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_60184a44-7c90-435e-938e-7bdadb357363" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityAddressCityOrTown_60184a44-7c90-435e-938e-7bdadb357363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b68b2eaf-21d5-4330-96a3-a993d52a2afa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityAddressStateOrProvince_b68b2eaf-21d5-4330-96a3-a993d52a2afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_39eaa84c-dcbb-4428-bbd3-d8efd0e7e7d5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityAddressPostalZipCode_39eaa84c-dcbb-4428-bbd3-d8efd0e7e7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f6e17170-467d-45ec-a906-b961b61dff32" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_CityAreaCode_f6e17170-467d-45ec-a906-b961b61dff32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4d78e506-2325-4304-a734-84b62af8527e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_LocalPhoneNumber_4d78e506-2325-4304-a734-84b62af8527e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f692ce84-9bd8-47c1-a14f-7783b365977d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_Security12bTitle_f692ce84-9bd8-47c1-a14f-7783b365977d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ed278c32-dfe0-45fb-a7d6-101ffc51dd32" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_TradingSymbol_ed278c32-dfe0-45fb-a7d6-101ffc51dd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2e6f2b75-0b72-4eb3-b182-b58da04a987e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_SecurityExchangeName_2e6f2b75-0b72-4eb3-b182-b58da04a987e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_03448b42-6627-4d1f-ac2a-d366f319ea2d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityCurrentReportingStatus_03448b42-6627-4d1f-ac2a-d366f319ea2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b8689c30-5e59-4b61-9485-5ccd266e58df" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityInteractiveDataCurrent_b8689c30-5e59-4b61-9485-5ccd266e58df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a06ecf59-b0f5-4c55-a389-cb8e8bce8a22" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityFilerCategory_a06ecf59-b0f5-4c55-a389-cb8e8bce8a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7a248127-551e-41e3-b4bb-b848c4d4c096" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntitySmallBusiness_7a248127-551e-41e3-b4bb-b848c4d4c096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8d9d5b52-8727-4a59-afb0-f256a9eb894c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityEmergingGrowthCompany_8d9d5b52-8727-4a59-afb0-f256a9eb894c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_37519566-777f-400f-a37b-46fc7f6c5f95" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityShellCompany_37519566-777f-400f-a37b-46fc7f6c5f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6245c7c0-f8d1-45ed-ba3d-e08998765c28" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6245c7c0-f8d1-45ed-ba3d-e08998765c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_62b48f19-c90b-441e-b093-8766e4ac6582" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_AmendmentFlag_62b48f19-c90b-441e-b093-8766e4ac6582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3a9df48b-6190-4715-86fb-8659044cd07a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_DocumentFiscalYearFocus_3a9df48b-6190-4715-86fb-8659044cd07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_595947e5-0aa9-4f15-89fe-546d9c89b359" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_595947e5-0aa9-4f15-89fe-546d9c89b359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f02515a1-0803-48ad-a8b9-f0e1c927b9c3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_EntityCentralIndexKey_f02515a1-0803-48ad-a8b9-f0e1c927b9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8cef654c-7ffa-4174-b565-195212c908cd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c534f494-f0f1-4d4a-b5ac-d753eeeed83c" xlink:to="loc_dei_CurrentFiscalYearEndDate_8cef654c-7ffa-4174-b565-195212c908cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4c7eb1b2-ac64-44ba-a53d-5b157c3bf01c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3a594107-d2e5-4b97-9655-57fc409bdaa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4c7eb1b2-ac64-44ba-a53d-5b157c3bf01c" xlink:to="loc_us-gaap_AssetsAbstract_3a594107-d2e5-4b97-9655-57fc409bdaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_659b3bc6-1f7c-4430-a19a-36f26b68eafc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3a594107-d2e5-4b97-9655-57fc409bdaa4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_659b3bc6-1f7c-4430-a19a-36f26b68eafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ad3bde88-ad4d-4c2f-9e96-727bf6f74869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_659b3bc6-1f7c-4430-a19a-36f26b68eafc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ad3bde88-ad4d-4c2f-9e96-727bf6f74869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_99f2bf10-90e2-4286-aa38-d7e734bb95aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_659b3bc6-1f7c-4430-a19a-36f26b68eafc" xlink:to="loc_us-gaap_OtherAssetsCurrent_99f2bf10-90e2-4286-aa38-d7e734bb95aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e72542fe-8df6-40ca-86da-d099a487c814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_659b3bc6-1f7c-4430-a19a-36f26b68eafc" xlink:to="loc_us-gaap_AssetsCurrent_e72542fe-8df6-40ca-86da-d099a487c814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9a5ecde7-eabc-4496-abe2-5c8a9b70ddaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3a594107-d2e5-4b97-9655-57fc409bdaa4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9a5ecde7-eabc-4496-abe2-5c8a9b70ddaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e211c430-206a-4e23-9777-9570076051d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3a594107-d2e5-4b97-9655-57fc409bdaa4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e211c430-206a-4e23-9777-9570076051d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_452a921b-563e-443c-95d0-46d9a6bf6a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3a594107-d2e5-4b97-9655-57fc409bdaa4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_452a921b-563e-443c-95d0-46d9a6bf6a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_440df3c0-e20c-48f3-a929-69e8b29f7ba7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3a594107-d2e5-4b97-9655-57fc409bdaa4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_440df3c0-e20c-48f3-a929-69e8b29f7ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_15196bc8-146b-4df7-93f9-43deeb0eb27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3a594107-d2e5-4b97-9655-57fc409bdaa4" xlink:to="loc_us-gaap_Assets_15196bc8-146b-4df7-93f9-43deeb0eb27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_45abd3a4-3839-4d20-80a6-5418562242b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4c7eb1b2-ac64-44ba-a53d-5b157c3bf01c" xlink:to="loc_us-gaap_LiabilitiesAbstract_45abd3a4-3839-4d20-80a6-5418562242b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a8bcb921-728e-472a-b955-2629dd57a5f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_45abd3a4-3839-4d20-80a6-5418562242b8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a8bcb921-728e-472a-b955-2629dd57a5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cbd7d4ea-f3db-41bd-9c42-96b6f13539e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8bcb921-728e-472a-b955-2629dd57a5f8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cbd7d4ea-f3db-41bd-9c42-96b6f13539e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_148928f7-100a-48f6-a8f4-e632f49a23fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8bcb921-728e-472a-b955-2629dd57a5f8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_148928f7-100a-48f6-a8f4-e632f49a23fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f35cfe97-658d-49b2-a0ab-2670b348c90e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8bcb921-728e-472a-b955-2629dd57a5f8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f35cfe97-658d-49b2-a0ab-2670b348c90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_294905bd-52a7-4ff2-ba83-551e5ab761b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a8bcb921-728e-472a-b955-2629dd57a5f8" xlink:to="loc_us-gaap_LiabilitiesCurrent_294905bd-52a7-4ff2-ba83-551e5ab761b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d1c63db7-54e5-43bc-af9b-956782c86e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_45abd3a4-3839-4d20-80a6-5418562242b8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d1c63db7-54e5-43bc-af9b-956782c86e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b3300a2e-f5c7-4ada-94d9-0eebeb4b143d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_45abd3a4-3839-4d20-80a6-5418562242b8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b3300a2e-f5c7-4ada-94d9-0eebeb4b143d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c1604af4-7260-4c59-8ca0-564c0f799e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_45abd3a4-3839-4d20-80a6-5418562242b8" xlink:to="loc_us-gaap_Liabilities_c1604af4-7260-4c59-8ca0-564c0f799e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_8e67906e-6b86-4b09-89a6-2c2cd94fdbc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4c7eb1b2-ac64-44ba-a53d-5b157c3bf01c" xlink:to="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_8e67906e-6b86-4b09-89a6-2c2cd94fdbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1ddcebdb-d101-4d55-9f57-c89744782e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_8e67906e-6b86-4b09-89a6-2c2cd94fdbc0" xlink:to="loc_us-gaap_CommonStockValue_1ddcebdb-d101-4d55-9f57-c89744782e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0cb88086-ac53-4f9b-a853-f23b73c98be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_8e67906e-6b86-4b09-89a6-2c2cd94fdbc0" xlink:to="loc_us-gaap_PreferredStockValue_0cb88086-ac53-4f9b-a853-f23b73c98be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c49c083a-725d-4ebb-b212-48bb00d544b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_8e67906e-6b86-4b09-89a6-2c2cd94fdbc0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c49c083a-725d-4ebb-b212-48bb00d544b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_323225d4-901b-4c83-b9c2-ca7399392271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_8e67906e-6b86-4b09-89a6-2c2cd94fdbc0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_323225d4-901b-4c83-b9c2-ca7399392271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_09c7e4bf-9ac1-4117-bf41-efdd1f5718b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_8e67906e-6b86-4b09-89a6-2c2cd94fdbc0" xlink:to="loc_us-gaap_StockholdersEquity_09c7e4bf-9ac1-4117-bf41-efdd1f5718b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_336b2fce-c5c2-442d-951a-e7dc875119a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4c7eb1b2-ac64-44ba-a53d-5b157c3bf01c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_336b2fce-c5c2-442d-951a-e7dc875119a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_60529d04-e0b1-49b2-bfbc-41be3cbebb23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f5733e6f-626f-4b59-86a5-6e18741377b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60529d04-e0b1-49b2-bfbc-41be3cbebb23" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f5733e6f-626f-4b59-86a5-6e18741377b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_542be3c3-a943-4c7b-b1f9-f572b9f7521d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60529d04-e0b1-49b2-bfbc-41be3cbebb23" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_542be3c3-a943-4c7b-b1f9-f572b9f7521d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ab3ca68c-f3ff-4e75-9d4c-6437b9ae6c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60529d04-e0b1-49b2-bfbc-41be3cbebb23" xlink:to="loc_us-gaap_CommonStockSharesIssued_ab3ca68c-f3ff-4e75-9d4c-6437b9ae6c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8bf9d900-ec13-4b7f-a33c-2d1466ee58d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60529d04-e0b1-49b2-bfbc-41be3cbebb23" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8bf9d900-ec13-4b7f-a33c-2d1466ee58d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_dba4a0d5-73ce-4e93-8c95-346df8fdd8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60529d04-e0b1-49b2-bfbc-41be3cbebb23" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_dba4a0d5-73ce-4e93-8c95-346df8fdd8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8bdd3975-f740-4f3f-b1e3-aa70404dca97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60529d04-e0b1-49b2-bfbc-41be3cbebb23" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8bdd3975-f740-4f3f-b1e3-aa70404dca97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8e5693a0-14eb-4b45-959b-b78596886d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60529d04-e0b1-49b2-bfbc-41be3cbebb23" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8e5693a0-14eb-4b45-959b-b78596886d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6fb838e4-807e-4cca-822e-c4a43b3d7274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60529d04-e0b1-49b2-bfbc-41be3cbebb23" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6fb838e4-807e-4cca-822e-c4a43b3d7274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ea6bfec9-bc8b-459b-9538-b1ff1c7ef5c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLossAbstract_f85e4988-0355-41ac-9352-58189f356c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea6bfec9-bc8b-459b-9538-b1ff1c7ef5c6" xlink:to="loc_us-gaap_OperatingIncomeLossAbstract_f85e4988-0355-41ac-9352-58189f356c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8f1b72ae-cbcc-4df2-ab69-151a0bf229ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_f85e4988-0355-41ac-9352-58189f356c98" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8f1b72ae-cbcc-4df2-ab69-151a0bf229ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8b838e1c-6ac3-4fa4-bd16-15359e605c64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_f85e4988-0355-41ac-9352-58189f356c98" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8b838e1c-6ac3-4fa4-bd16-15359e605c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_da132793-3b81-41ec-bf9f-d0cb6e93f017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_f85e4988-0355-41ac-9352-58189f356c98" xlink:to="loc_us-gaap_OperatingIncomeLoss_da132793-3b81-41ec-bf9f-d0cb6e93f017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b1cec34e-1f22-46cd-a099-dc4bfd191338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea6bfec9-bc8b-459b-9538-b1ff1c7ef5c6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b1cec34e-1f22-46cd-a099-dc4bfd191338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eab7a3e6-6fb3-4fc5-8b77-5ef0ba106e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea6bfec9-bc8b-459b-9538-b1ff1c7ef5c6" xlink:to="loc_us-gaap_NetIncomeLoss_eab7a3e6-6fb3-4fc5-8b77-5ef0ba106e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9d1fa076-a953-43f7-ad3c-079f9af60f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea6bfec9-bc8b-459b-9538-b1ff1c7ef5c6" xlink:to="loc_us-gaap_EarningsPerShareBasic_9d1fa076-a953-43f7-ad3c-079f9af60f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1fb847d5-42f5-445f-a7ae-933804d8a2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea6bfec9-bc8b-459b-9538-b1ff1c7ef5c6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1fb847d5-42f5-445f-a7ae-933804d8a2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70bd7d74-799d-40a3-b3f5-5c4bbf6858ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea6bfec9-bc8b-459b-9538-b1ff1c7ef5c6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70bd7d74-799d-40a3-b3f5-5c4bbf6858ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_99ef534e-46d0-450f-b96f-300060c28c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea6bfec9-bc8b-459b-9538-b1ff1c7ef5c6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_99ef534e-46d0-450f-b96f-300060c28c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_cf4fd0ce-c955-4f5b-b9f1-987d9f9bf2aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_84eaf5ef-7283-4486-86e1-1d12bad0689c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cf4fd0ce-c955-4f5b-b9f1-987d9f9bf2aa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_84eaf5ef-7283-4486-86e1-1d12bad0689c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d520c459-9ec4-4ad2-94ad-1042bf196cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_84eaf5ef-7283-4486-86e1-1d12bad0689c" xlink:to="loc_us-gaap_NetIncomeLoss_d520c459-9ec4-4ad2-94ad-1042bf196cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d57a02e-393b-450d-a2c9-9e70d4850f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_84eaf5ef-7283-4486-86e1-1d12bad0689c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d57a02e-393b-450d-a2c9-9e70d4850f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a902cbab-0919-4ac8-a0b6-394a57de2893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d57a02e-393b-450d-a2c9-9e70d4850f61" xlink:to="loc_us-gaap_ShareBasedCompensation_a902cbab-0919-4ac8-a0b6-394a57de2893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ca87ded3-bff3-4f1f-81b5-c514beac7a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d57a02e-393b-450d-a2c9-9e70d4850f61" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ca87ded3-bff3-4f1f-81b5-c514beac7a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_33921fc9-d799-4c3c-b8fe-6780aa94ca6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d57a02e-393b-450d-a2c9-9e70d4850f61" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_33921fc9-d799-4c3c-b8fe-6780aa94ca6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_852e309d-dc0e-4ddd-834c-2cf1745c6ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d57a02e-393b-450d-a2c9-9e70d4850f61" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_852e309d-dc0e-4ddd-834c-2cf1745c6ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25679df1-9105-4ded-aefd-5a2af757dbc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_84eaf5ef-7283-4486-86e1-1d12bad0689c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25679df1-9105-4ded-aefd-5a2af757dbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_314bd281-ddd5-4492-a8e7-1c8dd3af0589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25679df1-9105-4ded-aefd-5a2af757dbc0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_314bd281-ddd5-4492-a8e7-1c8dd3af0589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e05bc838-0a75-4a69-b2a6-1f2bb61b8e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25679df1-9105-4ded-aefd-5a2af757dbc0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e05bc838-0a75-4a69-b2a6-1f2bb61b8e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_16002d0d-5fd4-4e2b-b0cf-8a0d55519862" xlink:href="nltx-20210331.xsd#nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25679df1-9105-4ded-aefd-5a2af757dbc0" xlink:to="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_16002d0d-5fd4-4e2b-b0cf-8a0d55519862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseLiability_aede1eaf-206b-4bb2-8576-dcba4b954fc2" xlink:href="nltx-20210331.xsd#nltx_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25679df1-9105-4ded-aefd-5a2af757dbc0" xlink:to="loc_nltx_IncreaseDecreaseInOperatingLeaseLiability_aede1eaf-206b-4bb2-8576-dcba4b954fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1ae8287-4e6d-4646-9017-588a40fbea58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_84eaf5ef-7283-4486-86e1-1d12bad0689c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1ae8287-4e6d-4646-9017-588a40fbea58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3264bbcc-825e-455a-b19d-eea7d228b2fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cf4fd0ce-c955-4f5b-b9f1-987d9f9bf2aa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3264bbcc-825e-455a-b19d-eea7d228b2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2448d958-8d68-48e1-a41d-a615c6a1f44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3264bbcc-825e-455a-b19d-eea7d228b2fd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2448d958-8d68-48e1-a41d-a615c6a1f44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c69b826a-cdc9-4dc2-9a2e-8900beb67d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3264bbcc-825e-455a-b19d-eea7d228b2fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c69b826a-cdc9-4dc2-9a2e-8900beb67d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29a7d44a-8a2f-41d8-b8fd-1e328287a3e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cf4fd0ce-c955-4f5b-b9f1-987d9f9bf2aa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29a7d44a-8a2f-41d8-b8fd-1e328287a3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3e31105c-08d7-4268-9073-34d22d558cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29a7d44a-8a2f-41d8-b8fd-1e328287a3e5" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3e31105c-08d7-4268-9073-34d22d558cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_d4fda3f1-fae1-43f9-a43f-8f8448929d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29a7d44a-8a2f-41d8-b8fd-1e328287a3e5" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_d4fda3f1-fae1-43f9-a43f-8f8448929d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99d0f071-0317-4aab-9b92-038497af58d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29a7d44a-8a2f-41d8-b8fd-1e328287a3e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99d0f071-0317-4aab-9b92-038497af58d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f15e36bb-2245-4a82-90ab-7e4e5de587cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cf4fd0ce-c955-4f5b-b9f1-987d9f9bf2aa" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f15e36bb-2245-4a82-90ab-7e4e5de587cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4961866c-4f70-4394-b420-a913bb4aee2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cf4fd0ce-c955-4f5b-b9f1-987d9f9bf2aa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4961866c-4f70-4394-b420-a913bb4aee2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79b72b6a-f110-4c0f-a046-9b26da2afa61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cf4fd0ce-c955-4f5b-b9f1-987d9f9bf2aa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79b72b6a-f110-4c0f-a046-9b26da2afa61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_444bc49c-cd35-4e5e-86e7-ea22c17f48c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cf4fd0ce-c955-4f5b-b9f1-987d9f9bf2aa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_444bc49c-cd35-4e5e-86e7-ea22c17f48c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_cb446f3d-7f06-4240-a237-d78d514529c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cf4fd0ce-c955-4f5b-b9f1-987d9f9bf2aa" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_cb446f3d-7f06-4240-a237-d78d514529c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_28f7d2ab-8506-4f23-be97-de771532d277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_cb446f3d-7f06-4240-a237-d78d514529c3" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_28f7d2ab-8506-4f23-be97-de771532d277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3da05ffc-6727-4edd-8e40-3ec8a4e86fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_cb446f3d-7f06-4240-a237-d78d514529c3" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3da05ffc-6727-4edd-8e40-3ec8a4e86fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nltx-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d2d5652d-6b11-41c4-89de-6ecb1ac20cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3ce87c70-8f96-4bad-a12b-32122832acc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d2d5652d-6b11-41c4-89de-6ecb1ac20cef" xlink:to="loc_us-gaap_StatementTable_3ce87c70-8f96-4bad-a12b-32122832acc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9244a2c2-dd2b-47d0-88dc-759753744ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3ce87c70-8f96-4bad-a12b-32122832acc2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9244a2c2-dd2b-47d0-88dc-759753744ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb7a1ed5-772e-4878-9321-91557c786372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9244a2c2-dd2b-47d0-88dc-759753744ae3" xlink:to="loc_us-gaap_EquityComponentDomain_cb7a1ed5-772e-4878-9321-91557c786372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7d58861f-d30f-4445-b0f3-3bf4139b34ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb7a1ed5-772e-4878-9321-91557c786372" xlink:to="loc_us-gaap_CommonStockMember_7d58861f-d30f-4445-b0f3-3bf4139b34ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_546490a8-2302-4a24-b06b-257c4d48957e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb7a1ed5-772e-4878-9321-91557c786372" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_546490a8-2302-4a24-b06b-257c4d48957e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4c31d0c1-9ac2-4365-b337-f45af6795be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb7a1ed5-772e-4878-9321-91557c786372" xlink:to="loc_us-gaap_RetainedEarningsMember_4c31d0c1-9ac2-4365-b337-f45af6795be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_816af07a-3202-4716-ad44-8966f475240b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3ce87c70-8f96-4bad-a12b-32122832acc2" xlink:to="loc_us-gaap_StatementLineItems_816af07a-3202-4716-ad44-8966f475240b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_816af07a-3202-4716-ad44-8966f475240b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7b5b12a0-a469-4f69-80d6-0a549ae9cb11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_SharesOutstanding_7b5b12a0-a469-4f69-80d6-0a549ae9cb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aca46251-5cb3-4f40-b483-de78297f304d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_StockholdersEquity_aca46251-5cb3-4f40-b483-de78297f304d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e063acd6-426f-4497-8fab-cba8461a99c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e063acd6-426f-4497-8fab-cba8461a99c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d161b8a7-705e-43a0-9f8e-1eaf138df1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d161b8a7-705e-43a0-9f8e-1eaf138df1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ebde4e82-5f54-4168-8a9b-c8ddc1adf93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ebde4e82-5f54-4168-8a9b-c8ddc1adf93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d8a636c4-4078-4c19-839b-3cd40c146d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d8a636c4-4078-4c19-839b-3cd40c146d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6d9c62d0-bef4-4073-84ff-5afb4068b7e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_NetIncomeLoss_6d9c62d0-bef4-4073-84ff-5afb4068b7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_96b6f751-3a90-40ca-b2af-d78f2bcc8ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_SharesOutstanding_96b6f751-3a90-40ca-b2af-d78f2bcc8ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dfff5bed-bc32-44a7-b283-0bee9b62ec22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81deeac6-b803-4349-ac70-950641b97c72" xlink:to="loc_us-gaap_StockholdersEquity_dfff5bed-bc32-44a7-b283-0bee9b62ec22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Natureofoperations" xlink:type="simple" xlink:href="nltx-20210331.xsd#Natureofoperations"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Natureofoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6850254-a9c7-4e5b-9de4-d51dbd92ea6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_bfd9504b-f2cd-4898-ae78-87e13819c94b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6850254-a9c7-4e5b-9de4-d51dbd92ea6e" xlink:to="loc_us-gaap_NatureOfOperations_bfd9504b-f2cd-4898-ae78-87e13819c94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="nltx-20210331.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_68c6fbba-6837-4f3b-983d-2e41b3f2efa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_da105ecb-f87a-456c-9058-9bf85abd015a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68c6fbba-6837-4f3b-983d-2e41b3f2efa0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_da105ecb-f87a-456c-9058-9bf85abd015a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="nltx-20210331.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_91e2c553-7e48-4a24-acb8-1cc2bd0c82a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fb421ee9-47f6-4a10-88e8-97b28a52c2ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91e2c553-7e48-4a24-acb8-1cc2bd0c82a1" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fb421ee9-47f6-4a10-88e8-97b28a52c2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_8b5d9ab8-9b90-4a0c-bb39-c3f5d1421a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91e2c553-7e48-4a24-acb8-1cc2bd0c82a1" xlink:to="loc_us-gaap_UseOfEstimates_8b5d9ab8-9b90-4a0c-bb39-c3f5d1421a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_b50ce060-c200-4902-8a1d-bbea66e1ac93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91e2c553-7e48-4a24-acb8-1cc2bd0c82a1" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_b50ce060-c200-4902-8a1d-bbea66e1ac93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_69c5a359-ec58-4a63-8b05-a0e24cab9871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91e2c553-7e48-4a24-acb8-1cc2bd0c82a1" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_69c5a359-ec58-4a63-8b05-a0e24cab9871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_6f69cf9c-d567-4c6c-beb5-602af108d3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91e2c553-7e48-4a24-acb8-1cc2bd0c82a1" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_6f69cf9c-d567-4c6c-beb5-602af108d3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_3c818061-0b8b-4f2e-8f98-d28dbcaa6a16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91e2c553-7e48-4a24-acb8-1cc2bd0c82a1" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_3c818061-0b8b-4f2e-8f98-d28dbcaa6a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6b76332f-d541-4c89-9f38-213a22ad9fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91e2c553-7e48-4a24-acb8-1cc2bd0c82a1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6b76332f-d541-4c89-9f38-213a22ad9fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_622b4f56-f43c-435e-a903-dc9c98d197da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:href="nltx-20210331.xsd#nltx_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_622b4f56-f43c-435e-a903-dc9c98d197da" xlink:to="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0728784-3d5e-44c9-8e4e-5a18726ba470" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:to="loc_srt_RangeAxis_c0728784-3d5e-44c9-8e4e-5a18726ba470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_daebfcef-985a-439a-93af-eff4bd128d45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c0728784-3d5e-44c9-8e4e-5a18726ba470" xlink:to="loc_srt_RangeMember_daebfcef-985a-439a-93af-eff4bd128d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ffbea4cf-7471-4e6a-9cd5-c96566b2a35c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_daebfcef-985a-439a-93af-eff4bd128d45" xlink:to="loc_srt_MaximumMember_ffbea4cf-7471-4e6a-9cd5-c96566b2a35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ad782ae2-615f-49fb-8b2c-2e1276fe53ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ad782ae2-615f-49fb-8b2c-2e1276fe53ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f78e8d0-f272-4131-a733-96d2d527e25b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ad782ae2-615f-49fb-8b2c-2e1276fe53ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f78e8d0-f272-4131-a733-96d2d527e25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_5813d74d-bf1c-47ef-9c5f-2a1e867d6339" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f78e8d0-f272-4131-a733-96d2d527e25b" xlink:to="loc_srt_OfficeBuildingMember_5813d74d-bf1c-47ef-9c5f-2a1e867d6339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_821c6f5a-0b79-46f8-b8ad-3b4ca99ce0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_821c6f5a-0b79-46f8-b8ad-3b4ca99ce0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_02b02923-b272-4484-a595-9ca78bf3fe38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_821c6f5a-0b79-46f8-b8ad-3b4ca99ce0e0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_02b02923-b272-4484-a595-9ca78bf3fe38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0cdd2d45-2406-4416-831c-1dad5d80d688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_02b02923-b272-4484-a595-9ca78bf3fe38" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0cdd2d45-2406-4416-831c-1dad5d80d688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d3eaa46e-dea1-4841-a6c2-c919d908ba37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d3eaa46e-dea1-4841-a6c2-c919d908ba37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9a68114d-02e1-4d70-b8d5-823edb714c62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d3eaa46e-dea1-4841-a6c2-c919d908ba37" xlink:to="loc_us-gaap_ClassOfStockDomain_9a68114d-02e1-4d70-b8d5-823edb714c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedWarrantsMember_4c1ac131-a531-4745-adf6-8ea297d0eb15" xlink:href="nltx-20210331.xsd#nltx_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9a68114d-02e1-4d70-b8d5-823edb714c62" xlink:to="loc_nltx_PreFundedWarrantsMember_4c1ac131-a531-4745-adf6-8ea297d0eb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c2bbd2fd-bd1b-4968-afda-0954166dbacc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_5ee4d759-f045-461c-83ea-7b6081678fa3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_c2bbd2fd-bd1b-4968-afda-0954166dbacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c75fb017-507a-40ff-8240-c9e14dfe9608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c2bbd2fd-bd1b-4968-afda-0954166dbacc" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c75fb017-507a-40ff-8240-c9e14dfe9608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0656b923-7851-452e-8c55-3ce1c0faa615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c2bbd2fd-bd1b-4968-afda-0954166dbacc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0656b923-7851-452e-8c55-3ce1c0faa615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9e0e3971-77fb-47e7-9fa5-3b95abbec122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c2bbd2fd-bd1b-4968-afda-0954166dbacc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9e0e3971-77fb-47e7-9fa5-3b95abbec122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ClassOfWarrantOrRightNoticePeriod_b81e045d-8397-4ae4-b00a-55f6d6e9d930" xlink:href="nltx-20210331.xsd#nltx_ClassOfWarrantOrRightNoticePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c2bbd2fd-bd1b-4968-afda-0954166dbacc" xlink:to="loc_nltx_ClassOfWarrantOrRightNoticePeriod_b81e045d-8397-4ae4-b00a-55f6d6e9d930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Cashcashequivalentsandrestrictedcash" xlink:type="simple" xlink:href="nltx-20210331.xsd#Cashcashequivalentsandrestrictedcash"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Cashcashequivalentsandrestrictedcash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5586fba7-7377-4df5-b8a4-42461d32b308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock_90f1dc4e-d30c-4707-ae5f-ee494c15195e" xlink:href="nltx-20210331.xsd#nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5586fba7-7377-4df5-b8a4-42461d32b308" xlink:to="loc_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock_90f1dc4e-d30c-4707-ae5f-ee494c15195e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashTables" xlink:type="simple" xlink:href="nltx-20210331.xsd#CashcashequivalentsandrestrictedcashTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_83ca7ad7-00f2-4671-80d1-b9c27a20e928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ab8f5019-68c9-4b70-8f96-25b1c4172ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_83ca7ad7-00f2-4671-80d1-b9c27a20e928" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ab8f5019-68c9-4b70-8f96-25b1c4172ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_e9f23941-99c1-4f4e-8c35-559376f7e565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_83ca7ad7-00f2-4671-80d1-b9c27a20e928" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_e9f23941-99c1-4f4e-8c35-559376f7e565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#CashcashequivalentsandrestrictedcashAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cc9c4e8e-03c1-45dc-8b52-1723cb063cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_8a3948e0-21f7-417a-89bb-ef5ce5952103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cc9c4e8e-03c1-45dc-8b52-1723cb063cc7" xlink:to="loc_us-gaap_SecurityDeposit_8a3948e0-21f7-417a-89bb-ef5ce5952103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_328343ee-2571-4452-ba84-367513a22fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b8c59232-ee39-4952-be5f-d766180f609c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_328343ee-2571-4452-ba84-367513a22fe2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b8c59232-ee39-4952-be5f-d766180f609c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_01d87c87-0559-4186-bef8-c055952f3c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_328343ee-2571-4452-ba84-367513a22fe2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_01d87c87-0559-4186-bef8-c055952f3c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_de5c0abd-f538-4c8f-ba96-32795910bbf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_328343ee-2571-4452-ba84-367513a22fe2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_de5c0abd-f538-4c8f-ba96-32795910bbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Leases" xlink:type="simple" xlink:href="nltx-20210331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_33e51880-516b-42cb-b956-38b8d701c5a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_a3809452-3748-44ac-a7f7-14c68451e267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33e51880-516b-42cb-b956-38b8d701c5a3" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_a3809452-3748-44ac-a7f7-14c68451e267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_c4d4be2b-dfac-4496-9b7f-f5d4110496c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33e51880-516b-42cb-b956-38b8d701c5a3" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_c4d4be2b-dfac-4496-9b7f-f5d4110496c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_88c77387-ff3a-4455-bfe7-ed08c3a2f2dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1272edfb-ef07-4571-a008-034fbbf94401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_88c77387-ff3a-4455-bfe7-ed08c3a2f2dd" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1272edfb-ef07-4571-a008-034fbbf94401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ba4920f0-d9c7-4beb-8280-9db4a70426f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1272edfb-ef07-4571-a008-034fbbf94401" xlink:to="loc_srt_StatementGeographicalAxis_ba4920f0-d9c7-4beb-8280-9db4a70426f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dee6ae4f-0b36-46f9-8987-376907e9e066" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ba4920f0-d9c7-4beb-8280-9db4a70426f4" xlink:to="loc_srt_SegmentGeographicalDomain_dee6ae4f-0b36-46f9-8987-376907e9e066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_d9641d50-d9df-426c-81cf-1280f1259615" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_dee6ae4f-0b36-46f9-8987-376907e9e066" xlink:to="loc_stpr_WA_d9641d50-d9df-426c-81cf-1280f1259615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_125559cf-1d90-4dd9-a1da-381656fc5f22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1272edfb-ef07-4571-a008-034fbbf94401" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_125559cf-1d90-4dd9-a1da-381656fc5f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f94bb0b2-dcc8-4208-89aa-3f2c1d2a7205" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_125559cf-1d90-4dd9-a1da-381656fc5f22" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f94bb0b2-dcc8-4208-89aa-3f2c1d2a7205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_dfb0e912-830e-42ee-9e9a-6499b4f4c398" xlink:href="nltx-20210331.xsd#nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f94bb0b2-dcc8-4208-89aa-3f2c1d2a7205" xlink:to="loc_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_dfb0e912-830e-42ee-9e9a-6499b4f4c398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember_026693db-98c1-46b4-9cd3-ad3f2387e03f" xlink:href="nltx-20210331.xsd#nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f94bb0b2-dcc8-4208-89aa-3f2c1d2a7205" xlink:to="loc_nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember_026693db-98c1-46b4-9cd3-ad3f2387e03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1272edfb-ef07-4571-a008-034fbbf94401" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_97ee1a0e-b771-4a72-aaf8-775bf9c15663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_97ee1a0e-b771-4a72-aaf8-775bf9c15663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NumberOfOptionToExtendLease_b2bcac1e-dfa9-46cb-b134-0aac5ac79d4b" xlink:href="nltx-20210331.xsd#nltx_NumberOfOptionToExtendLease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_nltx_NumberOfOptionToExtendLease_b2bcac1e-dfa9-46cb-b134-0aac5ac79d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3e948d5b-076a-4053-aa54-5036856f4636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3e948d5b-076a-4053-aa54-5036856f4636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TenantImprovementAllowance_5a4e6bb6-0326-4575-a33b-0c30d91fe9af" xlink:href="nltx-20210331.xsd#nltx_TenantImprovementAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_nltx_TenantImprovementAllowance_5a4e6bb6-0326-4575-a33b-0c30d91fe9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TenantImprovementAllowanceReceivable_c9785339-672d-44c4-84d9-3379a21c728e" xlink:href="nltx-20210331.xsd#nltx_TenantImprovementAllowanceReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_nltx_TenantImprovementAllowanceReceivable_c9785339-672d-44c4-84d9-3379a21c728e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_7faf4663-a519-421f-9cb7-296fc4d6796e" xlink:href="nltx-20210331.xsd#nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_7faf4663-a519-421f-9cb7-296fc4d6796e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseLiability_7ff17bec-2d29-4d7e-a97c-b179f9e33144" xlink:href="nltx-20210331.xsd#nltx_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_nltx_IncreaseDecreaseInOperatingLeaseLiability_7ff17bec-2d29-4d7e-a97c-b179f9e33144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_42aceb63-8d94-4329-b36f-7ef6ca859740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_42aceb63-8d94-4329-b36f-7ef6ca859740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_c65f25cf-eb4e-41da-bf66-4a2fd5c4ec45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cc158418-1c7d-43c8-87e2-d7da651379fe" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_c65f25cf-eb4e-41da-bf66-4a2fd5c4ec45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Equity" xlink:type="simple" xlink:href="nltx-20210331.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_92964595-5597-44d0-a5e7-37de716e7b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_69b753b6-2c09-48e5-9e76-f11af8102589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_92964595-5597-44d0-a5e7-37de716e7b20" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_69b753b6-2c09-48e5-9e76-f11af8102589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquityTables" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_54df9274-9de6-4640-a525-c68a9a7a23da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e3c7df6b-e777-40f6-83bc-2c6fcf2f1ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_54df9274-9de6-4640-a525-c68a9a7a23da" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e3c7df6b-e777-40f6-83bc-2c6fcf2f1ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_447a9d5b-722e-4f25-b6a8-8b3095d739b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_54df9274-9de6-4640-a525-c68a9a7a23da" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_447a9d5b-722e-4f25-b6a8-8b3095d739b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8be7eb38-52c3-469e-8383-e18aba4fd9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_54df9274-9de6-4640-a525-c68a9a7a23da" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8be7eb38-52c3-469e-8383-e18aba4fd9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_891c050d-5bcd-4857-ae96-d0dbffb87c1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_54df9274-9de6-4640-a525-c68a9a7a23da" xlink:to="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_891c050d-5bcd-4857-ae96-d0dbffb87c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/EquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_22fd71e0-f067-4c0b-ae43-d03d54530f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a630ef7-2347-46a4-94d9-698a3686a6af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_22fd71e0-f067-4c0b-ae43-d03d54530f8a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a630ef7-2347-46a4-94d9-698a3686a6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_48ad2977-1f12-4178-9fe3-facffc39e580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a630ef7-2347-46a4-94d9-698a3686a6af" xlink:to="loc_us-gaap_AwardTypeAxis_48ad2977-1f12-4178-9fe3-facffc39e580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_667d58f9-5aa9-43ce-929d-5cb55ccfee82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_48ad2977-1f12-4178-9fe3-facffc39e580" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_667d58f9-5aa9-43ce-929d-5cb55ccfee82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b2611f09-e104-4d4c-a3e7-457c2e217c20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_667d58f9-5aa9-43ce-929d-5cb55ccfee82" xlink:to="loc_us-gaap_EmployeeStockMember_b2611f09-e104-4d4c-a3e7-457c2e217c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_aaa52237-be79-4f4b-bf88-f04e003ec6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a630ef7-2347-46a4-94d9-698a3686a6af" xlink:to="loc_us-gaap_PlanNameAxis_aaa52237-be79-4f4b-bf88-f04e003ec6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ace25562-1f20-4fb3-b053-80139079b3ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_aaa52237-be79-4f4b-bf88-f04e003ec6d6" xlink:to="loc_us-gaap_PlanNameDomain_ace25562-1f20-4fb3-b053-80139079b3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_A2020EmployeeStockPurchasePlanMember_8e581b40-16a3-4845-a6d2-1de3cbb66516" xlink:href="nltx-20210331.xsd#nltx_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ace25562-1f20-4fb3-b053-80139079b3ff" xlink:to="loc_nltx_A2020EmployeeStockPurchasePlanMember_8e581b40-16a3-4845-a6d2-1de3cbb66516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_77e4aea8-30a1-4375-b8a1-df942b227d61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a630ef7-2347-46a4-94d9-698a3686a6af" xlink:to="loc_us-gaap_StatementClassOfStockAxis_77e4aea8-30a1-4375-b8a1-df942b227d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ec78729e-b3c0-4a1c-b2a5-5a6a79fb459c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_77e4aea8-30a1-4375-b8a1-df942b227d61" xlink:to="loc_us-gaap_ClassOfStockDomain_ec78729e-b3c0-4a1c-b2a5-5a6a79fb459c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedWarrantsMember_56445eeb-e547-4d93-a1f8-858f3ec6ea98" xlink:href="nltx-20210331.xsd#nltx_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ec78729e-b3c0-4a1c-b2a5-5a6a79fb459c" xlink:to="loc_nltx_PreFundedWarrantsMember_56445eeb-e547-4d93-a1f8-858f3ec6ea98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a630ef7-2347-46a4-94d9-698a3686a6af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_88b804ec-d02d-4797-8e66-ecb849f4093a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_88b804ec-d02d-4797-8e66-ecb849f4093a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a0d2b7d5-1833-4105-ab2d-433ec2fb3414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a0d2b7d5-1833-4105-ab2d-433ec2fb3414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_73095508-cd69-4ca5-81f9-4694f1dda48f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_CommonStockSharesIssued_73095508-cd69-4ca5-81f9-4694f1dda48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f14dd4ea-89bc-401d-ad00-3355402e23fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f14dd4ea-89bc-401d-ad00-3355402e23fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8696dc0e-86e2-4126-9e40-6998252bbc57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8696dc0e-86e2-4126-9e40-6998252bbc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ClassOfWarrantOrRightNoticePeriod_00db6302-d2da-450b-9219-0db4c0e9256a" xlink:href="nltx-20210331.xsd#nltx_ClassOfWarrantOrRightNoticePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_nltx_ClassOfWarrantOrRightNoticePeriod_00db6302-d2da-450b-9219-0db4c0e9256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2b498ae7-60c1-45dd-b97d-05167c7a680b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2b498ae7-60c1-45dd-b97d-05167c7a680b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PercentageOfOutstandingStockPerStockholderMaximum_35c998b5-cd2a-4672-bf9b-179413a9458e" xlink:href="nltx-20210331.xsd#nltx_PercentageOfOutstandingStockPerStockholderMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_nltx_PercentageOfOutstandingStockPerStockholderMaximum_35c998b5-cd2a-4672-bf9b-179413a9458e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_54a6c4e9-282a-4743-95f3-32062aefed75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_54a6c4e9-282a-4743-95f3-32062aefed75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7211dbd4-7094-4888-be33-1518683bc1a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7211dbd4-7094-4888-be33-1518683bc1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_192389df-6289-439e-82da-c0a6fa168d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_192389df-6289-439e-82da-c0a6fa168d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5bff1ef9-11d7-42bc-a6db-42f487681dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5bff1ef9-11d7-42bc-a6db-42f487681dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9a00bb0-48a1-475d-8ba0-43a3257ee4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9a00bb0-48a1-475d-8ba0-43a3257ee4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f7cb2410-7474-45de-9d02-bd3329cdd1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f7cb2410-7474-45de-9d02-bd3329cdd1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ac1019e4-5e49-41ea-bcbd-18469bc9cb77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ac1019e4-5e49-41ea-bcbd-18469bc9cb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_80c54359-ab25-4d80-87d0-1eca817cf9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_80c54359-ab25-4d80-87d0-1eca817cf9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_f80836c5-44bb-4d15-8512-4f2bb5b7b945" xlink:href="nltx-20210331.xsd#nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_f80836c5-44bb-4d15-8512-4f2bb5b7b945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_4524a2e6-9994-4e6f-bfd0-e207f8932c95" xlink:href="nltx-20210331.xsd#nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76dda866-59e9-466f-ae36-f5e0cce30c6a" xlink:to="loc_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_4524a2e6-9994-4e6f-bfd0-e207f8932c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquitySummaryofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6a358f2b-863b-4fc8-9afc-8d95ea17907b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_409594aa-d0d4-4c76-b3b8-b8f64a75c1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6a358f2b-863b-4fc8-9afc-8d95ea17907b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_409594aa-d0d4-4c76-b3b8-b8f64a75c1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_60489a3b-0e44-4982-b49b-85eca42f022e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_409594aa-d0d4-4c76-b3b8-b8f64a75c1a3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_60489a3b-0e44-4982-b49b-85eca42f022e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d544b344-1989-4b9c-9cec-8d4465d6a750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_60489a3b-0e44-4982-b49b-85eca42f022e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d544b344-1989-4b9c-9cec-8d4465d6a750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8fde495f-9707-4d5e-ab8f-77380bcf6572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d544b344-1989-4b9c-9cec-8d4465d6a750" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8fde495f-9707-4d5e-ab8f-77380bcf6572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e88e5ec6-8687-4329-a05b-6d6f27e79b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d544b344-1989-4b9c-9cec-8d4465d6a750" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e88e5ec6-8687-4329-a05b-6d6f27e79b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e47c2e-9c32-4809-a79f-b0a6092e92c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_409594aa-d0d4-4c76-b3b8-b8f64a75c1a3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e47c2e-9c32-4809-a79f-b0a6092e92c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7efbcb87-f274-4e3d-8181-78f065352812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e47c2e-9c32-4809-a79f-b0a6092e92c3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7efbcb87-f274-4e3d-8181-78f065352812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquityScheduleofWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_247c36c2-4c04-4a6e-9dc8-525d6b173bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_08282235-6685-4dc8-bd84-c614a81ed578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_247c36c2-4c04-4a6e-9dc8-525d6b173bc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_08282235-6685-4dc8-bd84-c614a81ed578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c94e17e1-e3ee-4e2e-be6f-d89237e8094a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_247c36c2-4c04-4a6e-9dc8-525d6b173bc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c94e17e1-e3ee-4e2e-be6f-d89237e8094a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cbbcd6ac-868e-4058-974c-ed36a97f4876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_247c36c2-4c04-4a6e-9dc8-525d6b173bc1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cbbcd6ac-868e-4058-974c-ed36a97f4876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2ee92965-752f-4504-ab77-279eef701e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_247c36c2-4c04-4a6e-9dc8-525d6b173bc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2ee92965-752f-4504-ab77-279eef701e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquityScheduleofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dce6b1be-78d8-4326-8fbf-ece5857520c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07e77f94-c627-49cd-aed7-9ed65accf85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dce6b1be-78d8-4326-8fbf-ece5857520c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07e77f94-c627-49cd-aed7-9ed65accf85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e52e83ff-d334-4ce6-9dbf-e743ec2f8ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07e77f94-c627-49cd-aed7-9ed65accf85e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e52e83ff-d334-4ce6-9dbf-e743ec2f8ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3d5f3995-3135-4593-b577-93db53c0e66e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07e77f94-c627-49cd-aed7-9ed65accf85e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3d5f3995-3135-4593-b577-93db53c0e66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_da0aefe7-72c9-43a2-8706-e5f0ee01d362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07e77f94-c627-49cd-aed7-9ed65accf85e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_da0aefe7-72c9-43a2-8706-e5f0ee01d362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d962c5f3-0301-46aa-b123-b2379af15216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07e77f94-c627-49cd-aed7-9ed65accf85e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d962c5f3-0301-46aa-b123-b2379af15216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16a2ab82-5367-4648-b067-51e59fc00eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07e77f94-c627-49cd-aed7-9ed65accf85e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16a2ab82-5367-4648-b067-51e59fc00eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9cd7e3ba-894d-4874-9478-0d59f721962c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dce6b1be-78d8-4326-8fbf-ece5857520c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9cd7e3ba-894d-4874-9478-0d59f721962c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a3d491a1-efa8-4a1d-8894-2e32064703ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9cd7e3ba-894d-4874-9478-0d59f721962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a3d491a1-efa8-4a1d-8894-2e32064703ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6ddbf5cc-7f02-4f7c-86a7-a4a20216f1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9cd7e3ba-894d-4874-9478-0d59f721962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6ddbf5cc-7f02-4f7c-86a7-a4a20216f1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b5027924-61dc-4ed7-8250-707b5670a90e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9cd7e3ba-894d-4874-9478-0d59f721962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b5027924-61dc-4ed7-8250-707b5670a90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6f17aa09-52ca-4fcc-9fc9-a75b8e5ba54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9cd7e3ba-894d-4874-9478-0d59f721962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6f17aa09-52ca-4fcc-9fc9-a75b8e5ba54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2bcf021c-061b-41a6-9790-e7c1448caa25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9cd7e3ba-894d-4874-9478-0d59f721962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2bcf021c-061b-41a6-9790-e7c1448caa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a0cf67a1-7e08-438d-adb6-5cb595e0486e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dce6b1be-78d8-4326-8fbf-ece5857520c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a0cf67a1-7e08-438d-adb6-5cb595e0486e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7de6f474-8eb0-4925-bf99-f28133616b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a0cf67a1-7e08-438d-adb6-5cb595e0486e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7de6f474-8eb0-4925-bf99-f28133616b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_abaa32d5-97e2-4652-8f45-73b9030e65fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a0cf67a1-7e08-438d-adb6-5cb595e0486e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_abaa32d5-97e2-4652-8f45-73b9030e65fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4d266cf2-08e4-4fc4-9110-e97dff6c6d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a0cf67a1-7e08-438d-adb6-5cb595e0486e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4d266cf2-08e4-4fc4-9110-e97dff6c6d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_608bebee-f8ef-43b9-b2df-2d388375421e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a0cf67a1-7e08-438d-adb6-5cb595e0486e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_608bebee-f8ef-43b9-b2df-2d388375421e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4e8663a7-4e71-499a-8117-189b556bf77f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a0cf67a1-7e08-438d-adb6-5cb595e0486e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4e8663a7-4e71-499a-8117-189b556bf77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_74d6c4bc-0630-4a41-9470-908ab2d5e50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a0cf67a1-7e08-438d-adb6-5cb595e0486e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_74d6c4bc-0630-4a41-9470-908ab2d5e50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5fa87643-5217-407f-b597-69fd249da81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_250f7721-5952-4746-9283-3b9d09640912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5fa87643-5217-407f-b597-69fd249da81a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_250f7721-5952-4746-9283-3b9d09640912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c29a6a6-7cc9-41bc-b011-20308d30b27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_250f7721-5952-4746-9283-3b9d09640912" xlink:to="loc_us-gaap_AwardTypeAxis_7c29a6a6-7cc9-41bc-b011-20308d30b27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe9fb30b-1195-4b29-aac5-3c1e53d54b63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7c29a6a6-7cc9-41bc-b011-20308d30b27b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe9fb30b-1195-4b29-aac5-3c1e53d54b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5033c0b7-7c50-4576-8a59-8fe8dd300f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe9fb30b-1195-4b29-aac5-3c1e53d54b63" xlink:to="loc_us-gaap_RestrictedStockMember_5033c0b7-7c50-4576-8a59-8fe8dd300f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5054da3c-e53b-44f1-b087-80dbcc7441ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_250f7721-5952-4746-9283-3b9d09640912" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5054da3c-e53b-44f1-b087-80dbcc7441ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5054da3c-e53b-44f1-b087-80dbcc7441ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6ff9d83-c633-48d1-89e7-f2014e1664dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6ff9d83-c633-48d1-89e7-f2014e1664dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4f818dc4-a7f5-440a-83e0-d03101f0c7c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4f818dc4-a7f5-440a-83e0-d03101f0c7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c3fa0ae7-1889-4f4d-b43a-0cbbd57f7537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c3fa0ae7-1889-4f4d-b43a-0cbbd57f7537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4a74d925-496d-4846-b17e-c3b40580e78f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4a74d925-496d-4846-b17e-c3b40580e78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af1a820c-302e-4a32-9257-085bac6ffd06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_310d3d60-0282-4f6e-9c74-7ac35c487816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af1a820c-302e-4a32-9257-085bac6ffd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5054da3c-e53b-44f1-b087-80dbcc7441ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3664d162-53da-4119-9d59-732ce2315de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3664d162-53da-4119-9d59-732ce2315de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a81b1c74-88fa-447c-b33a-b41c71efe389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a81b1c74-88fa-447c-b33a-b41c71efe389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3e00d271-f211-4d86-b1c4-1327267fbf1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3e00d271-f211-4d86-b1c4-1327267fbf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9c4aa22f-a4a7-4059-877a-8611eb432abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9c4aa22f-a4a7-4059-877a-8611eb432abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cd211f53-effc-4dc1-b280-af5cad2d84ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_93b122d2-63b5-4394-b6a7-94949217f202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cd211f53-effc-4dc1-b280-af5cad2d84ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Earningslosspershare" xlink:type="simple" xlink:href="nltx-20210331.xsd#Earningslosspershare"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Earningslosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7b18f4ba-1f5d-4068-a151-3d9228224c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_569e68b8-2ac4-4507-93f7-610c97843cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b18f4ba-1f5d-4068-a151-3d9228224c67" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_569e68b8-2ac4-4507-93f7-610c97843cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EarningslosspershareTables" xlink:type="simple" xlink:href="nltx-20210331.xsd#EarningslosspershareTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/EarningslosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ae50064c-0363-4184-8fe9-e6704093cf6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f6ed6fa9-da00-411b-a954-7b10ecf564e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ae50064c-0363-4184-8fe9-e6704093cf6e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f6ed6fa9-da00-411b-a954-7b10ecf564e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails" xlink:type="simple" xlink:href="nltx-20210331.xsd#EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_76195101-1c15-4d10-ad6c-3c404a68ed3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a945b086-9678-4335-b2de-42060e0fba62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_76195101-1c15-4d10-ad6c-3c404a68ed3c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a945b086-9678-4335-b2de-42060e0fba62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_061b7cd9-d357-4ae5-b26e-ecfb4ac3608f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a945b086-9678-4335-b2de-42060e0fba62" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_061b7cd9-d357-4ae5-b26e-ecfb4ac3608f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_237acb8d-70b5-4ecc-992b-7c7a3db7f48c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_061b7cd9-d357-4ae5-b26e-ecfb4ac3608f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_237acb8d-70b5-4ecc-992b-7c7a3db7f48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2de0fd1b-d483-4b02-8a34-4f4e570693fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_237acb8d-70b5-4ecc-992b-7c7a3db7f48c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2de0fd1b-d483-4b02-8a34-4f4e570693fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_35629ae8-8adf-4786-82d2-025c9206e25d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_237acb8d-70b5-4ecc-992b-7c7a3db7f48c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_35629ae8-8adf-4786-82d2-025c9206e25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5fd91150-8a9e-426e-9b7d-b8272f6c592e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_237acb8d-70b5-4ecc-992b-7c7a3db7f48c" xlink:to="loc_us-gaap_EmployeeStockMember_5fd91150-8a9e-426e-9b7d-b8272f6c592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2f1a2e3f-d89e-417a-b7b6-ab40a9b965b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a945b086-9678-4335-b2de-42060e0fba62" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2f1a2e3f-d89e-417a-b7b6-ab40a9b965b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_df16dfbb-356c-4970-9290-41241d5295bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2f1a2e3f-d89e-417a-b7b6-ab40a9b965b0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_df16dfbb-356c-4970-9290-41241d5295bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>nltx-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nltx="http://www.aqxpharma.com/20210331"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nltx-20210331.xsd" xlink:type="simple"/>
    <context id="i797ac540a3b740b69e583df082006363_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icc523caa747b4d5eb5d5ca5694c0c619_I20210510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2021-05-10</instant>
        </period>
    </context>
    <context id="i72e0b8f57ad04762bb88e13980f63afe_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i119066f786864fd79f80c0f67e219cee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i721ff67bd330469e98cd841901180f38_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8ef7407a22bd487e896bbba912705914_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i266aceeba1c54778bbfe3444ba803e5b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4a3c3ccbbb4b4a8a9dea4828d5509b0f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ida9e53c7555c4440b86abfb9775901e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1041684bd2f5499d8dd06947bdad86bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ied83e64ea1b341e98a9122c058ff0cab_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i45378b9878734ebc86bd47e3bef959f0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2670e284ec83470abde183cca23912e2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i21996bf832504aa398e0b3fbeb65538e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0750d237a2a948d79ac2746dea7b630e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib50df656baa2413f963433dc3384d0a1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if4c61b32dc0641ba9b2270ba1aeb5cdf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ad21f0531d446c49ab28a1a53a165c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02841c927886459ea84b517e8630c500_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief2d01c144814d3782789c4d46b928c0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if8415c2681fa4e7d8847b9a1e693685a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5ab1dbbff5ce4c3e9ead9a82f62dedef_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3b5f0e7d56e3478eab62216caa641a6b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i24b77291445c421fa209b58e0176120b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idba78dc2d87a4ad5ab6727062f43f0f9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i60f915889b8c437cb2397db911f55730_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3c27f1e7af754f9fb0d20083db327bd7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1e27bb42a4374782b35ac38cec07ae0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i24f310adc03d4c76a4887bd28c38a5d6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1325199026084dc49257e149e0b3a800_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie7cd5ec78bdb4b6ead8826027dfad8c0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i186a9002297b4b929c09d8989bae5a4c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpaceAdditionalOfficesAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1820fca965074a6f98dbdf687a1aa94b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpaceAdditionalOfficesAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic81ac6cce2184282919e6dd0d38cfbd0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic47a8fba428642d0b3fb3e9e489dc7e3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9c816066ede34186900132e7d337049c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i96c754f9fd824cb2941da29469f252a2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i178f16263cfa423ea5c90d8ffe50b7f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i69e04e99cd904341a315c6717663230d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic7b28ced8c3b4718806223d24c59e395_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifa60425c3f5c4d85b3d489026b24a8a3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6fa730f0e05d4b36bba4fddc150cf94d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia5d5cc27aae8459ea2268fcc0dd30291_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iabf13b01541848a4a4d24235b9abaf91_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i113d3b53a82f4678a7755be62a27ead5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i59886d9904cc4c3ab0992b2f6912e53b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id43f9e75cf9e406b9efb82314fd3ead5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5fbcd4fa4d7841719a7590a1e6e12f2f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8565cb16e67b45f5a5e7d8807f927fe7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="option">
        <measure>nltx:option</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="offering">
        <measure>nltx:offering</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80L2ZyYWc6MDBmODJjZDg0YjM3NDQwZjlkMzM4OGZjZjgzMDFhOGMvdGFibGU6MmY3ZTM2YmQ4NzJlNGJlODgxZmQ3ZWIzMDcxOTQ5OGMvdGFibGVyYW5nZToyZjdlMzZiZDg3MmU0YmU4ODFmZDdlYjMwNzE5NDk4Y180LTEtMS0xLTA_2d5e8387-a5f2-44b4-87c2-d8e052a0f798">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80L2ZyYWc6MDBmODJjZDg0YjM3NDQwZjlkMzM4OGZjZjgzMDFhOGMvdGFibGU6MmY3ZTM2YmQ4NzJlNGJlODgxZmQ3ZWIzMDcxOTQ5OGMvdGFibGVyYW5nZToyZjdlMzZiZDg3MmU0YmU4ODFmZDdlYjMwNzE5NDk4Y182LTEtMS0xLTA_9e4ff311-4231-4851-90d9-cb4879ba2048">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80L2ZyYWc6MDBmODJjZDg0YjM3NDQwZjlkMzM4OGZjZjgzMDFhOGMvdGFibGU6MmY3ZTM2YmQ4NzJlNGJlODgxZmQ3ZWIzMDcxOTQ5OGMvdGFibGVyYW5nZToyZjdlMzZiZDg3MmU0YmU4ODFmZDdlYjMwNzE5NDk4Y183LTEtMS0xLTA_d10f45d7-5c46-4afc-8ca7-1642e91b1ca8">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80L2ZyYWc6MDBmODJjZDg0YjM3NDQwZjlkMzM4OGZjZjgzMDFhOGMvdGFibGU6MmY3ZTM2YmQ4NzJlNGJlODgxZmQ3ZWIzMDcxOTQ5OGMvdGFibGVyYW5nZToyZjdlMzZiZDg3MmU0YmU4ODFmZDdlYjMwNzE5NDk4Y18xMC0xLTEtMS0w_76b2c1b3-556c-4291-92bf-9a17e157e5b8">0001404644</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80L2ZyYWc6MDBmODJjZDg0YjM3NDQwZjlkMzM4OGZjZjgzMDFhOGMvdGFibGU6MmY3ZTM2YmQ4NzJlNGJlODgxZmQ3ZWIzMDcxOTQ5OGMvdGFibGVyYW5nZToyZjdlMzZiZDg3MmU0YmU4ODFmZDdlYjMwNzE5NDk4Y18xMS0xLTEtMS0w_47852c28-eabc-44ad-b48b-a29e9f5e43a7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDAx_d76713c4-4db5-4da9-a963-25d6cc434a9d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6NGRlYzBmY2E3ODU2NDg2YzkwZDk2Yjk5MDQ4NTBmMWYvdGFibGVyYW5nZTo0ZGVjMGZjYTc4NTY0ODZjOTBkOTZiOTkwNDg1MGYxZl8wLTAtMS0xLTE1MjM_89f84970-8226-46cf-99b3-2bbe83d50729">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8zMjk4NTM0ODg2NzMy_8181a407-2311-4888-a89b-a0f5d4614ba5">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6NmE3MjgxYzcwMzdhNGU3Mzk5ZDYxODk4OGEzMmY0NjAvdGFibGVyYW5nZTo2YTcyODFjNzAzN2E0ZTczOTlkNjE4OTg4YTMyZjQ2MF8wLTAtMS0xLTE1MjU_ffc79b5d-5cff-4d0b-bbb6-499e1a56053d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDAz_460dd580-ab4a-4e98-92cc-ec5371982dca">001-36327</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDAy_bf9b4cca-ae72-44c4-afa9-34a8be269c9d">Neoleukin Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6YjAwZmQ5MGI0Y2IzNGI5OGEyNGYwMjczNmU0MDZmYTMvdGFibGVyYW5nZTpiMDBmZDkwYjRjYjM0Yjk4YTI0ZjAyNzM2ZTQwNmZhM18wLTAtMS0xLTE1Mzc_e60ad720-59c3-4ca5-be58-17513b90512d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6YjAwZmQ5MGI0Y2IzNGI5OGEyNGYwMjczNmU0MDZmYTMvdGFibGVyYW5nZTpiMDBmZDkwYjRjYjM0Yjk4YTI0ZjAyNzM2ZTQwNmZhM18wLTItMS0xLTE1Mzk_6e752e84-32fe-4e3c-82b3-8433c26e825d">98-0542593</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDA0_7be60768-08e2-41a8-8742-c72c25702a54">188 East Blaine Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDA1_31113d1f-3e0c-40e7-8943-a62e00462e9c">Suite 450</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDA2_b0850576-1d76-45e7-9a79-27ba38adf235">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDA3_51bbf4db-8a69-4860-9103-fcf523cc3eef">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDA5_8dd01e5f-9fb9-4e88-8955-6845948dfef0">98102</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDIw_5f53f69b-c014-4951-bacd-64e94ab0f15a">866</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDI0_46f84c3f-5d13-485e-8b9e-914e6f1ee34b">245-0312</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6NmU2ZjEyZThjNGI0NDUyZGE4N2UzYjVhMTIxY2M4NmYvdGFibGVyYW5nZTo2ZTZmMTJlOGM0YjQ0NTJkYTg3ZTNiNWExMjFjYzg2Zl8xLTAtMS0xLTE1NDE_83965bc9-e72e-4a76-be15-65cc3f93c063">Common Stock, par value $0.000001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6NmU2ZjEyZThjNGI0NDUyZGE4N2UzYjVhMTIxY2M4NmYvdGFibGVyYW5nZTo2ZTZmMTJlOGM0YjQ0NTJkYTg3ZTNiNWExMjFjYzg2Zl8xLTEtMS0xLTE1NDM_ee24215f-ca8c-43dc-aeb7-b2b1aa60248c">NLTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6NmU2ZjEyZThjNGI0NDUyZGE4N2UzYjVhMTIxY2M4NmYvdGFibGVyYW5nZTo2ZTZmMTJlOGM0YjQ0NTJkYTg3ZTNiNWExMjFjYzg2Zl8xLTItMS0xLTE1NDU_529bfa66-da9c-4d1c-a85b-2876b60d1f44">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDE1_79ad0e71-b1b8-478c-ba31-bfd2e32b8e23">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDE2_39a893be-d406-479a-828a-dbd5c00c6fea">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6MzQ2MTIyNTAxZmJkNGI3OWI2MDQ0Y2FkYjUzM2JkMDgvdGFibGVyYW5nZTozNDYxMjI1MDFmYmQ0Yjc5YjYwNDRjYWRiNTMzYmQwOF8yLTAtMS0xLTE1ODI_22e50935-d394-4d5c-88d7-2a35a7974762">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6MzQ2MTIyNTAxZmJkNGI3OWI2MDQ0Y2FkYjUzM2JkMDgvdGFibGVyYW5nZTozNDYxMjI1MDFmYmQ0Yjc5YjYwNDRjYWRiNTMzYmQwOF8yLTMtMS0xLTE1ODQ_bd4c3b52-2b0e-4a3c-9275-e94232ed0b31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGFibGU6MzQ2MTIyNTAxZmJkNGI3OWI2MDQ0Y2FkYjUzM2JkMDgvdGFibGVyYW5nZTozNDYxMjI1MDFmYmQ0Yjc5YjYwNDRjYWRiNTMzYmQwOF80LTMtMS0xLTE1ODY_ea445021-d758-4a87-a710-da279067d62c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8xNjQ5MjY3NDQ1MDQz_c9de3b7b-4da2-4ae7-84fc-cc48d0020764">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="icc523caa747b4d5eb5d5ca5694c0c619_I20210510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xL2ZyYWc6NDYwZTVjMTZkYWMzNGUyY2FlMmQwYzg5OWY3YTgzNjQvdGV4dHJlZ2lvbjo0NjBlNWMxNmRhYzM0ZTJjYWUyZDBjODk5ZjdhODM2NF8zMjk4NTM0ODg1NjUz_5217f85b-ed56-4c63-9f6a-e5bfd3d5f526"
      unitRef="shares">42345720</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMy0xLTEtMS0w_6eca62de-f384-4b50-a169-2f61c61aa97e"
      unitRef="usd">178391000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMy0zLTEtMS0w_1680fabc-b825-44e3-8ec4-7d57b740edbc"
      unitRef="usd">192556000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfNC0xLTEtMS0w_d937d6c6-ff2d-4e2f-863c-02d481a509cf"
      unitRef="usd">2915000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfNC0zLTEtMS0w_74b09617-f811-44dc-b204-22dfa49ab6fd"
      unitRef="usd">1966000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfNS0xLTEtMS0w_d6e255e0-1797-4faa-8691-8beef6cadc10"
      unitRef="usd">181306000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfNS0zLTEtMS0w_9f7aadf9-b18f-41f1-9fcd-d1e4d9c68003"
      unitRef="usd">194522000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfNy0xLTEtMS0w_9c08c7e8-bd03-47f1-a1d8-cb6f9d608559"
      unitRef="usd">5110000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfNy0zLTEtMS0w_e130b09d-8b46-4ec1-ab38-a9990ec60cdf"
      unitRef="usd">3570000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfOC0xLTEtMS0w_a2a959a6-2361-4e45-a8c3-10c63ce5247e"
      unitRef="usd">11473000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfOC0zLTEtMS0w_102d2cf3-e219-452a-a60c-72f7adfb69cf"
      unitRef="usd">10154000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfOS0xLTEtMS0w_c6a74332-ab7d-498d-bddb-8063dfc4b423"
      unitRef="usd">293000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfOS0zLTEtMS0w_a9237de4-0254-4367-9a71-482a8202af02"
      unitRef="usd">347000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTAtMS0xLTEtMA_2156e46c-cd92-43e2-975f-b22b4569a2d9"
      unitRef="usd">1921000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTAtMy0xLTEtMA_f3173a81-8040-46ca-a5e4-8e46c474c574"
      unitRef="usd">1926000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTEtMS0xLTEtMA_9981a96f-43b0-45f2-b45d-75e52a3b810c"
      unitRef="usd">200103000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTEtMy0xLTEtMA_41f52134-33d1-4904-bc3e-64ee660c5bb7"
      unitRef="usd">210519000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTUtMS0xLTEtMA_82d1a181-c33c-4351-8f34-7635305590ee"
      unitRef="usd">7308000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTUtMy0xLTEtMA_6b4ad554-3475-4cc3-aa44-ab6d9b2bf446"
      unitRef="usd">7181000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTYtMS0xLTEtMA_65b10a39-8b42-4865-bfba-bf27e809fc18"
      unitRef="usd">1047000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTYtMy0xLTEtMA_7a99a45b-18c4-4c57-954e-9b8b255d8fe2"
      unitRef="usd">659000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTctMS0xLTEtMA_92de2549-8e3b-48cd-b850-09f241dbf26a"
      unitRef="usd">52000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTctMy0xLTEtMA_f190cd5e-c0cb-4401-ad81-7720a312139f"
      unitRef="usd">49000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTgtMS0xLTEtMA_58fed7f0-7ed2-4a8c-9b72-971e5aef41cb"
      unitRef="usd">8407000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTgtMy0xLTEtMA_6b0845aa-2573-46b1-bf93-0822534e2caa"
      unitRef="usd">7889000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTktMS0xLTEtMA_93c45be6-30e8-4dab-b61e-c153be7bc874"
      unitRef="usd">12606000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMTktMy0xLTEtMA_fb0bda72-fa11-4bc4-8d8c-71394131da24"
      unitRef="usd">11306000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjAtMS0xLTEtMA_0d60c502-a9f0-48d7-8ea2-3403de9c806f"
      unitRef="usd">122000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjAtMy0xLTEtMA_06fc9d6c-6a61-432b-95d0-1d9e064ba2e9"
      unitRef="usd">108000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjEtMS0xLTEtMA_7cfc1a8b-837d-4572-a13e-ac1a307369ef"
      unitRef="usd">21135000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjEtMy0xLTEtMA_10ef7548-3df4-43d9-9b4a-08757000a4ae"
      unitRef="usd">19303000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzUyOA_2dfcb8d6-7052-4ccb-a4c7-16ed746cc598"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzUyOA_ca6ae320-111c-438d-a9a6-cfb4d4c150d4"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzU0Mw_553c9764-406f-4fbd-958b-a6a8e86e58cd"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzU0Mw_7ebe67b0-20dc-48a4-9337-fffe1ddd5114"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzU1Ng_5a0f628e-b572-46c6-8499-ebb97fd1a6e6"
      unitRef="shares">42326033</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzU1Ng_ed61630b-d644-442b-a6b0-86bafe59b786"
      unitRef="shares">42326033</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzU2OQ_17efd600-5549-4cc0-92b4-4074e34c1e7e"
      unitRef="shares">42196296</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjQtMC0xLTEtOTQ0L3RleHRyZWdpb246NzRjOTM0M2UyM2MxNDQ4MGFiMmM3ZmRlNTY0ZDgxYjFfMzI5ODUzNDg4MzU2OQ_3b7e3ad2-6022-409e-afb6-58a613a6bba5"
      unitRef="shares">42196296</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMS0xLTEtMA_be575588-a0df-4023-842a-3d187ae48deb"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMy0xLTEtMA_8aded4a4-ed8b-4647-8686-70d2e4e024fe"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzUyNg_183089ea-e2d3-4bad-b382-f717aae15f46"
      unitRef="usdPerShare">0.000001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzUyNg_8ec7343d-6d54-48b4-a8af-71c05c3e5e00"
      unitRef="usdPerShare">0.000001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzUzOQ_0493a311-d913-47b3-8f6a-6e03843ecd7f"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzUzOQ_7353904d-26b9-43f9-ab90-e76000c7bd56"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzYwNw_8ac291ef-4c83-4fe9-98d4-f06e624288a5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzYwNw_b457ae89-df21-400e-a4a1-5f33d47140a1"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzYwNw_c84adfe8-b920-425d-aad5-d8997c37b71e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjUtMC0xLTEtOTU4L3RleHRyZWdpb246YmUwZmJkNTk4MjM3NDA0YzhjYTc4Yzc1ZGFhNTAzYmNfMzI5ODUzNDg4MzYwNw_cd726b63-5e88-4c3e-b85a-be8646b12847"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjYtMS0xLTEtMA_db200e1d-de43-4f59-a914-3101f11b4779"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjYtMy0xLTEtMA_39adcb93-40f8-48d4-8947-4068ef01e687"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjctMS0xLTEtMA_6e7d340c-3fe7-40db-8177-73bc8818a82c"
      unitRef="usd">526724000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjctMy0xLTEtMA_2ee01d08-51b5-4945-9b28-e34cff1265ff"
      unitRef="usd">524022000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjgtMS0xLTEtMA_0fd30f02-33d4-4e42-acc1-fded504df46b"
      unitRef="usd">-347756000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjgtMy0xLTEtMA_6cd095bf-ea3c-4b88-bef7-2d6af3851b01"
      unitRef="usd">-332806000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjktMS0xLTEtMA_ca93b3aa-6794-43c6-9506-698fe5d7699e"
      unitRef="usd">178968000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMjktMy0xLTEtMA_4064e8ec-a709-4468-a40a-da56f775762f"
      unitRef="usd">191216000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMzAtMS0xLTEtMA_39273899-cc7b-4770-a1e1-ccd957f969f6"
      unitRef="usd">200103000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8xNi9mcmFnOjAyOTA0ZGFjYzc3NDRlZjc4MTNhYTUwMWQ5NzMwNTBhL3RhYmxlOmJjYWFhM2Y5OTc4ODQ0M2JiZjk1NjVlNzYyZTEwYWIzL3RhYmxlcmFuZ2U6YmNhYWEzZjk5Nzg4NDQzYmJmOTU2NWU3NjJlMTBhYjNfMzAtMy0xLTEtMA_1f8e3590-4637-4210-af52-6901812eed5d"
      unitRef="usd">210519000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMy0xLTEtMS0w_b2eb9414-6c70-43cf-b878-088001de4660"
      unitRef="usd">9707000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMy0zLTEtMS0w_8de2fd80-3133-4f88-8826-eee9b4361943"
      unitRef="usd">5498000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfNS0xLTEtMS0w_880a598b-20fc-471e-8c3c-7c713e95da59"
      unitRef="usd">5241000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfNS0zLTEtMS0w_7cb96bd5-5c1c-41f0-899f-a1892eff27ad"
      unitRef="usd">3573000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfNy0xLTEtMS0w_87a5d99b-9209-47ff-b0c8-31130127e8cb"
      unitRef="usd">-14948000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfNy0zLTEtMS0w_f9c9805c-4cb2-46db-918e-188aee992d3a"
      unitRef="usd">-9071000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfOC0xLTEtMS0w_8dad52e8-fd17-472b-aa3f-0f2fb4576073"
      unitRef="usd">-2000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfOC0zLTEtMS0w_d9334f0d-dd1f-404a-83dc-ee75378de281"
      unitRef="usd">429000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfOS0xLTEtMS0w_413e2158-2431-4129-b701-5e834f22a514"
      unitRef="usd">-14950000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfOS0zLTEtMS0w_a4682a72-adb2-455f-b6fc-c0141317048f"
      unitRef="usd">-8642000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTAtMS0xLTEtMA_d6f40278-2b07-4bb7-b668-a84f0904c5f5"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTAtMS0xLTEtMA_ebd3ba38-459d-4769-b109-4aad6f3fa13f"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTAtMy0xLTEtMA_1a7b0390-ef14-4d16-8686-b80db9b19def"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTAtMy0xLTEtMA_42fc5b1e-fc50-4282-a439-2bec62bb5c04"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTEtMS0xLTEtMA_d1515bd7-2590-441f-831a-8d502c1a414f"
      unitRef="shares">54944421</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTEtMS0xLTEtMA_dadb8e3e-517a-44c4-97b6-953606d9ff21"
      unitRef="shares">54944421</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTEtMy0xLTEtMA_9da7aeea-40ca-45f2-a550-f39f91747a08"
      unitRef="shares">49168451</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yMi9mcmFnOjgzYjI0NTliNmE5ZDQ2NmRhYTcyYzVjMzQ4NzUxNGE0L3RhYmxlOjE0OTA1OTFkNTVlZTRmYWVhYTZkOTkxM2ZjOGU2YjdlL3RhYmxlcmFuZ2U6MTQ5MDU5MWQ1NWVlNGZhZWFhNmQ5OTEzZmM4ZTZiN2VfMTEtMy0xLTEtMA_f0a965b3-ce3f-437b-b3e0-4b78539e2d4b"
      unitRef="shares">49168451</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMy0xLTEtMS0w_a935c853-fe69-4c6e-97d8-9e5277f55c83"
      unitRef="usd">-14950000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMy0zLTEtMS0w_afbd6e99-c515-4f39-9205-032d318eba11"
      unitRef="usd">-8642000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfNS0xLTEtMS0w_f70a2c3d-bb0a-4d30-b262-91d14a45fde4"
      unitRef="usd">2420000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfNS0zLTEtMS0w_08ecd9c3-5da6-42bb-b84c-0b8f95b4ff22"
      unitRef="usd">683000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfNy0xLTEtMS0w_207ed9b7-a1c8-40f4-90d5-225ab01dbd30"
      unitRef="usd">247000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfNy0zLTEtMS0w_8c6d3dd4-e7a4-417a-b7e1-c618cddd77c9"
      unitRef="usd">171000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfOS0xLTEtMS0w_0a80aec5-c47c-433b-9124-5510b4089691"
      unitRef="usd">265000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfOS0zLTEtMS0w_7963bc35-05fe-443d-9d53-3773fe66c2c5"
      unitRef="usd">528000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTEtMS0xLTEtMA_a2ff24a0-bfa4-4f97-be45-d8324532b59e"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTEtMy0xLTEtMA_996001b6-aa8c-4fd8-a7af-8577f769d2e5"
      unitRef="usd">14000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTMtMS0xLTEtMA_da4c03e5-8f95-4d9f-b98f-0cb895182494"
      unitRef="usd">813000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTMtMy0xLTEtMA_350d8f5d-06b7-42a8-b629-e8687b7f02bc"
      unitRef="usd">-266000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTQtMS0xLTEtMA_4d140df7-886c-4274-ba82-3e29524c4eb5"
      unitRef="usd">-631000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTQtMy0xLTEtMA_769b0e5f-0077-4c3b-89e8-499989f75359"
      unitRef="usd">878000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTItMS0xLTEtMTI2MA_9faf77a4-ce43-4b69-9ed6-6194cafecb95"
      unitRef="usd">0</nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTItMy0xLTEtMTI2MA_291b31e7-3261-4a6f-b5e9-233f9d93c758"
      unitRef="usd">169000</nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <nltx:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTYtMS0xLTEtMA_34c7b900-5e72-433c-85b2-76c1ab79edc9"
      unitRef="usd">104000</nltx:IncreaseDecreaseInOperatingLeaseLiability>
    <nltx:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTYtMy0xLTEtMA_0627c4b4-77e6-46ad-a9c4-7952ae4fcf8b"
      unitRef="usd">-141000</nltx:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTctMS0xLTEtMA_c533b9bb-eeac-4c41-8e3e-d8ef065744ec"
      unitRef="usd">-13358000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMTctMy0xLTEtMA_4fb6ef5f-750e-4114-be92-fbbe2a3c5f3a"
      unitRef="usd">-6440000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjEtMS0xLTEtMA_d07e2f02-6076-437b-a7cc-368a09dd0357"
      unitRef="usd">1089000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjEtMy0xLTEtMA_6a4a22c1-cfd9-4bad-9c1d-17bd109fea40"
      unitRef="usd">107000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjItMS0xLTEtMA_63149497-141d-40b1-bc9a-503d3f65d276"
      unitRef="usd">-1089000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjItMy0xLTEtMA_b4c8d401-8f20-4fab-b057-a5025595dddf"
      unitRef="usd">-107000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjctMS0xLTEtMA_8a9a6b68-43d8-4bb2-8b43-dbafebc5f8cc"
      unitRef="usd">282000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjctMy0xLTEtMA_ff31b1bc-6d72-49d5-87df-41bcd463825c"
      unitRef="usd">3392000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjgtMS0xLTEtMA_01d8dab8-ae83-4a6d-aa40-163df23e27aa"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjgtMy0xLTEtMA_946b29a9-5686-4fe8-b1b9-1b1196517dfb"
      unitRef="usd">2000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjktMS0xLTEtMA_547f8927-504d-4202-8cb7-2c285aa10ac4"
      unitRef="usd">282000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMjktMy0xLTEtMA_57a12d47-10be-478b-b7c5-e7b3d157b1b2"
      unitRef="usd">3390000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzEtMS0xLTEtMA_00c0810d-3e81-448f-8744-b3c2e978029d"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzEtMy0xLTEtMA_57487ad1-2a46-4906-ad5a-cea7af5d6ed3"
      unitRef="usd">-11000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzItMS0xLTEtMA_9983bb33-dad5-4728-a967-71221c4f0bbd"
      unitRef="usd">-14165000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzItMy0xLTEtMA_7863909f-c7a8-4d62-843f-dbd5ab00e7c9"
      unitRef="usd">-3168000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzMtMS0xLTEtMA_0a538a13-a4c8-41e5-b15c-0c43b3eda9ed"
      unitRef="usd">193434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8ef7407a22bd487e896bbba912705914_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzMtMy0xLTEtMA_9ef81a7a-a16f-48ab-a20a-7a4d90a6a220"
      unitRef="usd">143093000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzUtMS0xLTEtMA_af10c7cb-a3d0-4ccf-ba26-07466d6216f1"
      unitRef="usd">179269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i266aceeba1c54778bbfe3444ba803e5b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzUtMy0xLTEtMA_631d204a-e41b-465e-bd64-a3d7ce6ee2f1"
      unitRef="usd">139925000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzgtMS0xLTEtMA_2e5175df-5905-4b70-ad0c-4f98b8ad224d"
      unitRef="usd">794000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzgtMy0xLTEtMA_25299278-6929-4dc0-9473-09bf71b734dc"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzktMS0xLTEtMA_6ebbe4b4-0eaf-4989-9dc6-1d145a7f0efa"
      unitRef="usd">1584000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8yNS9mcmFnOmNjNmM3NDZiNTBmNTRhMDM4NmEzOTc2ZGYxY2Y0N2I3L3RhYmxlOmRmMmEyZjRmYjIxMjQ1YmY4NzU3MGM1NmYxYTQxMmVlL3RhYmxlcmFuZ2U6ZGYyYTJmNGZiMjEyNDViZjg3NTcwYzU2ZjFhNDEyZWVfMzktMy0xLTEtMA_809e1c96-23c7-4c84-95b3-5b0cc9315e11"
      unitRef="usd">9614000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:SharesOutstanding
      contextRef="i4a3c3ccbbb4b4a8a9dea4828d5509b0f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMi0xLTEtMS0w_3ced02a9-3d1a-4bd3-8cb6-fb645acb4238"
      unitRef="shares">37996849</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ida9e53c7555c4440b86abfb9775901e1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMi05LTEtMS0w_9e658468-018d-4e53-8d3b-9a874927dc9e"
      unitRef="usd">441216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1041684bd2f5499d8dd06947bdad86bf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMi0xMS0xLTEtMA_86c2b7e8-2201-453d-b323-535a42d8c69d"
      unitRef="usd">-299529000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ef7407a22bd487e896bbba912705914_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMi0xMy0xLTEtMA_1e1c05c9-c3a1-4273-90bb-b13b4360358c"
      unitRef="usd">141687000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ied83e64ea1b341e98a9122c058ff0cab_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMy0xLTEtMS0w_3ebf0fea-195a-48df-9ed9-10dec6f79a0b"
      unitRef="shares">376311</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i45378b9878734ebc86bd47e3bef959f0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMy05LTEtMS0w_9077fd7d-e143-4f75-82ea-d4e6c2f9936d"
      unitRef="usd">3392000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMy0xMy0xLTEtMA_4e2b21fd-7f51-4174-bde1-8fb3ed3cc926"
      unitRef="usd">3392000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ied83e64ea1b341e98a9122c058ff0cab_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNC0xLTEtMS0w_729c266e-f030-49ed-a90c-d3a0e98f1a6a"
      unitRef="shares">13000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i45378b9878734ebc86bd47e3bef959f0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNS05LTEtMS0w_9001be4b-3a80-498b-a399-0689dee0a118"
      unitRef="usd">683000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNS0xMy0xLTEtMA_ff4550a7-3d03-4e24-b286-5efd17f0100f"
      unitRef="usd">683000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i2670e284ec83470abde183cca23912e2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNi0xMS0xLTEtMA_389db3ee-0c93-499d-95af-a5df508955f1"
      unitRef="usd">-8642000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNi0xMy0xLTEtMA_231d8d44-6df3-498e-bc7b-8bbe2265b2ab"
      unitRef="usd">-8642000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i21996bf832504aa398e0b3fbeb65538e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNy0xLTEtMS0w_77e4412b-e010-4205-a6a2-140f2ec7c49c"
      unitRef="shares">38386160</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0750d237a2a948d79ac2746dea7b630e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNy05LTEtMS0w_f34f5db3-1054-4466-8851-9ccfc140d372"
      unitRef="usd">445291000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib50df656baa2413f963433dc3384d0a1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNy0xMS0xLTEtMA_f26f9153-4edf-457b-86c5-f1541070fe24"
      unitRef="usd">-308171000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i266aceeba1c54778bbfe3444ba803e5b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfNy0xMy0xLTEtMA_48fee9c8-c13a-47fd-8435-58fefcb531a3"
      unitRef="usd">137120000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if4c61b32dc0641ba9b2270ba1aeb5cdf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfOS0xLTEtMS04MDI_43c57925-69f4-44d5-aa13-9e597ca7b212"
      unitRef="shares">42196296</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1ad21f0531d446c49ab28a1a53a165c3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfOS01LTEtMS04MTE_679f139d-8102-4a21-b46d-4297d108ee77"
      unitRef="usd">524022000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i02841c927886459ea84b517e8630c500_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfOS03LTEtMS04MTY_c637d7ec-3b8a-43a8-851c-b7558e03f1e5"
      unitRef="usd">-332806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfOS05LTEtMS04MjA_68789182-0bed-4737-9557-868bfa0afda6"
      unitRef="usd">191216000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ief2d01c144814d3782789c4d46b928c0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTAtMS0xLTEtODAy_92b15079-4062-460a-b436-77e44c8288d8"
      unitRef="shares">91737</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if8415c2681fa4e7d8847b9a1e693685a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTAtNS0xLTEtODEx_c792d1a0-faec-41af-87f6-08988507930a"
      unitRef="usd">282000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTAtOS0xLTEtODIw_3e8b8392-196b-493d-a616-cc663751a914"
      unitRef="usd">282000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ief2d01c144814d3782789c4d46b928c0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTEtMS0xLTEtODAy_f8789208-2dc5-42aa-a012-8a58b7d0128b"
      unitRef="shares">38000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if8415c2681fa4e7d8847b9a1e693685a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTItNS0xLTEtODEx_c85e4fbe-c548-4b7d-83a8-b74e512fd64f"
      unitRef="usd">2420000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTItOS0xLTEtODIw_215c2142-88fa-42e6-b05e-d94a0a6d5f68"
      unitRef="usd">2420000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i5ab1dbbff5ce4c3e9ead9a82f62dedef_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTMtNy0xLTEtODE2_842ced1f-fd93-49cd-929a-8c62d787d7fd"
      unitRef="usd">-14950000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTMtOS0xLTEtODIw_c1d3afe0-9676-4936-98bc-994471f5b61c"
      unitRef="usd">-14950000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3b5f0e7d56e3478eab62216caa641a6b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTQtMS0xLTEtMTgzMQ_300292f9-b97f-44ed-bbfd-98996538a334"
      unitRef="shares">42326033</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i24b77291445c421fa209b58e0176120b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTQtNS0xLTEtMTgzMQ_1fe1820a-6e23-46b4-8531-5dc0fce61ce5"
      unitRef="usd">526724000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idba78dc2d87a4ad5ab6727062f43f0f9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTQtNy0xLTEtMTgzMQ_b2e21fe0-216f-42c1-a9f8-ac7f921fda6c"
      unitRef="usd">-347756000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zMS9mcmFnOjJiNDRiM2M4YThhNTRmYmE4ODliMDBmOWI2MzM5OWUyL3RhYmxlOmFjNzMyY2Y1NjdlZDQ5ZGVhNTI0OTJlNjJlMmI3MTM5L3RhYmxlcmFuZ2U6YWM3MzJjZjU2N2VkNDlkZWE1MjQ5MmU2MmUyYjcxMzlfMTQtOS0xLTEtMTgzMQ_629bd104-664e-48b8-aa5d-9e537cbbff9c"
      unitRef="usd">178968000</us-gaap:StockholdersEquity>
    <us-gaap:NatureOfOperations
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV8zNy9mcmFnOjBjNDJiNzJjYmU4ZjRkMzY4MjJhZjhjYWYxN2FmYjY4L3RleHRyZWdpb246MGM0MmI3MmNiZThmNGQzNjgyMmFmOGNhZjE3YWZiNjhfNDQx_0985142e-ceec-4e1b-8d12-69a54af141a7">Nature of operationsNeoleukin Therapeutics, Inc. (&#x201c;Neoleukin&#x201d; or &#x201c;the Company&#x201d;) is&#160;a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using&#160;de novo&#160;protein design technology. Neoleukin uses sophisticated computational methods to design&#160;proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2NA_a86039c9-d31a-4911-a00a-f3708754c588">Summary of significant accounting policies&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements are presented in United States (&#x201c;U.S.&#x201d;) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information.&#160;&#160;Accordingly, these consolidated financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the Securities and Exchange Commission on March 25, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company sold all of the issued and outstanding capital stock of Aquinox Pharmaceuticals, Inc. (Canada) (&#x201c;Aquinox Canada&#x201d;) to an unrelated third party. On December 31, 2020, Neoleukin Corporation, the Company's wholly owned subsidiary, was merged into the Company. As a result, the Company has consisted of a single operating company since December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In management&#x2019;s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position of the Company as of March&#160;31, 2021, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Use of estimates and assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, the incremental borrowing rate utilized in the measurement of operating and finance lease liabilities, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical, clinical, and other accruals. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reclassified prior year changes in operating lease right-of-use assets and operating lease liabilities in the condensed consolidated statements of cash flows to conform to current year presentation. This reclassification had no effect on net cash used in operating activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company determines if the contract is or contains a lease. Lease liabilities are recognized on the lease commencement date based on the estimated present value of lease payments over the lease term. To determine the present value of the lease payments, the Company utilizes its estimated incremental borrowing rate based on information available at the lease commencement date as the interest rate implicit in the lease is typically not readily determinable. The related right-of-use assets are recorded net of any lease incentives received. Variable lease cost primarily includes building operating expenses as charged to the Company by its landlords and payments for lessor-owned assets that are not covered by a tenant improvement allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company includes options to extend the lease in its lease liability and right-of-use asset when it is reasonably certain that it will exercise that option. None of the Company's options to extend the rental term of any of its existing leases were considered reasonably certain as of March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases of office space and equipment, the Company has elected to not separate the lease components from the non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases of office space with a lease term of 12 months or less and which do not include an option to purchase the underlying asset, the Company has elected to recognize the lease payments in the statement of operations on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, restricted cash, receivables, accounts payable and other liabilities, approximate their fair values because of their nature and/or short maturities.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021, and December&#160;31, 2020, the Company had $156.3 million and $108.3 million in money market funds, respectively. Money market funds are level one financial instruments as they are valued at fair value, which is the closing price reported by the fund sponsor from an actively traded exchange.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:8.01pt"&gt;Earnings (loss) per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Common stock equivalents such as outstanding stock options and unvested restricted stock units are included in the calculation of diluted earnings per share only in periods of net income. Such common stock equivalents are excluded in the calculation of diluted net loss per share in periods of net loss as inclusion of such amounts would be anti-dilutive. Outstanding pre-funded warrants as of March 31, 2021 of 12,663,010 are considered outstanding as of their issuance date and are included in the basic and diluted net loss per share calculation because they are fully vested and exercisable at any time after 61 days' notice for a nominal cash consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Recently issued and recently adopted accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2019-12 &#x201c;Simplifying the Accounting for Income Taxes.&#x201d; The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 740 - Income Taxes and clarifying existing guidance to facilitate consistent application. ASU 2019-12 became effective for fiscal years and interim periods beginning after December 15, 2020. The Company adopted this standard on January 1, 2021 on a prospective basis. The adoption of this ASU did not have a material impact on the Company's financial condition, results of operations, cash flows, and financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY1OQ_42ee2120-f168-48d4-977d-7956a8716f2e">Basis of presentation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements are presented in United States (&#x201c;U.S.&#x201d;) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information.&#160;&#160;Accordingly, these consolidated financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the Securities and Exchange Commission on March 25, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company sold all of the issued and outstanding capital stock of Aquinox Pharmaceuticals, Inc. (Canada) (&#x201c;Aquinox Canada&#x201d;) to an unrelated third party. On December 31, 2020, Neoleukin Corporation, the Company's wholly owned subsidiary, was merged into the Company. As a result, the Company has consisted of a single operating company since December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In management&#x2019;s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position of the Company as of March&#160;31, 2021, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2NQ_aefff34c-0e04-4a64-9c4d-9790719df072">Use of estimates and assumptionsThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, the incremental borrowing rate utilized in the measurement of operating and finance lease liabilities, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical, clinical, and other accruals. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2MA_29d967d5-b47e-44b4-84d7-04f5a7790948">ReclassificationThe Company reclassified prior year changes in operating lease right-of-use assets and operating lease liabilities in the condensed consolidated statements of cash flows to conform to current year presentation. This reclassification had no effect on net cash used in operating activities.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2MQ_f1d802d3-c023-44f9-81e4-c35c00dc1f50">LeasesAt contract inception, the Company determines if the contract is or contains a lease. Lease liabilities are recognized on the lease commencement date based on the estimated present value of lease payments over the lease term. To determine the present value of the lease payments, the Company utilizes its estimated incremental borrowing rate based on information available at the lease commencement date as the interest rate implicit in the lease is typically not readily determinable. The related right-of-use assets are recorded net of any lease incentives received. Variable lease cost primarily includes building operating expenses as charged to the Company by its landlords and payments for lessor-owned assets that are not covered by a tenant improvement allowance.&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company includes options to extend the lease in its lease liability and right-of-use asset when it is reasonably certain that it will exercise that option. None of the Company's options to extend the rental term of any of its existing leases were considered reasonably certain as of March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases of office space and equipment, the Company has elected to not separate the lease components from the non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases of office space with a lease term of 12 months or less and which do not include an option to purchase the underlying asset, the Company has elected to recognize the lease payments in the statement of operations on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i60f915889b8c437cb2397db911f55730_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfMzI5ODUzNDg5NTcxMQ_969d1cf0-8091-4d12-b469-9ad85efc040b">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2Ng_8a5fbe6f-9889-4c10-9e12-49278606422d">Fair value of financial instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, restricted cash, receivables, accounts payable and other liabilities, approximate their fair values because of their nature and/or short maturities.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021, and December&#160;31, 2020, the Company had $156.3 million and $108.3 million in money market funds, respectively. Money market funds are level one financial instruments as they are valued at fair value, which is the closing price reported by the fund sponsor from an actively traded exchange.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3c27f1e7af754f9fb0d20083db327bd7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfMzI5ODUzNDg5NTc1Ng_12a614b8-e9c1-438e-bf49-d86394836d01"
      unitRef="usd">156300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1e27bb42a4374782b35ac38cec07ae0b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfMzI5ODUzNDg5NTc3NQ_08e5ec65-2289-4884-92ce-98c833439e57"
      unitRef="usd">108300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2Mg_785d90fa-5953-48f7-a15d-d94170d58a4a">Earnings (loss) per shareBasic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Common stock equivalents such as outstanding stock options and unvested restricted stock units are included in the calculation of diluted earnings per share only in periods of net income. Such common stock equivalents are excluded in the calculation of diluted net loss per share in periods of net loss as inclusion of such amounts would be anti-dilutive. Outstanding pre-funded warrants as of March 31, 2021 of 12,663,010 are considered outstanding as of their issuance date and are included in the basic and diluted net loss per share calculation because they are fully vested and exercisable at any time after 61 days' notice for a nominal cash consideration.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i24f310adc03d4c76a4887bd28c38a5d6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNDg4MQ_79c096ec-22e7-465c-a913-636a35e1f146"
      unitRef="shares">12663010</us-gaap:ClassOfWarrantOrRightOutstanding>
    <nltx:ClassOfWarrantOrRightNoticePeriod
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfMTY0OTI2NzQ2MDI4NQ_7b0e53bb-4366-41e8-b188-45116c011080">P61D</nltx:ClassOfWarrantOrRightNoticePeriod>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV80MC9mcmFnOjNhYTI1YTBhNTlhOTRlMDQ5MDZmZmM0ZTNhNTcwOTNjL3RleHRyZWdpb246M2FhMjVhMGE1OWE5NGUwNDkwNmZmYzRlM2E1NzA5M2NfNzY2Nw_7704dfee-12e2-4d0a-8a9b-3ae708a16c97">Recently issued and recently adopted accounting standardsIn December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2019-12 &#x201c;Simplifying the Accounting for Income Taxes.&#x201d; The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 740 - Income Taxes and clarifying existing guidance to facilitate consistent application. ASU 2019-12 became effective for fiscal years and interim periods beginning after December 15, 2020. The Company adopted this standard on January 1, 2021 on a prospective basis. The adoption of this ASU did not have a material impact on the Company's financial condition, results of operations, cash flows, and financial statement disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <nltx:CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RleHRyZWdpb246YWU4ZWFjYzAzZWM5NDcxNzkyNWVkYTRjY2I2YjgzMWVfNTUz_1a74ccfa-3353-4fb6-afef-7031ca663d73">Cash, cash equivalents and restricted cash&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash, included in other non-current assets in the condensed consolidated balance sheets, includes $0.9 million in cash deposits the Company maintains with its bank as collateral for the irrevocable letters of credit related to its lease obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hat sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nltx:CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock>
    <us-gaap:SecurityDeposit
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RleHRyZWdpb246YWU4ZWFjYzAzZWM5NDcxNzkyNWVkYTRjY2I2YjgzMWVfMTQ4_e0343f5a-7684-4707-a588-08dbb0477bf7"
      unitRef="usd">900000</us-gaap:SecurityDeposit>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RleHRyZWdpb246YWU4ZWFjYzAzZWM5NDcxNzkyNWVkYTRjY2I2YjgzMWVfNTU0_13de5cfe-63da-4aa5-8846-0545b09ad9b5">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hat sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RleHRyZWdpb246YWU4ZWFjYzAzZWM5NDcxNzkyNWVkYTRjY2I2YjgzMWVfNTU0_4a5c8147-a3fd-4d66-8e25-10d94bd45efb">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hat sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RhYmxlOmE2ZDQwYzJiN2E0NjRmMmY4NDlmZTMzMzk5Mzc4Mzc3L3RhYmxlcmFuZ2U6YTZkNDBjMmI3YTQ2NGYyZjg0OWZlMzMzOTkzNzgzNzdfMS0xLTEtMS0w_4ab1b2a6-26c5-42fa-a24e-84baa944f8de"
      unitRef="usd">178391000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RhYmxlOmE2ZDQwYzJiN2E0NjRmMmY4NDlmZTMzMzk5Mzc4Mzc3L3RhYmxlcmFuZ2U6YTZkNDBjMmI3YTQ2NGYyZjg0OWZlMzMzOTkzNzgzNzdfMS0zLTEtMS0w_b0d6ec06-1c5b-46a2-924f-46aa49ba1c26"
      unitRef="usd">192556000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RhYmxlOmE2ZDQwYzJiN2E0NjRmMmY4NDlmZTMzMzk5Mzc4Mzc3L3RhYmxlcmFuZ2U6YTZkNDBjMmI3YTQ2NGYyZjg0OWZlMzMzOTkzNzgzNzdfMi0xLTEtMS0w_13f42e25-5919-4914-b3b8-210e43a0a22f"
      unitRef="usd">878000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RhYmxlOmE2ZDQwYzJiN2E0NjRmMmY4NDlmZTMzMzk5Mzc4Mzc3L3RhYmxlcmFuZ2U6YTZkNDBjMmI3YTQ2NGYyZjg0OWZlMzMzOTkzNzgzNzdfMi0zLTEtMS0w_1b43425b-c077-4f67-ba3c-47c16f2781b3"
      unitRef="usd">878000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RhYmxlOmE2ZDQwYzJiN2E0NjRmMmY4NDlmZTMzMzk5Mzc4Mzc3L3RhYmxlcmFuZ2U6YTZkNDBjMmI3YTQ2NGYyZjg0OWZlMzMzOTkzNzgzNzdfMy0xLTEtMS0w_54531493-a6a1-4ef2-96d8-d5448c626b7f"
      unitRef="usd">179269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81Mi9mcmFnOmFlOGVhY2MwM2VjOTQ3MTc5MjVlZGE0Y2NiNmI4MzFlL3RhYmxlOmE2ZDQwYzJiN2E0NjRmMmY4NDlmZTMzMzk5Mzc4Mzc3L3RhYmxlcmFuZ2U6YTZkNDBjMmI3YTQ2NGYyZjg0OWZlMzMzOTkzNzgzNzdfMy0zLTEtMS0w_7861861e-69f4-45d8-8cd1-e8adf1594455"
      unitRef="usd">193434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMTY0OTI2NzQ0OTU0Nw_1315ee9b-5ea9-42e6-99e2-1a8f6d66359b">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into lease arrangements for its facilities as well as certain equipment, classified either as operating or finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a lease agreement, as amended by the execution of two subsequent amendments,&#160;for approximately 33,300 square feet of office space in Seattle, Washington for the Company&#x2019;s principal executive offices, a laboratory for research and development, and related uses. The lease commenced on January 15, 2020 and expires on February 1, 2029, with the option to extend the lease for two five-year terms.&#160;&#160;The lease provides for a tenant improvement allowance of up to $9.5 million. As of March&#160;31, 2021, there was a tenant improvement allowance receivable of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.3 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recorded in other current assets related to reimbursable build-out costs incurred by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a lease agreement&#160;for approximately 6,272 square feet of office space in Seattle, Washington, for additional office and laboratory space for research and development and related uses. In March 2021, the Company executed an amendment to this lease pursuant to which the contractual lease term was extended through September 30, 2026, unless terminated earlier, with the option to extend the lease for an additional 28-month term. The execution of this amendment was accounted for as a modification to the lease due to the extension of the lease term and an increase in lease payments, and the Company recorded an increase in the lease liability and related right-of-use asset of $1.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, and December 31, 2020, the Company&#x2019;s operating lease right-of-use assets were $11.5 million and $10.2 million, respectively.&#160;&#160;As of March&#160;31, 2021, and December&#160;31, 2020, the Company&#x2019;s finance lease right-of-use assets were $0.3 million and $0.3 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzY2MA_dc33993c-9040-4f45-b42a-a416437a472c">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into lease arrangements for its facilities as well as certain equipment, classified either as operating or finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a lease agreement, as amended by the execution of two subsequent amendments,&#160;for approximately 33,300 square feet of office space in Seattle, Washington for the Company&#x2019;s principal executive offices, a laboratory for research and development, and related uses. The lease commenced on January 15, 2020 and expires on February 1, 2029, with the option to extend the lease for two five-year terms.&#160;&#160;The lease provides for a tenant improvement allowance of up to $9.5 million. As of March&#160;31, 2021, there was a tenant improvement allowance receivable of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.3 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recorded in other current assets related to reimbursable build-out costs incurred by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a lease agreement&#160;for approximately 6,272 square feet of office space in Seattle, Washington, for additional office and laboratory space for research and development and related uses. In March 2021, the Company executed an amendment to this lease pursuant to which the contractual lease term was extended through September 30, 2026, unless terminated earlier, with the option to extend the lease for an additional 28-month term. The execution of this amendment was accounted for as a modification to the lease due to the extension of the lease term and an increase in lease payments, and the Company recorded an increase in the lease liability and related right-of-use asset of $1.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, and December 31, 2020, the Company&#x2019;s operating lease right-of-use assets were $11.5 million and $10.2 million, respectively.&#160;&#160;As of March&#160;31, 2021, and December&#160;31, 2020, the Company&#x2019;s finance lease right-of-use assets were $0.3 million and $0.3 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i1325199026084dc49257e149e0b3a800_I20210331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMjA5_13c5c2b7-3088-4c5a-a415-e68aa1a56ff4"
      unitRef="sqft">33300</us-gaap:AreaOfRealEstateProperty>
    <nltx:NumberOfOptionToExtendLease
      contextRef="ie7cd5ec78bdb4b6ead8826027dfad8c0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfOTAx_d1a91fbf-e71e-415c-81fc-75d2514455fa"
      unitRef="option">2</nltx:NumberOfOptionToExtendLease>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i1325199026084dc49257e149e0b3a800_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMTY0OTI2NzQ0OTU1OQ_c42f7789-f252-490e-a6ea-6fc7367ffa83">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <nltx:TenantImprovementAllowance
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfOTc5_a20c9101-c9a0-4f94-988d-02a056bba244"
      unitRef="usd">9500000</nltx:TenantImprovementAllowance>
    <nltx:TenantImprovementAllowanceReceivable
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMTU3Nw_74c7a09b-fa8e-4880-8ace-48238fa019f7"
      unitRef="usd">1300000</nltx:TenantImprovementAllowanceReceivable>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i186a9002297b4b929c09d8989bae5a4c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMjMwNg_ded3e68f-4c7a-4b4e-b0d0-62b723d3221c"
      unitRef="sqft">6272</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i186a9002297b4b929c09d8989bae5a4c_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMTY0OTI2NzQ0OTU3MA_2a033f74-9103-4305-8cc8-9de396724311">P28M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <nltx:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i1820fca965074a6f98dbdf687a1aa94b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzI5ODUzNDg4OTM2MQ_a26b0b91-a832-491e-b8ab-bb8e0c7aa84a"
      unitRef="usd">1600000</nltx:IncreaseDecreaseInOperatingLeaseLiability>
    <nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="i1820fca965074a6f98dbdf687a1aa94b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzI5ODUzNDg4OTM2MQ_bdd1566c-5598-47c4-b744-66ccb286c1dd"
      unitRef="usd">1600000</nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzU0MA_012f05c8-1db2-418e-a920-56c6d24e3cc9"
      unitRef="usd">11500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzU0Nw_6345d9dd-d3f0-44e1-969e-470e6684b84c"
      unitRef="usd">10200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzYzNw_b8d57cb4-c083-48b0-a667-85e54ea86ca3"
      unitRef="usd">300000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV81NS9mcmFnOmI4NTA5YzdhZDU4MzRjYjNiYTc1ODQwZmE4ODQ0MjUwL3RleHRyZWdpb246Yjg1MDljN2FkNTgzNGNiM2JhNzU4NDBmYTg4NDQyNTBfMzY0NA_97a3fc06-2121-4345-9cf2-dbf591e384ed"
      unitRef="usd">300000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMjU4MQ_cfec714f-bf81-4110-ba3b-378449d7e894">Equity&#160;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Common stock and pre-funded warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue  100,000,000 shares of common stock with a par value of $0.000001 as of March 31, 2021.  As of March&#160;31, 2021 and December&#160;31, 2020 the total number of shares of common stock issued and outstanding was 42,326,033 and 42,196,296, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the Company also has pre-funded warrants outstanding to purchase an aggregate of  12,663,010 shares of common stock. The pre-funded warrants are exercisable at any time, with 61 days' notice, for an exercise price of 0.000001, except that the pre-funded warrants cannot be exercised by the stockholders if, after giving effect thereto, the stockholders would beneficially own more than 9.99% of the outstanding common stock, subject to certain exceptions. The holders of the pre-funded warrants will not have the right to vote on any matter except to the extent required by Delaware law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is classified in the condensed consolidated statement of operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized compensation cost for all stock-based compensation plans was $23.8 million as of March&#160;31, 2021. This cost is expected to be recognized over a weighted average remaining vesting period of 3.00 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of stock options granted are estimated using the Black-Scholes option pricing model with the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected terms (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity and related information for the three months ended March 31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life&lt;br/&gt;&#160;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value &lt;br/&gt;(in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,846,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,891,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,205,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021, 91,737 shares of common stock were issued upon exercise of options with an aggregate intrinsic value of $1.0 million. During the three months ended March&#160;31, 2020, 376,311 shares of common stock were issued upon exercise of options with an aggregate intrinsic value of $1.3 million. The weighted-average grant date fair value of options granted during the three months ended March&#160;31, 2021 and March&#160;31, 2020 was $9.43 and $5.62 per share, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted stock unit activity and related information for the three months ended March 31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2020 Employee Stock Purchase Plan (&#x201c;2020 ESPP&#x201d;) was adopted by the Company&#x2019;s Board of Directors in March 2020 and approved by the Company&#x2019;s stockholders in May 2020. A total of 759,936 shares of common stock have been reserved for issuance under the 2020 ESPP.&lt;/span&gt;&lt;/div&gt;Subject to share and dollar limits as described in the plan, the 2020 ESPP allows eligible employees to contribute, through payroll deductions, up to 15% of their earnings for the purchase of shares of the Company&#x2019;s common stock at the lower of 85% of the closing price of the Company&#x2019;s common stock on the first trading day of the offering period or 85% of the closing price of the Company&#x2019;s common stock on the last trading day of the offering period. There are two six-month offering periods during each fiscal year, ending on May 15 and November 15.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkwNQ_79d27548-a898-4e5b-84d2-9cd881b9cfbd"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkxMQ_3b9015c2-a6f9-48a6-bb62-fd60099a7695"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkxOA_08c852b2-14e1-4c2d-beb8-69e6bb176c71"
      unitRef="shares">42326033</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkxOA_6802d460-30fa-4b94-b816-d5d7e734a389"
      unitRef="shares">42326033</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkyNA_a10b0cfa-c272-46fa-ab7b-2c6dc652a644"
      unitRef="shares">42196296</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkyNA_e8d2f445-9b50-4275-a318-a5dddde08dbe"
      unitRef="shares">42196296</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i24f310adc03d4c76a4887bd28c38a5d6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkzMA_3ab6c1c0-c2da-4725-bc65-9bbf30bda21a"
      unitRef="shares">12663010</us-gaap:ClassOfWarrantOrRightOutstanding>
    <nltx:ClassOfWarrantOrRightNoticePeriod
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTg5NQ_7b0e53bb-4366-41e8-b188-45116c011080">P61D</nltx:ClassOfWarrantOrRightNoticePeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i24f310adc03d4c76a4887bd28c38a5d6_I20210331"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTkzNg_8da9cbd2-284e-4098-91eb-ba8528aee0c1"
      unitRef="usdPerShare">0.000001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <nltx:PercentageOfOutstandingStockPerStockholderMaximum
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4OTk0NA_a99ec7f2-c40b-4f47-9636-3196de9fe1a9"
      unitRef="number">0.0999</nltx:PercentageOfOutstandingStockPerStockholderMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMjU4Mg_2e7c46eb-9e40-42c7-9be6-272de685a024">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is classified in the condensed consolidated statement of operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic81ac6cce2184282919e6dd0d38cfbd0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQ2ZTQ3NTFlODRiYzQ3YzM5MTA4NGNmMDA5MGQxY2NiL3RhYmxlcmFuZ2U6NDZlNDc1MWU4NGJjNDdjMzkxMDg0Y2YwMDkwZDFjY2JfMi0xLTEtMS0w_946bc114-0f7e-469d-80e0-5c65dc201ff2"
      unitRef="usd">1018000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic47a8fba428642d0b3fb3e9e489dc7e3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQ2ZTQ3NTFlODRiYzQ3YzM5MTA4NGNmMDA5MGQxY2NiL3RhYmxlcmFuZ2U6NDZlNDc1MWU4NGJjNDdjMzkxMDg0Y2YwMDkwZDFjY2JfMi0zLTEtMS0w_2a0aba38-18b3-45c2-9c89-4f280e6bdebb"
      unitRef="usd">283000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9c816066ede34186900132e7d337049c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQ2ZTQ3NTFlODRiYzQ3YzM5MTA4NGNmMDA5MGQxY2NiL3RhYmxlcmFuZ2U6NDZlNDc1MWU4NGJjNDdjMzkxMDg0Y2YwMDkwZDFjY2JfMy0xLTEtMS0w_145cda5f-f479-4aa6-9021-a81d7c0b4a42"
      unitRef="usd">1402000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96c754f9fd824cb2941da29469f252a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQ2ZTQ3NTFlODRiYzQ3YzM5MTA4NGNmMDA5MGQxY2NiL3RhYmxlcmFuZ2U6NDZlNDc1MWU4NGJjNDdjMzkxMDg0Y2YwMDkwZDFjY2JfMy0zLTEtMS0w_d1e5ecd7-9e55-4263-90dc-d5d059eb7f81"
      unitRef="usd">401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQ2ZTQ3NTFlODRiYzQ3YzM5MTA4NGNmMDA5MGQxY2NiL3RhYmxlcmFuZ2U6NDZlNDc1MWU4NGJjNDdjMzkxMDg0Y2YwMDkwZDFjY2JfNC0xLTEtMS0w_42a6dac9-5e94-471a-94bb-18e5c6930b0c"
      unitRef="usd">2420000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQ2ZTQ3NTFlODRiYzQ3YzM5MTA4NGNmMDA5MGQxY2NiL3RhYmxlcmFuZ2U6NDZlNDc1MWU4NGJjNDdjMzkxMDg0Y2YwMDkwZDFjY2JfNC0zLTEtMS0w_ca591192-762f-473d-a380-f1542c7ea417"
      unitRef="usd">683000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfODA2_a490fa3c-9b84-477f-820d-a119a44eef81"
      unitRef="usd">23800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfOTEw_dd9a9671-cf40-4f29-8ff6-0a6b97002799">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMjU3OA_fb781708-528b-4872-9343-4768a57b045e">The fair values of stock options granted are estimated using the Black-Scholes option pricing model with the following weighted average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected terms (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfMi0xLTEtMS0w_fb2b45fe-2ae3-43b1-8256-b1c709d363fd"
      unitRef="number">0.8968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfMi0zLTEtMS0w_e1f33154-e713-45fb-b48a-ec10ff00fc51"
      unitRef="number">0.9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfMy0xLTEtMS0w_46bc34b8-7e64-43a1-8951-e48add53a17a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfMy0zLTEtMS0w_39e24204-49e3-4b75-a9c4-d9934109bbb9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfNC0xLTEtMS0w_1e20de3c-0775-4172-8e5e-5dee8be41716">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfNC0zLTEtMS0w_e3904d87-df12-4afe-b598-f4c5a937d6bb">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfNS0xLTEtMS0w_21f3c167-874c-4f3b-a121-9fb8bb68e854"
      unitRef="number">0.0061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjQwMGM4MGI1OWQ3MjQ4NGVhYmFlYmI3ZTcwOGI2YjUyL3RhYmxlcmFuZ2U6NDAwYzgwYjU5ZDcyNDg0ZWFiYWViYjdlNzA4YjZiNTJfNS0zLTEtMS0w_89aef8b0-35a7-43bc-a3cc-493346626883"
      unitRef="number">0.0078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMjU3OQ_fca4a007-0a30-418c-9e8b-955c5018e636">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity and related information for the three months ended March 31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life&lt;br/&gt;&#160;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value &lt;br/&gt;(in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,846,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,891,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,205,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMS0xLTEtMS0w_1b07595f-b18c-4f42-ad69-3804e2300876"
      unitRef="shares">6846289</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMS0zLTEtMS0w_dea0e78a-3998-4538-9132-092fea08aeb0"
      unitRef="usdPerShare">6.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i178f16263cfa423ea5c90d8ffe50b7f9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMS01LTEtMS0w_22bc58fe-1973-4c5e-9d20-522ad284dab7">P8Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i119066f786864fd79f80c0f67e219cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMS03LTEtMS0w_43429dbf-3772-48a9-856e-da184fd6d945"
      unitRef="usd">53127000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMi0xLTEtMS0w_bf4635a1-1f4e-4de7-8f5a-9fbc6220b6dc"
      unitRef="shares">140800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMi0zLTEtMS0w_d56b650b-a372-4d4d-aee5-6ab8fbb1776c"
      unitRef="usdPerShare">12.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMy0xLTEtMS0w_fa0e5f60-de4b-429f-bbe4-c3a5d7d67a46"
      unitRef="shares">91737</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfMy0zLTEtMS0w_ffcf4edc-61a7-4a6f-9d12-a039c6d16916"
      unitRef="usdPerShare">3.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNC0xLTEtMS0w_7e447441-78b7-4e07-b7a4-74b89fbefea3"
      unitRef="shares">3774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNC0zLTEtMS0w_c9aae6f1-370d-4f2e-a710-4755dc758cd8"
      unitRef="usdPerShare">16.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNS0xLTEtMS0w_a2a32b46-8140-422c-b473-57ac9437b69f"
      unitRef="shares">6891578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNS0zLTEtMS0w_035c5a21-4900-441d-8fa2-7d2bdedb91cd"
      unitRef="usdPerShare">6.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNS01LTEtMS0w_b822ae79-1b1d-4b95-8857-f3e95a3d890d">P8Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNS03LTEtMS0w_8911f23f-d550-4648-b214-5e6b43d94f8b"
      unitRef="usd">40710000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNi0xLTEtMS0w_60ccd56e-6291-4e0e-9986-41957c0506da"
      unitRef="shares">2205214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNi0zLTEtMS0w_b8fd9b0d-4fc1-4abf-8f00-0c567c2ce63b"
      unitRef="usdPerShare">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNi01LTEtMS0w_77a4e97f-5df5-4866-9010-54d4f9898b1f">P7Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i72e0b8f57ad04762bb88e13980f63afe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOjFmOTA4M2I4MzgwZjQyMDk5ZDU5OTRhM2YxNDk3YjcxL3RhYmxlcmFuZ2U6MWY5MDgzYjgzODBmNDIwOTlkNTk5NGEzZjE0OTdiNzFfNi03LTEtMS0w_82f6ec4e-9a9b-4712-a05c-1fb403bb53d4"
      unitRef="usd">16908000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4ODY0NQ_fa0e5f60-de4b-429f-bbe4-c3a5d7d67a46"
      unitRef="shares">91737</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4ODU1NQ_698c281e-6c5d-4b85-bce3-9ea383f423d8"
      unitRef="usd">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4ODY1NQ_a070ff5c-74f0-43a3-8d41-fd2dd2085ea7"
      unitRef="shares">376311</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4ODYzOQ_c17c2654-87b5-4570-9124-df8f829bf6d1"
      unitRef="usd">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4ODcyMA_d98b4108-9d75-485d-a7cd-1aa6a6286846"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMzI5ODUzNDg4ODcyOA_28d3612a-a0c1-4005-9371-483c70d7eb3c"
      unitRef="usdPerShare">5.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMjU4MA_39e683d6-ca59-4d2a-9173-d3dbab906ce0">A summary of the Company&#x2019;s restricted stock unit activity and related information for the three months ended March 31, 2021 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i69e04e99cd904341a315c6717663230d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfMS0xLTEtMS0w_11cec3cc-9fda-4b53-99c0-2ff67d1a2fab"
      unitRef="shares">186500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i69e04e99cd904341a315c6717663230d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfMS0zLTEtMS0w_e7235523-160e-4efb-9844-d9dda0d0a3f5"
      unitRef="usdPerShare">8.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfMi0xLTEtMS0w_46d19543-1455-4546-86ed-04dae4c9ee00"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfMi0zLTEtMS0w_9ef5f863-a963-4b01-807d-de62ff47e085"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfMy0xLTEtMS0w_e743326b-76b3-44d5-a89f-4aa8b5fa1bf6"
      unitRef="shares">38000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfMy0zLTEtMS0w_b0205a34-8449-4343-b938-992c2f8d37a1"
      unitRef="usdPerShare">5.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfNC0xLTEtMS0w_326952b0-4978-4500-b1d2-19688f76f1eb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i167a8e7f49c841f88ccb028466963fe5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfNC0zLTEtMS0w_7e1354a6-9ffc-45da-b501-fd0fb6bb6d36"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic7b28ced8c3b4718806223d24c59e395_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfNS0xLTEtMS0w_ac5a57ba-7c16-46d5-b3df-b05e37377b89"
      unitRef="shares">148500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic7b28ced8c3b4718806223d24c59e395_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RhYmxlOmQzZGYyYTQwN2Y1YjRlOTRiZDI1MWYyMGIzYTYyZjhiL3RhYmxlcmFuZ2U6ZDNkZjJhNDA3ZjViNGU5NGJkMjUxZjIwYjNhNjJmOGJfNS0zLTEtMS0w_9dba81d6-8d0a-47de-9ea7-94be31584fa7"
      unitRef="usdPerShare">8.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ifa60425c3f5c4d85b3d489026b24a8a3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMTg5NA_0201d7df-3f0a-4942-96a0-eec00e7b9f59"
      unitRef="shares">759936</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i6fa730f0e05d4b36bba4fddc150cf94d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMTY0OTI2NzQ0NzE4Mg_c94772f9-4597-4980-806c-91095e1528f6"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ia5d5cc27aae8459ea2268fcc0dd30291_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMTY0OTI2NzQ0NzE4Nw_cacab82e-3dad-45e4-a8c8-18f7253bbca7"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ia5d5cc27aae8459ea2268fcc0dd30291_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMTY0OTI2NzQ0NzE5Mg_c5419a23-9e33-4b81-baf3-96fd9493a27e"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <nltx:EmployeeStockPurchasePlanNumberOfOfferingPerYear
      contextRef="ia5d5cc27aae8459ea2268fcc0dd30291_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMjQzNw_6edcecca-1cb3-48be-b0dd-30b572532afd"
      unitRef="offering">2</nltx:EmployeeStockPurchasePlanNumberOfOfferingPerYear>
    <nltx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="ia5d5cc27aae8459ea2268fcc0dd30291_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV82MS9mcmFnOjdlMmM5MDVhZGVlMDRiZGE4OGIzZjJkNTM4YWM0MmJiL3RleHRyZWdpb246N2UyYzkwNWFkZWUwNGJkYTg4YjNmMmQ1MzhhYzQyYmJfMTY0OTI2NzQ0NzE4MA_f927265d-dd36-40cd-86dd-68bcf74d6d44">P6M</nltx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RleHRyZWdpb246NTIwMGRiNzQ2ZmJkNGQxZDkwZDAwOTY4NDQ2MTNiN2RfMjAy_4145f1ef-5a75-4251-a7c1-61438b9ee839">Earnings (loss) per shareThe Company excluded the following potentially dilutive shares from diluted net loss per share as the effect would have been anti-dilutive for all periods presented:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,891,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,344,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable under 2020 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,062,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,478,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RleHRyZWdpb246NTIwMGRiNzQ2ZmJkNGQxZDkwZDAwOTY4NDQ2MTNiN2RfMjAx_719f941f-84e6-4c57-a717-8e12242a3b5f">The Company excluded the following potentially dilutive shares from diluted net loss per share as the effect would have been anti-dilutive for all periods presented:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,891,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,344,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable under 2020 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,062,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,478,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iabf13b01541848a4a4d24235b9abaf91_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfMi0xLTEtMS0w_168bdb5e-de31-4325-ba1e-4687ad6ba193"
      unitRef="shares">6891578</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i113d3b53a82f4678a7755be62a27ead5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfMi0zLTEtMS0w_3666a20e-a6e3-4cb3-8905-bedb3afcf2d2"
      unitRef="shares">5344927</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i59886d9904cc4c3ab0992b2f6912e53b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfMy0xLTEtMS0w_30d52489-ef19-44e6-8731-efe82d4633c6"
      unitRef="shares">148500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id43f9e75cf9e406b9efb82314fd3ead5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfMy0zLTEtMS0w_739597f4-9bbf-4fe9-83c1-eb8ff277093f"
      unitRef="shares">134000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5fbcd4fa4d7841719a7590a1e6e12f2f_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfNS0xLTEtMS0w_282518ab-e507-4f49-a232-ad2962f8d693"
      unitRef="shares">22521</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8565cb16e67b45f5a5e7d8807f927fe7_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfNS0zLTEtMS0w_39df8943-ba40-40c3-a52e-a7919487e6e9"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i797ac540a3b740b69e583df082006363_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfNi0xLTEtMS0w_af5d3b25-bdde-42c9-9cfc-90aca3666884"
      unitRef="shares">7062599</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i721ff67bd330469e98cd841901180f38_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlMzQyY2EzYjkxMjQzZGJiYTRlMDQxNTA1MWZhZjVlL3NlYzpjZTM0MmNhM2I5MTI0M2RiYmE0ZTA0MTUwNTFmYWY1ZV83My9mcmFnOjUyMDBkYjc0NmZiZDRkMWQ5MGQwMDk2ODQ0NjEzYjdkL3RhYmxlOjJkMmJhMGM5OGIzMzRlZTZhNGM2ZDcyZmI0ZGE1MDQ0L3RhYmxlcmFuZ2U6MmQyYmEwYzk4YjMzNGVlNmE0YzZkNzJmYjRkYTUwNDRfNi0zLTEtMS0w_60dd108c-505a-4fe0-a333-f573f84105e9"
      unitRef="shares">5478927</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569657595352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Neoleukin Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0542593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">188 East Blaine Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Seattle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">245-0312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NLTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,345,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001404644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569651896584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated&#160;Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 178,391<span></span>
</td>
<td class="nump">$ 192,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,915<span></span>
</td>
<td class="nump">1,966<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">181,306<span></span>
</td>
<td class="nump">194,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,110<span></span>
</td>
<td class="nump">3,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">11,473<span></span>
</td>
<td class="nump">10,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset, net</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">1,921<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">200,103<span></span>
</td>
<td class="nump">210,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">7,308<span></span>
</td>
<td class="nump">7,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">7,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">12,606<span></span>
</td>
<td class="nump">11,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current finance lease liabilities</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">21,135<span></span>
</td>
<td class="nump">19,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.000001 par value - authorized, 100,000,000 as of March 31, 2021 and December 31, 2020; issued and outstanding, 42,326,033 as of March 31, 2021 and 42,196,296 as of December 31, 2020.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.000001 par value - authorized, 5,000,000 as of March 31, 2021 and December 31, 2020; 0 issued and outstanding as of March 31, 2021 and December 31, 2020.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">526,724<span></span>
</td>
<td class="nump">524,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(347,756)<span></span>
</td>
<td class="num">(332,806)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">178,968<span></span>
</td>
<td class="nump">191,216<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 200,103<span></span>
</td>
<td class="nump">$ 210,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569672040200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated&#160;Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">42,326,033<span></span>
</td>
<td class="nump">42,196,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">42,326,033<span></span>
</td>
<td class="nump">42,196,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569660221672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 9,707<span></span>
</td>
<td class="nump">$ 5,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,241<span></span>
</td>
<td class="nump">3,573<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating expenses</a></td>
<td class="nump">14,948<span></span>
</td>
<td class="nump">9,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (loss), net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,950)<span></span>
</td>
<td class="num">$ (8,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common stock &#8211; basic (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common stock &#8211; diluted (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">54,944,421<span></span>
</td>
<td class="nump">49,168,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">54,944,421<span></span>
</td>
<td class="nump">49,168,451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569657484680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,950)<span></span>
</td>
<td class="num">$ (8,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,420<span></span>
</td>
<td class="nump">683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange (gain)/loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other non-current assets</a></td>
<td class="num">(813)<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(631)<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(169)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">104<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,358)<span></span>
</td>
<td class="num">(6,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,089)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,089)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">3,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment on finance lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">3,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash during the period</a></td>
<td class="num">(14,165)<span></span>
</td>
<td class="num">(3,168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">193,434<span></span>
</td>
<td class="nump">143,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">179,269<span></span>
</td>
<td class="nump">139,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment unpaid at period-end</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining ROU asset</a></td>
<td class="nump">$ 1,584<span></span>
</td>
<td class="nump">$ 9,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Right of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569657519496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,996,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2019</a></td>
<td class="nump">$ 141,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441,216<span></span>
</td>
<td class="num">$ (299,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued upon exercises of stock options (in shares)</a></td>
<td class="nump">376,311<span></span>
</td>
<td class="nump">376,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued upon exercises of stock options</a></td>
<td class="nump">$ 3,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Shares issued upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,642)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,386,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2020</a></td>
<td class="nump">137,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,291<span></span>
</td>
<td class="num">(308,171)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,196,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2020</a></td>
<td class="nump">$ 191,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,022<span></span>
</td>
<td class="num">(332,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued upon exercises of stock options (in shares)</a></td>
<td class="nump">91,737<span></span>
</td>
<td class="nump">91,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued upon exercises of stock options</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Shares issued upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,950)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,326,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2021</a></td>
<td class="nump">$ 178,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526,724<span></span>
</td>
<td class="num">$ (347,756)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569656171032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of operations</a></td>
<td class="text">Nature of operationsNeoleukin Therapeutics, Inc. (&#8220;Neoleukin&#8221; or &#8220;the Company&#8221;) is&#160;a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using&#160;de novo&#160;protein design technology. Neoleukin uses sophisticated computational methods to design&#160;proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569659747688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt">Basis of presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are presented in United States (&#8220;U.S.&#8221;) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information.&#160;&#160;Accordingly, these consolidated financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the Securities and Exchange Commission on March 25, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company sold all of the issued and outstanding capital stock of Aquinox Pharmaceuticals, Inc. (Canada) (&#8220;Aquinox Canada&#8221;) to an unrelated third party. On December 31, 2020, Neoleukin Corporation, the Company's wholly owned subsidiary, was merged into the Company. As a result, the Company has consisted of a single operating company since December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position of the Company as of March&#160;31, 2021, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt">Use of estimates and assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, the incremental borrowing rate utilized in the measurement of operating and finance lease liabilities, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical, clinical, and other accruals. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt">Reclassification</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reclassified prior year changes in operating lease right-of-use assets and operating lease liabilities in the condensed consolidated statements of cash flows to conform to current year presentation. This reclassification had no effect on net cash used in operating activities.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company determines if the contract is or contains a lease. Lease liabilities are recognized on the lease commencement date based on the estimated present value of lease payments over the lease term. To determine the present value of the lease payments, the Company utilizes its estimated incremental borrowing rate based on information available at the lease commencement date as the interest rate implicit in the lease is typically not readily determinable. The related right-of-use assets are recorded net of any lease incentives received. Variable lease cost primarily includes building operating expenses as charged to the Company by its landlords and payments for lessor-owned assets that are not covered by a tenant improvement allowance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes options to extend the lease in its lease liability and right-of-use asset when it is reasonably certain that it will exercise that option. None of the Company's options to extend the rental term of any of its existing leases were considered reasonably certain as of March&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases of office space and equipment, the Company has elected to not separate the lease components from the non-lease components.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases of office space with a lease term of 12 months or less and which do not include an option to purchase the underlying asset, the Company has elected to recognize the lease payments in the statement of operations on a straight-line basis over the lease term.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt">Fair value of financial instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, restricted cash, receivables, accounts payable and other liabilities, approximate their fair values because of their nature and/or short maturities.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, and December&#160;31, 2020, the Company had $156.3 million and $108.3 million in money market funds, respectively. Money market funds are level one financial instruments as they are valued at fair value, which is the closing price reported by the fund sponsor from an actively traded exchange.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:8.01pt">Earnings (loss) per share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Common stock equivalents such as outstanding stock options and unvested restricted stock units are included in the calculation of diluted earnings per share only in periods of net income. Such common stock equivalents are excluded in the calculation of diluted net loss per share in periods of net loss as inclusion of such amounts would be anti-dilutive. Outstanding pre-funded warrants as of March 31, 2021 of 12,663,010 are considered outstanding as of their issuance date and are included in the basic and diluted net loss per share calculation because they are fully vested and exercisable at any time after 61 days' notice for a nominal cash consideration.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt">Recently issued and recently adopted accounting standards</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2019-12 &#8220;Simplifying the Accounting for Income Taxes.&#8221; The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by Accounting Standards Codification (&#8220;ASC&#8221;) Topic 740 - Income Taxes and clarifying existing guidance to facilitate consistent application. ASU 2019-12 became effective for fiscal years and interim periods beginning after December 15, 2020. The Company adopted this standard on January 1, 2021 on a prospective basis. The adoption of this ASU did not have a material impact on the Company's financial condition, results of operations, cash flows, and financial statement disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569663923976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">Cash, cash equivalents and restricted cash<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash, included in other non-current assets in the condensed consolidated balance sheets, includes $0.9 million in cash deposits the Company maintains with its bank as collateral for the irrevocable letters of credit related to its lease obligations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hat sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:68.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,391&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,556&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,269&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,434&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Cash Equivalents And Restricted Cash Disclosure Text Block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569659578648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into lease arrangements for its facilities as well as certain equipment, classified either as operating or finance leases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease agreement, as amended by the execution of two subsequent amendments,&#160;for approximately 33,300 square feet of office space in Seattle, Washington for the Company&#8217;s principal executive offices, a laboratory for research and development, and related uses. The lease commenced on January 15, 2020 and expires on February 1, 2029, with the option to extend the lease for two five-year terms.&#160;&#160;The lease provides for a tenant improvement allowance of up to $9.5 million. As of March&#160;31, 2021, there was a tenant improvement allowance receivable of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded in other current assets related to reimbursable build-out costs incurred by the Company. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease agreement&#160;for approximately 6,272 square feet of office space in Seattle, Washington, for additional office and laboratory space for research and development and related uses. In March 2021, the Company executed an amendment to this lease pursuant to which the contractual lease term was extended through September 30, 2026, unless terminated earlier, with the option to extend the lease for an additional 28-month term. The execution of this amendment was accounted for as a modification to the lease due to the extension of the lease term and an increase in lease payments, and the Company recorded an increase in the lease liability and related right-of-use asset of $1.6 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, and December 31, 2020, the Company&#8217;s operating lease right-of-use assets were $11.5 million and $10.2 million, respectively.&#160;&#160;As of March&#160;31, 2021, and December&#160;31, 2020, the Company&#8217;s finance lease right-of-use assets were $0.3 million and $0.3 million, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into lease arrangements for its facilities as well as certain equipment, classified either as operating or finance leases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease agreement, as amended by the execution of two subsequent amendments,&#160;for approximately 33,300 square feet of office space in Seattle, Washington for the Company&#8217;s principal executive offices, a laboratory for research and development, and related uses. The lease commenced on January 15, 2020 and expires on February 1, 2029, with the option to extend the lease for two five-year terms.&#160;&#160;The lease provides for a tenant improvement allowance of up to $9.5 million. As of March&#160;31, 2021, there was a tenant improvement allowance receivable of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded in other current assets related to reimbursable build-out costs incurred by the Company. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease agreement&#160;for approximately 6,272 square feet of office space in Seattle, Washington, for additional office and laboratory space for research and development and related uses. In March 2021, the Company executed an amendment to this lease pursuant to which the contractual lease term was extended through September 30, 2026, unless terminated earlier, with the option to extend the lease for an additional 28-month term. The execution of this amendment was accounted for as a modification to the lease due to the extension of the lease term and an increase in lease payments, and the Company recorded an increase in the lease liability and related right-of-use asset of $1.6 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, and December 31, 2020, the Company&#8217;s operating lease right-of-use assets were $11.5 million and $10.2 million, respectively.&#160;&#160;As of March&#160;31, 2021, and December&#160;31, 2020, the Company&#8217;s finance lease right-of-use assets were $0.3 million and $0.3 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569656314296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity&#160;<div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt">Common stock and pre-funded warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue  100,000,000 shares of common stock with a par value of $0.000001 as of March 31, 2021.  As of March&#160;31, 2021 and December&#160;31, 2020 the total number of shares of common stock issued and outstanding was 42,326,033 and 42,196,296, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the Company also has pre-funded warrants outstanding to purchase an aggregate of  12,663,010 shares of common stock. The pre-funded warrants are exercisable at any time, with 61 days' notice, for an exercise price of 0.000001, except that the pre-funded warrants cannot be exercised by the stockholders if, after giving effect thereto, the stockholders would beneficially own more than 9.99% of the outstanding common stock, subject to certain exceptions. The holders of the pre-funded warrants will not have the right to vote on any matter except to the extent required by Delaware law.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt">Stock-based compensation expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is classified in the condensed consolidated statement of operations as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation cost for all stock-based compensation plans was $23.8 million as of March&#160;31, 2021. This cost is expected to be recognized over a weighted average remaining vesting period of 3.00 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of stock options granted are estimated using the Black-Scholes option pricing model with the following weighted average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.68&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected terms (years)</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt">Stock options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity and related information for the three months ended March 31, 2021 is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life<br/>&#160;(in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value <br/>(in Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,846,289&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,127&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,737)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled/forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,774)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,891,578&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.51</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,710&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2021</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,205,214&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,908&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, 91,737 shares of common stock were issued upon exercise of options with an aggregate intrinsic value of $1.0 million. During the three months ended March&#160;31, 2020, 376,311 shares of common stock were issued upon exercise of options with an aggregate intrinsic value of $1.3 million. The weighted-average grant date fair value of options granted during the three months ended March&#160;31, 2021 and March&#160;31, 2020 was $9.43 and $5.62 per share, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt">Restricted stock units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock unit activity and related information for the three months ended March 31, 2021 is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,500&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.19&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,000)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at March 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,500&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.89&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.91pt">Employee stock purchase plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;) was adopted by the Company&#8217;s Board of Directors in March 2020 and approved by the Company&#8217;s stockholders in May 2020. A total of 759,936 shares of common stock have been reserved for issuance under the 2020 ESPP.</span></div>Subject to share and dollar limits as described in the plan, the 2020 ESPP allows eligible employees to contribute, through payroll deductions, up to 15% of their earnings for the purchase of shares of the Company&#8217;s common stock at the lower of 85% of the closing price of the Company&#8217;s common stock on the first trading day of the offering period or 85% of the closing price of the Company&#8217;s common stock on the last trading day of the offering period. There are two six-month offering periods during each fiscal year, ending on May 15 and November 15.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569656209816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (loss) per share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (loss) per share</a></td>
<td class="text">Earnings (loss) per shareThe Company excluded the following potentially dilutive shares from diluted net loss per share as the effect would have been anti-dilutive for all periods presented:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,891,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,344,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable under 2020 ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,062,599&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,478,927&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569663800984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">Basis of presentation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are presented in United States (&#8220;U.S.&#8221;) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information.&#160;&#160;Accordingly, these consolidated financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the Securities and Exchange Commission on March 25, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company sold all of the issued and outstanding capital stock of Aquinox Pharmaceuticals, Inc. (Canada) (&#8220;Aquinox Canada&#8221;) to an unrelated third party. On December 31, 2020, Neoleukin Corporation, the Company's wholly owned subsidiary, was merged into the Company. As a result, the Company has consisted of a single operating company since December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position of the Company as of March&#160;31, 2021, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates and assumptions</a></td>
<td class="text">Use of estimates and assumptionsThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, the incremental borrowing rate utilized in the measurement of operating and finance lease liabilities, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical, clinical, and other accruals. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text">ReclassificationThe Company reclassified prior year changes in operating lease right-of-use assets and operating lease liabilities in the condensed consolidated statements of cash flows to conform to current year presentation. This reclassification had no effect on net cash used in operating activities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">LeasesAt contract inception, the Company determines if the contract is or contains a lease. Lease liabilities are recognized on the lease commencement date based on the estimated present value of lease payments over the lease term. To determine the present value of the lease payments, the Company utilizes its estimated incremental borrowing rate based on information available at the lease commencement date as the interest rate implicit in the lease is typically not readily determinable. The related right-of-use assets are recorded net of any lease incentives received. Variable lease cost primarily includes building operating expenses as charged to the Company by its landlords and payments for lessor-owned assets that are not covered by a tenant improvement allowance.<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes options to extend the lease in its lease liability and right-of-use asset when it is reasonably certain that it will exercise that option. None of the Company's options to extend the rental term of any of its existing leases were considered reasonably certain as of March&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases of office space and equipment, the Company has elected to not separate the lease components from the non-lease components.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases of office space with a lease term of 12 months or less and which do not include an option to purchase the underlying asset, the Company has elected to recognize the lease payments in the statement of operations on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text">Fair value of financial instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, restricted cash, receivables, accounts payable and other liabilities, approximate their fair values because of their nature and/or short maturities.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, and December&#160;31, 2020, the Company had $156.3 million and $108.3 million in money market funds, respectively. Money market funds are level one financial instruments as they are valued at fair value, which is the closing price reported by the fund sponsor from an actively traded exchange.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (loss) per share</a></td>
<td class="text">Earnings (loss) per shareBasic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Common stock equivalents such as outstanding stock options and unvested restricted stock units are included in the calculation of diluted earnings per share only in periods of net income. Such common stock equivalents are excluded in the calculation of diluted net loss per share in periods of net loss as inclusion of such amounts would be anti-dilutive. Outstanding pre-funded warrants as of March 31, 2021 of 12,663,010 are considered outstanding as of their issuance date and are included in the basic and diluted net loss per share calculation because they are fully vested and exercisable at any time after 61 days' notice for a nominal cash consideration.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued and recently adopted accounting standards</a></td>
<td class="text">Recently issued and recently adopted accounting standardsIn December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2019-12 &#8220;Simplifying the Accounting for Income Taxes.&#8221; The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by Accounting Standards Codification (&#8220;ASC&#8221;) Topic 740 - Income Taxes and clarifying existing guidance to facilitate consistent application. ASU 2019-12 became effective for fiscal years and interim periods beginning after December 15, 2020. The Company adopted this standard on January 1, 2021 on a prospective basis. The adoption of this ASU did not have a material impact on the Company's financial condition, results of operations, cash flows, and financial statement disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569656252776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hat sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:68.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,391&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,556&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,269&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,434&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hat sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:68.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,391&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,556&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,269&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,434&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569663770104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is classified in the condensed consolidated statement of operations as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text">The fair values of stock options granted are estimated using the Black-Scholes option pricing model with the following weighted average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.68&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected terms (years)</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity and related information for the three months ended March 31, 2021 is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life<br/>&#160;(in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value <br/>(in Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,846,289&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,127&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,737)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled/forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,774)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,891,578&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.51</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,710&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2021</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,205,214&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,908&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text">A summary of the Company&#8217;s restricted stock unit activity and related information for the three months ended March 31, 2021 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,500&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.19&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,000)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at March 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,500&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.89&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569671921592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (loss) per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive shares from diluted net loss per share</a></td>
<td class="text">The Company excluded the following potentially dilutive shares from diluted net loss per share as the effect would have been anti-dilutive for all periods presented:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,891,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,344,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable under 2020 ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,062,599&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,478,927&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569663761704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_ClassOfWarrantOrRightNoticePeriod', window );">Warrants, notice period for nominal cash consideration</a></td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nltx_PreFundedWarrantsMember', window );">Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding pre-funded warrants (in shares)</a></td>
<td class="nump">12,663,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 156.3<span></span>
</td>
<td class="nump">$ 108.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_ClassOfWarrantOrRightNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_ClassOfWarrantOrRightNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nltx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nltx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569671890824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Cash deposit</a></td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569663990536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and restricted cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 178,391<span></span>
</td>
<td class="nump">$ 192,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 179,269<span></span>
</td>
<td class="nump">$ 193,434<span></span>
</td>
<td class="nump">$ 139,925<span></span>
</td>
<td class="nump">$ 143,093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569658349032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_TenantImprovementAllowance', window );">Tenant improvements (up to)</a></td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_TenantImprovementAllowanceReceivable', window );">Tenant improvement allowance receivable reimbursable by the landlord</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Increase in right-of-use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase in lease liability</a></td>
<td class="nump">104<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">11,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WA', window );">Washington | Office space, principal executive offices and laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet of office space leased | ft&#178;</a></td>
<td class="nump">33,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_NumberOfOptionToExtendLease', window );">Number of option to extend leases | option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement extended period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WA', window );">Washington | Office Space, additional offices and laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet of office space leased | ft&#178;</a></td>
<td class="nump">6,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement extended period</a></td>
<td class="text">28 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Increase in right-of-use asset</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase in lease liability</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Right of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_NumberOfOptionToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of option to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_NumberOfOptionToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_TenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tenant improvement allowance pursuant to lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_TenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_TenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Element represents the carrying amount as of balance sheet date of amounts receivable related to tenant improvement allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_TenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569657289208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>offering </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">42,326,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,196,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">42,326,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,196,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_ClassOfWarrantOrRightNoticePeriod', window );">Warrants, notice period for nominal cash consideration</a></td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_PercentageOfOutstandingStockPerStockholderMaximum', window );">Percentage of outstanding stock per stockholder, maximum</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation cost | $</a></td>
<td class="nump">$ 23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost, weighted-average period recognized</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued upon exercises of stock options (in shares)</a></td>
<td class="nump">91,737<span></span>
</td>
<td class="nump">376,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised | $</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value for options granted in period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.43<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nltx_PreFundedWarrantsMember', window );">Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding pre-funded warrants (in shares)</a></td>
<td class="nump">12,663,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of pre-funded warrants (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nltx_A2020EmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance under employee stock purchase plan (in shares)</a></td>
<td class="nump">759,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares issuable under 2020 ESPP | 2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">ESPP max contribution rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">ESPP, purchase price of common stock, percent of market price</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear', window );">ESPP number of offerings per year | offering</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">ESPP offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_ClassOfWarrantOrRightNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_ClassOfWarrantOrRightNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>employee stock purchase plan number of offering per year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_PercentageOfOutstandingStockPerStockholderMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Outstanding Stock Per Stockholder, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_PercentageOfOutstandingStockPerStockholderMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nltx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nltx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nltx_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nltx_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569663867592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,420<span></span>
</td>
<td class="nump">$ 683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,402<span></span>
</td>
<td class="nump">$ 401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569663954680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">89.68%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (years)</a></td>
<td class="text">6 years 21 days<span></span>
</td>
<td class="text">6 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">0.61%<span></span>
</td>
<td class="nump">0.78%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569653885256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Stock Options Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Option Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">6,846,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">140,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(91,737)<span></span>
</td>
<td class="num">(376,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options cancelled/ forfeited (in shares)</a></td>
<td class="num">(3,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">6,891,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,846,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 6.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">12.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">3.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options cancelled/forfeited (in dollars per share)</a></td>
<td class="nump">16.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 40,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Number of Shares (in shares)</a></td>
<td class="nump">2,205,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 16,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569663717592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Nonvested Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, beginning balance (in shares) | shares</a></td>
<td class="nump">186,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units vested (in shares) | shares</a></td>
<td class="num">(38,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, ending balance (in shares) | shares</a></td>
<td class="nump">148,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units vested (in dollars per share) | $ / shares</a></td>
<td class="nump">5.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock units forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140569671928696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (loss) per share - Schedule of basic and diluted net loss per common stock (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">7,062,599<span></span>
</td>
<td class="nump">5,478,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">6,891,578<span></span>
</td>
<td class="nump">5,344,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">148,500<span></span>
</td>
<td class="nump">134,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares issuable under 2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">22,521<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>38
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M3G&X/#H\:+FK[E_64FN95<TM9P#>&,#WC93Z]<%<Z317>*O_ %!+ P04
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M90/P_DQ*\SRQVWES?!O^!5!+ P04    " #<0*Q2 TI;%W,#  #G"@  &
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M3':=6*HV=8%072!4>G5&O"Y(0K*(O@5W])YE&<ONP9EB*38DI^(<$*GVBBX
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MV:(DSZ!,X,IH*AV\TQEF3^MC9M332O:TELF+@%?"#F$R'D R2L8OX$UZF9.
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M:QP716JTGQAA0H9:W(P A&U#&84:0S6'NDVJ-]ED.B_6J]SC[(5WBHZC)I!
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MMBSO)IE)-KF7F=Y=)MG>?>CT RU1-KN2J".I..ZO+T!*LIVUL[=?VIW)ZH4
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MHZ91."R<-7(\8I/ZSBKC;Y;N!Q)NL)@OO66<G"MX.]"N.*</'9HKVHVRD2B
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MLK&:OG+2V>45TY++G8$W0AGS%EJD$ZN9QGED">^<HN* 6O6H] 54!M=*VMK
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MC4<!Z'Z0]!NK6M^\6V5I%/AE3;,7M7.@[Y6B@SUL7(!AFB__ %!+ P04
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M^&BXU4..WF?'.Z?R IGZ79_[6M920KA-'M"B+-''3!Q./A:_#E1(W2)%!$U
M@9 RA=N=C!RSV^C\_'0TF4Y8F$%:'QI%^AZ0:-;)'7 L.4VYUP +=EYN@N]7
MP%!5&?@Z4*!1TE8DTW-]$&N<7 @3C*&BQO,2R4R<3\'0UC^BA$P0$>=1QE(I
M6T4PW_'90R@PG?1W:),_:UOA".1!_038Y7>RM'R;,;CV8(U*%*9[+]+^3V>]
M&XR$9Y/IBY@*WG:P/+@!F^<]XM+BGVX2_?9B?MG-G]/Y>[==-^P6W01[?MUM
MHZ./44WE^Q-N3);;C%L#<F2[=QR XJ.\099+-#CIV\6GF'QRBL]R<JJPN59/
MTR2LX3G<@L8(M?W"*3Z5"(A<E7"FH9XG)#C=*]B5+?NFO1>OOP/Z:-%.B6=/
M)^)XA_E83%1H;Z*L73F]:G6\&P/32UE0@2#330V-S*G5:*AURQ=(\^M.A10L
MH!^'!J0*TMA2>P043QY\'B;QK#>#S$*MM#$<SQPRG5-,S_*X?=C19)<*-+?H
ME SI?Y2FI0EW!R-4<T+IN2J(%6<DQD2Z*3<(D1BE+KENYEM#2>4,.*3Z  ?'
M(<ANQ])7$#2<T7'2L'<:/AI,9D:#>=W.W'(P&]T_2#D9W*KSO0?][0"/TDR(
M%^S=V^[O$R[BK7R_//YQ Q!W11..2BVQ=3)^=G846[W\(]B&[^@7-@1;\^,:
MK;ARM #?Z6(O_Z #NK_:>/U?4$L#!!0    ( -Q K%+E@R==Z0(  -D(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;.U636_;, S]*X2Q0PL8=6(G
M;1(D 9JVPW884+3==AAV4&PZ%BI+KB0WW;\?)3M.UK5>=QUVB*T/\O&1>@H]
MWRI];PI$"T^ED&81%-96LR@R:8$E,R>J0DD[N=(ELS35F\A4&EGFG4H1Q8/!
M:50R+H/EW*]=Z^5<U59PB=<:3%V63/]8H5#;13 ,=@LW?%-8MQ MYQ7;X"W:
MS]6UIEG4H62\1&FXDJ Q7P3GP]EJ[.R]P1>.6W,P!I?)6JE[-_F8+8*!(X0"
M4^L0&+T>\0*%<$!$XZ'%#+J0SO%PO$-_[W.G7-;,X(427WEFBT4P"2##G-7"
MWJCM!VSS\013)8Q_PK:U'020UL:JLG4F!B67S9L]M75XBT/<.L2>=Q/(L[QD
MEBWG6FU!.VM"<P.?JO<F<ERZ0[FUFG8Y^=GE!3-%""D] 1]J_L@$2FN R8Q*
M;JSFJ<6LV3^Z8VN!YG@>60KLW*.T#;)J@L2O!$G@DY*V,' E,\Q^]8^(<,<Z
MWK%>Q;V GY@^@6080CR(ASUX25>%Q.,EO55P3[C:5R&$FWT)_*8KR_.U P?X
M=KZF35+:]QY2HX[4R),:O4+JEBY@5@L$E>^C/P_YTF'TPKI;/C,52W$1T#4V
MJ!\Q6-X5"+D2=$6YW(!U!PV55H\\0Q(#22%5,N6",W^5B%#Z=MUP"9;@"2&C
MR^Q6E31*\(PYDS433*8(7L(&+!3,NK\(L,J[6669<!'=Q+"2'G5*M2A5[0*:
M0FWE'T(82Z_2\VN90TZ9FAD<>4=5&^)MCH%D1= [7<$EIEBN4>]6!OMC^"WQ
M=S \FX3)=.A&TS@<CT\/E>+M)V<3_[OS*;U<P?#%$CKT:1B?3CUZ$HZ2$?0H
M;-PI;-RKL!U!.E,JC?P[E?5"_U?9/ZRRZ*#=E*@WOJD:J@;5JND\W6K7M\^;
M=K4W;YH^U6+#27P"<W(=G)R1JG332)N)595O7FMEJ17Z84'?'JB= >WG2MG=
MQ 7HOF:6/P%02P,$%     @ W$"L4FDV19GP!   B0P  !D   !X;"]W;W)K
M<VAE971S+W-H965T,34N>&ULQ5?;;MLX$/T5PMM=)( J4[(LR6EBP$G3"[!I
M R=M'Q;[P$ACFX@DNB1E)W^_,Y0M.XFC+?9E7RQ*G#ES.S.D3]=*WYL%@&4/
M95&9L]["VN5)OV^R!93"^&H)%>[,E"Z%Q5<][YNE!I$[I;+HAYS'_5+(JC<^
M==^N]?A4U;:0%5QK9NJR%/KQ' JU/NL%O>V'J9PO+'WHCT^78@XW8+\MKS6^
M]5N47)90&:DJIF%VUIL$)^<)R3N![Q+69F_-*)([I>[IY7-^UN/D$!2064(0
M^%C!!10% :$;/S>8O=8D*>ZOM^@?7.P8RYTP<*&*'S*WB[->VF,YS$1=V*E:
M?X)-/$/"RU1AW"];-[)1U&-9;:PJ-\KH02FKYBD>-GG84TCY*PKA1B%T?C>&
MG)?OA17C4ZW63),THM'"A>JTT3E945%NK,9=B7IV?/FSEO:1'=V*NP+,\6G?
M(BAM];,-P'D#$+X",&!7JK(+PRZK'/*G^GUTIO4HW'IT'G8"7@GMLT'@L9"'
M00?>H(UPX/ &W1'^-;DS5B,)_N[ C%K,R&%&KV#>-!1F:L9NK,KNWQ(Q<G:A
M2FP6(QS?+A]H#8<RV@E.;7ABEB*#LQ[VF0&]@MYXWTRV;P8:,TP:EA7"&#F3
M*"(K9A> DEB4JM&IC"ID+BR^&(L/["Q+ 6!_:P=EF#!LI@KL4W/";A<:X$EM
MV9%#5;4156Z.77WHA[,I>BETMF"X@2VQPE9?.OB-<X:]88''@Q2?83I@'Z%"
MFX43%SFR6E)IJ#UW&H$7\9!%/&"WRJ*L^;<$(+07H3-O6(PF.HH\;(L\["XR
M#L"\+H"2],-U-YJ>K-#S.;")P3&V=&D[5.%NY%LLS4Q(S5:BJ#%6-.#"PUHT
MA9AK49$UH3$CQLK2E:TVLIJ[NIX7 I.!#JJ"U)T66VJ9D4"I<J Q8A=.MJDH
M;:RW08A-$&(7Q,&"[RI,9,Y(=:4*3'M!'96._#AEO[,1]SG'9RN3RY5$VN6&
MT><G6Q9T:=C1(](%&13[/*:?(9M*<\]FY #R !CWXX!4_00-=)0R;DL9_W(I
M72>QKYM,3^A4P&@.%;$3\W";3K:G&UFB[--($-7C'[^E89"\,T_JW!Q)E$IJ
M! V%J[*LFJ.6!'#E4*RK3=G4!EQMKES#;><DM?]^]WZIRSO0+MP%DLB\)/#E
M ^A,8M]<(VW@Y?X4Z$@GVER@61J<-7;AGW*&W)_/-<RI3I]Q1^(!G;'OQ&3V
MM;8X6ZJ<U(1E[R$#Y\?&3<YB+XUB+TQ'U*9^%++43P)<#P=>$"9M5;;\#R+N
MI9QZ.@A][.KM/FR<QYDT"KQDD!RCR,#G.X1,5!D>]9#W,8<SD(1V-/"2)"+1
M(/;CP7-OGV44747L89(Z5X<C='5(KJ)+2<"W^:-CDS*/F7ZF'WHA'WIA$%%X
M/H]80NU"MKT13[L&5-*R.OG54VAZ\ZV3RIU _Y'**(G5SYH#A5A=5]+^KYS^
M2+1A[XF9'VB\-J3\HJJW*_25!M\A3@9I[ T=R5(_&-%A]C*L'25=^.$[E-ZN
M7E'8F#P:I![G_-BQ  G_BO2.I2\-/ W@69*"*&V]Q[8Z1*O^WO6P!#UWEV!L
M$557MKDIME_;>_:DN5[NQ)M+.AJ?8\.S F:HBO,9#SK=7'R;%ZN6[K)YIRQ>
M7=UR@?\50), [L^4LML7,M#^^QC_ U!+ P04    " #<0*Q2=3S]$-,"  #W
M!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6RE5$UOVS ,_2N$!PPM
MX-4?<9J/)0&:KL-V*!8TW788=E!L.A8J2YXD-^V_'R6G;@JTV6$72Z+)QT=1
MC[.=TG>F0K3P4 MIYD%E;3.-(I-76#-SIAJ4]*=4NF:6CGH;F48C*WQ0+:(T
MCL^CFG$9+&;>MM*+F6JMX!)7&DQ;UTP_+E&HW3Q(@B?##=]6UAFBQ:QA6URC
M_=ZL-)VB'J7@-4K#E02-Y3RX2*;+S/E[AQ\<=^9@#ZZ2C5)W[O"UF >Q(X0"
M<^L0&"WW>(E".""B\6>/&?0I7>#A_@G]LZ^=:MDP@Y=*_.2%K>;!.( "2]8*
M>Z-V7W!?S]#AY4H8_X5=YSM* \A;8U6]#R8&-9?=RA[V]W 0,([?"$CW :GG
MW27R+#\QRQ8SK7:@G3>AN8TOU4<3.2Y=4]96TU].<79QQ;3D<FO@1"AC3J%!
MZEC%-,+)+=L(-*>SR%(>YQWE>\QEAYF^@3F :R5M9>!*%EB\C(^(7T\R?2*Y
M3(\"7C-]!H,DA#1.DR-X@[[H@<<;_*OH%56[]M7^NM@8J^F-_#Z"G_7XF<?/
MWL!?DW2*5B"H$AIE45K.A'B$@HO6/<+NA@V46M6=$0N0I$#7@^<6O';S1Q,[
M!4]-PW*<!R11@_H>@\5MA7"IZH;)1\"'7+34%+!D+)4@3=)%_ ])8,:#85F2
MT$B#K2B@8A2_0235$>R''I*&"% 2%\U502B.I"3@*=Q6&O'%P_'==I\8OK76
M6"8+QY4DD=^!:IRH#9R'XTD2#D=C&(:#+ LGZ0AND%K)<\>W<VXEMP:2;!P.
MXQB201;&M*Z[^K@QK7OIY%5043[?U7JU@C0-AT3@_;MQFJ0?813&YV293"A3
M-AK[3*^]E>A C#7JK1\Y!G+52MOILK?V4^VB$_.S>S<2Z=UO.14IL*30^&PT
M#$!W8Z8[6-5X:6^4I4'AMQ5-9M3.@?Z7BAJ[/[@$_:Q?_ 502P,$%     @
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MQY)>,AJ?0/&]UNYL^.GJ_PW9'U!+ P04    " #<0*Q2[_>B7Y$"  !]!P
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MEOSP@]3Y&(,)9](\T:'6.A9*2JEX7L/@(*=%]<9O]3JT #?X O!JP+L4\&O
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M%G/3MA2+.<]5$F=L*9#,TY2*PRU+^/YZ@ =5P^<XVBK=X"SF.QJQ%5-/NZ6
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M%&?H*8N5O(1&>'Z,DP3ZRKFC )&VZP3E[+?%[*1G=@\]\DQM)7K(0A8>CW>
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MW@_^J]4=$8_XKN>= ._JB&<^F?5@G]38)^_'#MHF%<U"V/#G"$S>2J"KHXW
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M>- C)VZ#&3N^N#^8OV<K;11>T#\]G)<MYZ7CO/R(\[7$&X]GL96"&BYP@Z[
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M@D/"]0#U?<68/+SH"<J_/J;_ 5!+ P04    " #<0*Q2PPUHVQP#  #D"@
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M83;H]U/.U7IB#J@:V\%O4$L#!!0    ( -Q K%(G_K*R)P,  !$+   9
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M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V,V.@C 4AN%;(;T
MRSDJZD1<S<;MQ!L@6'XB4$([&;W[(;C C\QB-J9G15K"Z;OA">'X99K,U[9S
M5=V[Z-XVG4M5Y7W_H;7+*]-F;F5[TXUW"CNTF1^70ZG[++]EI=$<QXD>7F>H
MT_%U9G1Y].8_$VU1U+GYM/EW:SK_QV#]8X>;JXSQ*KID0VE\JO2]F;>=GBZT
M&B>KZ'Q-U7"^DM*A@QB".'S0&H+6X8,V$+0)'[2%H&WXH 2"DO!!.PC:A0_:
M0] ^?- !@@[A@RA&&6,!20NL!6A-R#4)\)H0;!(@-B'9),!L0K1)@-J$;),
MMPGA)@%R$])- NPFQ)L$Z,VH-PO0FU%O%J W+SZV!>C-J#<+T)M1;Q:@-Z/>
M+$!O1KWYG7H[_VB,FWN>:SS_G53[\5DS'S\MGYN+=WS"6<-?@],O4$L#!!0
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MM3!2V8,_ZWZ0S#X!4$L! A0#%     @ W$"L4@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #<0*Q2
M!_'>QN\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #<0*Q2F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -Q K%(2EX:;3 4
M  06   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " #<0*Q2%)!S< $%  #.$P  &               @(&0
M#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ W$"L4A\3
M5Y7? @  R@D  !@              ("!QQ(  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( -Q K%(#2EL7<P,  .<*   8
M  " @=P5  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #<
M0*Q2S PU#[L%   %%@  &               @(&%&0  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ W$"L4C)QLH-R!   -1(  !@
M         ("!=A\  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( -Q K%("<@^DZP(  %0&   8              " @1XD  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #<0*Q2L-C5<:T+  "P'@
M&               @($_)P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ W$"L4A(+IOPQ P  GP<  !@              ("!(C,  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( -Q K%)YP[U@O 0
M /D2   9              " @8DV  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ W$"L4D"&I41%!P  =!(  !D              ("!
M?#L  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #<0*Q2
M[B4NP;\"  #9!0  &0              @('X0@  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( -Q K%+-U3VD! P  ,$A   9
M      " @>Y%  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ W$"L4N6#)UWI @  V0@  !D              ("!*5(  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #<0*Q2:39%F? $  ")#
M&0              @(%)50  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( -Q K%)U//T0TP(  /<%   9              " @7!:  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ W$"L4B\6/WT<
M P  1PD  !D              ("!>ET  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " #<0*Q2\87A(08"   G!   &0
M@('-8   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( -Q
MK%+O]Z)?D0(  'T'   9              " @0IC  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ W$"L4BQ']',J!   U0X  !D
M         ("!TF4  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " #<0*Q2J5#UL9,%  !*%0  &0              @($S:@  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -Q K%+J>/"/WP(  , (
M   9              " @?UO  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ W$"L4AOW;3B) @  @P<  !D              ("!$W,
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #<0*Q2[:><
MPHX$   &$0  &0              @('3=0  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( -Q K%+##6C;' ,  .0*   9
M  " @9AZ  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
MW$"L4B?^LK(G P  $0L  !D              ("!ZWT  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " #<0*Q2XVRNN!P#   T$@  #0
M            @ %)@0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -Q K%*7
MBKL<P    !,"   +              "  9"$  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( -Q K%)$#A WUP(  !,2   /              "  7F%  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #<0*Q2_^2]XT(!  !%$   &@
M        @ %]B   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #<0*Q2JAT0L'8!   H$0  $P              @ 'WB0  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     (@ B "4)  ">BP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>50</ContextCount>
  <ElementCount>229</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated??Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated??Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated??Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated??Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Natureofoperations</Role>
      <ShortName>Nature of operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Cash, cash equivalents and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Cashcashequivalentsandrestrictedcash</Role>
      <ShortName>Cash, cash equivalents and restricted cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111105 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Earnings (loss) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Earningslosspershare</Role>
      <ShortName>Earnings (loss) per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Cash, cash equivalents and restricted cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashTables</Role>
      <ShortName>Cash, cash equivalents and restricted cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/Cashcashequivalentsandrestrictedcash</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/Equity</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Earnings (loss) per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/EarningslosspershareTables</Role>
      <ShortName>Earnings (loss) per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/Earningslosspershare</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Summary of significant accounting policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of significant accounting policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Cash, cash equivalents and restricted cash - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashAdditionalInformationDetails</Role>
      <ShortName>Cash, cash equivalents and restricted cash - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Cash, cash equivalents and restricted cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash, cash equivalents and restricted cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/EquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Equity - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Equity - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Equity - Schedule of Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails</Role>
      <ShortName>Equity - Schedule of Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Equity - Schedule of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails</Role>
      <ShortName>Equity - Schedule of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Equity - Summary of Nonvested Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails</Role>
      <ShortName>Equity - Summary of Nonvested Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nltx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Earnings (loss) per share - Schedule of basic and diluted net loss per common stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails</Role>
      <ShortName>Earnings (loss) per share - Schedule of basic and diluted net loss per common stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/EarningslosspershareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nltx-20210331.htm">nltx-20210331.htm</File>
    <File>exhibit101.htm</File>
    <File>exhibit311.htm</File>
    <File>exhibit312.htm</File>
    <File>exhibit321.htm</File>
    <File>nltx-20210331.xsd</File>
    <File>nltx-20210331_cal.xml</File>
    <File>nltx-20210331_def.xml</File>
    <File>nltx-20210331_lab.xml</File>
    <File>nltx-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>43
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nltx-20210331.htm": {
   "axisCustom": 0,
   "axisStandard": 11,
   "contextCount": 50,
   "dts": {
    "calculationLink": {
     "local": [
      "nltx-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nltx-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "nltx-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nltx-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nltx-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nltx-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 243,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 10,
   "keyStandard": 219,
   "memberCustom": 4,
   "memberStandard": 13,
   "nsprefix": "nltx",
   "nsuri": "http://www.aqxpharma.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.aqxpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Leases",
     "role": "http://www.aqxpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111105 - Disclosure - Equity",
     "role": "http://www.aqxpharma.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Earnings (loss) per share",
     "role": "http://www.aqxpharma.com/role/Earningslosspershare",
     "shortName": "Earnings (loss) per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of significant accounting policies (Policies)",
     "role": "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "shortName": "Summary of significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Cash, cash equivalents and restricted cash (Tables)",
     "role": "http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashTables",
     "shortName": "Cash, cash equivalents and restricted cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Equity (Tables)",
     "role": "http://www.aqxpharma.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Earnings (loss) per share (Tables)",
     "role": "http://www.aqxpharma.com/role/EarningslosspershareTables",
     "shortName": "Earnings (loss) per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nltx:ClassOfWarrantOrRightNoticePeriod",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Summary of significant accounting policies - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails",
     "shortName": "Summary of significant accounting policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i3c27f1e7af754f9fb0d20083db327bd7_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i72e0b8f57ad04762bb88e13980f63afe_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Cash, cash equivalents and restricted cash - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashAdditionalInformationDetails",
     "shortName": "Cash, cash equivalents and restricted cash - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i72e0b8f57ad04762bb88e13980f63afe_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i72e0b8f57ad04762bb88e13980f63afe_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Cash, cash equivalents and restricted cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash, cash equivalents and restricted cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i72e0b8f57ad04762bb88e13980f63afe_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i72e0b8f57ad04762bb88e13980f63afe_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated\u00a0Balance Sheets",
     "role": "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated\u00a0Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i72e0b8f57ad04762bb88e13980f63afe_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nltx:TenantImprovementAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nltx:TenantImprovementAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i72e0b8f57ad04762bb88e13980f63afe_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Equity - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails",
     "shortName": "Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "nltx:PercentageOfOutstandingStockPerStockholderMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Equity - Summary of Stock-based Compensation Expense (Details)",
     "role": "http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails",
     "shortName": "Equity - Summary of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Equity - Schedule of Weighted Average Assumptions (Details)",
     "role": "http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails",
     "shortName": "Equity - Schedule of Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i119066f786864fd79f80c0f67e219cee_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Equity - Schedule of Stock Options Activity (Details)",
     "role": "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails",
     "shortName": "Equity - Schedule of Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i69e04e99cd904341a315c6717663230d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Equity - Summary of Nonvested Restricted Stock Unit Activity (Details)",
     "role": "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails",
     "shortName": "Equity - Summary of Nonvested Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i69e04e99cd904341a315c6717663230d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Earnings (loss) per share - Schedule of basic and diluted net loss per common stock (Details)",
     "role": "http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails",
     "shortName": "Earnings (loss) per share - Schedule of basic and diluted net loss per common stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i72e0b8f57ad04762bb88e13980f63afe_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated\u00a0Balance Sheets (Parenthetical)",
     "role": "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated\u00a0Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i72e0b8f57ad04762bb88e13980f63afe_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i4a3c3ccbbb4b4a8a9dea4828d5509b0f_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i4a3c3ccbbb4b4a8a9dea4828d5509b0f_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of operations",
     "role": "http://www.aqxpharma.com/role/Natureofoperations",
     "shortName": "Nature of operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of significant accounting policies",
     "role": "http://www.aqxpharma.com/role/Summaryofsignificantaccountingpolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nltx:CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Cash, cash equivalents and restricted cash",
     "role": "http://www.aqxpharma.com/role/Cashcashequivalentsandrestrictedcash",
     "shortName": "Cash, cash equivalents and restricted cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20210331.htm",
      "contextRef": "i797ac540a3b740b69e583df082006363_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nltx:CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 18,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nltx_A2020EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Employee Stock Purchase Plan",
        "label": "2020 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2020EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Cash Equivalents And Restricted Cash Disclosure Text Block.",
        "label": "Cash Cash Equivalents And Restricted Cash1 Disclosure [Text Block]",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndRestrictedCash1DisclosureTextBlock",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/Cashcashequivalentsandrestrictedcash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nltx_ClassOfWarrantOrRightNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Notice Period",
        "label": "Class of Warrant or Right, Notice Period",
        "terseLabel": "Warrants, notice period for nominal cash consideration"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNoticePeriod",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "employee stock purchase plan number of offering per year",
        "label": "Employee Stock Purchase Plan Number Of Offering Per Year",
        "terseLabel": "ESPP number of offerings per year"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanNumberOfOfferingPerYear",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nltx_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Lease Liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Increase in lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Lease Right of Use Assets",
        "label": "Increase (Decrease) in Operating Lease Right of Use Assets",
        "negatedLabel": "Operating lease right-of-use assets",
        "terseLabel": "Increase in right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_NumberOfOptionToExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of option to extend lease.",
        "label": "Number Of Option To Extend Lease",
        "terseLabel": "Number of option to extend leases"
       }
      }
     },
     "localname": "NumberOfOptionToExtendLease",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nltx_OfficeSpaceAdditionalOfficesAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space, Additional Offices and Laboratory",
        "label": "Office Space, Additional Offices and Laboratory [Member]",
        "terseLabel": "Office Space, additional offices and laboratory"
       }
      }
     },
     "localname": "OfficeSpaceAdditionalOfficesAndLaboratoryMember",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space, Principal Executive Offices and Laboratory",
        "label": "Office Space, Principal Executive Offices and Laboratory [Member]",
        "terseLabel": "Office space, principal executive offices and laboratory"
       }
      }
     },
     "localname": "OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_PercentageOfOutstandingStockPerStockholderMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Outstanding Stock Per Stockholder, Maximum",
        "label": "Percentage Of Outstanding Stock Per Stockholder, Maximum",
        "terseLabel": "Percentage of outstanding stock per stockholder, maximum"
       }
      }
     },
     "localname": "PercentageOfOutstandingStockPerStockholderMaximum",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nltx_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre funded warrants [Member]",
        "label": "Pre Funded Warrants [Member]",
        "terseLabel": "Prefunded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "terseLabel": "ESPP offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nltx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nltx_TenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tenant improvement allowance pursuant to lease arrangements.",
        "label": "Tenant Improvement Allowance",
        "terseLabel": "Tenant improvements (up to)"
       }
      }
     },
     "localname": "TenantImprovementAllowance",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_TenantImprovementAllowanceReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Element represents the carrying amount as of balance sheet date of amounts receivable related to tenant improvement allowance.",
        "label": "Tenant Improvement Allowance Receivable",
        "terseLabel": "Tenant improvement allowance receivable reimbursable by the landlord"
       }
      }
     },
     "localname": "TenantImprovementAllowanceReceivable",
     "nsuri": "http://www.aqxpharma.com/20210331",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficeBuildingMember": {
     "auth_ref": [
      "r218",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Office space"
       }
      }
     },
     "localname": "OfficeBuildingMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r116",
      "r118",
      "r119",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r116",
      "r118",
      "r119",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r101",
      "r102",
      "r114",
      "r115",
      "r211",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r101",
      "r102",
      "r114",
      "r115",
      "r211",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "Washington"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r11",
      "r155"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r152",
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r120",
      "r122",
      "r158",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r122",
      "r148",
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Square feet of office space leased"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r49",
      "r93",
      "r95",
      "r99",
      "r104",
      "r163",
      "r165",
      "r169",
      "r199",
      "r203"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r26",
      "r49",
      "r104",
      "r163",
      "r165",
      "r169"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r123",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment unpaid at period-end"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r16",
      "r41"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r36",
      "r41",
      "r45"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r36",
      "r172"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash during the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r47",
      "r49",
      "r66",
      "r67",
      "r68",
      "r70",
      "r72",
      "r80",
      "r81",
      "r82",
      "r104",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of pre-funded warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Outstanding pre-funded warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for issuance under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock - $0.000001 par value - authorized, 100,000,000 as of March 31, 2021 and December 31, 2020; issued and outstanding, 42,326,033 as of March 31, 2021 and 42,196,296 as of December 31, 2020."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r39",
      "r92"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r30",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r64",
      "r66",
      "r70",
      "r71",
      "r72",
      "r76",
      "r77",
      "r202",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common stock \u2013 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r30",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r66",
      "r70",
      "r71",
      "r72",
      "r76",
      "r77",
      "r202",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common stock \u2013 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (loss) per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Earningslosspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation cost, weighted-average period recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares issuable under 2020 ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails",
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r55",
      "r61",
      "r63",
      "r79",
      "r105",
      "r110",
      "r112",
      "r152",
      "r153",
      "r154",
      "r161",
      "r162",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r46",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Non-current finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r181",
      "r185"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment on finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r106",
      "r197"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible asset, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r40",
      "r170",
      "r171"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Unrealized foreign exchange (gain)/loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]",
        "terseLabel": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease agreement extended period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r20",
      "r49",
      "r96",
      "r104",
      "r164",
      "r165",
      "r166",
      "r169"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r15",
      "r49",
      "r104",
      "r169",
      "r200",
      "r206"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r49",
      "r104",
      "r164",
      "r165",
      "r166",
      "r169"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r83",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Natureofoperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r36",
      "r37",
      "r40"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r27",
      "r28",
      "r29",
      "r40",
      "r49",
      "r54",
      "r56",
      "r57",
      "r58",
      "r59",
      "r62",
      "r63",
      "r69",
      "r93",
      "r94",
      "r97",
      "r98",
      "r100",
      "r104",
      "r169",
      "r201",
      "r208"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued and recently adopted accounting standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (loss), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r93",
      "r94",
      "r97",
      "r98",
      "r100"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss) [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r123",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock - $0.000001 par value - authorized, 5,000,000 as of March 31, 2021 and December 31, 2020; 0 issued and outstanding as of March 31, 2021 and December 31, 2020."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r151"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r17",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r108",
      "r207"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r6",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r160",
      "r228"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r5",
      "r41",
      "r45",
      "r198",
      "r204"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r112",
      "r155",
      "r205",
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r55",
      "r61",
      "r63",
      "r105",
      "r152",
      "r153",
      "r154",
      "r161",
      "r162",
      "r213",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r186",
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining ROU asset"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EarningslosspershareScheduleofbasicanddilutednetlosspercommonstockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive shares from diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EarningslosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r122",
      "r147",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r122",
      "r147",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r5",
      "r45",
      "r198",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r123",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r125",
      "r135",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Cash deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CashcashequivalentsandrestrictedcashAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Restricted stock units forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested, ending balance (in shares)",
        "periodStartLabel": "Non-vested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested, ending balance (in dollars per share)",
        "periodStartLabel": "Non-vested, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Restricted stock units vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "ESPP max contribution rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable, Number of Shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Outstanding, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options cancelled/ forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value for options granted in period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r127",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Stock Options Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r121",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/EquitySummaryofNonvestedRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r142",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected terms (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "ESPP, purchase price of common stock, percent of market price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, ending (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r47",
      "r49",
      "r66",
      "r67",
      "r68",
      "r70",
      "r72",
      "r80",
      "r81",
      "r82",
      "r104",
      "r110",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r51",
      "r52",
      "r53",
      "r55",
      "r61",
      "r63",
      "r79",
      "r105",
      "r110",
      "r112",
      "r152",
      "r153",
      "r154",
      "r161",
      "r162",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r79",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r9",
      "r10",
      "r110",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Shares issued upon vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r10",
      "r110",
      "r112",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Shares issued upon exercises of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/EquityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/EquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r110",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Shares issued upon exercises of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r13",
      "r14",
      "r49",
      "r103",
      "r104",
      "r169"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r48",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates and assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r65",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r64",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r229": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r231": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r232": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r233": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r234": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>44
<FILENAME>0001628280-21-009912-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-009912-xbrl.zip
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MXD05(;N-D<!NKP5/TB4JL^L8D4@D^.%)<?1W' 3XPHKT6$$]E22FI;DBIDR
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MLE&I[-[-DYPUQAN(]C,UXY0I'.8NVT(ID&@DB!J,N%(91548-H$# #$Q5]I
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MP<.U 5-6@U6F'S2FRTJTW";AK(IA[E!.I5 2)'&D,/:/B4)9S(P4M*&")7]
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M]]QU\)M1"+BU(,.+<3&-E?C-SZH\PPF(\6GKQ";.$)98"R4S9L6):5<D4BF
M6 18 5#*,.=IQL(STBZMRU/W90E%3+#L$D< "Z<\PL N"I%7@(56/']KFJ4H
M I%7L/4_5SV5+V4H9VPQ&.X1W-;T$Z8_Y5K3ZINI;&,J;H"EUIP&(7&68B'9
M^VO>Q*B &!7QTY6GE?V(&<9*J8-*/F)I? F<0-%3)C2GM#1"0^*5!B18-!U=
MU"OAW25L4U%[,:FV,194T@[_PUQ]9AI$QF%(V^@9LD.ZI)Y\]!TI"\]4)M/%
ME?87A:0O%3J]^=V\U8Q.UWHB#*) ^F:815II&XMGMTG'Q2<2;&@^C=M>2+2-
M5O3AJ_8ZQ\8@# A[67]C&4AJ9?N782KSVUZ>]$?S8X^VWX^]?-\_:;5,%1,S
M!/.*%+Y4$3$^H#L2IS#+QCF,9;HC=SE#/)N#W*:.?9PAMD%5R6TA5L(WJPW0
MN*5DTV@9%3E/<HNR-+==,@(,_@)IH; 1>#]-59:*$R.1VS-CVSG(LN,3;]"G
MSG5'G"*4H$"A#S&*G2>,D;8U#7E&0 !RKF^^O[O@D4_M^7> U5,!6#5O)QAE
M*B'+KQ12@MF"A1UX8K'8\=%^)!\M-/"(5L63N,K#=GWLG=$N0V>UZ0;FU3JM
MWJHNL%%/>2,%/;!&C$"LI_1>".KP="&YESB[VN_"V/\"GS(&#5Q1&$&@VC&^
M&!A-M#>.<Q^S@\<NE6T2%:ZYSWF-,;C(!(I"#&L.!G^"?D3E+3.(@.!OJ+:@
M01(W419OTH[/>R<M#)R2E>2KD,I<3!$MQAK 7*')/Y_J$?6TI;P)1AZPC3+Z
MU+8BL'2I2RKYHYF"+[??%'Q'P.J67T_F!'^H +? KS,W+622$%J=X^1E7YL
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ME[$2%$HF@,M829M3#Q(KP(_$D72?2ILH;6OT(^8T6@6L5$8G(L5CRXX!C50
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M%TM6%<Y4@!Y@$O'Y! /(68YW1G+%4I[@(\-TCA3G=)#;$2@@ 6NY69)(SN\
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MB+40_^O[)./%#-AW2$JWE4*)J,];T? 4@A714(2[<"NI!"P"1DD_(^;:@FZ
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MW4T7'B.^*[?;Y0,?W=2_X1,@_S'2Q?\ 4$L#!!0    ( -Q K%(D'C-6! 8
M %@:   .    97AH:6)I=#,R,2YH=&WM&=M.VTCT?;_B-&A;D'Q/@)*D2&D(
M;79I0A,CMD^KB3V.1S@>=SPF9+]^SXSM<,T656VAU2(4<,Z<^WW<?7$T[ON?
M3@<0RT4"IV=O3X9]:)BV?=[LV_:1?P3O_0\GT+(<%WQ!TIQ)QE.2V/9@U(!&
M+&76MNWE<FDMFQ87<]N?V(I4RTXXSZD5RK!QV%7?X"<EX>%OW1>F"4<\*!8T
ME1 (2B0-H<A9.H?SD.878)K5J3[/5H+-8PF>X[EPSL4%NR0E7#*9T,.:3M<N
MG[NV9M*=\7!UV W9);#P38,%S< [B((9G5&W%41[![,]VG(.""'-J(F_?[LH
MI(W'2YQ<KA+ZIK%@J1E3Q;_=\JS]W4QVEBR4<=MUG-\;^NAA-^*I1'X"\<M_
M2S+WB1$Q1WJ29XB.E"2]DB9)V#QM:Q4;):GZ>, 3+MI;CO[I*(@9D05+5NU7
M/EO0'$9T"1.^(.DK(T>WF#D5+"H/YNP?6C+1C\M2A7VDD["4UBJYGE)B<!6S
M&9/0]"SWM@:/DSU XU/Q1,*/!N.3P=F?PQ'X[P>3WNG@S!_VIP8,1WUKHS+/
M1?C^8.(/CX?]GC\<CS#S)M.SWL@'?_SL)7=?PYDUM?H63 =]+;W;W'6,9R]W
M;PJ]H_&I/SCZJ<Q=&_G V8/QL0IUF/8F;WNCP=0<_W4R^ 2]OJ\@GN-XC\WA
M[ZY+ZT%=ABD$/$UIH+H(+)F,0<84/A9$H(&3%4QHQH4$'B%'GM#B@J7@QU20
MC!:2!3DF=QI8L*VP7FZ]]CRGT^>+C*0K_>1V=@ )'W.Q -<Q/T+$A>;PN>0
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MI;KWRN*ZY.B1W;E&(3.L.X6\C_*%MQS59_G.1;_].?P74$L#!!0    ( -Q
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M"5;.@,%8 N T,2C>_GJ(A ^.0PA8.L <_6,(%#;)=A34D^C/^-3Q=@98JP3
MJ>0O8H0GVF' (8X*%BH/=# <,*DY(A$+C68% "+%%[&ZNX/R(0"\8QDN786#
M7?ZCW$GT6@G\2]]N.=TY_HE %K&K,JGW)"&\4:+3>"88DQ)HZ*('#S&)5BG6
M@#@DA?94.F\65HID"/XX19N*RLU_4YF'+T7VM43V.@\OM?..:@J\DR8ZDE2
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M 1@E X#62,60Q%31A16)[NY\*)M03JW,3NA 02F[;R&[U]8Y8=#)P!R W A
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M@Y,]7,5_?Z^NU[\??-M <7ZLTMC#\?\7^R?VO')9#Y5\D++;A6>'Q'H'L5:
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M9;DK.RG?57/U^G37(%QOT^8G1M<@?-^R\(R:SSTSL+>.%$& FD\+3HSSE,B
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ME!>JL+HPC*+]AC6HRAM,_7*1]\V+DO_E0_OT=90GI(8\E]R,FNJ>$M6MTP)
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M/1;EJ]V]$?@NB\27AM@\U/%&&JT6)\ZKI*!K%^A5T_?:?O2]U4U ;NW#6HU
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MMIFTWJ:%]E6QR)2RFA@>CABRYH>C5'KA;2X(8\@^I>1$,>N!FUJ993P#8:4
M8DCE5<0 R ]"MC\'C.Q_]\,D@,!<0C<&:[9^^/;Y=K*W=$6TQK8]?)V@SK^2
M2U3F[O-X;81KAP;R*7HW*F&^59K%<8NK] D[$X-DJI#8$0;NGZ*WMPI\T=W2
MU^HQ:+:OT<+MJV#W%R-@APT6L.5V^A "]AO=[\([!W_Y?BQD7WM?]XZ/"BF<
M2H,F0HD,L"$41%/AL-,@+5(GI.9Z*:\S,Y1)YGG!0?0.N5(ZI4(CQU&IDNFB
M:#U>^.0W;)[W#XP!3&(/@^?@D+UV,6)BGHT^-9S^=/8(9\"C[*CTR@%\P8Q;
M;APS.;FAPK5R; B-/WQ?'\,%HYAY@1&0L2]#&>_9 90>IZ_,)+:,TX3*^,M&
M-(G!]Q-S:3FC*D5J^H@9,7T[)@:M^B89C "<T;0Z\\)J"*?3A()1]X>/B24S
MXGYY%<H4):=83(0:KT\52.E:Z"$#^!Y3U'0Q>]WH=)SD*,#5N(*MV%YG._F$
M0[QL:O'5P!)N\NI5^[CTUGB!KN)7!^,XU;A*E4)U-DXLTT!0)#X<&-1V,M-<
M(T9_(C?#I"U0R'3%*L<&[$D_E1EKY@V;A3 >,IIJ9]/,<5OD&H0"$->9!'%-
M"Y??1;.0UQ@9M1^^E"/?[W]$\MW WB$/C[R[QWSOPU&A;*IR;T$J\P7AN;!$
M*YH1X&8Z$YX&RG.T=3;R/&L 8UL6S?2\NV/V].G!5-'%5+<8NER&%G3=RI-F
M(DK%Z.7+*7WV3(P5ZHGDAGDZYTEUQJ-7HO3]C ,>4+\< B GT==Z]Y4H5ACB
MG3X?DV6W/?RYFB:;O>&DC?$+(\6]@\-T_^ ]:UY\8'N[[SDH"X5)O<B, :4Q
MSPFG7A)#I21<4)K;E(*: #PMITLF>%CKP?]%8SL*Y67F5K>'\2?MTN(SQVE>
M3,3C\0;+W0\4\0ASF2D*T>]UX=<RV&E0EXBH;-QG1T61<A>\)Y1Y1KA+-9%:
M&9)I7Z12P]E32U6\> B<YHH)73"N0Y!:9H4HK"M4)EFV5"+BH\= &923IMG/
M_?%GVO5BV8&9^@21G>B^>]ZEOJY=1<P:GB0ZLY2JTF8Z+68X)6\LH5 N6?)'
M#_Z9)(:_W?GTQTR9K[C\*V_[?!K9]"2A_-/GR6WX:B"/<0&Q3S$@,)R/%8:9
MQR'\EHTEDP/],UJSR_)C:-SOF6^EQ69LRA]O<[2O],8Q<E5:%EP3$]H,1NYW
M>C^B*;]R!8#(["L!_Q1C#8>5'K-R8J][;AHG/YW>M'[$0>\4T =0)B%S@R^=
M!FW=K^8Z"?LX'K7*NAHPZ* M.@)T5=H!,]@QQ.\40R:KB'U8RLD2HO "SR_C
M]'$I<,5""R72&.P_&&=EQ<3FL71O/!!W-\I74829$ 455?9[,AMY,SY10TP5
MF"PRS/Y/#038/T\F\CNZA&'1QZ:TTB%</BP^9)+7#0_":;B6BV[M6'%$H]L"
M1HA&-7AQF7<P'UDS-;MA/D2KC/!=F?K=F$F&:,PDOLTE ,XD&5Z?N[#:IG:S
M6FJ";6PMM>S>:JF5DBKLPH*5>Z?K/DXT9_R.3LW=&\(\Z5ZK8IZ=M^W]=W^?
M'+*]LSWV][?]@P_9WH$5P!3;7]^]28'EM9J=]WSOXFU[D7D>?OG,OWYY^^WP
M8N?BZY<]T=RU/YL7W\^;7_[^#N/\=LC>L\-OQQ=[7_X.S8//%T=4%]S:H$F6
MH0TKF)SHX ,ITHQ:#>J3*[*EO"WI#0MYZC&8KTB%XD4AJ+/,PH;E(E]DG:^C
M7W+1=3DNH3#KO;R%E_C:P6R>,>SCHLMV5I\LG;,80S9.H*KBLZ].RC)EOUC0
M-;V?^HYAS.LXH6[90F(=)U15..=\U\?@[4UQ-3WXX=L[^,"/?)KQ+ A-BEQR
M M1;$"U 7TPEX#GL0&%"L?4JW597NI;BP7+E>@[F/-(=W:IR2V(4'WYM=/=[
M3!W VEM#+)LU,6^V@-Q^]&R5E@#R2+\TB_8]<+U) @0*.9-HUYYIMXY+YK>]
M=%;OLU2F/?%NU/;[8;53,P8[OV!<3X]HYKRPP1- <$VXUH)(R7.2"BY,JK13
M1BSB](-MVCPK7K%]+WGGN!964@Y0D 4'RFR>$^F9(#1UBAO'A0]F:><VC<6A
M]!UZF"04-:R(*57)X;* %A 7*AW3DB$WEA'68H3)<)4)Z=&5:8SG'XPZX\2M
M80^C],<:)2I7<_Z.P4GOK'O+I.S?;V0:+%W(Y39-DJQB'Z#()TX'_O?Q+_\"
M_>6TK<]_;W7CO.)-_YHOT"].E]H 13-C^765!*34MLP46A:P)]"T;U&5(K0=
MC0X+/8W*[W*YS3B]].MT^_+OKGHLS;8E*V[UV*N_RU-V+X/-+O]Z]K&QYU*U
MQBLZUBVT=7KL%G$WM\F6K27CL>B-X*ENL-0_<+WIEIEPC]3_;?7TYIV5:TQO
ML<W@DU^)I6J)<XMQ#8VOZ(460AKL8D^SZX@?P/*1&@&^OBP"^.;=W\H97]K?
M+7WN32/7G7_=&?)78TMWAJ^K8/@88;HIS2)O*]=7S2+?L*^['\X.+_YL-=F;
MM/GM8V>O<\B;N^T.C.%B[^*[V+NP<(_-EII%'GS]WMS]XQNVJ#D\^,":[P[/
MOWX[3O>_?&WCG?L'WR^:%\?PGPM[XT:1G](ST D,-4SGA.56$,Z")IIQ3R0W
M6BO.@W2^;!.9*?K+;2+7/"CWWD!W'JIOWD"W!KP7"GB4JC3/0R%SF?/@"A4P
MVSSDA6=46>\O"::O >^1 >]B G@F=;FW:4ZH%8;P7#.B& _XF^;*:&H9!G@I
MUA K^HAO*.#=K2+V>++HQT6GS25:"5LYM94P^Z3AYO;RU3RF7&<6K>%D'3AI
MS<A/- N<H1%5**JP?10G)C.2P*YXGNE4,Q:V7LEBS1;;]R<%7:O&OY2S=7M6
M7I^M^SQ;4U9-#<\X RYMTZ(@'+:&&)U9P@N+O9D*24WV2&?KV5N%#J+C8+7O
MI+$ZP.)6,E%EU\]@'UQOA%Z"\=QJ[>K.%NC98/8#V9L6$'P)X><_J+'^EEA_
M/B-'"2XRRE5&=*XIX3Z 6I8[29S@7-J<Y:8(:(=2#98O!ZW\DEIV!R?L:1BJ
M:JRML7;C3%TUUCX0UD[E:MA2"O_W)%>!$RX 9J5UE'BI7:!"<2X$FL"R!LC?
MSP9KH\C^SQA4,AL$/Q<3O.+ONL+P+T8D%76%X;K"\ -5&+YN5VZ:X"(V-L&%
MWUN"RWQ%U#*-KNJ(L2E1L\U/8T[[GL.SQ.&%._FZ^QFXX\=OA]^:\!Y+]X&;
M?NV\X?!ONO?M\]E2U.RW8[JWV_[69&^_-P^ .[YKMO;8GR?-B\_ =?_H'!X<
MP[\?SIL'?\PF8L._G],FVGNI\%X9(KQ6A#.?$Z4\(U3+D+L\SX0R2]W_4DJI
MMD$;KSGESFC'1)%YPX34(2L>.%IZ5<G;E[O%99,I9[-,J<P2E?*4\,"QW133
M!/8KYUFA><'LXK;*(E/66"ZD B4U99H[G6DE,FZ+U,OLINU.UDY,NI:>+KGO
MV@%O9K3W..<D\OI!V3FY3!*)!2.._;3[!.:/5#FGK;*1Q9G'UK^#:7+LM";W
M3,,KWRK;]@UFVF'$U-.9[H*;7FG[8*$P\KBRMC[N>U_.&#_ME-W(J_)%_J>W
MHTDBZUDOMJN&-8K987AI63"TE/EC^8AI.<_V^17U;?X3AHOZ9,8$52IE>2JY
MLUP!S7K*E4]-IF6:7F*[8VOHDSL@TF$.B&Z_B5'K?U4='C>EJ,W#H]NW'0$L
MRPK+3$&R%"N&6!%A31"?2ZVI%GD(?.M5EC6R=$4YF\%_1K&,C"^[S\Q5<(?S
M],GKX;#M&\D7T,[AV RK>E6KBM&>]EM=VSK5[3'9Q61W?!ZZ%)*V-B@B]OKG
M\0G8#2C&*)>].W_X=J\ZN*7WH4P:&^'!C"G9\UU[YC.ZJT3PJO[-:6P!"]^_
M]:8_D_*MR@)<<>S3>N1+71EP<)<2?J_JU#A'^KZP3GA;2.,,-[G73DHX!JQP
M 7ZUZ4JF?7F%IUA'!P["&;;@\=VY#.5F+#^V'_;C. YZ;^+H(^MYL:=@_V#G
MYY&C6M%@ O$%]03HWQ))@R6% .9)T>01]-8K@,#E(W"5/+8.JJTHA;2PA5>)
M:!]]UY_I-C8G>&'[MR"&T_T/1Y:S4!12D< $5AQ//=%PKD@>;)'E10@:Q9D
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MQX*SIC"$V=S97#"=8^SE$]C:^JROW%\O'0L<+61&I(2#X$DTJ*5$"P?_\]B
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MNY/!V%O-=Y\%"I(@,/[\^NW]&0B3)\UO?W;VW_VYT%.-6F\S:XD*3A-N1$:
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MQ@0QFGK"<UEHE\/O*MMZE3>DH@U1K-F_]-=/U[V'V,]CW:6LHD:,Z]*N:>9
MA\VT9('GA=1%(83Q.4.'BW;BFBY&-6)L.&), ]*S/,\U2SW1N<\(1V^'5"G
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M/>PY@LQ@C'G)PJ[#':?H</'5/5$^A:69K6\R&,7J(Q'N8._CK<!WNCZT "J
M^I-N*<^,7[\-6@$..A;_*V?HNT#\OBS.-40**SE825[X$D"@7ON'+_66GHOX
M/*PDE*7'?T$<0Y#"X?=;?JC[YUC]=XC0A,RN6@]<K[8?>GA^%[9L/!CLPV)C
M0[X*..&=9= .2 D-1/2QD76ZA)'UCA<13@_LTL("HGA4EA".8%[N3I1(\,15
ML@M<[D;6S^]4(SD[:;5]+ 3=,>UX^.:GW(@20BP2 T3K8>][;=#!4-:+I@]@
M6BC<ER)$N7$)>O1^3-9P,G:++&1X?NI+%@=[,8B93-H DQB"@(E%J#OCRN<M
MV(I!62,Y:EA1*,5J.+W%(4:.TX]<$>FQW4+".,:M]BLI9WO#\&!W<_!@4.YT
M)5UHBQ!:RI'V?(A2()**]:=#E%&/>UW8H0&B[G#ZQT2VK'2 TK1P!54L/GA0
M"EX1%& @YY$ ^_X8:&[HY_ ^J8Q4$>TC$9_"F8G47K*'"&8Z&M-:%:0$D)4K
M,?\[/'OR]@XL)]#(()X(>/T9/B^4-*5QG8'L1W#EAM%.Q4ON>U17CF%I#;=G
MELMMUGIMXG*-M:F2^900I]VWT6"("A:2[GFL+=^'"\Z[,"0["YI ]2T4?FVD
M>X!->X)Z"7+I&6;6&+/?^&H$0PM_PY&$.0Q*ND?9"=C9L1];@H:C#FI(_>K,
MX< PG6.E++U)HN9^-]D9'>/R23144]68H<>#*3^ .;_O@@+WVQ:J.G#4)U=M
M_:,QX> NP:+_\/4Q&CZ0_>_\9]3J]GXB$P-0L\!ZXNI/5)R)403_V %&Y$L3
M ZQO[!\"W^R5CRNM]]5@13G8!,93?3VY%\<#>G.4;J/>.QG"XLA+#] IVGV3
M3R-3SA#V%E -/CLGH&TCSP5]J>5:*+O 8*J';6.;$VP!$54J'/OB,!I+3R[7
MQ8T-/-$=TEL:5*/\?FFL@Q&H+S_&>FZUQ&C O<%HD]_PGFJEMOZQG7P^[4W$
MKHK'3.?0F-R&+5I 3HGD?"55X&R61KSZ[M>]_FGE5]].@/K^' &C02])';?R
MJW$K].7%K6PFJ*+#KX%2$1"<B_;)R M<Y9B<UF^R96>?<1VGTHCY6G<UG.#N
MS%F>'LF_YA3#0?);O%K_HSR'R PQRC2>CE@-L]5WT8UY'@_;DENRL?IDQK-;
MP55$J:M._TT8W"V;B5V:5OIX7<::_R; >6['U!]B.E=S>R"O-GK^2P5WB-*4
MBWYQ((0X,6#4:!!,WL-?_X0?5,Q9E,XKG;T4O#QV^>FBIF%:)4%7S%"W08)"
M^D7#TIB[X".G&M%O0+V]RKH-Q/9ZEXE_5 IV!\V0\!\^\ 1&3\:2W>)KC!_J
M>*:.4<L9OV\0S<P=T*I:P-_0YV%A):*4I[L8#(W"GF^C%!>_!$;>BZI+N0*S
M!ADW9RV--5]+02_J9S@B9-;H0' @_=BR8.K,('%6T2*\0B/'Y4"WZ]CK//8\
M3D<[&(Y<"PT @"1AU(\V8M"SHBFY-*O,#!Y.DN^6\M>);@?2;@7?J+3+RLF$
M]U1S7-K_J/U%?7;00@%M*M'%A22N-X#'=7M=\N[??\4UQW^'O9\M6[D=R\'B
M9E?O@#?"&HYC*P#A1T"_V&<"?2?1#M.:\3+-2R/X<#A&.(G$E0TJHEC4[0&Z
ME0[(N)CP^M+!W3-E=Z[MR=L'2>GN*Q?=1$-=C.KPK;B2&F=ZW/8$6!2(<5%T
MQU$8I.B)(ZX<%@IT*%+-&DB B  RABT_YX0 A<)^/^W!J^'#DY9IH9(>"1+!
MK]0NSGQ2.3K'@\7V=%@UN-=I#?S*<6"#+!CGQ#)4G<:X\:=1UH7_Q@<G.>V=
MH@4@.I7P]/4!,]!!BXOV>N<C.2@W10]'?:"S[ZUV&Q;DMZWF_V[](S[_MEK+
MHP-<Q!@,Y^I.>ID$>'()8:37K8C5]4?'<;U_^.AU/.OUOY?"=$D32:2)[1*R
M3N(7<ZC0\1A.T1IT\"55;D>, AI;Y2-*#/X%&WL&VXRF]V%\CH<1C%"20L8:
M]</RM;.$57G@(L"UHMEOWAH4-Z@T^52NI8@SV_$G$ ]:+F,0RL0QBWZ#&/X1
MS7]Q4O%V$,X1L&Z#L2M!';2B: >J3)LS3X)SB!RD'4-HXOB!; &<XLDNQST8
M'XJ2M?P$(:=OD+?\T(/2A@J<ZWLR..\Z."=^;(T]G7WC_$+A<\G,>RJ[6 \.
M\D$UBAAC49[3$MY+6]BBE0Q.\&ZY*SC?2=#+Q/P>-Q^7<0Q)YY4:MWKL<3TG
MI@WTZ'5@\CC$T/?_&2$<H;>SJCU>F1OZV.D.H]X"VBGL>6G31R]B(Z(^^B&6
M: EI+M8KC_WX8IQ/R4@:V+@LHOJLH3\R@*FU/][9Z@Y&^,J6+Y7=67_%F T^
M5;CX$DDH-H'K]^ H=!(,!(HN^C&21%]N]"/#/O7<Y"3'M4%+?LNB_186)IJ0
MSF?9.W[:]Q4B#Z-=8XY YR4BE*MT="N4E#V6KO"3!9D"&<I@B((</*5\[XP[
M A_;N,0+=8;ADI$33OU1.KI=!I'R9FTSI=.D=%TL>#)*S(M.+3\FCG:)'5>B
MQO+,XN&OIK>=[ "PG)9[@/B#W:6J"< RE3P15C%*$M%Z'G^##8=]&;N-AG,*
MRBKCY:-J%>N;IA_]E$S\'>@=0,#K1U==]'"-J::*6JA@!OA>I^2TRQXHD#3'
MIPZ=#8A84QPMO9MP0X0C=&;$3$/42,J."\"XEUP8^ABC+8<3#69&OJH<(Q@:
MC!$?^$ T'@-1'>LJ%F> #+H*'EP143*Q'H\YWIC.="5MS]N4X[>]]GEDY/X8
M"+@T=3U5@(RA([!>PTKG>!]#4*J +5@U?,\N;LK.Z6E[[ S^;>M]<Q=$R2AW
M'^-:H=T"=HHF$^5FV!_SS:FZ,#%/E/V9T3JHNR,4O(MHKBCW%@&SA6*"GCX-
M!6C@L4/T8DZ<Q9^W/Z&"U2N%XW*4#H"G5;J*XT#?[N[ 0"?VDE+F@='C<$KG
M%GX 5U6!;AA45 E?9Q@CZ-T82N$T]$XK+-6# 4:7X54@!Y9:'4CV<&HZ7@^B
M2SNJR25Q V&-B:J4 G0URB@FQJ:Z,SRW@F<\.-.W1$8>U8#Y"<)S06:(+\0
MSV0<=H;]4"KG;W0*CC6E^)R)"A=#">/DH[)^HMU$BXF(#$=_ ">@VQLNKN#\
MQI3Z%]R*DEAYZF+<\?_/WILVMW%D:X-_!='C&^$;4>35ZJ4],Q&R9-_1?=MM
MOY*[>^9C 4B0U2I4H6LAC?[U<];,DU59("B)(BA5?W"+)%!++B?/\ISGH52_
M.I)_?44S_@("Q'+QY*E.N Y_ T-P)0(OT=7'6^O]VMSNNLR""F;/^:T(;E!5
M-8*NUAK?!H5/L7^+0QLGA-FD/;.^RNE:W,O+T0?/GGX?X_,]FEN, S5_4Y&&
M,NLFPX,&R\LQIUPUH]G=M?@OJEAO&K*5^\'M?@O?+DO=IK !?/((;2NL3 BZ
M$,(GS\^!Z]Z+ 05_%-RN#M;"&G9.SJ#L"W+EL7* K\8CP>L:UE7;+MI\X]#W
M'M3OVO ;*0H2 !)C0HJIR5_G(+HKX@0/GE:.8:SD@6S-/L%OM"(716<C)H$0
M XP#!5/,>0HST.CEL(D\\R5]"M];1FU<U@U'5O$\8!&%PR:(5YI54<%ZY&&#
M:<$?SA?#\5@2[!!3/&A!NI -:PMN<EG\E9".+TB5B*_VHD>S 2$:CVZ\%C$A
MO":_K*CL)[^LY.^OE#EZXV!!H@[+;[@B\^U[MKO<^^'^H]O7TBDEF ]&?"#>
M0WTI_&.C[PL1QY9BHKIY)[J,FI?,X?C?3\$'9X?[O1SN@!<$EQ1W;VL]#1OG
M, J"CE<*(PG*0 84XCXP$VLZ.=!;80 83QF"RJR[.\B2W8079>"[7QQXM* 6
M.I_O:#!#T4A!?[R>XLATKOM^:-WWR5SW/7%+"P[3UE&2&;TUV<%:WD+LKBNQ
M^^?*98O+_<XU9RV5DAZ(+5T< &G?^]";O(.<=R9-P$Z;GPU&=$G,9>"8V*JX
M\JDU*8L&$*3I^!CBU=AI!1>!)I[MKJ]"\.W:@1W50Y9"+KXMWE_/U[1AQ0-
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M:QC?CCKF?MO),$6YRIDIU$B_J<B8IH)YC.)NS:#^YETOA09,RL$Q<G92^%@
M/T3 -9G]%H*.E (SJ; -M)-SE1 *.LI#O+=V[*)KT+>4<!YI*9-9>_2#U2.G
M7SW^ 5UO#K^U1XIUX.AK7B(-W<(60J^= %8U TC)/T[(+:Z;6M5.T>]E,\+Z
M9 ,Q017OTQFP>G51>ICCZL].)NT+/\P&859(^!@>UG1"QMC%V>V\J^GA2D%H
ML[)=5JEY\="I@*FU#,[^0EHAPTLQ1F">P[NDT"Z0Y58Z1U0.*8O4!ENII7D:
MN936[T'_<9:E^V 8R9,91C+#2.X;1C);V/>QL,D2#Y:%B6,HM*I\@!F=I^G#
MITE -5HQ\9IN@4RHAGFZR!6L0IPM0?G-Z[T%83?4[U9<49C7R-/Y)&IO\^1:
MA=W598X 6+@^A*VKUM)$)#)>2@7#3$K!VS7YU'GF[G+FZKY#$$]FE1<34D^-
MNRK@00PV33)B$&TPL=L-.+4X6Q+JN%KQ%;C;T5=D; _'0[J8% A'U5H%3U ^
M8PKYQJF->87=U0H+,:@5; R-"QG.@&?L7[N-$ZD!K],]W<V J<%-71;U<'$)
M^C-6)". R4 S=$#@CB<.V2'+>"*@DTS(^2-HAS]G,+1SL&ZY4%Z4\BNO:IC)
MJQ6:F@L*A_Q<I'+(*H912ZWNR/#Y0S*(TM\QK^:[7,TW:9@-,_PT?U'&&^/\
M>9(^P22)KL^..X*#&L)* %[2S6;BAGE>[OXH&&I%4I8,$:(X 1X3$8IM9XR]
M $>%*Q5#<H%0+IP[V^YE OVY3G6X02-_%K5O"RTO(V+KJ^*B* E92DP (H4T
MS?PWP(-:V>\46TM!Q5]P%\%EQ HCU>(.=/9;TCYI\3_QZFM*(8X=JF'-U!+2
M:>W/L!GXPRJ69A/ISGQ1$O!IH]_,!C7L"0V4!"MO +5NROI:ZK A(\,U[Z"O
MHU7T<HP3/%+5[/M/,#EIR/X;*CV_"7"P5Q+K[K/%JP&TX.406O">#0J?0K'M
MEIT+OQXA?T&P*%H^0\P%Z08)/_, 2J<J9<RA+<7PL%R"GD\D2E9$4A^!M7>1
MVDM)SK=ZDR6!.,EFIYH[P\  H9FS+4Y!='==LYQ;O*L"(6EX*;2;J75_BR3_
M?6KZ/7X>-')4O&PP_T.=84'86.[8"7+5FR573)S(N/>__N7LR:/'&?^04\X
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MW)V;RQ/^B53$SA?_0*4 >8L"(D_742>D]"NY"HEV,_/8<FLX)_JV9R'U2PB
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M?OS&;R'L=<4TK:1.>0/[=4>CX-_U',:L[<( 65/,QC,4L/RE_-4I4<!B">:
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MJ-T/87K$A#"-#9QB+*:TNNGD%1.5T3;"AN2!7AQ/U AG)[TBL8Y\F??5ZG)
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MR-LK&-%T697GNBI7PDKNQ,35H')N4W*A4]S$.4B%K1$5<JA;;\M CMK^BPM
MTW:^&N;EZ,DT?^HN7D&?SFY+$27*D9+AYB1_YG>GN)16)8.?,[Z7M59,@.L5
MM)E<-L;Z=;.C=4PQZ@%PXXJ?"$' Q=B>[;(6#)Z1/Z!%VA$[L0 OB")JEE9J
M6K>RU(>AI5(=/" V*RDQRF'V)ISYO?'=;7J'R\HYUY5C[BN0OH#)";DKK.$F
M2!<+@7< HNCY."98\%'7E3BN#JICLA->;J<2V8>2J%K)!>1N\NI )DW%P=4
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MG18^>5PJ%S&L%IN!\(?O W8E @UIC"9XEU)-&\\9+0,#OF9$ %A76#0W050
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MZ] FQ4#TYX3U%0_R$UWG/SK22Q6_I@&Q#+ M'I=(^/7!9HQLSI7ZI"O>W</
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MCWUJ[EESN0%1KM#=>E26YBWI\CB!XSV0JV<5+(% DJ2I>@\#ZN_HYB08M]P
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MXDNZ*I=M)G+$R !UQDE8FQ'P(NOW%(196A?U"^VFT<(+-=%!#Y<4G$-8=]:
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M#YEI70JQV G>S[%TM_7YV0/ %ERC&-/R0W!JP\]*4-3!]'TTY2+IBBP-PG;
M&0%=-0*L-!3'Q.-C/=$9_L^>E2/P6"BDGEI=A%SRO9#Q-2HX0CABJ(K?] ?*
M<A1ND.5QQ'?B _O"_7$^X&/M$B=?9"?E>&\D_+J9,!<?L,7S#&;LX\HQQ]UY
M'/NK$D*FP[(.UYPL!MH?O=L([K^<+U%=YN;]YH8<SW5;WC'#RT YR=CG/JQH
M\__P*? [ "(LG/KJN%@MI^/A)AWN=(9Q!'*9E \V*<YQ,):8\@X9.#03#/<'
MTPXP$=YE6CZ87+EH%TAQZ@/W?_T/'VQ&U6?RHD.'_V&NU=5#S^]S<X$S]0V3
MW1C'7TE] ^0G5,0R:<]AXF^IQ T[RJ=F%>9U^%>/<G"S$%[E;1X4^[%%@,.$
MW;5PQ ;[0B;OE&''TJ->8#_O"_OYTP7V<X']7& _0]B/LX" 21#88Q!9 '5[
M+2*;G$W*<D(/.&FN'*& W1."";!VS%D%5"P5QN94T<RH3YAPI-+I6DTMW:O=
M0>H$<;S%?GNCW<55T&V8\BH=#JF;IJU^:P*B.6I#^9Q7C,I*O40B#N4PQBDU
MSREA0).E=C[")V>(BU\BJ>\Z:QXG#G"&^XUGH1BV$D">*IL)HHC#ZE4."-HK
MA>\!'^#A45_QX+A,J]$8'SW C.$.LG47!(TS5%L:[RGM*<]SC5+)785J+#42
M-WM" /1UTH@4S71"PP&5/D$)UPW?/GMS!?==\K?GD[^5G@7:^+(4Q6I,-BTH
MV7S<^.0J";3=Z$XNA'UG-+$HQ:S#D@OY99SG7?!QS87&Y1PG+#HX[4'KK>Q(
MY;J Y#G5UT"#4-'^($:6?LL23-SHJ-0]=VUU",^B27_B1^W0A>1FI,/PO(GN
M4'G;M$EFBSLP16>+RZ%K_^O:7Z!PU5+:,/'D/#:]-/(?.+ZGEOT=@]X2M8*=
MC8)=3NH8:$QS/X^O0)A[:CC&5V[I0H3-2\(/R95BR)<[1IN6B!OZELYJDA M
M)KT_=OQ IUW'3=\2>,DK-@.$(RZ?]^$2'] EN_>!-GETQ.+2W'76AF"$I4+F
MOW:NMO<"O4SH)=/] 6TPDG:V/=0"7X;\@Y(S)I">J=O% T< Q>LL&RL$)C!X
M;5CS(6B([_IXF:D/!O5@G4G&@:5V9:,F,^0 P_>XH6=='N.(/ULS?F<?SYG*
M'-#+3'V@F?)(93G@P6(JF9MV*EMSF8T/-1N!FG(HQXDF//7I(*8CLF?(^2@U
M8IR>&IQU#1\_;17BCR]%UP_JEEDCJ]:Z,QWT(M>;9UCT\"!B[K(S5TZ\+YBJ
MCZ,$GB'\A\VS6>S@?=4DOWO-W1XJUN-0[':/IRD/Z^KS2C+QCZLW5VC53197
MNAS($L< /!PT6CN4/V/HI:EW(.Q*WW\CB=7//O_4$7HI*^K1Z_HNE6)LPYU_
M9[X"7V![?1U6(!->?/:\6'SZR:>?%&P'U_/#B#SZWU_]#<TSBW__X^=7SQ?Q
M^;:(VRD_K2UX<72-[Z[(]25A:$D=K5VC48?J7N <%6@DM6\SMQP-] __J]SM
MO_R:&I'6A(<OV_9(OBG>X-^?7WV2[I]8<9=!)WMYG)YO;1*C=V'$?7Q@?X_X
MR(QYPL*(9T#%HINW)3<B'4/9=ES*J[D?DX;P\X);1PZ+_E!1!6]]M?A'#:2V
MK$-DB5KIOI)'&EZ+4Q9\^L1U.)BGYW\6OAYZS(4\YWWK.Y%@42O;EBU GST9
MOR,]KZKM_!C'Y&4O?&S_W2Q51:Q;[)1U47AK7[[XX9LW_*E<%$M(5P-&^3J
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M]N"0CE\!CXCD@#BJSK<PO#*/\X"1&HY=:$,^OFA2XC;S6P9L=7ZIWG/B%G;
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MR3),8YJS%P_I$\28=!T>+]V:-ZRNF<5LIX]*FDIO3C%^R@<PROZ6"EL_W5
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MR7<5@/E -@L]FA2@@IP:72:'JC8&PEL@F43\3WBQZ>H#H4U &9C\DX+@T.+
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MYK_ZINUWEX5X/@M1UH LQ%K;0U29"CIC4Z[-+D8)B>:?9>E+5FTC)FF<T[4
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M^--//M.595F5OTBQ\&5*W"S^1E$%\PRP$HJFZ0@3NRV/?F*(EJ"IA5'?)U)
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M,GX/2ZU(G2CSR@?O(]F)'7&CVL*9&Z;N1H%C8B_6'*HF_&=\[HZD'YS@E#S
MW#5)&;G38?.F<B9=^1[FD]> %G/U/J1.+<_&%A%)$FJ=&W[-C?=3-2R<.E[=
M- +%'"4W_D=D*Q8ODA82N3?5)AV'M/F8V("/F!-C11F\:,]X%]"C/P@!B->=
MA_<)&"&Z*KR'X-@.M%6XN"86LU"MT(K<%-_424 ]*NEVS:K"'71,Q"@;#7[#
M6!8,<*;0GLOD$B9\H)+I64$8Y@Q[%U\K,058R\R[I@@_7B;PIR"*C8MM$YUC
M6J=L1 1,'315+WR3##8_%@JL-K]9J@[=@:QTJ5CL;D>UL%80UJSUG%_ ')VP
M[E>!L;_;INO;@1B[6RRTUF>N2W:05@J H*-F4F3EJ?T;R@C2_/W$":[C1K\A
M^TT3L"($J_)0/'(B"8<1-KK7XXSPK_^[W^WC[HUV@]R.K[1"\H;^U.\M0/GT
MD^>?PH;]]ZNOWH@30S6I%>I9B\^>%_25+VR9/&*!T/%I?H<#VYMTM9VA7&%9
M4I6G?D98MVT%QX_XO VU]N]Q'UQ](@<E)?TE&F.Y:F"<5-TZ_]WS\>_6?6N%
M.X(,4]$"XG2LXTX&:1.7<[PDE7BB^\-F;,#D7LZNYB/9[5#!:OVN^CW?_!<8
M@D__.'J5ANZ@M_CP8V';_A>?S'CT=:>&U X3/PLM]<+$EP@_4R$9%AYU2Q5V
MF3-*1@)3WI;5]@'&Z6KQ!J DZCG:NF>Y:1JF=U>@%< #*.O=-7Y _2 R?B6Z
M)3RX>AKAL#622!K0%SR7/^!YZ#VCB[KC47O^R;/_39-1>-Z::5L!]9I3AA?Q
M[H0=;Y;;ZEH.3NXA @W#S]%UA1D&!6G=E5RZ_"FH;QK'@HYIV@2I6,=10&7\
M]B?,^S)5S&F0=9*Y^2A-]=7BN\VP)/BP&SC8K@"-3&99OBOGC)"*R&*?*B[F
M>04I5LK%D&]2W8$KM>K3__<I.B#\FBN:@7+Q;W$-4M_/:A6VDDTC*=?VWS!"
M6&)09=A1=0+N'H:GK:Z;EG01W+ICWU/7:>Y-Y F5JRE0DHW)Y_'_O=.8?/J.
M8S)?<CEO7R3N(_5"[&R[[YS78QXY#_DR3/YP >@7);?*O(MF07,5C8?;[<RK
M%%+5/MJKU9#JZZ945#-ILV0_ZSN@7DB68WO4II[L?A]> >,,0'P?D]I@,K>*
MHY'6U>& ")3<E,&T\/=([J;;"01817];#C 9PH)DMZ>&TU7<X([BU-9CLX7D
MS;1%^X!<)Y?5D*\&]%FEF><=K4<UI4]30NWURQ>OOG)N2GS M2AMT'(B@?'=
MHFT.*=,1#4\T!W+AQJ\\ Y#S>I'\-3)+*8?A-?S*)2E0VQ7,2YYR[D[#A2^U
M^0?6YO]XJ<U?:O,?NS9_,?&/-O%4M1LZ^\RP6W6/BSC?S=G^%>L9IXIE=PE;
MI^ZHCXUPE"1GU=>04=0 ?3&E2^N:DKA4)D#+"@G&N7+(X))=?B7.G2LC!N6.
MTB_;DEI3?<J>D=+C47\W>_4+C?UT'*;X/L\H\ML! ?\T%3EY'$+\GVM!*'*1
M!,!!VCA(?AC2.@Y"C+=\(P5YW/5[;*Z/'LD^3C8R:77.B'1"?Q$@]+(#S\P@
MM!P0"CF6M6J:8$: \/(4R'6%>F8>5]M24E&D$FV3:NEH@3<<*$J1^G^<Z,-Q
MCSNE'^21]Y4O/;LO.7 JKPYI:Q]HC$KEKK;5D[>[F.=L*XD3LARANT8-Z*8,
MJG@TYXC%Q_6\WQ"&_Q4$_JJ:..RW ^81UU$+@AO;F,T=67TO+P:JZ_I07@_2
M[[:DW<D2#] X4_[767R\H\FB[D:W#--C2;?*E.E_&C:!!CRY$*ER[\KYKJ\T
M[Q&"Z<AZA"2TJUHMX<.FICK'H;EF&%MJ?*+T->;/MP."";<_6$>IM+]RQXKD
MHO+V_#9-J$?&4+WTL!(Q6<+UZ71RX&P7'<XF%1/BN)14Y5'EU]D;ZGK1GM=N
MT"8'V,#.Q*_IW=KK:"J908R07LHOQ2@I>0BE%J.Z!?DQD+*GOW5=.'APA>K:
M2^=<WC0%9+QG@V(HAP(O^CJ&PG$B0(_@N*923SS=9K.A=YY,\</8'YN>NQE#
MV$HC'_V-YKD[<.*)_D','G6^):W5[4<%^(=.L6[4 A#WQG[<-"\*\1Q"QN<A
M@[&6M,C1<EU\I3;U#NBEQR3+NG*9CH9<OHK7)+F0DEGEYOQ.%GCV9HD?H@XD
M/UNV%2I=*DDWNI_G25%&@M05QH7#U!LV[@;;T1;.&\$"5>M<08:/U5^RY^OC
M'0N<@]_$%Z3]MB,T8LE@&F[=(S/#9,N,VWEHHG,Z[2X0,MW>Y2JZ!'%?;8^:
M\GH F*:80M((1JV[66RVC>!AD]02#&8&D!)>OD1IJ+4\NN0FKOB:62+ZCJN=
MP])=7H%^]!+XJ/'AXDW9+LLXPL]>_;R-^Y(P&9+M[.9Z2CETM.61UL9P1; M
MFUH1[+Q9 &[?9_*J)CJR)$4JYH+OM^G;NHIS6NKR0,=U\D[J^198>\+:\4\^
M>/F*<7>9_CJ$M8@[,?N:+UC+::*DCW>A?$NW)?@!)62B]R-]R9G3JN7V1SS5
MB_%-*,HJ@<5943AP9#X]UY&,WEOY%#7YJG[$/L94Z#Z,OX2'(GQ.Q( 73UG:
MS/%$ZRH-XV^8ET6?=%=UEH;FL5)J(#Q&M9L&(WB0O)RPPGL:O1"0#C4N);$L
MNZJ[ROO4__#)'PR?/%[R:/B5QNZMY?L[E&5<!8CC"$S3.NP#,FR4SB !$&HW
ME_)?-&4DH0F2#DKY"]/G^R[#ORI>#LW_'5!WS'$H.+S#8\M(L,7T!#53;A/R
M#0>P^O2,71>T@\+;I1>?[C>1,GK<T,S4U\[<<+Z:Z,@8K3:LV8Q4"X--,%0?
MS;H1$;E 9IJE?Z^S@,E9"]$A8<0+M]_$.5@WF!0A2G6-G"@(P<ECOT8S?V3(
MT&TRT*1SSY2C5>-3;S92%]NS@BBYPEG9^^CR$6S!B1B9F9+3==_6S=TVK*\U
M&;3;"[Q?/0P["KK./'=>)^K\(4DHK,&\4I,D$[T9OYM?G\,YLCS&P!=1W!F+
M^=E5XVE"$F\R*JXP2)F*75A7ENLP4[2);@@"A*\3QLT])@\/7U->%IE4YX;)
MJ<&D^<";\9T8Y._7A[?L"" GSB!?O4SG$<Z)^$.:'):&C0.Q8YU9HFJP<G>U
MDVJE'2</ME^%SS?WM;E]Z';AYWI<^9PRBFI1/?0+6>Z 8$EQG]I%+M,\-3#4
M,3(WEH\]FX?9+F+4H.GL&3UOGM/#+ZC)J?@YK:JJOHD'["AA/NU"3WC(<]!T
M2+VKWPQLFYPM:;XH;0:?YSUG#$NNVKS#:6J)!YQ\PK@]=H7F)O1X>CHO5?'W
MK8K_Z5(5OU3%/W95_",M_KES3VB,FB[,)1=0;87]7AW-)2(?Q <+P\M+?'N?
MA(#6V@)I2@=S 5?:K^B3[O'Z=A;PHUHU7%!.?R^[=?FOQ1M<^7O<&L;\[R_>
M?/WB__ 3O?GF94J<2KV7<5"'FX8+/U>+;].1"*?F.!TY/_KX+80_U)P5=H;D
MT)5..4M:Z-5$12RY=,2\/8!S*E<\PD7*2*)QV$EY4X35&4NH9NUY?MZY@/1Q
MZT0/2-.H!^USWXC+40L(;2N<A>6*/8Y-&R.2,P_QI+G-;0WD?ZD\N(Y+8@8;
M+B%SSA?QP%&DVS%#>Q!'7S(J1W5IN6_48?YLK7+)6&["^:4>&T?L! **BILE
MXRM1!VMJ(<]H,"B#M!)*5.G!)%/2U^C77+/_JG%H =GJ%JP2$K[0/[M^%^<P
M#K;V<-(S2(>EF#H*CV0T.R';K1+Y16(NH'>U88U6!8[^,FRK<.N8JA\PNLW8
M@ R_4Q!&ABM7U)O(VA$H$X.& 5T6>TZ?%$#5**< &FY2 JS@5(SX><40=H-R
M&595O*R]6VZ&L!AVX=SS(#^*!@5%6''?HS7:($(:)HB0S\$P"__LU]<&HE9&
M@6?"GBEHI4T9PY-CD3+ \-[6S1UAAN)7&CHJK4N'*E>P]FQL8.]C%%&^I>#+
MTAK4-&53+_=956U<[))/- *L.,[5ND?"@C<U6GR$8+6@[\41)D('Z>"_:ZQ@
MNP_-GO<9L:^22I.<>;0;Z,1JL6*R2:>>ZQ7MHS@ ])#NM?AY)L=7CGF_;(HL
MORJ+ONLW'/H<W#[I%FM&FMB P2C#E//8.BIV3;(^S0/,$!]I V,$F=N%1B>T
MQKIS*WEI.O)[,@2R'R5\Y["2P2M'H8D+[]K_^RORI<#FT/JBK!D5I3MS%%.%
M#2[AEJKK!?F- HQ$F9L.#/57D;5TIY OLI*)Q15H\U!^,+2TBSE3& YT=YN.
M#+Q.AAC;*[_VU>+KT$4G*LQDGVPJ=M'ZL@T?N(K9-'9J4)KT_B]_>"5+0^M&
MHO0C"AQ<)[P+Z $L8)AO^RU5"A0(4>XH6\Y-GWJ_VZJ-.SC>+]O_[!Y&*W1<
MTC(\E"M2)ZO+Z#LR$TU)J0]4-:E0>L#FK+JXK^^T[Y70#W8>)UFR0!1]E&+5
MA7JU>.ENHK2_=$BE!%5%NY[8HE$JZIK]332:_KHH#71Q? =7$]2F,_'K0,P3
M6M4A[-2F)\=W"UYA3KC&M1.7SK-F0POY-L8J_&<;!S Q;(E6-RZ0T&J>5= 7
MS(1BM*QR"9H5XS?AN07)2:WVU99L10N17NBZU>]*YRW_&+E,M_#>^.11U;7]
MWD GO,32ZO7RM1)%3)D)#1Z&Y6:_"P=$$?_)/$$"@J-7BN:[@YE/^7?5Q?I/
M,&%,+#><)6U>I30:,'':94-9 %/,[O?%[YR<7EO&!1#?M U\W/!D_=)FX/>>
MG#>-A\5^Q6(;KNE_,EL?_<[^H. ?P/G0<"==L-2X2Q0??FZ5WR2=@'P0PY[8
MM^3H]2B$ZC!Z.)>33+?0U1-'8MVO*"MY&[;-?B?Z&-=M200L0U04)AVG4C3N
MV.4'OFYY*)/=0:,\<2=<-T*MO-\2L&8]^-D87)ER_,S3DL)UQ4A)O8F9W-+&
M0"I:Q,_8&R&0#E,P(SK'\N67%3L1'_EJ\6,CE<6#=52)&V_C--H_OO!<ZHA@
M%8L!IC4+BAP:%09X*<T2P[C &F,UJ[QFGRUVIHZUI9J==98WX4K>T/@ IX ]
MX*=6TS<&0L'D.UD32\5@*IZBIV7T'GX_S6)J922$(6*6$T<.H=$*LP)I=_;.
MUZO,4DSFW$)T-F[^U<=HA:3<FCMR5Z()IQH\)?B&)WYG9SRY!8?\VYMM$R/J
M8G'3M^0/U+C"<7_3"%@*OU+1V;MX4M)2];+=5%PD4Q'V%12W.R%"8@KWD2"W
M.Z'5C4&RK=Z5C(MACP;Q4++XSIHRFL&<K!+[(ZPA_0,#$T_*S3.*8N)?$?U+
ME7M5MMB;&EL#%$$!>V+5C-N.!&!3J<H>@<(<JW<R*A(V'QIZBN%I5&QV^:BU
M?3_5TX.6-;UJHIV(3NDSEI^,8]N3(F\<CU:9#6%>_;F23 NGGUR1L%DB#6IG
M CI0*U4:/&&9^-WIB*DX+O6%0QTJN9I"=U42C&)AH5HI*=1?B^_7M"/O-WD1
MDPN&)RL>!!4=KTY+MQ??WQ?]W-,(18;JV$>;WL;;M3T&DIY_&;C0"J3N6JE8
ME0W@.M#A'!UDP!AHXIA E& ,-?D=AX?._>I4V"GX;&<2>-.F01D.5_06^, I
M1GB :#%XV[A3BLE,3+U4) LR/,J.=H4!)._N]UG?!YL)[V4(SIPWZ9<B[ .+
ML'^^%&$O1=B/6H0]*^_T)P&*5$Q6O4XM2NS&ZV&\-EK(3%0UB=3C@QSNEGB=
M/9RWRXHS,1@@V3=O9U$!(97#^,X.2QA/Y4,%<W;NGNV+J:&XNV>@_?DD,?L
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M]MZVP(<#>YCQ3K\_7)S$-[M]<WPROOKLJ(OIS>YD/)RC;%C,9KW^_<>7]WX
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MF9A2DP3XM$=:1X$\MS$&S8EA6^7"5SF%TWH0I?\-J#G=:_Q\,MV'>7\>.]]
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M( *Z^F7+)CITR(1P1!N>2IF])%8F1P2*ZSEJ@MM[7<_.;WL4-M]1N3WN7+4
M;W<]7IF%VC.J^;<IG*&*9M.!R1ZG&XT3D&*X7'%62MB"(=SI'&72QNEN3-CV
MS0^(%565WF-;_$Y@7P]]&(Y*:V63,S,!(N&)N[(' ,0[$]&=04TX0.M+V0LU
MKE[YB#BQFYHK-(N_DZH#R7V$@$RUR4F4'Q$&H3,QD'7T5CDCJ]21WHGJ8="D
M?P-4:";_<C@NJ]M::%&KS%7,!(($(EGR)&2M2]/#G%24$#N=3MR:&W=@>EC,
MZ$OYMWEA^PDS5\5>U ,Q;CBD' AD:HKWRXBGU*(S+',(V4E)J]QU> >FDVE%
ML'=0N;_*3Z$-P54!R;^@^3#Q%Q_+==QM 4GPTG&:*4DNHB0! K'<4N)2D-[0
M<I=:E[LJ.IU:V8CB6(WL>S-QT[>J>SZP]'Y!H9N0EH4G74#UW<!@(YK#MS/H
MR5I-+54?C <)0'N0F5!T=TK5NB/664.$T8X:<$!UESSE*=K_CD8(AS3_-AKN
MT^RSB\G@][-!<AJ]%E4$2KG<D1F)9>C/,)0J,Z[<VN9VTTL=3R%^]Z'Y]*P\
M#BW,;/L5*5_=M.[B98?MA]"3RIO=]=7CUE';X.%J(^MLG,YBG)_/1^6>^>=P
M,8$X7&[37JU7;_+E?E?+7,2FE"M(4[E]*B5'?'%7A65:Z1S1C^U2*]NMB<D^
M2!_2JG\XD_6X/]$5^"_^'*X1+\=6%\R]=S[:$>P1VB0=C@];LK W8_;=AVE7
M[#@H0Z !@[J(X9WD.%JM\X@]\\@2]X;3_IHVG10![^KP]&WQ;QL;]GWN8-%I
MX/V%C_!V,AS'X04*\1GB?#;\!(M?3E&<USXTD_*<+Y>MEW*@X!@G5E! S #$
M@?-$2^>"S#(*MW*P<4.Z?D< !VXZ=1#3-@>V2]\U/S<P7Q?7W8&5<JV=2($X
M&QDZJ$&6QEN"^(3J*<7+=/4^X_LYU.7%CX@[O=MAX_S3[VF9Y26G7[VT6XWJ
MS>M1]ZQ#70=BI=:428C:>NZ$]M)(;2VS+"69,G=2"3JX#6<G3>Q^+N6KO^]/
M*QW.ED0;@V9"1<>B#$X%'D5B*H-+@AEG!YN@[:2AOFN=.SRU/VWN7.O,O,O:
MZAB\D)))9:ERWH"T43">G!MT>'X/%T#_N'IU^5DYCO<!%DVQKC_RUG]IZUC*
M'=C7^Q1&I^2MUD3A4H7SC\[$@] D*Z Q@J!1^QI;./M#[_$2Q<7UU6?SV<=F
M,OP_2 -K@Z4XO9!$2V&/<8980"5!#%:Z+*D35;1R!Z;#;W@>F%UWW,*XEWUJ
MM..ZAO;63]Y,VF1N:N^.> N3%NW T\2#28HP*P21C"KB0P$K!$2>@\ IHS*%
M-F%[S%3JQ5XU6@^LLOW5=#I'IAM!G5+H?L:D4>SH%;$L%P4XF=';\=+F@\Q$
M"SR/F3H[VZ5""]I;L&[>1I*91#<8/(8L(1))6<)P@E(BA%*2<N B'V;U.NJ%
M,*=&G%TM5*%GX+WWV5CM=(H4B-50>F=R31Q(2K1SEBL>0E15.B*=WK5"QV91
MGY;JNP3]_BMR*$U!E^N1$T^>2$4#<9PY@C^6"-IQM1I=?#LW#QV)&14TWV/A
M^9V\??$9)G$X+4G5"%>_G"Y_.V4#'J2S'@S1Y6)EJ5(BP9E$J&+:1..UI56:
M7>^$]M$P[G V[;'H?=&B"+&A#OP'1'9CTEP$ NCXE_]^;$;XIN6M%(.2,7,V
M*'3K. X;;3@)V07"C)-,>"=5Q^-26[_ZT=#I ):I4![_XOQBU'P!> ^33R7!
MOU9WOS3C3S#%T+)5T_379N9'-W__4S,ML_1_P^P=Q.;#N,UE*.EUE*@^;HM@
M1@KB5!9$<*JYAPS)5"FNKR;1HV'R:7&C0NU_-<$63LK+9K+\4?D<&QC.6 I)
M$D/+"1AK+0D@!&&*66U%B,Q7B3H.*^9?P^-T6'1[S+C]VPSCTK5($CV?3TH+
MW1;E(@?0_G+12V)ZZ3FE 7-<V%+KJ;EUY2HMC.:*UQZIU]DS;9.LTI)F>ZB/
MCKN5K;DFD;Q_G^M=-;8BR?35>"%L.Q9?C6<H_G08VZSY0(6<&61'<*P9(GF(
MQ.L4\*LLK=%E'[Y*<Y%#"/?X2'YJC%DS+/;>8-E7R'^U<>VEA+]#"6]QM?H$
M$PQBVE\^]S.XND-^D)RG- 2**U#ICVS*/='!X[?""ZY,Z:3>Y5*F@X^0+>7\
M:["<$(_6C)L^=YI^\A=#'-B+Q>\=3-&?@^)^O9S/YA,HJV3;$R>;&+ADM-SI
M*4O&!XA+%,/U) 1W,246JYP*WAKIH^-N75NN8=_>.U4[*VR9-KJ*/>;AJN3\
M'8ZO@8^,,@>2*)"H1@:>A!@2859J%V)ITE+GSH]* CTZ+I\$,]90?N_[2%K4
MX7[!PJI@;^>3^-%?I>)O%KTLLJT#2Z.20KE2V:*(3)82:Q(E#**WS,1<J?=I
M/9$>)^V/SXXUQ-^O6=75<&P176(=^?%5!\Z<81F _S?XR2!;:H6."%0&C"(2
M4\0JQHG,/ 053'"K/6DV[-1L^^9'0[GZ=EG#HOTV_';6U)5DB]USJ;CT'#1Q
MKN00 =45,@X%X-1DZP2/KANY>@+TN#AW#"NNH>+>>X:7+?C?Y'LEFFX2:7$X
MW'@M*&1#N) &5>DE<:71I';6"VVUUZO]6GM:N/N2X%!MF8Z].A_%XL?N\W0I
M_0+^Y2WLTOK$G3&$Y3+],V,).A""9!]SCL*!LE4:"GZ%XEB='HY$A-7N]#L;
MI$*%^^Z*N!9CG%K7PY]?7O+>1:::-S76$.HX=SWNP95M(_-#&?I;(;'6IEQ(
MXXCRY2(!$8$X[A)1,2@58P:P5>Z8_';(>\\ME2?.W6WL6X&S7X5PRV/G@6O&
M,G4$&$77.,E(O("V[U#DP#':YU46YS583C"VJ6[D314R.UJHPA''2^G:$>6]
M5YP+0P*4B^6S#!A(65NN@09*!41=9[?_)HC'[<GM;(X*9\]6B-\%34T7[!2<
MI]W-L\'.>^BVP@JRBBH"5TIS7&#1(C('04*YV<92)APU+HA<)1MQ IY&-4-O
MH=*^VU"=%75OS/,NER.+7A,+DA*FO2C7?:M2OH-X$X@8@M:*K2P!&S*B7=YV
M>)=@'W,T-75986G??*>[,2 ]>$L$+;4FPB@22M5)RD[RP+E)NDKEQD9$CWO1
M[\=0]<X/W[Q&O@NBFE[ ;4C'\01ZLMGZHW?[*KQ&WXK;R" ::[@#$D3$R=.S
M2 +W"@,C[8W+02H7OV4*W.,B'(P!V^BY;Y_A[01>SDLOK,L#G\NE36DI%4 @
MH,ITEYP@GF5++(;&Q2$"W[$UY887'-XSV%?Q3<]:V^@0U&@"^'Y^?NXG7YJ%
M^+?*3EY\+E_"WIW>MGM-?ZW?]A!OI1><-D:JY*TQ2<FD3.#.:@92<2HBXW&P
MRPL/<'BOW&H8VZ_*+<9?'ZPJ1ZZFU_NB($"6U!-Q47#T6JDCA>WH&'M-'0?'
M8Y6+I'N68^]-SL6;(*T'LC3AP$ .,5A#,B^%LR 2*>TIB;&9:B44MZQ*3K\;
MO,-/H\=DXZUMT?Y-6"-,NXI!^M'=(AZ1U"DGO2>))A0J&HVK6+#HB&0MO5&1
M^2JCN(HTAZHJ.27R'I\6IU)N\FJ,RSE<N=NOEW*VKK:FTCI?+F(&B?(XRTF0
M+J!'!=%+GBGG52J=[\!T_%S&T0C3U#%<A7!V [3+/;X.X&HF.>Y$=YQ\1V^V
M[,:1/0QQ<+9@)""#0'S,E8/@P46<[R$2FZ34*F&LJ*KLL1^!)?>D1(Y#DFWT
M7X$<Y5 =/O#CV3@]AT\P:BX*QJ5S>;D3D!-(IS)QIESZE!00CS,H,498&F+6
MRE2)$CI@.WR(T*,UF[JFJ.#M_PO&,/&C<DU%.D=53V?EJNA/\#5(L!9P7&AB
M-<8E[1W1GJI =-(8I(!QP58Y5-X)W4-B3/_F..CE'9<^7Y-7#IB?3:?S\\5!
M]/VS=EN\I,><W:ZBK63LA(S2>:YT=%&&$+T)7CD= T\R9VH&>PFYI]5N=I8Y
MBT@\_&V/]KKK\34LU5F<U5M,#*4R\@0F,IF]=M[8H+B+V?(0)+MEHXZ"[9<+
MOVI5A<O*;#*,)9%4WOL;ZJH_8^WRM@J9\9V%73$E6M)C4,@=2TPZXZUAGC%5
M1IV,3*35!/DV[SWZ)2J**IF\B 04.K)29D8"Q17!TA1B-+(<(C]* 7?U2U1V
M1H#V78S3A=U?C='*\[:>XD8[T'?-:/2RF93/#P2C222-:N"VG";5)7MF)#$^
M"A6E-7:U .G(.MY6PA.L@^Z7^;UU<*C*G1J9_%T%O2W?["-,?OWHE_)/KV;)
MQ6GL0=8YNV0%B;I<8F(3(]9!V<&@3 +36J9T4H-D6PF_H4%2EZ5]C:6J%#O&
M :R=!?VZ,== 9LMLBI)XDTLS ^J)%4!)HF@GEFDT=;I8'4K OT;2H4?2'@2K
M<(JCGIS_V4X75W)&D3TM%P P:]LJ^42"%)[0&$)2)ALE3JO3UI8"_C60#CV0
M]B!8A6+H>G*B%3(,;XHJO9')E>Y,3J=R<D"3P R0*(*DRE(P=6Z#.Z",?PVG
M0P^G_6C6XZ52AW=F?6;><AJ)H!R(]((3%-L0:E7P$3W=1$\KJ;!?O'22IKBW
M!>[-$>1$8)PG3K0(JC17ER1H;XB3^#_.#$8AQVF5<%@]?$.3Y)%S12? PV\J
M"NZNCH$HL3[3G"A1KIACS!&7E"-&\ A<,)6@RL5%IR#\-S0 3V$$G.!HWHJ^
MW]00WK;#O+<LL.*&6IM1$=)$$@3&3T'B3QED$'6*2DY& W\-YM,<S#6)_ UG
MU#I,;4!IXH:1S!DKG9Q+_!8E88(;KDT.F56Y1_5D-/#7B#[-$5V3R-]B:F\^
M@>G]6G!1>L]Y)EZB!25%)\4:XXG5C$&0@B/R;VLX;R/^7V/Y-,=R-0I_FQG%
M^W40$TYB60D".4><S"(C@5M*?%;1)YZLA&]L&.\:+^]S&';?ACQ<T6P,9T0Y
MQ<N5NIHX;@41P27JM*2NSL'LQ]A*?:^,WU$L?BIG6[_N:&LB=UY[34R,Y4JB
M@($-18>(4T%M$C1P4\6??V"MU+<BPIVMU+<QR+?2A;J+3'^U4M^^E?I67#E$
M.^I=#/VMD#B#RP%%((PY=)5#.9'EHR(B,ER#DI)!UVEO\<V0=ZM6ZB?'W6WL
M6^=,[\W#*)?MNZ@0D0:#6E*T-.C6Q/H2X62P";5$LZVR$;86S0F&R]4-??NX
M[YY6.E23-3\9#\<?INA83M$CFA8E[71D;-US>CD,=B_ E6->+GKE>>8F42X-
M=0%X\ J-IJ1AFOK!?5![T&#K[.UV]&[STVII<QW8%9U2*ZR2/D8IJ?1<6[ V
MXH  _,8YRM;J]#;L'C1[?= R^.DP^G%*P]$<Q]D89LO/Q?9>R6G;+7&/,Y"]
MO;R6W7I0Q8J9+77> /,L1I!*^9"I%XGYG*0-S(FU9MX-QIZQZ7@V;-\R_ 3O
M(<XGJ%.8OO@<1W.4YB6N#V4=F,^6380N8;^%2;L*7*<'>&:>@\@D60?EHA9/
M@@F:^""I=\%I%>K<$-:3 'L'^?OA.#MOYN/9(&6F4PZ!"*4CD<[0<O$(KG",
M2Y84=RI4.?/5"_K#>RM'8>^M;,+!+5^U0>&>XBRR,]Y)U)C5Q&ECB11"D< 3
M:I9338'B!*<K)V;[$.-0V=F3H/$1&7 RB=K]!/_QR_H'M-$WU2R8F!Q)0ADB
M/11]:" 0<T!_4&A:Y[1'19F.GT0^/%/[G?M[8TR%],AZ9#>B^B[X:N:8[P-X
MI'SQJ3"B$U/W-.<Q:,>%\3'81 PM!100(W&.!V*BP1 KF"QME1LICD.W^S*\
MWRK;MK%B[6LT%P40R\PBSOPT)Q8(1NJ"R$ YL5[(<A05E*':B5RE_<]&1*<2
M5>UJO+NNQ]Q9\Q4BH#6]J:;OWO^V!(=1&7<>+$)*F4B#[H(M55R4J^C040"N
MJ@3F=Z)Z8-3HSP('NGA7Y>084Q0AE7"K3(XNF$2"Y89G'96KTYC\)"[>/=PL
ML8.V-YX(V+#GL_QQ^2?X*?SS;_\/4$L#!!0    ( -Q K%(E7B/!!'   .3/
M!  5    ;FQT>"TR,#(Q,#,S,5]L86(N>&ULW+U[D]RXD2_Z_WX*7OO$[DQ$
MPT.0( C8NWNB1P\?Q=5,ZTH:^_A.W*C 4ZHSU56]Q2J-VI_^ GQ4L>O! E@@
MFUJ';4G=))#Y _%#(I'(_/?_^?5^$7U1ZV*^6O[''^"?XC]$:BE6<K[\]!]_
M^.7C:T#^\#__\U_^Y=__+P#^]X_OWT8O5V)[KY:;Z,5:L8V2T>_SS>?H[U(5
MOT5ZO;J/_KY:_S;_P@#XS_*E%ZN'Q_7\T^=-E,0)//SM^L\II)BHA *9YQP@
MG"6 40@!)Y*KA(D<IMG-IS\G,$&0*P)D3!1 G.> P4P!DJ4TEEF>RS@M&UW,
ME[_]V?X?9X6*C'++HOSG?_SA\V;S\.<??OC]]]__])6O%W]:K3_]D,1Q^D/S
M]!_JQ[\>/?][6CX-*:4_E+_=/5K,3SUHFH4__.^?WGX0G]4] _-EL6%+83LH
MYG\NRA^^70FV*3&_*%=T]@G[+] \!NR/ $Q "O_TM9!_^,]_B:(*CO5JH=XK
M'=D_?WG_YFR7] ?[Q ]+]<F.[#NUGJ_DAPU;;]XRKA9&^K*US>.#^H\_%//[
MAX5J?O9YK?3I9A?K]9-6K9342@FQE?*/YSK[X0KQ \F[.98U@'"ENC^'DK$+
MTY^#B?O1\(,:7N!6-U>+7'U0KY9RK&]WU]75H@\O<:C/8K5ABQ$^BWTW+9$7
M]@=OS=_J;FQ#'61:]E-3=TM4]76CEE)5;/FDZ6@N_^,/YF^S;0$^,?8PNS4+
MWIU^K]CBE:'SC7JW7CVH]>9Q%B/&2)QRD"BH 9*Q! 29OZE,JQAE1%"-9IO=
MMSU32_#+AT:,LB^WCO[@H>GFS(Q=JV*U78O]6G>_.+6 F;7+KG;DAR6[5\4#
MJU\PTEJSH%+@/S_\UY:M5:25VD0K;?ZKYT)%Y=/10ID52?[[#WL=KP!X,1IL
MBV$1LR):J*R0425EU(AY%JN5>"+/PAH.J_4A$"OA#,23"5F"H%G!2RWJ)@PB
M2?R#6FR*YB? _@3$L#8N_GBQKQ^.QOMVW2C"UN+"8-1/_"!6QFQZV( GXV+-
M3#^--RN_3Z5"V@CQAVBUEFIM#.,3"AU]P!\^F_GPH_WP7ZSN']2R*"V\V_7:
M? /*&LT_/NX?><<>[8]N?V=K^>J_MO/-XQMC)JY+X[JXVWQ6ZX^?V?+NP391
M_-4TL2G>+*NE9I:@C!O2DB"G"AK&D<80QID$*68QQD207$,?QAE+\*DQV'ME
M!)\+NXTI-BOQ6[1=SC=%],D*;7[VW7P9%5;OXGL_)AOM0W!CQBD.[\!,6^H#
M[+9(1FVEHY;6$7^,VL_5FD>EZC=1I7S4TCXJU8\V1O^H!N FJB"(S*=2@1".
MQ\<>MI#KPFBRC[K.C#TBA^O6Z/WW6P??JJ)0ZJTU 5^J0JSG91_&5E=O-NJ^
MF*49R8R%S(%2! .D4@1(DA,0$QI3DO-8RMQG^;K0W]16G4K<FZ@4^"9JB1S]
M:H6.2JG_/[\EYQ+F;BM%0"0')OAK0?1F8T=H0I+HI2Y'Y3Y'_0\IR_6U:YCF
MSACOA@F7G\INBH]F4_^C$?VW&9:YA(AF0%&4 Y1K"JC0#% D:"R8S)/$RT[N
M[FYZ/&/%ZT,C9P'U89$0,(U$(CM1*SHIHE^MM%$I;G *N81+> 8YV^,S$,@E
M[4_SQ\6W_.A#JOFL.<CZ:%Z=)3AC)(8*8!5G9D--.> XCP'C(DEP'"=)YF21
M'#8\-4K8G=Y9X=R8X0BK;@ZX!H&!9[N;\LZS^IRF^_E;-!.X4.)/GU9??C"O
M5'/7_.5PRAXU-\KD/*=$,PW/_GYD#UF]3;G;;NQ1JCV=?K/<K.?+8B[^QA9;
M-8LSE>72K/(DA1 @P3.SJT^EV5TD4BD>9PC*45QBER2=&B6T!+V);C]]6I>'
M+M%.Z*B4>B3_U\5A'MCA%7+PIN_AVOFPGGP#KB,_GC_+=50FX<"Z*.RWX;%R
MQ3R8B\JYP^=9>9XZR/ZZ7A7%+)$0TSSA@!)C,"+%*> 02Q!GD$*52?/+;,PU
MYX2,DUMM*DF?\8BE8SS'65RN'*5O:%DY/!JQ/S':3F=%Z1B**:TEI\3\IE:1
M#IQ#KQ]=7?5;.?:'Q"]8\?EV6?YA#U2^L(4]2IG1G*4$ZQ@D7#.S]4@AX'F6
M@3A64F9I)D62^"P#ESJ<&J>W3M&%D=2/QR^BZT;*(3$;F&%;<%DA(V/L5']I
MB1N.(EV!"<EW%_L<E;Q<$3AD(N?W^M'*FZ585Z<BU9]OEK="K+:F8<-JC"^4
MZ='\9+U5\NV<\?EBOIFK8J8IBI70 F19C@!"D  J" 0TR3%..5=YYD4V_<28
M&@4U,D</E=#EI&*5V-%B+[<?-_4<(C?&&A[X@7FL42#ZKE'A>VOJ[8;B76LH
M:D6BMPY#X4UQUR$9DOAZ2C(J'5Z'UB%)7MF:'W4N%YNO)WI\>CCTWEXVNM._
M%.JV*)0Q(&"289(G&)C_I0"E3 -.DPSHA/,LS5.:"C%K!\:?G;J]^G>:L1<O
M (3=@S>GG664=E1>SP(K#;;F'ZP4VHTG^XT'83&5#"&0,;N"<6FWD1H!2..4
ML413K)Q6L.%&8\2%:T>BACF/QV'(8>A>I08']WD6IX.#_JC4P$;D&QVBV\$_
M?5F?I)5[VN?#_HD8W]08.-L&5V%8F02V";O0PSBME_E^C8ZRNE^E;[.H7]=(
M3[^\^*SD=J'N]*O[A\7J4:D/:OUE+M091]!B45^<M?<WQ.K3<O[/Y@;>BU6Q
M*3Y:HV/&,IRA/!$@)]BL,2F* <^X!KG*..0L3A)$O#SS0T@YM;7HI$MW[WB[
MB5Y]M1J:WU8NBX?YABVL8C?1[;VU^:)?2[T\(U>'^0(<??G//:XC>O.'&5)_
MG_V0D ?UV@\BZ+A^^R&Q/O+<#]I9S]7%WNZS7WIU <+VOUI:Y]WMUWDQ0RCC
MB4@)H"G, ,KL-3K-S,:$TTSSA FN8J]5HJNWJ;%]?;UI+V3TJQ73E[P[ 78D
MX5"P#4RFWHCY<Z,+$D$YKK/#<;G*1?<CSG%ZZ=ISOP_V;NA/ZIZK]0RG*&&$
M8)"D]NZ25@D@*=) 9$K0E.=40*^[2R=[F1I7M(ZL2BFC7\I[LM^]__"+;]S&
M:51]#_EZ8C7>R5X%TZ^5B $9HA."8<[PVAT]T\'="5W/G]:=>GAJ]_G_9J15
MLHE2^+NR>VHE;[^8C?8G588PO#3$]IK-UU78:XX9Y'DLS2@Q"!#,#.MD.0,*
M8XIE@HEB$[GP[ZG9A)FNG1'@2ZE5&:TF5XL%6Q?1@UI7D6N3R0W@^U$Y6F=3
MD7="1#]>=H$*HW8(78-35 -51=E%%JK(8C69J.VAQG\2D7G!E?LVXOF&&M/Q
M$AWT%?#J3 C%N]5B+A[W=VDSQ=,$TP0H*05 #"> RI@"3C'/%=8P1WVS(!SV
M-;55MO_-Y--0NJUD@0 :>&UYDMB@B'ZM)(T&O)#<B<A ^0R.NGNN7 ;G].[(
M8W#VE7X<\?1XK8F2>7RQ7:\-@<U4(@51"0=:Y H@";$Q_84 6F88BD01G:0^
M--'=W=28XC!6I7<LWP64W1@D''8#D\C!&?O-+O#N\2:JI0W'(FZHA"22"SV.
MRB5NVA_2B>-;/>+C[LHTG!_LAW$KY=P:/6Q1_;"X+7/4KM9V0!]KUQM*-4PA
MBH'.)+=FB 0DS1102B<9SB"CS(E?^G0^.;:I4IB6\M]$;*=!G=NT*$])%SLE
M/$*%?$>EFX^&QGIH=GH"\U[XZ*X%\U[^RV[4Z_'VB,P:$/>1 K,\\0\4C=43
MM\Y@+-\VQXO%ZJGMDU"LOFWXK1K%>C-[;_?5]53(->-4)PE@A%" 8I0"BB$#
M.I<PCPF$"7,Z%3]H=VI<;X\.Y\5F+LQW_Y-9A+?KRFWWZ\O5/9LO'<GF$+QN
MWKX"DJ$]FGW1<.: ,[IWF(7FC99):/YU: X>-CG*[#ZC1S-QS_UZY!.HM[O$
MCYRD,,D9!SGE9CJK' ,J<P1L6GJ5IWF><[]0R*M%FAP37.O-OR)M9X !'O@8
MI]>P3?W\9: <H>% GL0AQ]OGR30:#L5@QPK'+4\MHN#U:JW5?&/6[>+RR2^2
MB& 5)T#'- 8H(=I,$IB!A!D#&U&,8\RF$4[@H];4UI4SL02Z4FGRX01>7]1S
MQQ(,]9U,?2%S#B1H ?3?*8:@S[A/8FT-J]FWL3X/,IKCA0[TDN[:6W&G92UC
M')N(!M-?I6-1;.^KGY5W)_;GXXS%3#$F >-9!A"2U.X!;?T%B&G&$QUGJM]U
MN!#B36W=;K2S=U*/F+*E1=]K;D&&U''!?;:!&GKA;(U1Q^)8A6'OH^D:%=O#
M6%]Q&R;"8I@!&.::6Q )G^E^6TATSU]L"]J+?\KZ5\M-N4(9$F1B,_^BS)+#
MF@B&6.0Q%AD':5HE(\T,VS,&,I)RS!5->.J<PKZKHZFQ=25KU!+6VK'L8IB#
M'[K==!L2LX&)LR]<7FGQ7;"X(DU^9_.CI<UW4;*=1M_I^8'<2L6%K)FOOJJU
MF!>J.!,8V_S^W7HNU"QC.<,I569,4&;K=QFJ48@"R*6BFF&$<AK4?114_*D1
M6),26=5"CN07"OM)!/+_/-M 3\#/4[BF5=Z!T'DMI'DJ*K$8T9<SR!B.ZK,)
MJ\&T?#.#C(ZW#V88*:[UM5S*^+K??2LH**=F\<-:)P!A3@&%"0=009*H5(I8
M> 5E]Y!A:LM8(WBYEAEF\\]M'&QT?'TC@V ^\(KB#/=([@UO#(?Q8;B+\4R.
M"F^<SGLC_)OR=SE\4&*[-MN65U_%9TO>/YM/<B8X2Q%C"K T9P!Q(@%/$@6(
MT'G.I?D-=ZI[<JZ#J5%;(V/4"!E9*=T]"R=!O.Q1N!::H6U:/U2\' A=JE_A
M.#C9[&@.@RZEVHZ"SN?ZV3@_JXTEAW?KU9>Y5/+'QU\*>PEV=POEUCHDREM5
MM]R0"A.;61YC)$5"01Q#"9 0"+ <VZIZ&=0"DRSW,W'\19@:#>PO5;&=K'[&
M3(]A<+-EA@5W8"(QPE=62R.^W0A_9S4P&]SO6_EB]UI$OS9Z!#1F^H,8TI;I
M(<6HIDQ_E XMF2M:ZIL-T!A#GU<+\T91G?;_O-JHE_-"+%8VXKUU8)XD,.8I
M K$6W)"?+07,,@ZRA,54<XPH\LNWX]KSU#BO$M8W)Z KS(X;M2' &]HX:LG\
M;TV,EA4[VLL]4)5Q;[C")A1T[7SDY(*>F!PG&O1M(%S@3]N'UCYKKOGQ\2 R
M)$VU2E*=F=%)!$"0:T"XK4F6X"3+5 PUO#K8QT^DJ9':D^"1=H1(8V'X$M[U
M@]8_G&>XH1CQ3.1D;NI*D9O=H(P>J-,/VJ&#<SRE>O: G'XHN@3A]&SYRC0M
M;Y9B=:_>E@6 "8T3D1. ,EMJ'J7$L*PD '(B,1.()RII2@M]7&W8PHUQ3W3E
M-&^?5A':=SC<'"[[B%:['9JJTLGWS<W2@M:-$/LB-786EDJ\Z#LKX/F#_/Z9
M5X[5'R3=2JN;Y\FQ<JSGV<0J)Q[MF<-MGW*HB0;C&5$*)Q 0F%*S/8P9H"A+
M $9YS*0TVT7K&W.?\,==>)E,HTUT40G7/PO3"2S=)OIU" T\SUO"#9!>Z;SJ
M07.S'?<R;DJVLUH>96([_V3?D-KWZM/<>IB6F_)H1C%HZT! (+., [.*(T!R
M928ZA!F30FJ9.<6WG>M@:ONA.B9T+Z3G^=9)$"^?;UT+S<"SVA.5'@&RIU6_
M.C#VH-F1 V)/*W4<"'OFN2OKO)CMP9&G9G>68E9MJ1$3 &MIS'6I!" Z,7]+
M(,VQI *EN%>]EZY>IS;9=T+OO!^';DJ'LY4K!L'5YQL8VL']O0%0[5\OQ@6E
M0>K&=';\//5C7+ X6T?&Z>6IY7[X>;6L"A1<OJ=/$$<I000(>S<(Q1 "%K,<
M)"B.-4Z0% S-'LJ02X/)>N-(A!-0S8<,#A4<\&Q[M025 C<1-RO><FG= 9R9
MAX2:> ((C\]**T%RG2' LPP;BQD30!);8QN)!&:9%B25]6?U:GFARO:4%//_
MJ!KUQOFDU%+^M_R>'(V$"8@Z)1MDM&0B.WC^.Z42\1_S;R.1B(=>T[JJ,N)(
MCI=$I(=L_<S-JCKW;MN%D8JQU&;>TR0%B)K%F>5< ZVHP#CA$"FO.YM/FY_:
M)O="&7D7P-R6H/XP#+P85((-LNL\K7-(,CSH851:.JW=(4&<>6KDG:$ADXI6
MCFEGNRDVK+0.WQN#\/5J;9^?I>8_V.8 RK'0 &70\ $R0Z!%GD.$$\*%7\7C
ML22?&L'\O+79?7?99WPOM8TVX ,;TD,.X_2M9;L3J]0_83C?1"T(HE\M"%&-
MPA0RSO8=N4G8O-["?QN&;=\Q"6:]]A:@IXDJQ&J[M,$:946M]K675(H<00I!
M)F1L%BII,]12!A#A%#&,88:\%JKS74UM9=E+&C6B]CZ1Z0#8T;P- MO0IFX_
MQ/SMWHM@!+6!S_<VKCU\4>LCV_CR&R/;R?7>NT5B7?DD+,'IVG[B*5<LSG*@
MM75L$TP Y1P#!1/)%$9IG/L=&8^NPM3X[6G ?=^T-5/Y/@:VKT<9]>D;VCO'
M<PN(BRF/ACEQ?[:1G(3AW5^+;\,"OWJ4@IGBUTO2-QCR5DHS_8LR).)N7=[.
M-:#/B,(QM>L?0;E9":4QQIG6"E"%(,ECD@N._((B3W<TM?6J#@.LA;4IA>W1
MUFH=-0+[QDF>P;=[)0F)VL!\WQ^P'B&4W6A<'4IYIOF10RJ[E3P.K;SP_-3"
ME_Y6GH<UF=YFE##)&;:W*61FB]-0>W^5 RS2E,LTRS65S:6JYXXD>2JZTR1\
M>DEK8/(Z4X*F.H$LPT7*$)&..TG/^RT\=QQ(C_']9HQJQUB/"H)]JM$)V-(]
MAVT2%K2O[-^&W=QS1,8+NSC3?[^ET+"J,B_9E'LOU1>U6#W8/E]5=U_K0K#:
MF,6Q8A)@R<PJQG)[UT"F(,MTCG*9"R:]'-@.?4[-<FY$+M-2RKW0/6\)NZ#N
MMEX$QG)@JG\"8TO>J!;X<GET;V;V "@DJ;IT.RH?>N!P2&4^K_9EH0V;+Y5\
MQ=8VJ+RX%6)[OUU8J_*ETG,QW\PX@=I03P*43K@A(90  A4#.4VU^17,\\0K
MA]_E+J?&02T)#065(OJRSD6474DG)':#<TXE;-1(&WW71K(6.& F W=TPA+.
MQ5Y'YAM7%([IQOG-*].?O%7&^'IO79%W^I="E8%P,X(20S1Q#E :VQO3>0I8
M;/;L(LF8I)@F&'H136=O4^.8?9J/A94V6EMQP4J#K?D'ZQ&)VHVU&]T$0W!@
MIMF#5PIZ$[UOT#/"1J6T ^1+Z0)ED,PI)SM\GAPJ7;J?S:;2^5+_2F9BM7Y8
MK>L$3H:L7MC @?7CBY54LSBC*LUS""07$B"B). BQ0!G"J-8(2)BIZ-WQ_ZF
MQBJOFD)=+9E;SO1:\LB*[E_CK MWUX.(8&B.<QYQ%9"]JI\YP!.@"%I7+Z/7
M0G-0^51)-)?7^IDM-L'P05F$H[()3W_0>G(7+$>YP@DR&Z<TCQ-CXQA2HA!1
M$*>(BPQ*+9E72LT@4DV-L*R8-T?E1\R"OC^#V!4I.?S9DWHE/8,=PPRUFW4U
M^@ .S)$CCIVWT184ZY#&71C!1C4"@V)Y:"R&;?S:_,EG:N(\3;M+$9$9UPPH
MIF-[*U( FJ74F)P0<1XKEFN_2I9>W4^-P=MYD8.7[W(:#\?SWL%0'OK4U@7@
MD=(<^T W3$IC)PF>*7VQ#SKG4Q5[M?+L,?'5G<:9R*00,DE!RK,<()QF@&08
M@Q2A)$DPQ9C@$5,$G9/39UJ/E^_G28#RZ80_XT;<G!WF%"=QGFL-<@TSL_3E
M">#<C+K*$<Q3EL:8T]%2]H0;Y.'S[SP9XA,)>"8ROHY+Z7..V-"K[5 7#RI-
M)Q (=6D0)A'Q=%;(;R.TZ1+& T;\'W34ST!X=?^P6#TJ]4&MO\R%.BW>+BM-
M*4E19OMN__[%JMC\O-K\0VW>*['ZM)S_4\F9RA*SB" -8JE3@)BR7C&"08:%
MBK&&)-7:9_,TF*13VV?]LESO9*OB<FOV$6V6$D83OT5DN*%V6TPF,8 C+BHG
MJ];L]&O6$*N0+?T5/:I-M-?I)KJ]MV[N<,O(X/"'7$Z&$W;4965PS ^7E^$[
MO/+>V#O3-EO\O_.'\C"19#E/5,: I!B:-0+F@##S07"!A" RYU207K?&GG0S
M-8(_O )5"1L9:7N=UYY$UO68]EJ\QCF=]8:J_UVQDTB$NBGVM/'GN2=V4L&S
MM\1./^U' L5Z,[O3VO#1C]OYPIJN=3QV+*2&D.1 R,RF<:$4D!P1D,8XUY1*
MFE"G.JKG.IC:Q*]DC,I?N\WRL]!US^\0@ P\LVLL&OD"AJE?4K[#3C&OMFP4
M\Z_#&7VV[5'F\B7-FEE\\;DKG,G\\MZ5'^Y=WYF/YC.K+Z/?:?/V?5V2[YTR
MGY,MF953FE*5@E0;:P#E"-E;G6;;*"'A$)N-9))X)U(91-2I<<JK#^_>W40/
MM=C10YG;8J7M9M%(7NT?;VRZ;RN\_<4]6_]FMAH//1.H##/^'N[(9Q_5Z?LE
M&W7K3"?V.+'Z&CY47T.M=& 7Y: #$]Q7.8RTXSLM!T7]I/=RV!ZO6)K:SM%9
M!D66HQB#6-LBC%(Q0+-8 8RXXIRB/(MUSW/*=C_3/&?\L3IP:I\Q7G?V] 1:
MK86&L8AM@*,M;LL5H$1((%4N%**08=JOG,=UP Y_MK>#M3[7"XBIQP+8%Z4Q
MUJVG9V&!%YA3B@=?%YYT,CZ=G]+Q) N??+ ?>;XS&*KU6LF2D*L2*[FM!(4E
M UENZ9.E$%"1*:!$FL=QGJ8D<_+,=?0Q-4MZ)V*=# 5$_R/^4VS_ Z,'MHZ^
M6*'-3]EV\WFUKISTV8WYM?U?Q IK9_U47L5.X4UDOC%8W\D6Y>:K^6G\ERB.
MYD6Q-1W9WZ]:>:#=&_F3'^&<&F(WRKERX 8FG?V8U:9M*>!-]*;$-QS_=* 0
MDH%.=3,J!W7H><A"78_Z'Q*\7(DR-<='8TH6<VM5OE</J_5FQBFD4E!#/QI:
MSX#A(&8L#$"00A)*I6.>NQX1G.MD:DS4R!GM!8TJ2=W/!LX">OED( 1, \_[
M'@AY'0E<@N"* X&S38]V''!)N?9AP,5GGR<NM4YO:4-EZX V8Y4@N_$ !&L%
M$)0<<$@$$#)-86*,F"09-17SD813(YF6@$W,VKY@R?.%*AZ/K,?6Z+G&:_HN
MP5VHXHEAGTZHXME!F%*HXK&0WU2HXEF,0X<JGN^HYV7=EM.0K>_6Y5U@61J>
M[]2Z%&66\4QQIH6]BIL#E.$4T!AI@% L-1%20NJ4AMBCSZGQ^HNG!S^[C6N(
MZJ\N0^!&UX&!'9B #XY/#*:K=94C0%8[3GND4M%OP)NM[A %O;?JT.VXMU+=
M<3BZ<^KQJA\I+1>;K[-;"^$NY*[LI3GG,)]/D^HQP3&4*0(,Y3% 6C+ 1"(
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MFAL#P5'2*//^E%)&]1^\2:22ZB'^M*XZA!^78*FGKA#ARJL.U>5_PAE-<):
MG.;6BE766XP)R#*(<9HE*,ZR7M<<IIG"81_(WROQPE/L'"F_-R)#L[(S&/TO
M- R7;N!I#\]SD:'[NO_II_ROZ[^W''+[=5[,1*(3QNSLA+$$2#$*&,8YR'1B
M-NY(X3AQNI;PI-4ISM%YL2FOF_]D-NW;=?V16F$][N7O8;MPX-H7C!&F9P\<
MO"[@'^E][87[?8.C7; _TJ%]H?[XESWS^3\HFX-M^:ET(U5U>/4OA2K3BM_>
MK]:;^3_+);_.T3;#,>444F%F*;71CAH!DDEJX&*IR%/)I/3+]N\IP-1F=5O$
MRO%9ZU/7U%U;C<!*@ZWY1Z]2 ;XCY+9Z#XG[P 2R$[VIP?N^P=C(7Y4?N(F>
MC$NM0\!2!#W1"UJHP%>&<<L8]$3HJ,A!WW;Z\>$[,T!JO5:R#"BMKB>]*8JM
MDC-.L<"IA"!#:0P0YS&@C.4@X33%*LXU$<R'^<YW-36.VTE:^;%NF@L\\U+:
M_FZL#K#=2"P,A /3U1Z]#Q5Z]?7&2M!PG'09C)#LT]';J#QS6>M#1G%XHQ]W
M_*PVMMC2N_7JRUPJ^>.CH2GY9ED5)3<,=BLV\R_EM949(1"GG&"0Y3P%B#(!
MF#;_%,:6DKE*%*5PMEEMV,*-2]R[]N*6G0 #'AFK354/[Z&6W?I+=2-WQ':"
M^U&+QUBX4<TP" ],/1;<LN#<NQ:XWUG)H_GR^V@G?'1[&69O/O)'+"0_>?0^
M*E_YHW+(7SU:>)YJ,7]3A;WXO92[(*^5_5&=W\8ZCVX_?5J71W%OEIOU?%G,
M154(66IB,_@:4D3*%@Y()2"<"*!3B5&6)3 1_@&^SZ')U"RYEL1FB]3('.V$
MKL)%QZTYT_\S&?AH<LS!G_Y!Y>XHLL*C+,&P#R=?E3^^B:[\P$:O=G/UX$[B
M(/-J9;Z-8\U08Q:ZOL[U O5;H&\7Y02ITZ@<*= X!"6,XPR:U53G$@&D&0<<
M*PFTTDSG<4*@6_)COVZGMO1]M)N9RH%1$YQH$Z&ZX"*\9@#<UJGPL(ZXJ.P6
MB_VDN0GO=O6#*"0U._8\*H_ZH7%(>IYO7Y4NX^_,?A:;NW7IOWV2X'+WRZ+^
M;0%G4&*8X8P"KLN42ZGUM H.,$IYJGG,H-_]OEY23(V_=GEN'ZS 96XE,_OT
M=FFW];_7T@>YBM]OT-Q(;O"A&)CS=OD]:B'-;*B.GVX.$A&WGBEV#P7TKEP%
MY "I0CP%>8YL(OVP.I-PI&=C/6FTS+U1^JNKG:^AQ%AK>_F98<.0"*9F'8X1
MX#(C(L50>R;Q/>Q@:N3WHIU\!$3_(_Y3;/\#HP>VCKZ45UQ!Q+:;SZOU_)_*
M[%:-R7L35_^+6#EA?S*H?XY2>!/9^T#E]O6E$F7)N>:G\5^:(RW[VU4[_21*
M;M($W\1I>KXY\PRD^":AN'[FJ/WS]Y_<AMV18Z\8S*'ILQK'^B"LE.XF^$'8
M.?V#LMYA'^,2VAD-C[CJW'/^U\2:@N2OYX5@BW\HMGYM?E+,<)KI&,$<P%S8
M=.+*%EA,M*&C3*09DR+!3O% '7U,C8P:,:-*SL@*&I62NE\>.P=G]PP/!-+
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M3A(5$Y"F, $(X1RPF'.0,RR9)DHKZ>1@.MO#U(RFYGY$)654BAD9.;WOD1P
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M.OH;.;W&9<V/$VTXO-./1][5T=OOS*>P,9O=5TT ]X^/'TV+93!41F2,4Z2
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MX$39HJ,"4P@I2XG7W/<786K4L!,U=$&_KF%PHY!AP1V882X4^-O#_CQUV!U
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M-#!_5@A5 @[C?.Q$(*05=KJC40VN3ET/;:ONAWN&D=H]IQGN\EHZ%N:9C"'
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M8$,/L;^-R$/_<0@6AMBC:_^8Q%=F/=P\OIXOU/J%:>G3:OTX$V:_@#EB9K>
ME=D\" @XUF;=P1J*F#-)B=.MX3/M3VYE*$6,2AFC1DCW ,13"';S> !<!N9<
M/TB\H@T[%+\BSO!4JZ-%&':HU(XM['JLI^DI/BNY7:@[[>2\N%V40U/>H#ET
M3UC'1?%1?=W\:)[Y;9;B7&B>(1!S(0"220YH#@F /,540@TSZ>4S'TS2J9')
MA^W]/5L_VL/&#RWG^!/#Q9+XLG"L?S+\6#L:G5,8P>?V:-<C)^O2\0_S395B
MZ,:&59JM9>T3B:QR4:E=R+/.H4<@J 4YF+#CVHU#8WYD+0[>8;^EQG1ZOUJ6
ME/:3*O/((YA3 44*<BPRLT1P"1B6 L@\IDFF%:/2R<5\MH>I47LE8$7K?MQ]
M#)X;YUX%R<!<V48C^K42+R#9G54])$D==S(JN9S5\9 4SC_8;S*_6Z\>U'KS
M^&YAO:++,LO[@UWA/IKV7J[NV7PY@RI/)*$9((F]H$RE BR5.4AM96Z2L$RD
MT&=Z._0YM0G_=K7\5&=J^_@D3UOT:R6P9X"X"^QNQ! 8S(&IX@H<O7G# YF0
M3.+2[:C<XH'#(=OXO-HS%X^4Y2DX6[QC<_EF65O2]=J8IQ0)A04@F<H!@E0
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M.$(RW$$/HW+1:>T.6>/,4SVO9-DK8$7MEMN%!*=)JF5&L-F!,V7OWFO $-0
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MT]BNN[G-ZAKIYBY8&92Z%(2^L:YO9ZS*YT('@)A@3#7"FX*;BL+ERF$M>GT
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M<ZMM:!]@YJ8M3<(*K2+-+RVX/?,##1HH.Q4Y%?UC[YCW9[Y'H>SAE/DMIST
MS\1%MX<S=UJ:VT.;/6-DFSVHUK[4DTX?HG>NFFV.,&,QCY4+F5(9 IBA!&!!
M!, DDEA&6#*!G2)F+3J=FU[<8S[>_FU@]R_U8S, =GK0-ZTCZSL/C+K'V3I0
MY#7JUJ;?:6-P'9@XB<AU>?:<7FH/ZD?UVS__T7RB?NCHE'_^X_]02P,$%
M  @ W$"L4HKD' VX/@  :.$" !4   !N;'1X+3(P,C$P,S,Q7W!R92YX;6SM
MO6MS6TF.)OQ]?D5M[==%5]XO'=.SX2K;'8[77?:Z7-,[^X61%Z3-;8GTD)3+
MGE__(DG=1<D4>9(GY=[N*%F6Z'-P>1()()' O_[/+Z<G/WS&Q7(ZG_WE1_XG
M]N,/.$OS/)U]^,N/O[]_">['__EO__(O__K? /[WS^]>__!\GLY.<;;ZX9<%
MAA7F'_Z8KC[^\/>,RW_\4!;STQ_^/E_\8_HY /S;^A_],O_T=3']\''U@V""
MW_[MXL^2>^-0>,C61E!&"PB><X@N1Q0A62[U__CP9\&%XA$=9.805(P6 M<(
M3DO/LK8V,[E^Z,ET]H\_UR\Q+/$'8FZV7/_U+S]^7*T^_?FGG_[XXX\_?8F+
MDS_-%Q]^$HS)GRX^_>/YQ[_<^?P?<OUI[KW_:?W;RX\NI]L^2(_E/_WOO[W^
M+7W$TP#3V7(59JF^8#G]\W+]P]?S%%9KF7^3KA_N_43]&UQ\#.J/@ N0_$]?
MEOG'?_N7'W[8B&,Q/\%W6'ZH?_[^[M6-5X;__/+I8UB<AC^E^>E/]1,__3(G
M/+P-'RJ]ZW^_^OH)__+C<GKZZ>3R9Q\76/[RX^QD]06J8IG<O/6_7_WCGZX(
M^+3 )6%FS?!K^L'Y,^K;]B0&OZQPEG'#Y<5K3N;IQH=.JHSGBXM_>1(BGJQ_
M.LDXG:R?_"PN5XN05I.DI2K**RBL<%!9!8@Z)(*EEDC_RTZFF[Q7NI=$^%HE
M2TQ_^C#__!,]F%0C6/VF"H8!X^<*^>]W7KH1T7[47ZS#]_3921'!Y!@E)!D9
M**LC!%,"Y(3*T#KARL4!B+_^SINT7U?PLT7Z8;[(N"!S<O'2L$AWE'T3RN>?
M^.E36-"#('V<GN2+?UWMRA!Z6\T'D-]&.43NCS\0UP47"\RO-[JYE[DU9RLR
MLKC^Y!!Z_U]G84%///GZ#C_-%ZM)1*6-$0I09PL*R4K&S 18'CQZ7CQ+94 (
MW'K]3F@0_:/A$*EV HRWN)C.\XM9?D[;\\3GS -)!93R!11+!IPQ"G(4.;B2
ML<@A87'CY3N!0O8/BOTEV@DDWB_";#FM@C^'M1!!(K,>;%(:5#(.O$X:C+-,
M.>$PYB$VN_O>OQ,P5/_ .$BN(V/CQ6PU77U].3W!7\].(RXF3@AT2EEPR,@1
M][0;!F$-N=G2F\R3=<8/@(G;[]T)"[I?+!PDQRXP\ X_3*L09JM?PRE.>(@^
MB*! B"A %6V =D$)):"R] W]D@^&@YOOW@D+IG<L'"#/+O#PBL+_!9FSM>!_
M(_GC+_.SV6KQ]9=YQDD.5C#M$4KTNL*;@%X\P9MB<N2IQ.+88/!XD)2=T&)[
M1\MPTNX"/._#EU>9Q#<MTTU^X]PJ<E^!;@-(P0-%6!;!N:2 -$]BR^BDLX/!
MYAXB=@*,ZQTP0TBX"Z@\RYE4L#S_X_5TAGR2'..*4PSN;%&@7++D0&4/60KG
M+<_<BC 83+80L!-$?.\0.52RG<)#3##$K)%S,#PGBKTR@E>)093!9FL]LR(W
MA(?8+>G%GAX^'B?:GO#Q"WW[9O%^_L=L8AAW*BA%T9=GH*0F%J1#L#&''*6V
MTLBAT7'U^MVPT7%&= BQ]H2,M3/U9O%V,?\\G26<1..BP%! \$R^E)0,O D4
MG7DOLQ;DHY?!]Y9;-.R&D8[SI(,)N">@O)TO5^'D_TP_K5UNZ3$$IT@6*5+\
MKH2#&+.$[+!DAA9MUD/#Y 8%NX&DX[SI0,(=&2+5 CY;8%C370QRRRV9/V,S
M*(V)4,THDO>&1]HQ2Y%B %!<?^=N,.@X2[JW $=6?#V9/WG[<3Z[R.BI;!UJ
M(E9(4>T:4Q"L5.!4-&33G!86!U#^[??N!H".4Z,'"7)D$/R&Z6Q! .8BOI^N
M3BJ O4CH%/B8'877B4/@JH"U3D9IM+=VB-#C]GMW T''.=&#!#DR"-XO0JV#
M^NWK:9R?3# +ZY(4D N2'=,E$GJS <YX*4GSG ?9 VZ\=#?U=YSDW%^$G1B
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M]A%/3BZHEU9SKXVA>-K6\E1&CI)<WZPIR1:3=/'#I:^OOWDW3'2<KSQ0F%U
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MI?/]62F6BTP,4#"RK*[46Z?"@_'HHO#%QK"EO<B@SO(5->.TM&IAA Z6=0>
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MLNQAT79\\C!6;A\V!K)\SRY?\_;\-9> ,RZ9$F, XR0!KD@"G),9!-*&*8O
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M@+HSLN063]M_>KYXF(A,^-J^?[T2%<4D07M-*RA8%XLL*)M,C3R$Z''MVU#
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M:\T\G,AA+F)$A.*PD)*BARAR 9&E<])J)7B7P=*._#WM+.*36%^#P:N757>
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MSUIX'9OLY(-0WZ,CV1IXPZ)_#Q2T/UTX_T7]$L,2_^U?_G]02P$"% ,4
M" #<0*Q2V"5(VE4?  "UOP  #@              @ $     97AH:6)I=#$P
M,2YH=&U02P$"% ,4    " #<0*Q2#K)UP<\'  "H)   #@
M@ &!'P  97AH:6)I=#,Q,2YH=&U02P$"% ,4    " #<0*Q2'@><_;D'  #G
M)   #@              @ %\)P  97AH:6)I=#,Q,BYH=&U02P$"% ,4
M" #<0*Q2)!XS5@0&  !8&@  #@              @ %A+P  97AH:6)I=#,R
M,2YH=&U02P$"% ,4    " #<0*Q2!FJ.$VVH 0!1EPT $0
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M+3(P,C$P,S,Q7VQA8BYX;6Q02P$"% ,4    " #<0*Q2BN0<#;@^  !HX0(
M%0              @ &LA@( ;FQT>"TR,#(Q,#,S,5]P<F4N>&UL4$L%!@
0   *  H >@(  )?% @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
